

Kent Academic Repository

Piper-Brown, Elliot (2019) *The role of phosphorylation in the control of Ras activity and localisation in S. cerevisiae.* Doctor of Philosophy (PhD) thesis, University of Kent,.

Downloaded from

https://kar.kent.ac.uk/82793/ The University of Kent's Academic Repository KAR

The version of record is available from

This document version UNSPECIFIED

DOI for this version

Licence for this version CC BY (Attribution)

Additional information

Versions of research works

Versions of Record

If this version is the version of record, it is the same as the published version available on the publisher's web site. Cite as the published version.

Author Accepted Manuscripts

If this document is identified as the Author Accepted Manuscript it is the version after peer review but before type setting, copy editing or publisher branding. Cite as Surname, Initial. (Year) 'Title of article'. To be published in *Title of Journal*, Volume and issue numbers [peer-reviewed accepted version]. Available at: DOI or URL (Accessed: date).


Enquiries

If you have questions about this document contact ResearchSupport@kent.ac.uk. Please include the URL of the record in KAR. If you believe that your, or a third party's rights have been compromised through this document please see our Take Down policy (available from https://www.kent.ac.uk/guides/kar-the-kent-academic-repository#policies).

The role of phosphorylation in the control of Ras activity and localisation in *S. cerevisiae*

Thesis submitted to the University of Kent for the degree of PhD in Cell Biology

Elliot Piper-Brown



Declaration

No part of this thesis has been submitted in support of an application for any degree or other qualification of the University of Kent, or any other University or Institution of learning.

Elliot Piper-Brown

September 2019

Acknowledgements

Firstly, I would like to express my sincere gratitude to my supervisor Dr Campbell Gourlay for giving me the opportunity to conduct this research and for his constant support, guidance patience, and for sharing his vast wisdom in both science and life. The completion of thesis would not have been possible without the support and belief from my friends. I would like to thank Peter, Joey, Melisa, Sophie T, Zakary, and Daniel for being so wonderfully supportive and caring, I am forever in your debt.

As this research was funded by the BBSRC, I would like to thank them for their financial support which made this research possible. Many thanks to Tea pot hill and the gents from CHS. 'Floreat Domus Chathamensis'

Finally, I would like to express my deepest gratitude to my family, who have supported me throughout my life and have always been there for me, I dedicate this thesis to them.

Contents

| Acknowledgements | 3 |
|--|-------|
| List of Figures | 10 |
| List of tables | 16 |
| Abbreviations | 17 |
| Abstract | 21 |
| Chapter 1 | 23 |
| Introduction | 23 |
| 1.1 <i>S. cerevisiae</i> as a model organism | 24 |
| 1.2 The Ras superfamily | 25 |
| 1.3 The Ras protein subfamily | 27 |
| 1.4 Posttranslational modifications of Ras | 32 |
| 1.5 Ras protein trafficking | 33 |
| 1.6 Ras protein phosphorylation | 36 |
| 1.7 RAS/cAMP/PKA signalling in <i>S. cerevisiae</i> | 38 |
| 1.8 Regulation of RAS/cAMP/PKA pathway activity | 41 |
| 1.9 The GPCR System- Regulator of the cAMP/PKA pathway | 44 |
| 1.10 Processes regulated by PKA activity | 46 |
| 1.10.1 PKA modulation of ribosome biogenesis | 46 |
| 1.10.2 PKA modulation of the stress response | 46 |
| 1.10.3 Regulation of metabolism | 48 |
| 1.11 Ras and the Cell Cycle in S. cerevisiae | 48 |
| 1.12 Ras and its involvement in Cell fate in Yeast | 49 |
| 1.12.1 The involvement of the Ras/cAMP/PKA signalling network in regulating quiescence | 49 |
| 1.12.2 Ras and its role in yeast apoptosis and regulated cell death | 50 |
| 1.13 Ras signalling in the regulation of autophagy | 51 |
| 1.14 Ras in nutrient acquisition | 53 |
| 1.14.1 Di/Tri-peptide uptake mechanisms in <i>S. cerevisiae</i> | 54 |
| 1.15 Ras signalling in human cells | 57 |
| 1.16 The use of <i>S. cerevisiae</i> for the study of human Ras proteins | 59 |
| 1.17 Aims of this study | 60 |
| Chapter 2 | 64 |
| Materials and Methods | 64 |
| 2.1 Growth conditions and media for the culture of Saccharomyces Cerevisiae and Escherichia co | li 65 |
| 2.1.1 Water used in study | 65 |
| 2.1.2 Yeast extract, peptone, dextrose (YPD) growth media | 65 |

| | 2.1.3 Synthetic complete (SC) drop-out medium | 65 |
|---|---|----|
| | 2.1.4 Nitrogen Starvation Media (NS) | 66 |
| | 2.1.5 Yeast extract and Tryptone (YT) Growth Media | 66 |
| 2 | 2 Saccharomyces cerevisiae strains used in this study | 67 |
| 2 | 3 Escherichia coli strains used in this studyDH5α: | 67 |
| 2 | 4 DNA Methods | 68 |
| | 2.4.1 Plasmids used in the study | 68 |
| 2 | 5 Transformation of plasmid DNA into S. cerevisiae and Escherichia coli | 72 |
| | 2.5.1 Transformation of <i>S. cerevisiae</i> using the lithium acetate method | 72 |
| | 2.5.2 Transformation of S. cerevisiae using the lithium acetate method without heat shock | 73 |
| | 2.5.3 Transformation of <i>Escherichia coli</i> with plasmid DNA | 74 |
| 2 | 6 Escherichia coli competent cell preparation | 74 |
| 2 | 7 Molecular Biology methods | 75 |
| | 2.7.1 Plasmid DNA purification from Escherichia coli (mini prep) | 75 |
| | 2.7.2 Plasmid purification from <i>S. cerevisiae</i> | 75 |
| | 2.7.3 Yeast genomic DNA extraction | 76 |
| | 2.7.4 Whole cell RNA extraction from <i>S. cerevisiae</i> | 77 |
| | 2.7.5 Illumina library preparation and sequencing | 78 |
| | 2.7.6 Analysis of RNA-Seq data | 79 |
| | 2.7.7 Quantification of nucleic acid samples | 80 |
| | 2.7.8 Restriction enzyme digest of DNA | 80 |
| | 2.7.9 Agarose gel electrophoresis | 81 |
| | 2.7.10 Polymerase Chain Reaction (PCR) | 82 |
| | 2.7.11 Generation of yeast gene knock outs using LoxP marker cassettes | 84 |
| | 2.7.12 Invitrogen Gateway Cloning Reaction | 84 |
| | 2.7.13 BP Cloning Reaction | 85 |
| | 2.7.14 LR Cloning Reaction | 85 |
| | 2.7.15 DNA sequencing | 86 |
| 2 | 8 Biochemical Methods | 87 |
| | 2.8.1 Whole cell protein extraction for SDS PAGE | 87 |
| | 2.8.2 Polyacrylamide gel electrophoresis | 87 |
| | 2.8.3 Coomassie staining of SDS-PAGE gels | 89 |
| | 2.8.4 Semi-dry transfer of proteins to PVDF membranes | 89 |
| | 2.8.5 Immunoblotting procedure | 90 |
| | 2.8.6 ECL detection (Enhanced Chemiluminescence) | 90 |
| | 2.8.7 Stripping of PVDF membrane | 91 |

| 2.8.8 Antibodies used in study | 92 |
|--|--------|
| 2.9 Cell biology techniques | 93 |
| 2.9.1 Absorbance assays for growth rate analysis of S. cerevisiae cells | 93 |
| 2.9.2 Cell counting using a haemocytometer | 94 |
| 2.9.3 Viability assay | 94 |
| 2.9.4 Di/Tri-peptide supplementation viability assay | 95 |
| 2.9.5 Hydrogen Peroxide Sensitivity Assay | 96 |
| 2.9.6 Copper Sensitivity Assay | 96 |
| 2.9.7 GFP-ATG8 autophagy assay | 97 |
| 2.9.8 Chronological Ageing Assay | 97 |
| 2.9.9 Clonogenic Survival Assay of wild type cells overexpressing RAS2 ^{S225A} , RAS2 ^{S225E} or a control | |
| 2.9.10 Flow Cytometry | 98 |
| 2.9.11Flow cytometry to monitor DHE fluorescence to detect superoxide radicals | 99 |
| 2.9.12 Flow cytometry to detect Propidium Iodide uptake to assess necrosis | 99 |
| 2.10 Fluorescence Microscopy of yeast cells | 100 |
| 2.10.1 Fluorescence Microscopy | 100 |
| 2.10.2 Sample Preparation | 100 |
| 2.11 High Resolution Respirometry | 101 |
| Chapter 3 | 103 |
| Yeast as a model organism to study the effects of RAS2, RAS2 ^{S225A} or RAS2 ^{S225} overexpressi | on 103 |
| 3.1 Introduction | 104 |
| 3.2 Construction of the <i>RAS2</i> mutant alleles- site-directed mutagenesis substitution of the Ras2p phosphorylation site Serine ²²⁵ by Alanine or Glutamate | • |
| 3.3 Expression of RAS2, RAS2 ^{S225A} and RAS2 ^{S225E} alleles in S. cerevisiae | 107 |
| 3.4 Analysis of the effects of phosphorylation of Serine ²²⁵ upon Ras2p localisation | 111 |
| 3.4.1 Microscopic analysis of wild type cells expressing GFP-Ras2p, GFP-Ras2p ^{S225A} or GFI Ras2p ^{S225E} | |
| 3.5 Analysis of the effects of phosphorylation of Serine ²²⁵ upon the activation of Ras | 115 |
| 3.5.1 Microscopic analysis of wild type cells expressing Ras2p, Ras2p ^{S225A} , Ras2p ^{S225E} co-e with an GFP-RBD probe | • |
| 3.6 Growth analysis of yeast cells overexpressing RAS2, RAS2 ^{S225A} or RAS2 ^{S225E} | 121 |
| 3.6.1 Overexpression of RAS2 ^{S225A} or RAS2 ^{S225E} in yeast cells leads to growth defects | 122 |
| 3.6.2 Overexpression of either RAS2 ^{S225A} or RAS2 ^{S225E} in yeast cells leads to decreased cel | • |
| 3.6.3 Overexpression of RAS2 ^{S225A} or RAS2 ^{S225E} in a yeast cells leads to a sensitivity to oxid | dative |
| stress | 128 |

| 3.6.4 Overexpression of <i>RAS2</i> ^{S225A} or <i>RAS2</i> ^{S225E} in yeast cells leads to copper sensitivity |
|---|
| 3.7 Chronological ageing analysis of <i>S. cerevisiae</i> cells overexpressing <i>RAS2</i> ^{5225A} |
| 3.7.1 Overexpression of <i>RAS2</i> ^{s225A} in wild type cells reduces chronological life span |
| 3.7.2 Flow cytometry to analyse the levels of ROS in wild type cells expressing RAS2 ^{S225A} |
| 3.7.3 Flow Cytometry to analyse the levels of necrosis in wild type cells expressing RAS2 ^{5225A} 137 |
| 3.8 The overexpression of either <i>RAS2</i> ^{5225A} or <i>RAS2</i> ^{5225E} in wild type cells presents no significant abnormalities in cells ability to regulate autophagy |
| 3.9 Analysis of the effects of the overexpression of <i>RAS2</i> ^{S225A} or <i>RAS2</i> ^{S225E} upon mitochondria morphology |
| 3.9.1 Microscopic analysis of wild type cells overexpressing <i>RAS2</i> ^{S225A} , <i>RAS2</i> ^{S225E} or an empty plasmid control and co-expressed with a GFP-mitochondria probe |
| 3.10 Respirometry to assess mitochondrial function in wild type cells overexpressing <i>RAS2</i> ^{5225A} or <i>RAS2</i> ^{5225E} |
| 3.11 Sequence alignment between Ras2 and human N-Ras suggests that Serine ²²⁵ is conserved in human N-Ras at Serine ¹⁷³ |
| 3.11.1 The expression of NRAS, NRAS S173A or NRAS S173E induces growth defects in wild type cells 151 |
| 3.11.2 Expression of NRAS, NRAS S173A or NRAS S173E in yeast cells leads to a reduction in viability 153 |
| 3.12 Discussion of Results |
| Chapter 4 |
| Probing the Ras/cAMP/PKA pathway |
| 4.1 Introduction |
| 4.2 Growth analysis of the overexpression of $RAS2^{S225A}$ or $RAS2^{S225E}$ in a $\Delta pde2$ background 166 |
| 4.2.1 Over expression of $RAS2^{S225A}$ or $RAS2^{S225E}$ in a $\Delta pde2$ background leads to growth defects 166 |
| 4.2.2 The Overexpression of either $RAS2^{S225A}$ or $RAS2^{S225E}$ in a $\Delta pde2$ background leads to a further decrease in viability when compared to the overexpression of $RAS2$ mutants in wild type cells . 168 |
| 4.3 Growth analysis of wild type cells co-expressing PDE2 and the RAS2 mutant alleles 170 |
| 4.3.1 The co-expression of <i>PDE2</i> in wild type cells overexpressing <i>RAS2</i> ^{S225E} rescues growth defects |
| 4.3.2 The expression of <i>PDE2</i> in wild type cells overexpressing <i>RAS2</i> ^{S225A} or <i>RAS2</i> ^{S225E} rescues viability |
| 4.4 Growth analysis of the effects of the deletion of <i>TPK1</i> , <i>TPK2</i> or <i>TPK3</i> on wild type cells overexpressing <i>RAS2</i> ^{S225A} or <i>RAS2</i> ^{S225E} |
| 4.4.1 Deletion of <i>TPK2 or TPK3</i> reduces growth defects in cells overexpressing <i>RAS2</i> ^{S225A} or <i>RAS2</i> ^{S225E} |
| 4.4.2 Analysis of viability in $\Delta tpk1$, $\Delta tpk2$ or $\Delta tpk3$ cells overexpressing $RAS2^{S225A}$ or $RAS2^{S225E}$ 179 |
| 4.5 Growth analysis of the double deletion of tpk1/tpk2, tpk3/tpk2 or tpk1/tpk3 on wild type cells overexpressing RAS2 mutant alleles |
| 4.5.1 Overexpression of <i>RAS2</i> mutant alleles in tpk <i>1-3</i> double deletion backgrounds leads to no rescue of growth defects |

| 4.5.2 Analysis of viability in cells overexpressing RAS2 ^{S225A} or RAS2 ^{S225E} in a Δtpk1/ Δtpk2, Δtpk1, Δtpk3 or Δtpk1/ Δtpk3 background | |
|--|-----|
| 4.6 Microscopic analysis of GFP-Tpk1p, GFP-Tpk2p or GFP-Tpk3p cells overexpressing RAS2 ^{S225A} , | |
| RAS2 ^{S225E} or an empty plasmid control | |
| 4.7 Discussion | |
| Chapter 5 | 203 |
| The role of nutrient availability in the growth of <i>Ras2</i> ²²⁵ mutant strains | 203 |
| 5.1 Introduction | 204 |
| 5.2 Growth on nutrient rich media rescues viability in wild type cells overexpressing RAS2 ^{S225A} or RAS2 ^{S225E} | 208 |
| 5.3 Determination of the component of YPD that allows <i>RAS2</i> ^{S225A} or <i>RAS2</i> ^{S225E} to escape growth cessation | 209 |
| 5.3.1 Supplementation of Yeast Extract to minimal media rescues viability in wild type cells expressing <i>RAS2</i> ^{S225A} or <i>RAS2</i> ^{S225E} | 209 |
| 5.3.2 Increasing the glucose concentration in the growth media does not rescue viability in wild type cells overexpressing RAS2 ^{5225A} or RAS2 ^{5225E} | |
| 5.3.3 Supplementation of Peptone to minimal media increases viability of wild type cells overexpressing <i>RAS2</i> ^{S225A} or <i>RAS2</i> ^{S225E} | 212 |
| 5.4 Supplementation of Peptone to minimal media increases chronological life span of wild type overexpressing RAS2 ^{S225A} | |
| 5.5 Supplementation of peptone to minimal media protects cells from necrosis | 216 |
| 5.6 Supplementation of peptone to minimal media retards ROS accumulation in cells | 217 |
| 5.7 Supplementation of Peptone to minimal media protects cells from oxidative stress | 219 |
| 5.8 Leucine supplementation does not rescue viability in wild type cells overexpressing RAS2 ^{S225A} RAS2 ^{S225E} | |
| 5.9 Deletion of the di/tri-peptide transporter <i>PTR2</i> does not further attenuate viability in wild typ cells overexpressing <i>RAS2</i> ^{S225A} or <i>RAS2</i> ^{S225E} mutant alleles | |
| 5.10 Deletion of <i>CUP9</i> in wild type cells overexpressing <i>RAS2</i> ^{S225A} or <i>RAS2</i> ^{S225E} rescues growth defe | |
| 5.11 Deletion of CUP9 in wild type cells expressing RAS2 mutant alleles rescues viability | 228 |
| 5.12 Deletion of <i>UBR1</i> does not further attenuate viability in wild type cells overexpressing <i>RAS2</i> ^s or <i>RAS2</i> ^{s225E} | |
| 5.13 The effects of di-peptide supplementation on the viability of wild type cells overexpressing to RAS2 mutant alleles | |
| 5.14 Discussion | 234 |
| Transcriptome analysis of <i>RAS2</i> ^{S225A} or RAS2 ^{S225E} overexpressing cells | 238 |
| 6.1 Introduction | |
| 6.2 Illumina library preparation and RNA sequencing | |
| 6.3 Quality control analysis of RNA-Seg reads | |

| 6.4 FastQC output | 41 |
|---|----|
| 6.4.1 Basic Statistics24 | 41 |
| 6.4.2 Phred Score | 42 |
| 6.4.3 N content | 43 |
| 6.4.4 Adapter Content | 44 |
| 6.5 Principle Component Analysis | 45 |
| 6.6 Analysis of RNA-Seq reads using the Galaxy online platform | 46 |
| 6.7. GSEA analysis of cellular processes differentially regulated by the overexpression of <i>RAS2</i> ^{5225A} | 48 |
| 6.7. GSEA analysis of cellular processes differentially regulated by the overexpression of RAS2 ^{S225E} 25 | 50 |
| 6.8 Further analysis of the gene sets enriched upon overexpression of RAS2 ^{S225A} in wild type cells 25 | 52 |
| 6.9 Further analysis of the gene sets enriched upon overexpression of RAS2 ^{S225E} in wild type cells 25 | 55 |
| 6.10 Discussion | 58 |
| Chapter 7 | 51 |
| Final Discussion | 51 |
| 7.1 Modification of the Ser ²²⁵ residue of Ras2p is important for localisation, activity, and function of Ras proteins | |
| 7.2 Overexpression of <i>RAS2</i> ^{S225A} or <i>RAS2</i> ^{S225E} results in aberrant Ras/cAMP/PKA signalling and entry into state of reduced growth | |
| 7.3 Genome-wide transcriptome analysis of wild type cells overexpressing RAS2 ^{5225A} or RAS2 ^{5225E} . 26 | 65 |
| 7.4 Sequence alignment between Ras2 and human N-Ras suggests that Serine ²²⁵ is conserved in human N-Ras at Serine ^{S173} | 67 |
| 7.5 Targeting Ras membrane interaction as an anti-Ras cancer therapy | 58 |
| 7.6 Conclusions and future investigations 27 | 72 |
| References | 76 |
| Appendix29 | 96 |
| | |

List of Figures

| Figure 1. Ras protein cycling between active and inactive states through the action of GEF and GAP protein | ıs. 29 |
|---|------------------|
| Figure 2. A 3D representation of the crystal structure of the human Ras protein in its GDP-bound conformation | ition. |
| Figure 3. The human Ras protein hypervariable region (HVR). | |
| Figure 4. Posttranslational modifications play an important role in dictating sub-cellular Ras trafficking an | |
| localisation. | |
| Figure 5. The activation of Ras1 and Ras2 is dependent on nutrient availability. | |
| Figure 6. Positive and negative feedback in the Ras/cAMP/PKA pathway. | 43 |
| Figure 7. Mechanisms of how glucose and intracellular acidification modulate adenylate cyclase activity | 45 |
| Figure 8. The protein kinase PKA, switches on or off the activities and signals transmitted through the Sch | and a |
| TOR pathways | 47 |
| Figure 9. A schematic illustrating the two predominant types of autophagy in yeast – macroautophagy and | |
| microautophagy. | 52 |
| Figure 10. Schematic representation of the multiple effectors activated by human Ras proteins and the | |
| different impact these interactions have on cell fate | 59 |
| Figure 11. A schematic of the Ras2 protein sequence indicating the location of the phosphorylated serine | |
| residues. | 62 |
| Figure 12. Maps of the plasmids used in the Gateway cloning reaction. | 72 |
| Figure 13. Sequence alignment of the yeast Ras2 and Ras1. | _ 105 |
| Figure 14. A western blot showing the detection of Ras2p in cells overexpressing RAS2, RAS2 ^{S225A} , RAS2 ^{S225A} | ^E or |
| an empty plasmid control in a wild type background | _ 108 |
| Figure 15. A bar chart representing the change in Ras2p band intensity relative to the Pgkp loading control | l of |
| wild type cells overexpressing RAS2, RAS2 ^{S225A} , RAS2 ^{S225E} or empty plasmid control | _ 109 |
| Figure 16. A western blot showing the detection of Ras2p in cells over expressing RAS2, RAS2 ^{5225A} , RAS2 ^{5225A} | ^{SE} or |
| an empty plasmid control in a wild type background | _ 109 |
| Figure 17. A bar chart representing the change in Ras2p band intensity relative to the Pgkp loading contro | l of |
| wild type cells overexpressing RAS2, RAS2 ^{S225A} , RAS2 ^{S225E} or an empty plasmid control | _ 110 |
| Figure 18. A western blot showing the detection of Ras2p in Δ ras2 cells over expressing RAS2, RAS2 ^{5225A} , | |
| RAS2 ^{S225E} or an empty plasmid control. | _ 110 |
| Figure 19. A bar chart representing the change in Ras2p band intensity relative to the Pgkp loading contro | l of |
| Δ ras2 cells overexpressing RAS2, RAS2 ^{S225A} , RAS2 ^{S225E} or an empty plasmid control | _ 111 |
| Figure 20. Images taken by fluorescent microscopy of wild type cells overexpressing either GFP-RAS2, GFP- | - |
| RAS2 ^{S225A} or GFP-RAS2 ^{S225E} during logarithmic and stationary phase of cell growth | _ 113 |
| Figure 21. Graphical representation of the localisation of GFP-Ras2p in wild type cells expressing either GF | P- |
| RAS2, GFP-RAS2 ^{S225A} or GFP-RAS2 ^{S225E} during logarithmic phase of cell growth. | _ 114 |

| Figure 22. Graphical representation of the localisation of GFP-Ras2p in wild type cells expressing either GFP |)_ |
|---|------------------|
| RAS2, GFP-RAS2 ^{S225A} or GFP-RAS2 ^{S225E} during stationary phase of cell growth | 115 |
| Figure 23. Fluorescence microscopy images of wild type strains overexpressing RAS2, RAS2 ^{S225A} , RAS2 ^{S225E} of | r an |
| empty plasmid backbone control using a GFP-RBD probe during logarithmic and stationary phase of growth | 1. |
| | 118 |
| Figure 24. Graphical representation of the localisation of active-Ras in wild type cells expressing either RAS. | 2, |
| RAS2 ^{S225A} , RAS2 ^{S225E} or an empty plasmid control during logarithmic phase of cell growth. Cells were culture | d in |
| SD -URA/-LEU growth media | 119 |
| Figure 25. Graphical representation of the localisation of active-RAS in wild type cells expressing either RAS | 2, |
| RAS2 ^{S225A} , RAS2 ^{S225E} or an empty plasmid control during stationary phase of cell growth. | 120 |
| Figure 26. A diagram depicting the growth phases of S. cerevisiae cultivated in rich medium supplemented | with |
| glucose | 121 |
| Figure 27. Growth analysis of S. cerevisiae wild type cells overexpressing RAS2, RAS2 ^{S225A} , RAS2 ^{S225E} or empt | :y |
| plasmid control. | 123 |
| Figure 28. Growth rate analysis of S. cerevisiae wild type cells overexpressing RAS2 or RAS2 5225A or RAS2 5225A | ^E 124 |
| Figure 29. Growth rate analysis of a S. cerevisiae Δ ras2 strain overexpressing RAS2, RAS2 ^{S225A} , RAS2 ^{S225E} or α | an |
| empty plasmid control | 125 |
| Figure 30. Growth rate analysis of S. cerevisiae Δ ras2 cells overexpressing RAS2, RAS2 ^{S225A} , RAS2 ^{S225E} or an | |
| empty plasmid control | 126 |
| Figure 31. A colony forming efficiency assay of S. cerevisiae wild type or $\Delta ras2$ cells overexpressing RAS2, | |
| RAS2 ^{S225A} , RAS2 ^{S225E} or an empty plasmid control grown in SD –URA media | 128 |
| Figure 32. Spotting assay of wild type cells overexpressing RAS2, RAS2 ^{5225A,} RAS2 ^{5225E} or an empty plasmid | |
| control. | 129 |
| Figure 33. Growth analysis of S. cerevisiae wild type cells overexpressing RAS2, RAS2 ^{S225A} , RAS2 ^{S225E} or an er | npty |
| plasmid control | 130 |
| Figure 34. Growth rate analysis of wild type cells overexpressing RAS2, RAS2 ^{S225A} , RAS2 ^{S225E} or an empty | |
| plasmid control. | 131 |
| Figure 35. Spotting assay of wild type cells overexpressing RAS2, RAS2 ^{S225A,} RAS2 ^{S225E} or an empty plasmid | |
| control. | 132 |
| Figure 36. A chronological ageing assay of wild type cells over expressing RAS2 ^{5225A} or an empty plasmid con | ntrol |
| grown in SD –URA. | 134 |
| Figure 37. A bar chart presenting the percentage of DHE positive cells in wild type cells overexpressing | |
| RAS2 ^{S225A} or an empty plasmid control | 136 |
| $\textbf{\textit{Figure 38.}} \ \textit{A bar chart presenting the percentage of PI positive cells in wild type cells overexpressing RAS252 and 1.00×10^{52} are the percentage of PI positive cells in wild type cells overexpressing the percentage of PI positive cells in wild type cells overexpressing the percentage of PI positive cells in wild type cells overexpressing the percentage of PI positive cells in wild type cells overexpressing the percentage of PI positive cells in wild type cells overexpressing the percentage of PI positive cells in wild type cells overexpressing the percentage of PI positive cells in wild type cells overexpressing the percentage of PI positive cells in wild type cells overexpressing the percentage of PI positive cells in wild type cells overexpressing the percentage of PI positive cells in wild type cells overexpressing the percentage of PI positive cells in the percentage of PI po$ | 25A |
| or an empty plasmid control | 138 |
| Figure 39. A western blot showing the detection of GFP in GFP-ATG8 cells overexpressing RAS2, RAS2 ^{S225A} , | |
| RAS2 ^{S225E} or an empty plasmid control | 141 |

| Figure 40. Images taken using fluorescence microscopy of wild type strains overexpressing RAS2 ^{5223A} , RAS2 ^{5223A} |
|--|
| or an empty plasmid control co-expressed with a GFP-mitochondria probe during stationary phase of growth. |
| |
| Figure 41. A typical respirometry profile generated from the Oroboros oxygraph-2k145 |
| Figure 42. A bar chart showing the routine, leak, ETS and NMT O2 flux values for wild type cells overexpressing |
| RAS2 ^{S225A} , RAS2 ^{S225E} or an empty plasmid backbone control |
| Figure 43. The oxygen flux ratios between the Routine and ETS (R/E) and the Leak and ETS (L/E) are shown for |
| wild type cells overexpressing RAS2 ^{S225A} , RAS2 ^{S225E} or an empty plasmid backbone control149 |
| Figure 44. Sequence alignment of the Ras2 protein and human N-Ras shows that Serine ²²⁵ of Ras2p (circled) is |
| conserved in N-Ras at Serine ¹⁷³ 151 |
| Figure 45. Growth analysis of S. cerevisiae wild type cells overexpressing RAS2, RAS2 ^{S225A} , RAS2 ^{S225E} or empty plasmid control |
| Figure 46. Growth rate analysis of S. cerevisiae wild type cells overexpressing RAS2 or RAS2 ^{5225A} or RAS2 ^{5225E} . |
| |
| Figure 47. A colony forming efficiency assay of S. cerevisiae wild type cells overexpressing NRAS, NRAS ^{S173A} , |
| NRAS ^{S173E} or an empty plasmid control grown in SD –URA media |
| Figure 48. Growth analysis of cells overexpressing RAS2 ^{S225A} , RAS2 ^{S225E} or empty plasmid control in $\Delta pde2$ |
| background167 |
| Figure 49. Growth rate analysis of cells overexpressing RAS2 ^{S225A} , RAS2 ^{S225E} or an empty plasmid backbone |
| control in Δpde2 background168 |
| Figure 50. A colony forming efficiency assay of S. cerevisiae wild type and $\Delta pde2$ cells overexpressing RAS2 ^{S225A} , |
| RAS2 ^{S225E} or an empty plasmid control, grown in SD –URA |
| Figure 51. Growth analysis of wild type cells co-expressing PDE2 with either RAS2 ^{S225A} , RAS2 ^{S225E} or empty |
| plasmid control 172 |
| Figure 52. Growth rate analysis of wild type cells overexpressing RAS2 ^{S225A} , RAS2 ^{S225E} or an empty plasmid |
| backbone co-expressed with PDE2 |
| Figure 53. A colony forming efficiency assay of wild type cells overexpressing RAS2 ^{S225A} , RAS2 ^{S225E} or an empty |
| plasmid backbone co-expressed with PDE2 |
| Figure 54. Growth analysis of cells overexpressing RAS2 ^{S225A} , RAS2 ^{S225E} or empty plasmid control in Δ tpk1 (A), |
| Δtpk2 (B) or Δtpk3 (C) 177 |
| Figure 55. Growth rate analysis of wild type cells overexpressing RAS2 ^{S225A} , RAS2 ^{S225E} or an empty plasmid |
| backbone in Δ tpk1 (A), Δ tpke2 (B) or Δ tpk3 background (C). |
| Figure 56. A colony forming efficiency assay of S. cerevisiae wild type, $Δ$ tpk1 (A), $Δ$ tpk2 (B) or $Δ$ tpk3 (C) cells |
| overexpressing RAS2 ^{S225A} , RAS2 ^{S225E} or an empty plasmid control, grown in SD –URA182 |
| Figure 57. Growth analysis of cells overexpressing RAS2 ^{S225A} , RAS2 ^{S225E} or empty plasmid control in a Δ tpk1/ |
| Δtpk2 (A), Δtpk1/ Δtpk3 (B) or Δtpk1/ Δtpk3 (C) |
| Figure 58. Growth rate analysis of yeast cells overexpressing RAS2 ^{S225A} , RAS2 ^{S225E} or an empty plasmid |
| backbone in a Δ tpk1/ Δ tpk2 (A), Δ tpk1/ Δ tpk3 (B) or Δ tpk1/ Δ tpk3 (C) background185 |

| Figure 59. A colony forming efficiency assay of wild type, Δ tpk1/ Δ tpk2 (A), Δ tpk1/ Δ tpk3 (B) or Δ tpk3/ Δ tpl | λ2 |
|---|--------------------|
| (C) cells overexpressing RAS2 ^{S225A} , RAS2 ^{S225E} or an empty plasmid control, grown in SD –URA. | 188 |
| Figure 60. Images taken by fluorescent microscopy of GFP-Tpk1p cells overexpressing either RAS2 ^{S225A} , | |
| RAS2 ^{S225E} or an empty plasmid vector control during exponential and stationary phase of cell growth | 191 |
| Figure 61. Graphical representation of the localisation of GFP-Tpk1p in cells expressing either RAS2 ^{S225A,} | |
| RAS2 ^{S225E} or an empty plasmid control during the logarithmic (A) or stationary (B) phase of cell growth | 192 |
| Figure 62. Images taken by fluorescent microscopy of GFP-Tpk2p cells overexpressing either RAS2 ^{S225A} , | |
| RAS2 ^{S225E} or an empty plasmid vector control during exponential and stationary phase of cell growth | 194 |
| Figure 63. Graphical representation of the localisation of GFP-Tpk2p in cells expressing either RAS2 ^{S225A,} | |
| RAS2 ^{S225E} or an empty plasmid control during the logarithmic (A) or stationary (B) phase of cell growth | 195 |
| Figure 64. Images taken by fluorescent microscopy of GFP-Tpk3p cells overexpressing either RAS2 ^{S225A} , | |
| RAS2 ^{S225E} or an empty plasmid vector control during exponential and stationary phase of cell growth | 197 |
| Figure 65. Graphical representation of the localisation of GFP-Tpk3p in cells expressing either RAS2 ^{S225A,} | |
| RAS2 ^{S225E} or an empty plasmid control during the logarithmic (A) or stationary (B) phase of cell growth | 198 |
| Figure 66. A schematic demonstrating how the miss localisation of Ras $2p^{5225}$ to the nuclear envelope effect | :s |
| PKA activity | 202 |
| Figure 67. A colony forming efficiency assay of S. cerevisiae wild type cells overexpressing RAS2 ^{S225A} , RAS2 ^S | ^{225E} or |
| an empty plasmid control grown in SD —URA media and plated on either SD-URA or YPD | 209 |
| Figure 68. A colony forming efficiency assay of S. cerevisiae wild type cells overexpressing RAS2 ^{S225A} , RAS2 ^S | ^{225E} or |
| an empty plasmid control grown in SD –URA media and plated on either SD-URA or SD-URA + Yeast Extract | . 210 |
| Figure 69. A colony forming efficiency assay of S. cerevisiae wild type cells overexpressing RAS2 S225A , RAS2 S | ^{225E} or |
| an empty plasmid control grown in SD –URA media and plated on either SD-URA (2 % glucose) or SD-URA (| 4 % |
| glucose). | 212 |
| Figure 70. A colony forming efficiency assay of S. cerevisiae wild type cells overexpressing RAS2 ^{S225A} , RAS2 ^S | ^{225E} or |
| an empty plasmid control grown in SD —URA media and plated on either SD-URA or SD-URA + Peptone | 213 |
| Figure 71. A chronological ageing assay of wild type cells over expressing RAS2 ^{S225A} or an empty plasmid co | ntrol |
| grown in SD –URA and plated on SD-URA or grown in SD-URA + Peptone and plated on SD-URA + Peptone. | 215 |
| Figure 72. A bar chart presenting the percentage of PI positive cells in wild type cells overexpressing RAS2 ^{s.} | ?25A |
| or an empty plasmid control grown in -URA (A) or -URA + Peptone (B) | 217 |
| Figure 73. A bar chart presenting the percentage of DHE positive cells in wild type cells overexpressing | |
| RAS2 ^{S225A} or an empty plasmid control grown in -URA (A) or -URA + Peptone (B) | 219 |
| Figure 74. Spotting assay of wild type cells overexpressing RAS2, RAS2 ^{S225A,} RAS2 ^{S225E} or an empty plasmid | |
| control grown on -URA (A) or -URA + Peptone (B) in the presence of hydrogen peroxide | 221 |
| Figure 75. A colony forming efficiency assay of S. cerevisiae wild type cells overexpressing RAS2 ^{S225A} , RAS2 ^S | ^{225E} or |
| an empty plasmid control grown in SD –URA media and plated on either SD-URA or SD-URA + 150 μg/ml οϳ | £ |
| leucine | 223 |
| Figure 76 . A colony forming efficiency assay of S. cerevisiae wild type or Δ ptr2 cells overexpressing RAS2 ^{S22} | 5A |
| RAS2 ^{S225E} or an empty plasmid control grown in SD –LIRA media | 225 |

| Figure 77. Growth analysis of S. cerevisiae wild type and Δ cup9 cells overexpressing RAS2 ^{S225A} , RAS2 ^{S225E} or |
|--|
| empty plasmid control |
| Figure 78. Growth rate analysis of S. cerevisiae wild type or Δ cup9 cells overexpressing RAS2 ^{S225A} , RAS2 ^{S225E} or |
| an empty plasmid control |
| Figure 79. A colony forming efficiency assay of S. cerevisiae wild type or Δ cup9 cells overexpressing RAS2 ^{S225A} , |
| RAS2 ^{S225E} or an empty plasmid control grown in SD –URA media |
| Figure 80. A colony forming efficiency assay of S. cerevisiae wild type or Δ ubr1 cells overexpressing RAS2 ^{S225A} , |
| RAS2 ^{S225E} or an empty plasmid control grown in SD –URA media230 |
| Figure 81. A colony forming efficiency assay of S. cerevisiae wild type cells overexpressing RAS2 ^{S225A} or an |
| empty plasmid control grown in SD –URA media and plated on SD-URA supplemented with a di-peptide at a 1 |
| mM concentration 232 |
| Figure 82. A colony forming efficiency assay of S. cerevisiae wild type cells overexpressing RAS2 ^{S225A} or an |
| empty plasmid control grown in SD –URA media and plated on SD-URA supplemented with the di-peptides; |
| Leucine-Leucine, Alaline-Leucine, Tyrosine-Alaline and Histadine-Leucine at a 1 mM concentration 234 |
| Figure 83. The average Phred score for each base across the length of the sequencing read 243 |
| Figure 84. N content across all bases within the reads from RNA isolated from wild type cells overexpressing |
| RAS2 ^{S225A} (Sample 1) |
| Figure 85. Adaptor content across bases within the reads of RNA isolated from wild type cells overexpressing |
| RAS2 ^{S225A} (sample 1) |
| Figure 86. Principle component analysis of the RNA-Seq data obtained from wild type cells overexpressing |
| RAS2 ^{S225A} , RAS2 ^{S225E} or an empty plasmid control246 |
| Figure 87. Global gene expression changes in wild type cells overexpressing RAS2 5225A when compared to a wild |
| type control249 |
| Figure 88. Global gene expression changes in wild type cells overexpressing RAS2 ^{5225E} when compared to a wild |
| type control 251 |
| Figure 89. Gene sets shown to be upregulated upon the overexpression of RAS2 ^{5225A} when compared to the wild |
| type control. Cytoplasmic translation (A), cytosolic ribosomes (B), ribosome biogenesis (6), translation |
| elongation (D) , preribosome (E) and ribosome assembly (F)253 |
| Figure 90. Gene sets shown to be upregulated upon the overexpression of RAS2 ^{S225A} when compared to the wild |
| type control. Chromosome condensation (A), kinetochore and microtububle based processes (B), sister |
| chromatid segregation (C) , the regulation of mitotic-metaphase-anaphase transition (D) , U2 Type splicesomal |
| complex (E) and microtubule based processes (F)254 |
| Figure 91. Gene sets shown to be upregulated upon the overexpression of RAS2 ^{S225E} when compared to the wild |
| type control. Cytoplasmic translation (A), cytosolic ribosomes (B), preribosome (C), ribosome biogenesis (D), |
| translation elongation (E) , and ribosome assembly (F)256 |
| Figure 92. Gene sets shown to be downregulated upon the overexpression of RAS2 ^{S225E} when compared to the |
| wild type control. Chromosome segregation (A) , chromosome condensation (B) , organelle fission (C) , sister |
| chromatid segregation (D) nuclear division (F) and microtubule based processes (D) 257 |

| Figure 93. Sequence alignment of the Ras2 protein and human N-Ras shows that Serine ²²⁵ of Ras2p (circled) | is |
|---|-----|
| conserved in N-Ras at Serine ¹⁷³ | 268 |
| Figure 94. A graphical representation of the location and frequency of mutations surrounding the Ser ¹⁷³ of | |
| NRAS | 272 |

List of tables

| Table 1. Phosphatase and kinase enzymes predicted by the PhosphoPep database to effe | ct |
|---|----------------|
| Ras2p phosphorylation | . 61 |
| Table 2. Percentage of auxotrophic selection drop-out supplement added to media | . 66 |
| Table 3. The Saccharomyces cerevisiae strains used in this study | 67 |
| Table 4. Plasmids used in the study | 68 |
| Table 5. Yeast transformation reagents for the heat sensitive transformation protocol | 73 |
| Table 6. The basic reaction mixture for a restriction digest used in this study | 81 |
| Table 7. Standard PCR reaction composition used in this study | <i>83</i> |
| Table 8. Standard 3-step PCR cycling protocol used in this study | <i>83</i> |
| Table 9. LR Cloning reaction | 86 |
| Table 10. SDS-Page reagents | 88 |
| Table 11. Recipes for ECL solutions | 91 |
| Table 12. The protocol setting used to measure growth rate |) 3 |
| Table 13. Basic statistics output from FastQC analysis of the RNA sequencing reads | |
| aenerated from RNA isolated from wild type cells overexpressina RAS2S225A | 42 |

Abbreviations

| Aa | Amino acid |
|---------|--|
| ADP | Adenosine diphosphate |
| Amp | Ampicillin |
| AntA | Antimycin A |
| APS | Ammonium persulfate |
| АТР | Adenosine triphosphate |
| ATPase | Protein that hydrolyses adenosine triphosphate |
| Вр | Base pairs |
| cAMP | Cyclic adenosine monophosphate |
| CWG | Campbell Wallace Gourlay |
| Da | Dalton |
| dH₂0 | Deionised water |
| DMSO | Dimethyl sulphoxide |
| DNA | Deoxyribonucleic acid |
| dNTP | Deoxyribonucleotide triphosphate |
| E. coli | Escherichia coli |
| ECL | Enhanced chemiluminescence |
| EDTA | Ethylenediaminetetraacetic acid |
| ER | Endoplasmic reticulum |
| Et al | Et allia (and others) |
| Etbr | Ethidium bromide |


| ETC | Electron transport chain |
|--------|--|
| ETS | Electron transport system |
| FACS | Fluorescence-activated cell sorting |
| FCCP | carbonyl cyanide p-trifluoromethoxy phenylhydrazone |
| GDP | Guanosine diphosphate |
| GEF | Guanosine exchange factor |
| GFP | Green fluorescent protein |
| GO | Gene ontology |
| GPCR | G-protein coupled receptor |
| GTF | General transcription complex |
| GTP | Guanosine triphosphate |
| IMS | Intermembrane space of mitochondria |
| kDa | Kilo Dalton |
| Кg | Kilogram |
| LB | Lysogeny broth |
| Leu | Leucine |
| LiAc | Lithium acetate |
| M | Molar |
| МАРК | Mitogen activated protein kinase |
| МАРКК | Mitogen activated protein kinase kinase |
| МАРККК | Mitogen activated protein kinase kinase kinase |
| mRNA | Messenger RNA |
| mQ | Milli-Q |

| NADH | Nicotinamide adenine dinucleotide |
|-------------------|------------------------------------|
| OD ₆₀₀ | Optical density measured at 600 nm |
| ORF | Open reading frame |
| PBS | Phosphate buffered saline |
| PCR | Polymerase chain reaction |
| PEG | Polyethylene glycol |
| Рер | Peptone |
| Pi | Inorganic phosphate |
| PI | Propidium iodide |
| PDS | Post-diauxic shift |
| РКА | Protein Kinase A |
| PVDF | Polyvinylidene fluoride |
| PTM | Post-translational modification |
| RFP | Red-fluorescent protein |
| RNA | Ribose nucleic acid |
| RNA-Seq | Ribose nucleic acid sequencing |
| ROS | Reactive oxygen species |
| RPM | Revolutions per minute |
| S. cerevisiae | Saccharomyces cerevisiae |
| SD | Synthetic Dropout |
| SDS | Sodium dodecyl sulphate |
| STRE | Stress response elements |

| TE | Tris EDTA |
|-------|--|
| TEMED | N, N, N', N'-Tetramethyl ethylenediamine |
| TF | Transcription factor |
| TOR | Target of rapamycin |
| Tris | Tris(hydroxymethyl)aminomethane |
| U | Units |
| URA | Uracil |
| UTR | Untranslated region |
| UV | Ultraviolet |
| V | Volts |
| WT | Wild type |
| YPD | Yeast extract dextrose |
| YT | Yeast extract tryptone |
| μ | Micron |
| μg | Microgram (10 ⁻⁶ gram) |
| μΙ | Microliter (10 ⁻⁶ litre) |

Abstract

Ras proteins are small GTPases that act as molecular switches within cells that link extracellular stimuli to intracellular effectors. Ras proteins play a conserved role in the control of both cell growth and proliferation. As a result, mutations that induce the constitutive activation of Ras proteins are often associated with changes in cell behaviour that can lead to disease, such as human cancer. The localisation of Ras is crucial for its function and this is controlled by post-translational modifications. However, the roles for such modifications in regulating Ras localisation and its activity are poorly understood. We have identified that the phosphorylation of Serine²²⁵ of Ras2, a protein that is essential for the control of both growth and proliferation in S. cerevisiae, plays an important role in the regulation of its localisation and activity. Modification of this residue leads to changes in the distribution of GTP-bound Ras2 within the cell. This drives cells towards a novel state of growth cessation that is dependent upon the activity of the cAMP/PKA signalling pathway. We show that this quiescent state is characterised by an uncoupling of cytoplasmic and nuclear process that govern cell growth and division. We suggest that cells can escape growth arrest and re-engage in the cell cycle if the Ras/cAMP/PKA pathway activity is reduced, additional nutritional supplementation is provided or if nutrient uptake processes are elevated. Thus, the Serine²²⁵ reside plays an important role in the control of Ras2 localisation and activity that allows the cell to co-ordinate nutritional availability with growth and cell division. My thesis highlights that post-translational modifications in regions outside of the highly conserved Ras GTPase domain may be targeted to change cell fate, for example by switching a pro-growth signalling programme to one that drives a growth cessation. This has implications for the development of novel therapeutic approaches for cancers driven by oncogenic Ras proteins.



A word cloud generated from the contents of this thesis.

Chapter 1 Introduction

1.1 S. cerevisiae as a model organism

The exploitation of eukaryotic organisms as biological models has been fundamental for biological discovery. Model organisms such as yeast, nematodes and flies can be utilized to rapidly elucidate the function of genes and their role in cellular pathways, processes, and compartments. Enhancing the understanding of how genes function is crucial if we are to understand basic cell biology and why mutation can lead to dysfunction that underlies disease.

Saccharomyces cerevisiae (S. cerevisiae) is a single-celled eukaryote and therefore shares the cellular structure and organisation of higher eukaryote cells. Coupled with the relative simplicity of genetic manipulation, short-doubling time and broad range of molecular tools and resources available, S. cerevisiae is regarded as an important model organism [1][2]. In 1996, S. cerevisiae became the first eukaryote to have its complete genome sequenced and published [2]. A wide range of genetic and molecular tools have been developed to facilitate research using S. cerevisiae. For instance, a collection of yeast strains comprising deletions of non-essential open reading frames (ORF) was generated and made accessible [3][4]. Furthermore, other collections exist with genome-wide coverage such as a collection comprising of GFP-fused chimera proteins that aid in the visualisation of endogenous yeast proteins [5][6]. Supporting these resources is a freely accessible online database; 'The Saccharomyces genome database (SGD)" which provides key biological information on S. cerevisiae along with research and analytical tools to enable investigations on the relationship between gene sequence and gene function (www.yeastgenome.org/).

The available resources have enabled the roles of almost 85 % of the 5800 protein-coding genes of *S. cerevisiae* to be determined. Such annotation, coupled with the advantages of the system as a whole offers an important resource, for example it has been shown that ~ 17 % of yeast genes exist as members of orthologous gene families associated with human diseases [7]. The expression of human proteins in yeast cells can also be instrumental for the discovery of chemical or protein inhibitors of their activity using high throughput screening methods [8]. Such assays are based on the principle that demonstrable functions of human proteins may be manipulated by chemical compounds or further genetic manipulation [9][10]. As such research conducted on *S. cerevisiae* has been instrumental in uncovering the role of many proteins in higher eukaryotes, including humans [9]. A good example lies in the study of small GTPase proteins of the Ras superfamily

1.2 The Ras superfamily

The Ras superfamily comprises of small Guanosine Triphosphate Hydrolases (GTPases), which range from 20 to 40 kDa in size. The Ras superfamily includes over 150 members in humans with evolutionary conserved orthologues present in several organisms including *Drosophila melanogaster*, *Caenorhabditis elegans* and *S. cerevisiae*. The superfamily is divided into five main branches based on sequence and functional similarities; Ras, Rho, Arf/Sar, Rab and Ran [11]. While similar to the heterotrimeric G protein α subunits in biochemistry and function, Ras family proteins act as monomeric G proteins, functioning as molecular control switches [12]. Post-translational modifications and structural differences dictate their subcellular localisation and the proteins that serve as their regulators enable GTPases to function as efficient modulators of complex cellular processes.

Rab family proteins make up the largest branch of the Ras superfamily with 61 members currently identified [13]. Rab proteins are associated with membrane organisation due to their regulatory role in intracellular vesicular transport between organelles in both the endocytic and secretory pathway [14]. The second branch of the superfamily comprises of the ADP-ribosylation factor (Arf) family proteins and like Rab proteins, have been implicated in the regulation of vesicular transport [13][14]. The regulation of Arf GDP/GTP cycling is controlled by distinct GEF's and GAP's [15].

Rho proteins form the third branch of the superfamily with twenty known Rho proteins identified with RhoA, Rac1 and cdc42 being the most studied. Rho proteins function as vital regulators of extracellular-stimulus-mediated signalling networks which regulate gene expression, cell cycle progression and actin organization [16]. Moreover, Rho GTPases are also involved in cell polarity, cell shape and cell-matrix interactions [17].

The fourth branch encompassing the most abundant small GTPase in the cell, is the Ras-like nuclear (Ran) protein. Ran is best characterised for its role in nucleocytoplasmic transport of RNA and proteins [18]. Unlike other small GTPases, Ran activity is dependent on a spatial gradient of the GTP-bound form of Ran. A single human Ran protein is regulated by a Ranspecific nuclear GEF and cytoplasmic GAP. The resulting effect is a high concentration of RanGTP in the nucleus, facilitating the directionality of nuclear import and export within cells [19].

1.3 The Ras protein subfamily

The final branch of the Ras superfamily and the focus for this study are the Ras proteins. The activation of Ras proteins, as with all G proteins, is dependent on the exchange of bound GDP for GTP and is deactivated through the hydrolysis of GTP to GDP [20] (Figure 1). Ras proteins function as intracellular signalling molecules transforming extracellular stimuli into intracellular responses at a given target via the utilization of complex intracellular signalling pathways.

All Ras proteins share a conserved G-domain, the functional domain that binds to GTP/GDP, therefor it is not surprising that all Ras proteins present a common mechanism of action. Ras proteins function as binary molecules switching between an inactive GPD-bound state and an active GTP-bound state. The activation of Ras proteins leads to subsequent activation of signalling cascades which differ depending on the organism and specific Ras protein activated [21][22]. Most proteins who interact with Ras to activate downstream signalling pathways, share a conserved domain known as the RAS-binding-domain, or RAS association (RA) domain. The presence of this domain was exploited and used for the identification of novel Ras effectors which were found via cDNA library screens by probing for the presence of RA domains [21]. The conserved mechanism of action shared between Ras proteins is reliant on a conserved sequence consisting of a set (1-5) of G box GDP/GTP- binding motif elements which begins at the N-terminal domain and form a G-domain of approximately 20 kDA in size [23]. The N-terminal domain contains short sequences of amino acids involved in the recognition of phosphates and guanine nucleotides. Important motifs within the G-box domain include switch I and switch II, which regulate the conformational changes between GTP- and GDP-bound Ras proteins [24][25]. The conformations of active and inactive sites

present significant changes which correspond to the switch I and II regions with these small variations leading to different affinities for active or inactive Ras proteins towards Ras regulators and effectors [20].

As with all G-proteins, Ras activation is dependent on the exchange of bound GDP for GTP and is deactivated through the hydrolysis of GTP to GDP; this cycling between active and non-active states is regulated by GEF's and GAPs (Figure 1) [26]. The Guanine Exchange Factors (GEFs) regulate Ras activation via the exchange of GDP bound to the Ras nucleotide binding pocket for GTP and GTPase Activating Proteins (GAPS) regulate the subsequent deactivation [26]. The cycling between activation and deactivation of Ras proteins is integral for the coupling of external stimuli to effector proteins within signal transduction cascades.

An example of such an effector protein found in higher eukaryotic systems is RAF, a serine-threonine kinase which interacts with Ras through the previously mentioned RBD, the Raf1 protein binds to active GTP-bound Ras making it a very useful tool for the investigation of Ras activation within living cells [27]. Ras1 and Ras2 guanine nucleotide binding and GTPase activities have been characterised and the C-terminal third of the nucleotide sequence of yeast Ras displays significant overlap with human RAS. Furthermore, human RAS suppresses the loss of yeast RAS genes, thus supporting functional similarities between yeast and human RAS genes [28].




Figure 1. Ras protein cycling between active and inactive states through the action of GEF and GAP proteins.

Active Ras interacts with the downstream targets in signalling cascades to induce a cellular response. Ras activation is dependent on the exchange of bound GDP for GTP and is deactivated through the hydrolysis of GTP to GDP; this cycling between active and non-active states is regulated by GEF's and GAPs [26].

In *S. cerevisiae* two proteins are expressed which are homologous to human Ras, Ras1 and Ras2. The *RAS1* and *RAS2* genes are located on chromosome XV and XIV [29], respectively, and encode two highly similar proteins of 309 and 322 amino acids in size [29] [30].

Ras proteins function as GTP-binding proteins which regulate the nitrogen starvation response, sporulation, and filamentous growth in yeast. In *S. cerevisiae*, *RAS2* has a paralog, *RAS1*, which arose from the whole genome duplication [31]. Ras1p and Ras2p share the same function, but differ in their levels of gene expression [32][33].




Figure 2. A 3D representation of the crystal structure of the human Ras protein in its GDP-bound conformation.

Courtesy of http://www.rcsb.org/structure/2ERY.

Previously, the yeast Ras proteins were thought to have exclusive roles within the cell as Ras1 was unable to complement growth defects caused by the deletion of *RAS2*, such as reduced growth on non-fermentable carbon sources and decreased levels of intracellular cAMP [34][35]. However, these questions have been explained by the differential regulation of the mRNA production and protein translation of *RAS1*. The level of *RAS1* mRNA and protein synthesis are reduced during the mid-logarithmic growth phase and during growth on non-fermentable carbon sources [32], while *RAS2* mRNA levels are high during all growth phases on both fermentable and non-fermentable carbon sources [36][32]. To confirm that *RAS1* and *RAS2* differ only by their level of expression, *RAS1* was put under the constitutive ADH1 promotor. Here, *RAS1* was able to fully supress the phenotype of a *∆ras2* strain and the

hyperactive mutant of *RAS1* replicated the phenotypes observed in an constitutively expressed *RAS2* strain [37].

In humans the Ras protein family is comprised of 25 members, which are predominantly localised to the plasma membrane. These proteins are highly conserved within the GTPase domain, but mutations can lead to the constitutive activation of Ras. Investigations have estimated that ~50 % of all tumours are result of mutations involved in the constitutive activation of Ras signalling [26]. A number of human oncogenes implicated in a variety of cancers have been identified including *N-RAS*, *H-RAS* and *K-RAS* [38][39][40][29].

Proto-oncogenes play an essential role in signal transduction and the execution of mitogenic signals, therefore when over-activated they become tumour-inducing agents. Ras genes are examples of proto-oncogenes, which encode for proteins involved in the regulation of cell proliferation and differentiation. Ras plays an important role in the cell cycle and is linked to several human cancers and as such has been extensively researched in recent years. Previous investigations have identified that mutant alleles of the human Ras protein are linked to a number of human cancers, further highlighting Ras as an important target for cancer research [41]. Sequence analyses have revealed the importance of the amino acids at positions 12, 13 and 61 in Ras proteins. Mutations that cause the alternation of residues can lead to the overactivation of Ras via GAP impairment [41].

The proto-oncogenes *K-RAS*, *H-RAS* and *N-RAS* are often termed as the 'classical' mammalian Ras proto-oncogenes and as such are the most extensively studied among all the Ras superfamily members due to their direct involvement in tumorigenesis. *H-RAS* mutants are present in 12 % of cases of bladder carcinoma whereas *N-RAS* mutations are predominantly found in malignant melanomas and hematopoietic tumours [42]. Mutations in *K-RAS* are the

most common mutation associated with cancer disease with 60 % of pancreatic cancers, 34 % of colorectal and 16 % of lung cancers expressing oncogenic *K-RAS* isoforms [43].

1.4 Posttranslational modifications of Ras

Posttranslational modifications such as methylation, ubiquitination and most commonly phosphorylation can diversify protein function and enhance regulation [44]. The regulation of yeast Ras proteins is not explicitly regulated by their GTP/GDP binding state, but also by post translational modifications, which can dictate Ras sub-cellular localisation. The sub-cellular localisation of Ras proteins determines the class of effectors and regulators that are available and thus determines the downstream signalling activity [22][21].

Ras proteins undergo a series of posttranslational modifications which are important to control both activation and its localisation to the cytoplasmic side of the plasma membrane [21]. The C-terminal domain of the Ras protein contains a CAAX (C= cysteine, A = aliphatic amino acid, x + terminal amino acid) motif, which is essential for membrane targeting and activity [44][45][46][47]. The first posttranslational modification of Ras processing is farnesylation. The cysteine in the CAAX motif is targeted by farnesyltransferase, which catalyses the addition of a farnesyl isoprenoid [48]. It has been shown that the addition of geranylgeranyl isoprenoid to the CAAX motif can substitute farnesylation but only when farnesyltransferase is blocked by specific inhibitors [49][49][47]. Following this modification, Ras membrane interaction is initiated and Ras is targeted to the endoplasmic reticulum (ER) [50]. After farnesylation the proteolytic removal of the AAX amino acids from the CAAX motif via the enzyme Rec1 occurs, leaving a prenyl cysteine at the C-terminus [51]. Isoprenylcysteine Carboxymethyltransferase (ICMT) performs carboxyl methylation on the prenyl cysteine, which has been hypothesised to play an essential role in Ras signalling [52].

The previously mentioned posttranslational modifications are the minimum signals required for movement and tenure to the plasma membrane.

Ras proteins are most frequently found associated with membranes and research has focused

1.5 Ras protein trafficking

upon its function at the plasma membrane. Importantly, the site of Ras localisation can dictate its function via its interaction with regulatory partners and downstream effectors [21][53]. In S. cerevisiae, the precise mechanism of Ras trafficking from cytosol to endomembranes has yet to be elucidated but in the mammalian system it is known that N-Ras and H-Ras transit to the plasma membranes occurs via vesicular transport following palmitoylation [54][55]. Experimental evidence exists to suggest that N-Ras and H-Ras localised on the plasma membrane can also be depalmitoylated which promotes its translocation back to the golgi apparatus [56]. Due to the lack of palmitoylation sites in K-Ras (Figure 3), the mechanisms controlling its movement to the plasma membrane is unknown but it is known to be dependent on a poly-lysine region close to the hypervariable region that does not rely on golgi/endomembrane trafficking [53]. A fluorescent probe consisting of the Ras Binding Domain (RBD) of Raf-1 fused to GFP was developed to confirm that signalling occurs from Ras proteins on the surface of the golgi apparatus. The probe binds specifically to active Ras proteins, revealing that Ras activation can be found to occur at both the ER and golgi apparatus [57]. Furthermore, in addition to signalling from the golgi, studies have shown Ras activation at the ER compartment when N-Ras and H-Ras proteins deficient in palmitoylation accumulate on the ER and in the cytosol [53][50]. Collectively these studies highlight the importance of the regulation of Ras localisation for its activity.




Figure 3. The human Ras protein hypervariable region (HVR).

The HVR influences the variability in function between the Ras isoforms, it undergoes PTM's to allow membrane interaction and localisation.

In yeast, Ras proteins also undergo PTM to regulate their localisation and activity [50][58]. The initial PTM observed for both Ras1 and Ras2 is the removal of a methionine at the N-terminus, followed by C-terminal modifications such as carboxyl methylation, farnesylation and palmitic acid addition [59][60][61]. Ras1p and Ras2p farnesylation at the cysteine of the CAAX box motif is catalysed by a farnesyltransferase, comprised of α and β subunits encoded by *RAM2* and *DPR1/RAM2*. Experimental evidence has shown that Ras protein localisation in mutants of either *RAM1* or *DPR1* present a cytoplasmic localisation [62]. In *S. cerevisiae* the palmitoylation of Ras proteins is catalysed by Palmitoyltransferase (PAT), encoded by the *ERF2* and *ERF4* genes [60]. The protein products of these genes are localised in the ER and perform palmitoylation using palmitoyl-CoA [62].

Through the use of fluorescent labelling of Ras proteins and their partners, it has been shown that Cdc25, Ira2 and Cyr1 are localized on endomembrane's although the activation of adenylyl cyclase by Ras2 occurs solely on the plasma membrane in *S. cerevisiae* [63][64]. Ras has been shown to be anchored to the ER by the Ras inhibitor, Eri1 [65]. More current studies highlight that the localisation of active Ras is dependent on the activity of Protein Kinase A (PKA). A feedback regulation on Ras2 localisation has been suggested, based on PKA-dependent phosphorylation; Ras2 was shown to localize mainly on the plasma membrane in glycerol-growing cells, while glucose-addition causes a rapid re-localisation of large part of the protein to the cytoplasm [66]. The overexpression of the *TPK1* subunit drives both Cdc25 and Ras2 away from the plasma membrane [67]. Furthermore, active Ras has been shown to localise in the nuclear compartment [68][69].

Other studies reveal a potential role for the mitochondria for correct Ras localisation [70]. For example, an aberrant accumulation of activated Ras at the mitochondria in response to nutritional depletion was reported in cells lacking *whi2*, a protein phosphatase activator involved in the general stress response [70].




Figure 4. Posttranslational modifications play an important role in dictating sub-cellular Ras trafficking and localisation.

Although the mechanisms of Ras trafficking to many intracellular sites has yet to be determined.

Despite our extensive knowledge on how Ras protein modifications lead to plasma membrane localisation, we know relatively little on how they are targeted to other compartments of the cell (Figure 4). This lack of knowledge necessitates future investigations to elucidate which modifications and mechanisms regulating Ras localisation within eukaryotic cells and the significance of localisation for cell function.

1.6 Ras protein phosphorylation

Phosphorylation is an important posttranslational modification and is used to control the function, localisation, or activity of many proteins [71]. Phosphorylation is the chemical addition of a phosphoryl group to an organic molecule and is catalysed by a kinase. The

subsequent removal of a phosphoryl group is called dephosphorylation and is catalysed by a phosphatase. Protein phosphorylation can occur on serine, threonine and tyrosine residues and is widely considered as the most abundant post-translational modification in eukaryotes [72][73].

In yeast, both Ras1 and Ras2 are phosphorylated and phosphorylation occurs exclusively on serine residues [74]. Tryptic phosphopeptide analysis highlighted only two major phosphorylated tryptic peptides of the Ras2 protein[74][75]. Further investigations showed that phosphorylated Ras2 proteins are predominantly localised in the plasma membrane, where the action of these proteins occurs [74]. Thus, suggesting that phosphorylation may not merely be a random event but rather play a physiologically significant role [74][75].

Specific serine residues have been identified within yeast Ras1 and Ras2 proteins that can be phosphorylated [74][75]. Although there are 31 serine residues in the mature Ras2 protein, it has been shown that only serine residues at positions 6, 198, 202, 207, 214, 224, 225, 235, 238, 262, 275, 285 and 291 are identified as putative Ras2 phosphorylation sites [75]. Interestingly, activated alleles of both *RAS1* and *RAS2* proteins have been shown to be less stable and less phosphorylated than proteins from cells expressing wild-type alleles of *Ras2* [75].

Serine²¹⁴ of Ras2 is the preferred site of phosphorylation; however, the protein kinase(s) responsible for Ras2 phosphorylation can phosphorylate a variety of serine residues in the vicinity of serine²¹⁴ when this site is altered [75]. When Ras2^{S214} is replaced by the non-phosphorylatable residue alanine, cells exhibit reduced glycogen accumulation, elevated cAMP levels and increased activation of cAMP signalling by glucose [74]. Furthermore,

increased PKA-dependent activation of Ras2-GTP was observed suggesting that phosphorylation is controlled via feedback regulation of the Ras-cAMP/PKA pathway.

Among *ras* gene products, phosphorylation is not limited to yeast proteins. In humans, the activity of H-Ras mutant proteins can be modulated by phosphorylation. The constitutively activated H-Ras^{G12V} mutant can develop a second mutation resulting in the substitution of alanine for a threonine at position 59. Phosphorylation occurs on the HRAS^{Val12-Thr59} mutant proteins at threonine-59 and functions as a suppressor of the G12V mutation [76]. Furthermore, experimental evidence also shows that PKC agonists induced phosphorylation of serine¹⁸¹ resulting in the fast translocation of K-Ras from the plasma to endo-membranes [77].

Although evidence exists to suggest that Ras proteins can undergo phosphorylation events which regulate its activity. Surprisingly, the phosphorylation of Ras2p in *S. cerevisiae* has not been studied regarding its regulation of intracellular localisation despite significant evidence existing linking Ras phosphorylation to its localisation in humans.

1.7 RAS/cAMP/PKA signalling in *S. cerevisiae*

In *S. cerevisiae*, Ras proteins, once activated, interact with adenylate cyclase at the plasma membrane, triggering the synthesis of cAMP from ATP (*Figure 5*) [78]. Adenylyl cyclase, encoded by *CYR1*, is a large protein consisting of 2,026 amino acids. The protein structure comprises of four domains: N-terminal, middle repetitive, catalytic and a C-terminal domain. The middle repeat consists of a 23-residue amphipathic leucine-rich motif called the LRR domain (674-1300 aa). The LRR domain is the principal site of Ras interaction and the N-

terminal domain of the LRR (676-756) has been identified to be a Ras Associating Domain (RAD).

Upon cAMP production by adenylyl cyclase, cAMP binds to the Bcy1 protein, the regulatory subunit of PKA, activating PKA. The regulation of Ras/cAMP/PKA signalling is essential for orchestrating many cellular processes including growth, proliferation, cell cycle progression, stress responses and the control of ageing in yeast cells (*Figure 5*) [79]. Mutations resulting in the inappropriate activation of PKA induce cell cycle arrest in G1, glycogen accumulation and prolonged survival when exposed to starvation [78].

An increase in intracellular cAMP levels results in the activation of PKA via the dissociation of the PKA regulatory subunit Bcy1 [80] and the PKA catalytic subunit(s) encoded by *TPK1*, *TPK2* and *TPK3* [81][78]. The genes *TPK1*, *TPK2* and *TPK3*, control cAMP-dependant protein kinase activity in *S. cerevisiae*. The PKA subunits Tpk1, 2 and 3 share overlapping functions but also have been shown to be involved in the regulation of several separable functions. Tpk1 has been identified to play a role in the branched chain amino acid biosynthesis pathway, mitochondrial DNA stability and mitochondrial iron homeostasis [82]. Whereas Tpk2 has been shown to impact iron uptake, trehalase synthesis and water homeostasis [82][83]. However, constitutive PKA activity can prove deleterious, with the overexpression of *TPK3* shown to inhibit growth [84].

The production of intracellular cAMP is tightly regulated through feedback loops and the action of phosphodiesterases, which catalyse the degradation of cAMP [85][86]. Saccharomyces cerevisiae contains two cAMP phosphodiesterases, PDE1 and PDE2, which encode a low-affinity (Pde1) and a high-affinity cAMP phosphodiesterase (Pde2) that are unrelated in primary sequence [85][86]. Pde2 is an Mg2-requiring, zinc-binding enzyme with

a Km for cAMP of 170 nM [87][88]. It controls the basal cAMP levels in the cell and thereby protects it from changes in the extracellular environment [89].




Figure 5. The activation of Ras1 and Ras2 is dependent on nutrient availability.

In the presence of glucose Ras proteins are activated via the GEF proteins cdc25 or Sdc25 which catalyse the liberation of GDP and the binding of GTP. Adenylate cycle is activated inducing the production of cAMP. cAMP functions as a secondary messenger and binds to the inhibitory unit of PKA, releasing the catalytic unit, phosphorylating downstream targets resulting in the activation of multiple downstream cellular processes or the inhibition of transcription factors that control the stress response. This pathway is inhibited by the hydrolysis of cAMP via the action of Pde1 and Pde2 and by the GTPase activity of the GAP's Ira1 and Ira2.

1.8 Regulation of RAS/cAMP/PKA pathway activity

In *S. cerevisiae*, Ras protein activation is finely tuned by two classes of regulatory proteins: Cdc25 and Sdc25 guanine nucleotide exchange factors (GEFs) [90][91][92], and Ira1 and Ira2 GTPase activating proteins (GAPs) (*Figure 6*) [93][94] [95]. The molecular mechanism of the modulation of Ras proteins activity is conserved in higher eukaryotes, as highlighted by the functional interchangeability of Ras proteins and their regulators in yeast and mammals [96]. The *CDC25* gene of *S. cerevisiae* encodes for the Ras protein activator (GEF) and is required to produce cAMP. The Cdc25 gene product is a ~180 kDa polypeptide with a C-terminal highly conserved RAS-GEF catalytic domain (1,121–1,573 aa) [97]. Mutants that result in the constitutive activation of Ras2, such as *Ras*^{val19}, have been shown to supress the effects of mutations in *CDC25*, as constitutively activated *Ras*^{val19} does not require the exchange factors for its activation [98]. Furthermore, the gene S*DC25* has also been shown to prevent Ras GEF activity [90].

Despite Cdc25 being the first Ras GEF characterised [99], the precise mechanism of how its activity is regulated and how the Cdc25/Ras/cAMP pathway transduces the signal originated by nutrients is still unclear. Inconsistent reports have put forward either the necessity [100][101] or the dispensability [102] of Cdc25 for Ras and adenylate cyclase activation upon glucose stimulation, however Cdc25 was eventually shown as necessary for Ras2 GTP-loading after glucose refeeding [103].

The Cdc25 protein is tightly bound to membranes [104], although protein solubility increases upon hyper-phosphorylation within the 114-348 amino acid region and results in Cdc25 becoming less available for the association with Ras [105]. Glucose-induced hyper-phosphorylation of Cdc25 upon glucose addition has been shown to directly inhibit Ras GEF

activity rather than affinity for Ras [106][105]. Cdc25 activity modulation by phosphorylation is prevented by nutrient starvation and is hypothesized to be a part of a negative feedback loop resulting from PKA activity (Figure 6) [105][106].

The IRA proteins, encoded by the genes *IRA1* and *IRA2* have been shown to inhibit Ras activity in yeast [95]. The *IRA1* and *IRA2* genes encode large proteins, 3092 and 3079 amino acids respectively, that share similar amino acid sequence and have related, even if not identical, functions. A region of approximately 360 amino acids in the middle of these gene products, called the GAP domain, is responsible for activating intrinsic GTPase activity of Ras [95]. It has been shown that IRA1/IRA2 gene mutations suppress *CDC25* mutations, double deletion mutant's of $\Delta cdc25$ and $\Delta ira1/\Delta ira2$ are viable. Ira2 (Ras-GAP) is regulated by ubiquitination, a posttranslational modification resulting in protein degradation by the proteasome.

More recent studies have shown that the Ubp3 protein interacts with the Ras GTPase-accelerating protein, Ira2, and regulates its level of ubiquitination. Ubp3 is an Ubiquitin-specific protease and regulates PKA activity by controlling the ubiquitination status of Ira2p [107]. It has been suggested that the addition of glucose to the growth media stimulates ubiquitination and Ira2p inactivation resulting in Ras-GTP accumulation and therefore elevated PKA activity. The regulation of Ira2 by ubiquitination is a highly conserved mechanism in Ras signalling [108].




Figure 6. Positive and negative feedback in the Ras/cAMP/PKA pathway.

This schematic shows the relationships among the main components of the Ras/cAMP/PKA pathway. The cycling of the Ras2 protein between its inactive state (Ras2-GDP) and active state (Ras2-GTP) is regulated by Cdc25 (A) and Ira2 (B). Ras2-GTP activates adenylate cyclase Cyr1 (C), which induces the synthesis of the second messenger, cAMP (D). Increased cAMP levels result in PKA activation (E) through binding to the PKA regulatory subunits and liberating its catalytic subunits. The degradation of cAMP is catalysed by Pde1 (I) and Pde2 (J), which functions as a major negative feedback mechanism in this pathway, as both contribute to the decrease in the intracellular level of the second messenger. The active form of PKA performs three main regulations in this pathway via the phosphorylation of different components: a positive regulation of Pde1 (H) and of Ira2 (G), and a negative regulation of Cdc25 (F). The increased activity of the phosphorylated forms of both Pde1 and Ira2 result in switching off the signal—by either a faster degradation of cAMP by Pde1 (I) or to a diminished fraction of active Ras2 by Ira2 proteins (B), both positive regulations result in a negative feedback control of the whole pathway. The negative regulation of Cdc25 by PKA results in a partial inactivation of the GEF activity (A), and therefore a reduced activation of the Ras2 protein, which results in a decreased activity of the adenylate cyclase and therefore contributes to lowering the cAMP level.

1.9 The GPCR System- Regulator of the cAMP/PKA pathway

Working in parallel with Ras to activate PKA is the GPCR (G-protein coupled receptor) glucosesensing system, composed of the Gpr1 receptor and its cognate G protein, Gpa2 (Figure 7) [109][110]. GPR1 encodes a seven-transmembrane G protein-coupled receptor that interacts with Gpa2 [111][112], a small GTP-binding protein which is homologous to the mammalian Gα subunit of the heterotrimeric G proteins [113]. The binding of glucose to Gpr1 activates Gpa2, which stimulates adenylate cyclase to increase cAMP levels and thus activation of PKA [112]. The Gpr1-Gpa2 system is responsive to both glucose and sucrose but not structurally similar sugars including fructose or glucose analogues [114]. The deletion of GPA2 has been shown to confer the typical phenotype associated with reduced PKA activity [112], with GPA2 or GPR1 inactivation slowing several PKA-controlled processes including the repression of STR responsive genes and the induction of genes encoding ribosomal proteins [115]. Addition of glucose to cells elicits a rapid acidification of the yeast cytoplasm inducing PKA signalling (Figure 7) [116]. However the Gpr1-Gpa2 system is not required for intracellular acidificationinduced PKA activation and does not play major role in controlling the basal cAMP level [112] [115].

Surprisingly, activation of Ras is dependent on sugar uptake but it does not require the presence of a functional GPCR system [117]. The precise mechanisms by which glucose activates Ras activity is still unknown with no sugar-sensing system identified that could function as an upstream activator of Cdc25 to transmit the glucose signal to the Ras protein [118]. Evidence suggests that Cdc25 may not itself be the signal receiver for the glucose induced cAMP response but instead the glucose induced increase in Ras2 activation may be

mediated through the inhibition of Ira1/2 proteins, thus confirming the early reports indicating Ras as an important mediator in glucose-induced cAMP signalling [102].




Figure 7. Mechanisms of how glucose and intracellular acidification modulate adenylate cyclase activity.

Glucose binds to the Gpr1 receptor, activating cAMP synthesis through the Gpa2 protein, while intracellular acidification functions through the Ras proteins. Gpr1 and Gpa2 constitute a glucose sensing GPCR system. The transient cAMP accumulation triggered by glucose activates PKA, which causes transient changes in several systems containing components controlled by PKA-mediated phosphorylation. The phosphorylation of downstream targets resulting in the activation of multiple downstream cellular processes or the inhibition of transcription factors that control the stress response. The red arrows represent downregulated process and the green arrows indicate upregulated processes.

1.10 Processes regulated by PKA activity

1.10.1 PKA modulation of ribosome biogenesis

The activation of PKA regulates growth by promoting the expression of the cell's translation machinery. PKA activates Rap1, which in conjunction with the high mobility protein Hmo1, recruits the nutrient-regulated Fhl1-Ifh1 complex to RP gene promotors to induce the expression of the corresponding genes [119][120][121][122][123][124]. Furthermore, PKA inhibits Yak1-mediated activation of the transcriptional repressor Crf1, which, following phosphorylation by Yak1, substitutes the coactivator Ifh1 of the fork head transcription factor Fhl1 to downregulate RP gene expression [123][124]. In addition to the regulation of ribosome biogenesis, PKA functions to control the regulation of the elongation step of RNA Pol II-mediated transcription [125].

1.10.2 PKA modulation of the stress response

As well as stimulating growth, PKA also functions to supresses several stress responses, such as the inhibition of the dual-specificity tyrosine phosphorylation-regulated protein kinase, Yak1. PKA sequesters Yak1 in the cytoplasm through the phosphorylation of Serine²⁹⁵ [126][127]. Whereas the downregulation of PKA, as seen during the transition into the diauxic shift, enables Yak1 to enter the nucleus and upregulate its transcriptional targets. These include Pop2 of the Ccr-Pop2-Not1-5 complex, which when phosphorylated by Yak1 results in G_1 arrest and the activation of the zinc-finger transcription factor Msn2, which in combination with its paralog Msn4, induces the expression of \sim 200 stress response element-containing genes in response to a multitude of environment stimuli, including glucose depletion during the diauxic shift (*Figure 8*) [126][128][129]. Moreover, the protein kinase Rim15 has been shown to mediate growth inhibition in the absence of PKA activation. Rim15, a PAS protein

kinase family member, positively controls the initiation of the quiescence program and its kinase activity is directly inhibited through PKA-mediated phosphorylation [130].




Figure 8. The protein kinase PKA, switches on or off the activities and signals transmitted through the Sch9 and TOR pathways.

Sch9 positively controls the post-diauxic shift (PDS) driven gene expression via Gis1 and Rim15. TOR and PKA control the stress response element (STRE) driven gene expression via Msn2/4 and Rim15. GTF stands for general transcription complex. Arrows and bars refer to positive and negative interactions. Dashed lines refer to potential cross-regulation.

Lastly, PKA inhibits autophagy through the phosphorylation of the protein kinase Atg1 and its regulator Atg13. This inhibits the recruitment of the Atg1–Atg13 complex to the preautophagosomal structure, the nucleation site from which autophagy pathway intermediates are formed.

1.10.3 Regulation of metabolism

Many of the physiological changes that occur as cells approach and/or transition into the diauxic shift phase of growth are under the post-transcriptional control of PKA. PKA antagonizes the metabolic transition from glycolysis to gluconeogenesis as well as the induction of trehalose and glycogen synthesis. This is achieved via the activation of the glycolytic 6-phosphofructo-2-kinase, Pfk2 and pyruvate kinases Pyk1/2 [131][132], the inhibition of the gluconeogenic fructose 1,6-bisphosphatase, Fpb1 [133], the activation of the glycogen phosphorylase Gph1 [134] and inhibition of the glycogen synthase Gsy2 [135].

1.11 Ras and the Cell Cycle in S. cerevisiae

Ras activation is dependent on the presence of growth factors and pro-survival signals, specifically growth factors in the case of human Ras and glucose in the case of yeast Ras [136][137]. Ras stimulates cell cycle progression which is associated with an increase in cell size and protein synthesis in yeast [138][139][140].

The RAS/cAMP/PKA pathway in yeast regulates several essential intracellular processes including the cell cycle, ribosome production, cells size and mass, and growth rate. These processes are strictly interdependent [109]. The specific growth rate of the cell is determined by the rate of mass accumulation, which in turn depends on nutrient availability, with cell cycle progression and cell size both dependent on growth rate and mass accumulation [141][142][143][144]. The modulation of the cell cycle is also under the influence of the RAS/cAMP/PKA pathway. Ras activation can lead to a change in the expression of cyclins (Clns) [145], which form complexes with cyclin-dependent kinases (Cdks) to promote entry into S phase of the cell cycle. Ras activation leads to the suppression of *CLN1* and *CLN2* expression

but not *CLN3* [145][146]. Moreover, PKA has been shown to directly phosphorylate Whi3, a negative regulator of G1 cyclins leading to progression into S Phase of the cell cycle [147].

Ras signalling has also been identified as a regulator of DNA damage checkpoint recovery. The DNA damage checkpoint functions to maintain genome stability by arresting the cell cycle and promoting DNA repair. Upon the deletion of *ira1/2*, PKA regulatory elements are hyper activated and after checkpoint downregulation cells undergo a permanent mitotic arrest [148].

1.12 Ras and its involvement in Cell fate in Yeast

1.12.1 The involvement of the Ras/cAMP/PKA signalling network in regulating quiescence

Cells spend a large proportion of their life in a temporary non-proliferating cellular state, known as quiescence. Establishing quiescence and maintaining the capacity to re-enter the proliferation cycle are critical for cell survival and must be closely regulated to avoid pathological proliferation. Quiescence is linked with a number of phenotypes, including a reduced rate of protein synthesis, thermo-resistance, and accumulation of storage molecules [149]. Quiescent cells are often considered as G1-arrested cells with only 5-10 % of cells entering quiescence from other cell cycles other than G1 [150]. Although, in both yeast and mammalian systems, a prolonged G1 arrest does not recapitulate the hallmarks of quiescence establishment [151]. Therefore suggesting that quiescent cells are not wholly G1-arrested cells, although the molecular mechanisms linking quiescence entry and cell cycle regulation are still yet to be elucidated [152].

In *S. cerevisiae*, quiescence entry is initiated by nutrient limitation, and is regulated, at least in part, by a complex interplay between nutrient-sensitive protein kinases, PKA and Tor [153].

Both PKA and TORC1 are positive key regulators of cell growth that participate in the cell's decision whether to transition into quiescence. For example, cells with dysregulated, enhanced PKA activity, such as the $RAS2^{val19}$ mutant, characteristically fail to acquire many physiological features of the quiescence program as they enter stationary phase growth [154]. Whereas cells with absent or reduced PKA activity, induce growth arrest and hold cells in a G_0 -like state [154][147].

1.12.2 Ras and its role in yeast apoptosis and regulated cell death

The RAS/cAMP/PKA signalling has been shown to be an important regulator of cell death in yeast [155][156][157]. An increase in Ras signalling has been correlated with an increase in typical apoptotic markers such as phosphatidylerine externalization, increased reactive oxygen species (ROS) accumulation and DNA fragmentation [158][159]. There are three distinct known stimuli that induce RAS/cAMP/PKA hyper-activation and subsequent cell death and these include; changes in actin cytoskeletal dynamics, exposure to ammonium and osmotin [158][160][161]. Osmotin is a protein synthesized by plants in response to the presence of pathogenic fungi. When in contact with *S. cerevisiae*, osmotic binds to Pho36 – a seven transmembrane domain receptor-like polypeptide that regulates lipid and phosphate metabolism, resulting in the inappropriate inactivation of Ras signalling leading to the induction of regulated cell death [162].

An alternate stimulus for Ras-mediated apoptosis in yeast is mediated by the actin cytoskeleton. Changes in the actin cytoskeleton caused by either the use of drugs or the presence of mutations can lead to the formation of F-actin aggregates, which function as a trigger for the constitutive activation of Ras2 and apoptosis [158]. Ammonia was also shown

to cause programmed cell death in ageing yeast cultures via the activation of the RAS/cAMP/PKA pathway [158][160].

In *S. cerevisiae*, the role of mitochondria is fundamental in the regulation of cell death. When dysfunctional the mitochondria have been shown to be the main source of ROS accumulation in yeast cells [160]. The accumulation of ROS within cells is a central event in the regulation of programmed cell death in yeast as the addition of antioxidants to yeast cells was shown to supress the apoptotic phenotype [156][163][164]. The RAS/cAMP/PKA pathway has also been shown to regulate cell death in acidic environments [164]. Supplementation of acetic acid induces intracellular acidification, which leads to RAS/cAMP/PKA activation and subsequent cell death [164]. Further supporting the integral role of Ras within the regulation of apoptosis, is that the deletion of the *RAS* genes has been shown to suppress the apoptopic phenotype of yeast cells. However, following the suppression the apoptosis, necrosis is induced within these cells. Furthermore, the hyper activation of the Ras pathway by the constitutive active allele *RAS2*^{val19} or by deletion of *PDE2* increases apoptotic cell death [164][165].

1.13 Ras signalling in the regulation of autophagy

Autophagy is the natural, regulated mechanism of the cell that disassembles unnecessary or dysfunctional cell components allowing the orderly degradation and recycling of cellular products. In *S. cerevisiae*, both macroautophagy and microautophagy take place (*Figure 9*). Macroautophagy occurs when random cytoplasm and dysfunctional organelles are sequestered by an expanding phagophore, resulting in the formation of the autophagosome. The autophagosome fuses with the vacuole membrane, discharging the autophagic body into the vacuole lumen and sequestered cargo is broken down by vacuolar hydrolases.

Microautophagy occurs when cargos are directly taken in by the invagination and exposed to vacuolar hydrolases for degradation

In S. cerevisiae, Ras proteins mediate autophagy through the activity of PKA. Upon activation, PKA phosphorylates Rim15 and Msn2/4 which inhibits the translocation of these proteins to the nucleus to initiate the transcription of autophagy genes [162][163]. Furthermore, PKA activity also inhibits autophagy via the direct inhibition of ATG13, which is integral for autophagy initiation [163].




Figure 9. A schematic illustrating the two predominant types of autophagy in yeast – macroautophagy and microautophagy.

Macroautophagy occurs when random cytoplasm and dysfunctional organelles are sequestered by an expanding phagophore, resulting in the formation of the autophagosome. The autophagosome fuses with the vacuole membrane, discharging the autophagic body into the vacuole lumen and sequestered cargo is broken down by vacuolar hydrolases. Microautophagy occurs when cargos are directly taken in by the invagination and exposed to vacuolar hydrolases for degradation.

The RAS/cAMP/PKA pathway has been shown to be highly interconnected with the TOR pathways which are also involved in the regulation of autophagy in yeast. Both Tor and Ras often control overlapping effectors, including effectors involved in autophagy, resulting in a similar cellular response, such as the inhibition of the stress response, cell cycle progression and ageing. *S. cerevisiae* encodes for two Tor kinases, *TOR1* and *TOR2* respectively, with *TOR1* providing the most significant contribution to autophagy [166]. Upon the presence of nitrogen, Tor1 is activated, resulting in the repression of autophagy via the direct inhibition of the Atg1 complex and sequestration of the transcription factors Rim15 and Msn2/4 in the cytosol [167][168]. During starvation conditions or treatment with rapamycin, TOR is inhibited and autophagy is induced [168]. Moreover, the Tor1 complex directly phosphorylates and activates Sch9p, which inhibits the autophagy process. The inactivation of both PKA and Sch9p is sufficient to initiate autophagy, suggesting that both kinases are synergistically involved in the negative regulation of the autophagy process [168][169].

1.14 Ras in nutrient acquisition

The availability of key nutrients, such as amino acids, nitrogen compounds, and sugars, dictate the developmental programs and growth rates of yeast cells. Several overlapping signalling networks including the Ras/cAMP/PKA, AMP-activated kinase, and the TOR1 complex, apprise cells on nutrient availability and influence the cells transcriptional, translational, posttranslational, and metabolic profiles as well as dictating cell fate.

Much of the glucose-induced signalling in yeast functions through the Ras/cAMP/PKA pathway. 90 % of the transcriptional changes that occur on the addition of glucose to glucose depressed cells can be recapitulated by activating this pathway. Conversely, inhibiting this pathway concurrent with glucose addition eliminates most of the glucose induced responses.

Thus, Ras and the PKA pathway is necessary for the majority of the transcription changes of the cell in response to glucose addition [170]. Considering the Ras proteins role in glucose signalling it would not be wrong to postulate that Ras may function within the processes underpinning other nutritional sensing pathways in yeast, including peptide transport.

1.14.1 Di/Tri-peptide uptake mechanisms in *S. cerevisiae*

Peptides are composed of sequences of amino acids and once catabolized provide the essential building blocks required for protein synthesis. In addition, certain peptides and amino acids can be utilized as a nitrogen source and can act as signalling molecules that alter cell behaviour. For example, the branched-chain amino acid leucine, has been shown to control TORC1 activity [171][172]. TORC1 senses and responds to nutrients to promote cell growth and the inhibition of catabolic processes, such as autophagy. Branched-chain amino acids such as leucine function by affecting the 'nucleotide binding status of the Exit from G o Complex' (EGOC) GTPase subunits Gtr1 and Gtr2 in Saccharomyces cerevisiae [173][174]. Amongst other TORC1-stimulating amino acids, arginine abundance in mammalian cells is proposed to be sensed by the lysosomal transporter SLC38A9 and conveyed to mTORC1 via the Rag GTPases [175][176], while glutamine levels appear to be transduced to control both yeast and mammalian TORC1 independently of the EGO/Rag GTPases [172].

In mammals, amino acids exert a major role on the regulation of protein synthesis through the control of the kinases mTOR and Gcn2, which have been shown to have opposing effects on protein synthesis [172][177]. The regulation of Gcn2 activity by amino acid availability relies on the capacity of Gcn2 to sense the increased levels of uncharged tRNAs upon amino acid scarcity [177]. Gcn2 is activated during scarcity of an essential amino acids and

phosphorylates the α -subunit of eukaryotic initiation factor 2 alpha (eIF2 α) [178]. This leads to the general inhibition of protein synthesis.

Due to the multifaceted role of amino acids and peptides in biological systems, it is therefore not surprising that microbes have evolved a multitude of mechanisms to facilitate peptide and amino acid uptake. The study of such mechanisms has been extensively examined in yeast, with amino acid uptake mechanisms presenting high conservation in mammals.

Saccharomyces cerevisiae has two distinct peptide transport mechanisms, a di-/tripeptide (the PTR system) and a tetra-/pentapeptides (the OPT) transport system. The PTR family of peptide transporters transport a number of substrates, including amino acids, nitrates and di/tri-peptides [179]. *PTR2* encodes an integral membrane protein (Ptr2p) involved in the physical translocation of peptides across the plasma membrane.

PTR2 encodes an integral membrane protein of 601 amino acids containing 12 membrane-spanning domains which transport substrates by the means of proton-motive force [180]. The transporter is specific for di-/tripeptides, with a preference for peptides containing hydrophobic amino acids. In *S. cerevisiae* the regulation of *PTR2* expression is strongly affected by the composition of the extracellular environment. In the absence of the preferred nitrogen sources *PTR2* expression is induced [181][182]. The import of di/tripeptides composed of basic or bulky hydrophobic N-terminal residues increases *PTR2* expression via reducing cellular levels of Cup9p, the homeodomain-containing transcriptional repressor of *PTR2*. Specific di/tri-peptides function as both as ligands and regulators of the E3 ubiquitin ligase Ubr1p. Ubr1p mediates Cup9p degradation system that is governed by the identity of N-terminal amino acids [183][184]. Most di/tripeptides are too small to be degraded by the proteasome and are assimilated as nutrients by intracellular peptidases. However,

di/tripeptides with basic (Type 1: His, Lys, or Arg) and bulky (Type 2: Ile, Trp, Leu, Tyr, or Phe) N-terminal residues can compete with larger protein substrates and bind at the Type 1 and Type 2 Ubr1p substrate-binding sites. Once bound, Ubr1p-mediated degradation of Cup9p is allosterically activated via the release of the Ubr1p auto inhibitory domain, revealing a substrate-binding domain that binds an internal degron in Cup9p [185]. Relief of Cup9p repression of *PTR2* results in enhanced *PTR2* expression. A positive regulatory feedback loop is created where di/tripeptide uptake perpetuates Ubr1p-mediated Cup9p degradation, upregulating *PTR2* expression and thus increased di/tripeptide uptake.

Although Ptr2p is the major transporter of di/tripeptides in *S. cerevisiae*, di/tripeptides can also be imported with a low efficacy by Dal5, whose primary function is the import of nitrogen sources, such as allantoate and ureidosuccinate [186]. As aforementioned, the peptide transporters Opt1 and Opt2, which have partially overlapping functions, import peptides of 4–5 residues. In addition, Opt1 is a high affinity importer of glutathione, a "noncanonical" tripeptide [187]. In the same way as the Ptr2 transporter of di/tripeptides, the expression of *OTP2* is down-regulated by Cup9p, whereas the expression of *OPT1* is independent of Cup9p [187]. In addition to *PTR2* and *OPT2*, the N-end rule pathway also controls the expression of *DAL5*, but in a manner contrary to that of the other two transporters: whereas Cup9p is a transcriptional repressor of *PTR2* and *OPT2*, Cup9p up-regulates the expression of *DAL5* [179][187].

1.15 Ras signalling in human cells

Human Ras proteins transduce pro-survival signals from the extracellular space to the intracellular compartment via tyrosine kinase receptors (TKRs). Upon ligand binding, the dimerization of the receptors triggers a conformational change that activates the catalytic tyrosine kinase domain, which enables the autophosphorylation of the intracellular carboxylterminal domain and therefore induces its activation [188][189]. The phosphorylated domain of the TKR recruits GEFs, activating Ras, allowing it to signal downstream [190]. Active Ras proteins can activate at least 20 different effectors, including the RAF (rapidly-accelerate fibrosarcoma) kinases, phosphatidylinositol-3-kinase (PI3K) and RAL guanine nucleotide-dissociation stimulator (RALGDS) (Figure 10). Other effectors associated with Ras protein activation include RIN1, T-lymphoma invasion and metastasis-inducing 1 (Tiam 1), Af6, Nore1, PLCS and PKC [191][192].

Activated RAF kinases phosphorylate and activate the MAPK/ERK kinase. Signal transduction along the Raf/MEK/ERK pathway starts with the activation of Ras by TKR's, G-protein-coupled receptors and/or intergrins (Figure 10) [193]. These membrane proteins form large signalling complexes upon activation and recruit and activate Ras proteins by promoting the exchange of Ras-bound GDP with GTP. The process is regulated by the interaction of Ras with GDP/GTP-exchange factors, such as SOS (son of sevenless). After the small G-proteins recruit the MKKKs c-Raf (and, if present, A- and B-Raf) to the plasma membrane, where RAF is activating causing phosphorylation, changes in its conformation and protein interactions occur [193]. The MEK-1/2 serine residues are phosphorylated by RAF leading to MEK-1/2 activation. ERK-1/2 is then phosphorylated by MEK-1/2 at threonine and tyrosine residues in the TEY motif of the activation loop. This dual phosphorylation event is linked with ERK-1/2 activity and can be

used to measure indirect quantification of the serine/threonine kinase (ERK) activation [194].

Upon activation, ERK can phosphorylate over 80 different substrates in the cytoplasm and nucleus.

In the phosphatidylinositol-3-kinase PI3K pathway, activated PI3K catalyses the production of Pip3 (phosphatidylinositol-3,4-triphosphate) by the phosphorylation of Pip2 (phosphatidylinositol-4,5-diphosphate). Pip3 activates the phosphatidylinositol dependent kinase 1 (PDK1), resulting in the activation and recruitment of AKT to the membrane [195]. The primary downstream effecter of activated AKT is mTOR (the mammalian target of rapamycin), which is a serine/threonine kinase. mTOR can form two distinct complexes, depending on the proteins it interacts with. The mTOR complex (mTORC1) primarily functions to promote the transcription of genes associated with energy metabolism, cell cycle progression and cell proliferation.

The mTOR complex 2 (mTORC2) mainly functions to phosphorylate AKT which results in cell survival and proliferation. Furthermore, AKT phosphorylation promotes telomerase activity, inhibition of apoptosis and blocking the release of cytochrome C from the mitochondria, downregulation of pro-apoptopic factos and pro-caspase 9, and regulates modulators of angiogenesis via activation of nitric oxide synthases [196][137][195].

Ras stimulates the RAL (RAS-like), GTPases, promoting the activation of phospholipase DI (PLD) and CDC42/RAC-GAP RAL binding protein 1 (RALBP1). These, among other pro-survival

functions, promote the progression of the cell cycle, inhibiting transcription factors involved in then cell cycle arrest, including the FORKHEAD transcription factors [191] [197].




Figure 10. Schematic representation of the multiple effectors activated by human Ras proteins and the different impact these interactions have on cell fate.

1.16 The use of *S. cerevisiae* for the study of human Ras proteins

Human Ras proteins play a fundamental role in tumorigenesis and exhibit sequence homology with yeast Ras homologous [198] [199]. As such efforts have been made to use *S. cerevisiae* to investigate the molecular mechanisms of Ras proteins with the aim of understanding their roles and regulation in higher eukaryotes. The use of *S. cerevisiae* as a model to study the role of Ras proteins has been important for understanding the post-translational processes required for the translocation of Ras proteins to the plasma membrane [200]. Notably, the use of the *S. cerevisiae* mutant, $\Delta dpr1$, revealed that the acylation was not the first

translational modification in the processing of Ras proteins [201]. Furthermore, the first Ras effector and first guanine-nucleotide exchange factor (GEF), adenylate cyclase and Cdc25, were identified in yeast [30] [78]. Such discoveries, particularly that of Cdc25, facilitated the identification of analogous proteins in humans [78]. In addition to the discovery of GEF proteins, yeast has been valuable for enhancing our understanding of the GTPase activating proteins (GAPs) through the discovery of *IRA1* and *IRA2*. The functions of the GAP-coding *NF1* gene, which when mutated is responsible for neurofibromatosis type 1, were uncovered thanks to the similarity with the *IRA* genes of *S. cerevisiae* [78]. Moreover, the expression of the *NF1* gene in yeast suppressed the phenotypes associated with the deletion of *IRA* genes, such as heat shock sensitivity, demonstrating that the mammalian and yeast GAPs are interchangeable and therefor highlighting the similarity between yeast and mammalian Ras protein activation [38]. Such examples highlight the importance of the use of *S. cerevisiae* as a model organism in modern biology.

1.17 Aims of this study

The localisation and signalling of Ras on the plasma membrane has been extensively studied. It has been shown that Ras undergoes a series of posttranslational modifications that dictate its subcellular localisation. Evidence exists to suggest that Ras proteins can undergo phosphorylation events which regulate its activity. Surprisingly, the phosphorylation of Ras2p in *S. cerevisiae* has not been studied regarding its regulation of intracellular localisation, despite significant evidence existing linking Ras phosphorylation to its localisation in humans. This study aims to further investigate whether Ras2p phosphorylation provides a mechanism that regulates Ras2p trafficking inside the cell.

In the laboratory of Dr Campbell Gourlay, previous bioinformatics investigations identified potential kinase and phosphatase enzymes that may influence Ras2 protein phosphorylation. This data was generated using the PhosphoPep (v2.0) database, which provides information sourced from tandem mass spectrometry experiments regarding phosphopeptides and phosphoproteins. The PhosphoPep database proposed twelve phosphatase and kinase enzymes that effect Ras2p phosphorylation and identified several serine residues that may be phosphorylated (*Table 1* and *Figure 11*).

Table 1. Phosphatase and kinase enzymes predicted by the PhosphoPep database to effect Ras2p phosphorylation.

| Gene deletion | Protein function | Ras2 phospho-peptide level in deletion strain | Identified sequence |
|--------------------|---|---|-------------------------------|
| YIL035C (CKA1) | Protein kinase, functions in cell growth and proliferation | 2.2-fold DOWN | R.NAS*IES*KTGL AGNQATNGK.T |
| YGR262C (BUD32) | Protein kinase, required for tRNA modification | 2.2-fold DOWN | R.KMS*NAANGK. N |
| YIL042C (PKP1) | Mitochondrial protein kinase, functions in the negative regulation of pyruvate dehydrogenase | 1.5-fold DOWN | R.NAS*IES*KTGL AGNQATNGK.T |
| YLL010C (PSR1) | Plasma membrane phosphatase, involved in general stress response | 3.1-fold DOWN | R.NAS*IES*KTGL AGNQATNGK.T |
| YNL307C (MCK1) | Protein kinase, involved in chromosome segregation, mitotic entry, genome stability | 1.6-fold DOWN | R.NAS*IES*KTGL AGNQATNGK.T |
| YPL042C (SSN3) | Cycline dependant protein kinase, involved in phosphorylation of RNA polymerase, and glucose repression | 1.5-fold UP | K.GSGANSVPRNS *GGHR.K |
| YDL047W (SIT4) | Phosphatase, required for golgi to ER traffic, like human PP6 | 1.6-fold UP | K.NVNSS*TTVVN AR.N |
| YKL126W (YPK1) | Protein kinase; phosphorylates flippase activator Fpk1p, homolog of mammalian kinase SGK | 1.6-fold UP | K.NVNSS*TTVVN AR.N |

| YKL139W (<i>CTK1</i>) | Catalytic subunit of C terminal domain kinase, like human CDK12 | 1.7-fold UP | K.NVNSS*TTVVN AR.N |
|----------------------------|---|-------------|------------------------------|
| YPL042C (SSN3) | Cycline dependant protein kinase, involved in phosphorylation of RNA polymerase, glucose repression | 2.4-fold UP | K.NVNSS*TTVVN AR.N |
| YPL031C (PH085) | Cyclin-dependent kinase, involved in cellular response to nutrient levels and environmental conditions and cell cycle | 1.6-fold UP | R.NASIES*KTGLA GNQATNGK.T |
| YLR019W (PSR2) | Plasma membrane phosphatase involved in general stress response | 3.9-fold UP | R.KMS*NAANGK. N |
| YAR019C (CDC15) | Protein kinase of the mitotic exit network | 1.7-fold UP | R.KMS*NAANGK. N |

MPLNKSNIREYKLVVVGGGGVGKSALTIQLTQSHFVDEYDPTIEDSYRKQVVIDDEVSIL
DILDTAGQEEYSAMREQYMRNGEGFLLVYSITSKSSLDELMTYYQQILRVKDTDYVPIVV
VGNKSDLENEKQVSYQDGLNMAKQMNAPFLETSAKQAINVEEAFYTLARLVRDEGGKYNK
TLTENDNSKQTSQDTKGSGANSVPRNSGGHRKMSNAANGKNVNSSTTVVNARNASIESKT
GLAGNQATNGKTQTDRTNIDNSTGQAGQANAQSANTVNNRVNNNSKAGQVSNAKQARKQQ
AAPGGNTSEASKSGSGGCCIIS

Figure 11. A schematic of the Ras2 protein sequence indicating the location of the phosphorylated serine residues.

Residues circled are those identified to be phosphorylated by the PhosphoPep database.

Previous studies from the laboratory of Dr Campbell Gourlay reported that the deletion of either $\Delta sit4$ or $\Delta ssn3$ led to significant changes in GFP-Ras2 protein localisation during both logarithmic and stationary phases of growth. Interestingly, the phosphorylation sites that were predicted to be affected upon the deletion of either SSN3 or SIT4 were found to be identical and focussed upon the serine residue at position 225 of Ras2p. Two-dimensional electrophoresis was used to identify whether the deletion of either SIT4 or SSN3 resulted in

changes to Ras2 protein phosphorylation. Two-dimensional electrophoresis of $\Delta sit4$, $\Delta ssn3$ and wild type cells identified a putative Ras2 phosphorylation event occurring in both $\Delta sit4$ and $\Delta ssn3$ cells that was not present in wild type cells. This was represented by the appearance of a negatively charged spot in $\Delta sit4$ and $\Delta ssn3$ cells which disappeared following the treatment with alkaline phosphatase. The negatively charged spot occurring in a similar position in both $\Delta sit4$ and $\Delta ssn3$ cells was hypothesized to be the phosphorylation of serine 225 of the Ras2p.

In the present study, we therefor sought to investigate whether modification of Serine²²⁵ led to any changes in Ras2 protein localisation or activity within the cell and whether this was accompanied by any phenotypes in cells expressing either *RAS2*^{S225A} or *RAS2*^{S225E}.

Chapter 2 Materials and Methods

2.1 Growth conditions and media for the culture of Saccharomyces Cerevisiae and Escherichia coli

A Prestige Medical bench-top autoclave was used to sterilise all media. Media was autoclaved at 121 °C, 15 lb/sq.in for 11 mins. All liquid cultures of *Saccharomyces cerevisiae* were incubated at 30 °C with constant rotation at 200 rpm. All liquid cultures of *Escherichia coli* were incubated at 37 °C with constant rotation at 180 rpm. For solid medium 2 % w/v granulated agar (Oxoid technical agar No. 3) was added prior to autoclaving.

2.1.1 Water used in study

Pure deionised water (dH_2O) was produced by Thermo Scientific Barnstead NanoPure Diamond water system. dH_2O was then further sterilized via autoclaving.

2.1.2 Yeast extract, peptone, dextrose (YPD) growth media

Ingredients included 2 % w/v glucose (Fisher), 1 % w/v yeast extract (Oxoid) and 2 % w/v bactopeptone (Difco).

2.1.3 Synthetic complete (SC) drop-out medium

This media was prepared as follows; 2 % w/v glucose (Fisher), 0.77 % Yeast Nitrogen Base without amino acids (Kaiser, Formedium), yeast synthetic complete drop-out media supplement (Formedium). The source of nitrogen for yeast cells grown in this media is ammonium sulphate.

Upon the transformation of cells with plasmid DNA, successful transformants were selected for using auxotrophic selection media through the addition of the appropriate Yeast Synthetic Complete Drop-Out Media Supplement (Formedium).

Table 2. Percentage of auxotrophic selection drop-out supplement added to media

| Amino acid drop-out | Required % |
|---------------------|------------|
| Uracil | 0.19 |
| Leucine | 0.164 |
| Uracil and Leucine | 0.174 |

2.1.4 Nitrogen Starvation Media (NS)

The media was prepared as follows; 2 % glucose (Fisher), 0.675 % Yeast Nitrogen base without amino acids and ammonium sulphate (Difco), 0.193 % yeast synthetic dropout Kaiser mixture without Uracil (Formedium).

2.1.5 Yeast extract and Tryptone (YT) Growth Media

YT growth media was prepared as follows; 0.1 % w/v yeast extract (Oxoid), 1 % w/v analytical grade sodium chloride (Fisher) and 1 % w/v bacto-tryptone (Difco).

For the selection of successfully transformed *E. coli* containing the plasmid of interest, antibiotic resistance markers were used. Ampicillin (Sigma-Aldrich) was added to the growth medium after autoclaving to select for successfully transformed *E. coli* containing plasmids with the *AmpR* gene integrated. Ampicillin was added to a final concentration of 100 μ g/ml, from a 100 mg/ml stock solution in sterile deionised water. To select for *E. coli* colonies containing the gene for kanamycin resistance, kanamycin (Sigma-Aldrich) was supplemented to the growth media after autoclaving. Kanamycin was added to a final concentration of 50 μ g/ml from a 10 mg/ml stock solution in sterile deionised water.

2.2 Saccharomyces cerevisiae strains used in this study

Table 3. The Saccharomyces cerevisiae strains used in this study

| Strain | Genotype | Source/strain ID |
|---|---|------------------|
| BY4741 | MATa hisΔ1 leu2Δ0 met15Δ0 ura3Δ0 | CGY424 |
| BY4741 Δcup9 | MATa his3∆1 leu2∆0 met15∆0 ura3∆0 ∆cup9::KANMX | KO collection* |
| BY4741 Δubr1 | MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 Δubr1::KANMX | KO collection* |
| BY4741 Δ <i>ptr2</i> | MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 Δptr2::KANMX | KO collection* |
| BY4741 Δras2 | MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 Δras2::KANMX | KO collection* |
| BY4741 Δ <i>pde2</i> | MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 Δpde2::KANMX | KO collection* |
| KAY836 – wt | MATa ura 3-52 leu 2 his4-539 | CGY370 |
| KAY23- <i>Δras2</i> | Δras2::leu2 MATa ura 3-52 leu2 his4- 539 | CGY371 |
| BY4741 + Δcox4 | MATa his3Δ1 leu2Δ met15Δ ura3Δ Δcox4::HIS | CGY638 |
| KAY836- <i>RAS2</i> ^{ala18, val19} | his3Δ1, leu2Δ, ura3Δ, met15Δ, RAS2(ala18, val19) | CGY372 |

^{*}Yeast MATa Collection was purchased from Open Biosystems and was produced by the EUROpean Saccharomyces Cerevisiae Archive for Functional analysis (EUROSCARF).

2.3 *Escherichia coli* strains used in this studyDH5 α :

Competent *E. coli* cells were used in this study, the genotype of these cells: *F- endA1 glnV44* thi-1 recA1 relA1 gyrA96 deoR nupG Φ 80dlacZ Δ M15 Δ (lacZYA-argF) U169, hsdR17(rK- mK+), λ -.

DB3.1: Competent *E. coli* cells were used in this study, the genotype of these cells: F- gyrA462 endA1 glnV44 $\Delta(sr1-recA)$ mcrB mrr hsdS20(rB-, mB-) ara14 galK2 lacY1 proA2 rpsL20(Smr) xyl5 Δleu mtl1.

TOP10: Competent *E. coli* cells were used in this study, the genotype of these cells: *F- mcrA* $\Delta(mrr-hsdRMS-mcrBC)$ $\Phi80lacZ\Delta M15$ $\Delta lacX74$ recA1 araD139 $\Delta(araleu)7697$ galU galK rpsL (StrR) endA1 nupG.

Strataclone Solopack: Competent *E. coli* cells were used in this study, supplied by Agilent technologies (Product reference: 200184), the genotype is not published.


2.4 DNA Methods

2.4.1 Plasmids used in the study


Table 4. Plasmids used in the study


| Strain | Description | Selective marker | Source |
|-------------------------|--|------------------|-----------------------------|
| pDONR221 | Gateway Entry Vector | N/A | Addgene |
| pAG426GPD-EGFPccdB | Gateway Destination Vector | URA3 | Addgene |
| pAG416GPD-EGFPccdB | Gateway Destination Vector | URA3 | Addgene |
| pCG347- Active GFP-Ras2 | PYX212 RBD x3GFP URA3- TPI | URA3 | Leadsham |
| pCG46 | pYX142-mtGFP | LEU2 | (Westermann & Neupert 2000) |
| pCG381 | Gateway entry vector PDONR221 RAS2 KAN ^R | URA3 | Addgene |
| pCG502 | PDE2 | LEU2 | CWG plasmid collection |
| pCG557 | Gateway Destination Vector 1H2 416-GPD- ccdB- AMP ^R | URA3 | CWG plasmid collection |
| pCG558 | Gateway Destination Vector 1H3 426-GPD-ccdB - AMP ^R | URA3 | CWG plasmid collection |
| pCG565 | Gateway Expression Clone Ras2 ^{S225E} 416- GPD-EGFP- AMP ^R | URA3 | CWG plasmid collection |
| pCG566 | Gateway Expression Clone | URA3 | CWG plasmid collection |

| | Ras2 ^{S225A} 416-GPD- EGFPAMP ^R | | |
|--------|---|------|---|
| pCG571 | Gateway Expression Clone Ras2 ^{S225E} 426- GPD-EGFPAMP ^R | URA3 | CWG plasmid collection |
| pCG572 | Gateway Expression Clone Ras2 ^{S225A} 426- GPD-EGFP AMP ^R | URA3 | CWG plasmid collection |
| pCG582 | RAS2 in PCG557 AMP ^R | URA3 | This study |
| pCG583 | RAS2 in PCG558 AMP ^R | URA3 | This study |
| pCG586 | Ras2 ^{S225E} in PCG558 AMP ^R | URA3 | This study |
| pCG587 | Ras2 ^{S225A} in PCG558 AMP ^R | URA3 | This Study |
| pCG588 | Ras2 ^{S225E} in PCG557 AMP ^R | URA3 | This Study |
| pCG589 | Ras2 ^{S225A} in PCG558 AMP ^R | URA3 | This Study |
| PCG593 | <i>N-Ras</i> ^{S173A} in PCG558 AMP ^R | URA3 | This study |
| PCG594 | <i>N-Ras</i> ^{S173E} in PCG558 AMP ^R | URA3 | This study |
| PCG595 | N-Ras in PCG558 AMP ^R | URA3 | This Study |
| PCG597 | Gateway Expression Vector <i>N-Ras</i> 416-GPD- EGFP- AMP ^R | URA3 | This Study |
| PCG598 | Gateway Expression Vector <i>N-Ras</i> ^{5173A} 416- GPD-EGFP- AMP ^R | URA3 | This Study |
| PCG599 | Gateway Expression Vector <i>N-Ras</i> ^{5173E} 416- GPD-EGFP- AMP ^R | URA3 | This Study |
| PCG600 | Gateway Expression Vector <i>N-Ras</i> 426-GPD- EGFP AMP | URA3 | This Study |
| PCG601 | Gateway Expression Vector <i>N-Ras</i> ^{5173A} 426- GPD-EGFP AMP ^R | URA3 | This Study |
| PCG602 | Gateway Expression Vector <i>N-Ras</i> ^{5173E} 426- GPD-EGFP AMP ^R | URA3 | This Study |
| PCG636 | Low copy plasmid expressing GFP-ATG8 | URA3 | Professor Frank Madeo, University of Graz. |



Created with SnapGene®








Figure 12. Maps of the plasmids used in the Gateway cloning reaction.

A) pAG416GPDccdB destination vector. B) pAG426GPD destination vector. C) pAG426GPD-ccdB-EGFP destination vector. D) pAG416GPD-ccdB-EGFP destination vector.

2.5 Transformation of plasmid DNA into S. cerevisiae and Escherichia coli

2.5.1 Transformation of *S. cerevisiae* using the lithium acetate method

A sterile inoculation loop was used to pick a fresh colony of yeast. The colony was inoculated into 5 ml of appropriate medium and grown overnight at 30 °C with shaking at 200 rpm. A 1 ml volume of fresh overnight culture was transferred to a 1.5 ml microcentrifuge tube and harvested in a bench-top centrifuge at 3000 rpm for 4 min at room temperature. The supernatant was discarded, and the pellet resuspended in 1 ml of 1x TE buffer at pH 8.0. The cells were pelleted as previously described and resuspended in 1 ml of 1M lithium acetate (LiAc) in TE at pH 8. Cells were pelleted again and resuspended in 0.1 ml of 0.1 M lithium acetate (LiAc) in TE at pH 8. 15 µl of single stranded carrier DNA (boiled herring sperm DNA, 10 mg/ml) was added to the suspension and mixed. 2µl of plasmid DNA at 100 ng/µl was added to the mixture and the mixture vortexed briefly. 700 µl of 40 % polyethylene glycol (PEG 4000 [Sigma]) in 0.1 M LiAc in TE was added and the mixture vortexed briefly. The microcentrifuge tube was then incubated at room temperature for 90 mins with rotation. A 42 °C heat shock for 20 mins followed. Cells were pelleted by centrifugation as previously described and resuspended in 200 µl of sterile deionised water. The cell suspension was spread onto agar plates with the appropriate selective media and incubated at 30 °C for at least 2 days to allow colony growth.

2.5.2 Transformation of S. *cerevisiae* using the lithium acetate method without heat shock

For some strains that displayed sensitivity to heat shock an alternative protocol was used. In these cases, a sterile inoculation loop was used to pick a fresh colony of yeast. The colony was inoculated into 5 ml of appropriate medium and grown overnight at 30 °C with shaking at 200 rpm. A 2 ml volume of fresh overnight culture was transferred to a 1.5 ml microcentrifuge tube and harvested in a bench-top centrifuge at 3000 rpm for 4 mins at room temperature. The supernatant was removed, and the pellet was resuspended, using a bench top vortex, in the reagent cocktail listed in **Table 2.5**. The microcentrifuge tube was incubated at room temperature overnight. The supernatant was removed, and the pellet was resuspended in 200 μ l of sterile water and plated on the appropriate media. Plates were incubated at 30 °C for at least 2 days to allow colonies to grow.

Table 5. Yeast transformation reagents for the heat sensitive transformation protocol

| Transformation reagents |
|---|
| 37 % polyethylene glycol (PEG)-4000 from a 50 % w/v stock |
| 0.1 M LiAc from a 1 M stock |
| 0.1mg ssDNA from a 10 mg/ml stock |
| 0.11 M 2-Mercaptoethnaol (Sigma M6250) |
| 0.4 – 1 μg plasmid DNA |
| Sterile Deionised water to a volume of 324 μl |

2.5.3 Transformation of Escherichia coli with plasmid DNA

A 50 μ l aliquot of competent cell (for preparation protocol refer to Materials and Methods, Section 2.6) suspension was thawed on ice. A volume of plasmid DNA at a concentration of at least 20 ng/ml was added to the solution of competent cells and mixed gently. The suspension was incubated on ice for 1 hour and then incubated at 42 °C for 90 secs. 200 μ l of YT media was added and the suspension was incubated at 37 °C for 30 mins. The suspension was then spread onto YT agar containing the appropriate antibiotic to select for transformants and incubated at 37 °C overnight. Plates were checked for colony growth the following morning.

2.6 Escherichia coli competent cell preparation

E. coli cells (DH5 α) were grown overnight in 10 ml of YT at 37 °C with constant shaking at 180 rpm. The overnight culture was subcultured and diluted in 28 ml YT media to 0.2 OD₆₀₀. The culture was incubated at 37 °C with constant shaking at 180 rpm until the culture reached an OD₆₀₀ of ~0.7. The time at which the culture would reach the required OD₆₀₀ was calculated using the following formula.

[(Log (OD₆₀₀ wanted) – Log (OD₆₀₀ read))/Log2] x doubling time = time to required OD₆₀₀

A 3.75 ml aliquot of pre-heated glycerol (35 °C) was slowly added to the culture. The cell suspension was then incubated on ice for 10 mins. Cells were then harvested by centrifugation at 4000 rpm for 10 mins at 4 °C. Harvested cells were then resuspended in 28 ml of ice cold MgCl₂/ glycerol solution (0.1 M MgCl₂, 15 % glycerol [v/v]). After resuspension, cells were harvested by centrifugation at 3800 rpm for 8 mins at 4 °C and resuspended in 6.25 ml of iced T-salts solution (0.0075 M CaCl₂, 0.006 M MgCl₂, 15 % glycerol [v/v]). A 20-minute incubation period followed. Cells were harvested via centrifugation at 3600 rpm for 6 mins

and resuspended in 1.35 ml of T-salts solution. The cell suspension was then aliquot into prechilled microcentrifuge tubes and stored immediately at -80 °C. Competent cells were ready for use after 24 hours.

2.7 Molecular Biology methods

2.7.1 Plasmid DNA purification from *Escherichia coli* (mini prep)

A sterile inoculation loop was used to pick a fresh colony of *E. coli* which contained the plasmid of interest. The colony was inoculated into 5 ml of YT media supplemented with the appropriate antibiotic and grown overnight at 37 °C with constant rotation at 180 rpm. Cells were harvested in a benchtop centrifuge at 8000 rpm for 3 mins at room temperature and the supernatant removed. The plasmid DNA of interest was extracted from the cell pellet using a Qiagen QIAprep Spin Miniprep Kit according to the manufactures' instructions.

2.7.2 Plasmid purification from *S. cerevisiae*

To isolate plasmid DNA from a yeast strain, the Invitrogen ChargeSwitch plasmid yeast mini kit was used. A sterile inoculation loop was used to pick a fresh colony of yeast containing the plasmid of interest. The colony was inoculated into 5 ml of appropriate medium and grown overnight at 30 °C with shaking at 200 rpm. A 1 ml aliquot of the overnight culture was taken and placed in a sterile 1.5 ml Eppendorf. Cells were then spheroplasted and lysed. The lysate is extracted and placed in a fresh 1.5 ml Eppendorf in a low pH buffer and ChargeSwitch beads are added. The ChargeSwitch beads bind DNA of specific sizes in a low pH environment. The sample is then placed into a magnetic platform (MagnaRack). The beads and DNA are retained in the Eppendorf tubes containing them, and the remaining lysate is washed through and discarded. Following the wash phases, the DNA is eluted by the addition of a low salt buffer.

The addition of the low salt buffer raises the pH in solution and neutralizes the surface charge on the beads, causing the DNA to disassociate from the beads. The concentration of plasmid DNA isolated from yeast using this methodology is relatively low for any future processing or downstream applications. Therefore, the extracted plasmid DNA was then amplified by transforming into bacterial cells (Materials and Methods, Section 2.5.3).

2.7.3 Yeast genomic DNA extraction

Following the yeast transformation protocol described in Materials and Methods, Section 2.5.1, individual colonies were re-streaked onto separate plates containing the appropriate media and labelled as individual clones. A sterile inoculation loop was used to pick a fresh colony of the clone of interest. The colony was inoculated into 5 ml of appropriate medium and grown overnight at 30 °C with shaking at 180 rpm. 1 ml of the overnight culture was aliquot into a fresh 1.5 ml Eppendorf tube and cells were harvested using a benchtop centrifuge spinning at 13 000 rpm for 1 minute. The supernatant was discarded, and cells were washed with 1 ml of sterile de-ionised water using the same centrifuge settings as previously described. The supernatant was discarded, and cells were re-suspended in 500 μl of lysis buffer (100mM Tris pH 8, 50 mM EDTA, 1% SDS). 50 mg of acid washed glass beads were added to each sample, bringing the sample volume up to 1.25 ml. Samples were then vortexed for 1 minute to lyse the cells. To separate the lysed cell debris from the glass beads; a heated needle was inserted into the bottom of the Eppendorf, the existing Eppendorf was placed into a fresh second Eppendorf and centrifuged at 2 000 rpm for 5 mins. To each sample, 275 μl of 7M ammonium acetate (pH 7) was added. A 5-minute incubation period at 65 °C, then a further 5-minute incubation on ice followed. To each sample, 500 µl of chloroform was added, followed by a brief vortex stage, and then centrifuged at 13 000 rpm for 2 mins. The supernatant was extracted and moved to a fresh Eppendorf tube and 1 ml isopropanol was added and briefly mixed by inversion and incubated at room temperature for 5 mins. The sample was then centrifuged at 13 000 rpm for 5 mins and the isopropanol facilitates the precipitation of genomic DNA out of solution. The supernatant was discarded, and the pellet was washed in 70 % ethanol. The ethanol was removed, and the pellet was air dried and suspended in 50 μ l of sterile deionised water.

2.7.4 Whole cell RNA extraction from *S. cerevisiae*

The extraction of RNA from yeast cells was performed using the E.Z.N.A. Yeast RNA Kit Spin protocol. A sterile inoculation loop was used to pick a fresh colony of yeast. The colony was inoculated into 5 ml of appropriate medium and grown overnight at 30 °C with shaking at 200 rpm. The cells were then subcultured and diluted to a calculated OD₆₀₀ of 0.1 and grown for 24 hours. 5x10⁷ yeast cells were harvested from the overnight culture in a 15 ml Falcon tube via centrifugation at 4 °C for 5 mins at 1000 g. The supernatant was discarded, and cells were resuspended in 480 microliters of SE Buffer/lyticase solution. The pellet was resuspended using a vortex for 1 minute. The cells were then incubated at 30 °C for 1 hour to ensure complete lyses of cells. The spheroplasts were then pelleted via centrifugation at 400 g for 5 mins at room temperature. The supernatant was carefully removed and 350 µl of YRL buffer and 50 mg of glass beads was added to the pellet. Using a vortex at 13 000 rpm for 5 mins, the suspension was mixed to lyse and homogenize the sample. The homogenised suspension was then centrifuged at 13,000 g for 3 mins at room temperature. The supernatant was carefully removed and transferred into a new Eppendorf tube. An equal volume of 70 % ethanol to the lysate was added and mixed thoroughly using a vortex for 15 secs. The entire sample, which was around 700 µl, was added to a Hibind RNA mini column assembled in a 2 ml Eppendorf. The sample was then centrifuge at 10 000 g for 30 secs at room temperature and the flow through was discarded. 350 μ l of RNA wash buffer 1 was added to the column and the sample was centrifuged as above.

A DNA denaturing phase followed to ensure denaturing of any residual DNA in the sample. 75 μ I of the DNase1digestion reaction mixture was added onto the surface of the HiBind RNA membrane in each column and incubated at room temperature for 15 mins. 350 μ I of the RNA Wash Buffer 1 was added onto the surface of the HiBind RNA membrane and allowed to soak for at least 5 mins. The sample was centrifuged at 10 000 g for 15 secs and the flow through was discarded. 500 μ I of RNA Wash Buffer II was added to the column and centrifuged and flow through discarded, as in the preceding step. Using the same collection tube, the spin cartridge was centrifuged at 10 000 g for 1 minute to dry the HiBind matrix. The column was transferred to a sterile RNase free 1.5 ml Eppendorf and the RNA was eluted with 50 μ I of DEPC water. Samples were then stored at -80 °C until required for downstream applications.

2.7.5 Illumina library preparation and sequencing

Before library preparation, the quality and quantification of RNA samples were evaluated with TapeStation (Agilent) and Qubit (Thermal Fisher) at the Centre of Genome-Enabled Biology (Aberdeen) by Dr Jin Pu. The samples with the minimum RIN of 8.0 was proceeded. The input of RNA was based on the specifically measured RNA concentration by Qubit. The mRNA-Seq libraries were prepared using TruSq Sample Preparation Kit (Illumina) according to the manufacturer's instructions. Briefly, Poly-A RNA were purified from 500 ng of total RNA with 1ul (1:100) ERCC spike (Thermal Fisher) as an internal control using RNA purification oligo(dT) beads, fragmented and retrotranscribed using random primers. Complementary-DNAs were end-repaired, and 3-adenylated, indexed adapters were then ligated. 15 cycles of PCR

amplification were performed, and the PCR products were cleaned up with AMPure beads (Beckman Coulter). Libraries were validated for quality on Agilent DNA1000 Kit and quantified with the qPCR NGS Library Quantification kit (Roche). The final libraries were equimolar pooling and sequenced using the High Output 1X75 kit on the Illumina NextSeq 500 platform producing 75 bp single end reads. For each library, a depth 20-30 M reads were generated. The quality of sequencing was analysed by FastQC and MultiQC.

2.7.6 Analysis of RNA-Seq data

The analysis of RNA-Seq samples was performed using the Galaxy web platform (www.usegalaxy.org) [202]. The quality of the RNA sequencing reads was checked using FastQC v0.11.5 [203] with default settings. Low quality ends (Phred score < 20) and any adaptor sequences were trimmed using TrimGalore! v0.4.3 [204]. Reads which became shorter than 40 bp after trimming were not progressed for further analysis. After trimming, the quality was checked again using FastQC v0.11.5 [203] to ensure correct trimming. There were no Poly-A reads (more than 90 % of the bases equal A), low quality reads (more than 50 % of the bases with a Phred score < 25) or ambiguous reads (containing N). After processing, the mean Phred score per read was 37. Processed reads were aligned with the reference S. cerevisiae genome S288C version R64-2-1 20150113 (SacCer3) using HISAT2 v2.1.0 [205] with single-end reads and reverse strand settings, remainder of settings were set to default. After alignment, the number of mapped reads which overlapped CDS features in the genome (using S. cerevisiae genome S288C version R64-2-1 20150113 (SacCer3) were determined using featureCounts plug-in v1.6.3 with default settings [206]. Reads aligning to multiple positions or overlapping more than one gene were discarded, counting only reads mapping unambiguously to a single gene. Differential gene expression analysis between conditions was

performed using DESeq2 v1.18.1 [207] with default settings. To identify the cellular pathways which differentially expressed genes are within we conducted Gene Set Enrichment Analysis (GSEA; Broad Institute) [208]. To conduct a GSEA analysis, a list of significantly ($q \le 0.05$) differentially expressed genes, ranked from the most upregulated to the most downregulated were uploaded into the GSEA database and compared to a gene set data base (S288C version R64-2-1_20150113_features gtf annotation file).

2.7.7 Quantification of nucleic acid samples

The concentration of DNA in samples was obtained using either a Thermo Scientific Nanodrop-1000, Biophotometer (Eppendorf) or a Spectrostar Nano UV/Vis spectrum absorbance microplate reader (BMG Labtech). To determine the DNA/RNA concentration from the OD_{260} reading from the Biophotometer, the following equation was used: DNA/RNA concentration (μ g/mL) = OD_{260}/OD_{280} ratio dilution factor. No dilution of sample was required for use of the Nanodrop-1000 and readings were obtained from an analysis of a 1 μ l aliquot sample.

2.7.8 Restriction enzyme digest of DNA

Enzymatic scission of DNA at specific sequence points was achieved using restriction endonucleases from New England Biolabs, Promega and Roche. The buffers used were supplied by the manufactures and the recommended protocols were used.

Table 6. The basic reaction mixture for a restriction digest used in this study

| Reagent | Volume |
|---------------------------------|-------------------------------|
| Restriction digest buffer (10x) | 2 μΙ |
| Bovine Serum Albumin (BSA) | 0.2 μΙ |
| Restriction Endonuclease | 1 μΙ |
| Plasmid DNA | 1.5 μΙ |
| Sterile water | Up to a final volume of 22 μl |

The reagents listed above were added to the pre-determined volume of sterile water required for a 22 μ l reaction mix. All digests underwent a 2-hour incubation at 37 °C. For analyses of the digested products, 10 μ l of the sample was loaded onto an agarose gel.

2.7.9 Agarose gel electrophoresis

For the analysis of DNA fragments and plasmids, agarose gel electrophoresis was undertaken. Typically, agarose gels were composed of 0.8 % (w/v) agarose (Melford, MB12000) in TAE buffer.

Recipe for 1x TAE Buffer: Tris base 4.84 g, Glacial acetic acid 1.14 ml, 0.5 M EDTA, pH 8.0 2 mL, Milli-Q water to 1 L final volume.

For higher percentage agarose gels, up to 1.5 % gels were used to better resolve smaller fragments. The agarose was dissolved in 1x TAE by heating in a microwave oven until the solution became clear. The solution was cooled to ~60 °C before ethicium bromide (10 mg/ml)

was added at a concentration of 0.0167 μ g/ml. The mixture was poured carefully into a gel forming cassette, and a comb was inserted. The gel was left to cool and set for up to an hour. Once the gel had solidified, it was placed in an electrophoresis tank and 1x TAE buffer was added in sufficient quantity to cover the gel surface by 2-3 mm. The comb was then removed. A Promega 1 kb DNA ladder (G57511) was added to the first well and 6x loading buffer containing bromophenol blue was mixed 1 in 6 with the DNA samples. Typically, 10 μ l of sample was loaded into the subsequent wells. For analysis of restriction digestion products, 10 μ l of sample was loaded. A voltage of 80 V was applied to the tank for 30-60 mins until the DNA bands had migrated the desired distance. The DNA fragments were visualised by short wavelength (312 nm) UV transillumination.

2.7.10 Polymerase Chain Reaction (PCR)

For the amplification of DNA sequences, the polymerase chain reaction (PCR) was utilized. The PCR reaction was performed using the Roche 'High Fidelity PCR System and Techno TC-3000 thermal cycler.

1-5 μ l of plasmid DNA was used as the source of the template for PCR reaction. The following reagents were mixed on ice in an Eppendorf PCR tube:

Table 7. Standard PCR reaction composition used in this study

| Reagent | Volume Added | Final concentration |
|------------------------------|--------------|--------------------------------|
| (10x) High Fidelity Buffer + | 5 μΙ | 1x (1.5 ml MgCl ₂) |
| 15 mL MgCL ₂ | | |
| Reverse Primer, 100 pmol/ | 1-5 μΙ | 300 nM |
| μΙ | | |
| Forward Primer, 100 pmol/ | 1-5 μΙ | 300 nM |
| μΙ | | |
| Template DNA | 1-5 μΙ | 0.1-250 ng |
| dNTP mix, 10 mM each dNTP | 1 μΙ | 200 μM each dNTP |
| High Fidelity Enzyme Mix | 1 μΙ | 3.4 U/reaction |
| Sterile Deionised water | Up to 50 μl | - |

PCR reactions were conducted using the cycling conditions described in Materials and Methods, Table 2.7.10.2. After the completion of the reaction, a 5 μ l aliquot of the PCR product was run on an agarose gel. The products of the PCR reactions were purified with the Qiagen 'PCR Purification' kit according to manufactures instructions.

Table 8. Standard 3-step PCR cycling protocol used in this study

| Cycle Step | Cycle | Time (mins) | Number of Cycles |
|----------------------|------------------|-------------|------------------|
| | Temperature (°C) | | |
| Initial Denaturation | 94 °C | 5 mins | 1 |
| Denaturation and | 1) 96 °C | 1 min | 30 |
| | 2) 52 °C | 1 min | |
| Annealing/Extension | 3) 72 °C | 1 min | |
| Final Extension | 72 °C | 5 mins | 5 |

2.7.11 Generation of yeast gene knock outs using LoxP marker cassettes

This procedure was taken from Gueldener et al (2002) [209]. For the generation of yeast strains that contained deletions of specific genes, DNA cassettes were created that recombined with specific regions of the genome to replace the genes encoded within that region.

PCR primers were designed to incorporate 19 or 22 nucleotides that are adjacent to the LoxP sequences flanking the marker, as well as 45 5'nucleotides that anneal with sites on the beginning and end of the target gene to be deleted. The newly designed primers are used in a PCR reaction to generate a DNA sequence consisting of a selection marker flanked by the LoxP sites and a sequence corresponding to regions close to the start and end of the ORF of the target gene. Following the completion of the PCR reaction, the disruption DNA cassette was purified using the genomic DNA extraction (Materials and Methods, Section 2.7.3). The purified disruption cassette was transformed into yeast cells (Materials and Methods, Section 2.5.1). The transformation of the disruption cassette leads to a recombination event allowing the selection marker to replace the target gene. This is achieved due to the recombination driven specificity of the 45 nucleotides flanking the selection marker that are specific for the ORF of the target gene. A successful transformation procedure therefore should produce null mutants of the target gene.

2.7.12 Invitrogen Gateway Cloning Reaction

The Invitrogen Gateway© cloning method was used for the generation of plasmids used in this study. The Gateway system is a cloning method based upon the site-specific recombination of the *lambda bacteriophage*. Two types of recombination sites have been engineered to recombine uniquely between the two ends of a source sequence and a host

vector. The sites have been constricted to enable the recombination reaction to be completely reversible using two sets of catalytic proteins. These two reactions are called LR and BP, so named because of the recombination sites involved in each reaction: LR recombines attL and attR sites, BP recombines attB and attP sites. The recombined sites transform by swapping opposite halves into the opposite set, so attL and attR become attB and attP and vice versa. Vectors engineered to contain these sites have been given the names: Entry Clone, Expression Clone, Donor Vector, and Destination Vector.

2.7.13 BP Cloning Reaction

For the generation of the entry vectors used in this study the Invitrogen Gateway BP cloning reaction was performed. The plasmid containing the *RAS2* nucleotide sequence was extracted and purified using a Qiagen Spin Miniprep Kit and sequenced by Source Bioscience. $0.5~\mu l$ of the purified plasmid DNA was mixed with $0.5~\mu l$ of pDONR221 and $4~\mu l$ of TE buffer in a clean PCR tube. The BP clonase II enzyme was thawed on ice for $\sim 2~mins$ and then vortexed for 2 secs. $1~\mu l$ of BP clonase II was added to the reaction mixture and incubated at room temperature for 1~mins. To terminate the reaction, $0.5~\mu l$ of Proteinase K solution was added to the reaction mixture. The mixture was then vortexed briefly and incubated at 37~C~mins for 10~mins. Samples were incubated at -20~C~mins for 24~mins hours

2.7.14 LR Cloning Reaction

For the generation of the expression clones used in this study, an Invitrogen Gateway LR cloning reaction was used. The LR reaction enables the recombination of the gene of interest contained within an entry clone with a destination vector.

Table 9. LR Cloning reaction

Reagent

| Entry Clone Plasmid DNA | 75 ng/μl |
|---------------------------|----------|
| Destination Vector | 50 ng/μl |
| LR Clonase II | 0.5 μΙ |
| LR Reaction Buffer (5x) | 2 μΙ |
| TE Buffer pH 8 | 2.75 μΙ |

Volume/Mass

The LR reaction mixture listed above was incubated at room temperature for 1 hour. 0.5 μ l of proteinase K was added followed by a 10-minute incubation period at 37 °C. All destination vectors used in this study contain ampicillin and chloramphenical resistance genes. *RAS2* expression clones with a GPD promotor were sequenced with the GPDPro-F primers and the entry clones with M13F.

2.7.15 DNA sequencing

The sequencing of purified plasmid DNA samples was carried out by Source Bioscience Lifesciences, based in Cambridge. The plasmid DNA was sequenced via the Sanger sequencing methodology. Purified by plasmid DNA samples a concentration of 100 ng/ μ l were sent for sequencing with the associated primers at a concentration of 5 μ M. The data from the sequencing reaction was received electronically and analysis of data was carried using ApE- a plasmid editor V.1.17 Copyright © 2003-2008 by M. Wayne Davis.

2.8 Biochemical Methods

2.8.1 Whole cell protein extraction for SDS PAGE

The generation of protein samples required for polyacrylamide gel electrophoresis was achieved using the methodology described in von der Haar et al, (2007) [210]. The concentration of cells in a culture was estimated from the optical density. 2×10^8 cells were harvested via centrifugation for 2 mins at 13 000 rpm. For log phase cultures at an OD_{600} of 0.7 this was around 10 ml. If quantitative electrophoretic analysis was required, the number of cells in a culture was counted under a microscope using a haemocytometer. The volume containing a defined number of cells was harvested using the centrifugation procedure as described above.

Harvested cells were resuspended in 200 μ l of lysis buffer (0.05 M EDTA, 0.1 M NaOH, 2% w/v SDS, 2% v/v β -mercaptoethanol) and incubated at 90 °C for 10 mins. After incubation, 5 μ l of 4 M acetic acid was added and the sample was vortexed for 30 secs before a second 10-minute incubation at 90 °C. 50 μ l of loading buffer (50 % glycerol, 0.25 M Tris-HCl pH 6.8, 0.05 % bromophenol blue) was added to the sample. The sample was then centrifuged for 90 secs at 13 000 rpm in a bench microcentrifuge prior to loading.

2.8.2 Polyacrylamide gel electrophoresis

Polyacrylamide gels were prepared using the recipe listed in Materials and Methods, Table 2.8.2. Each gel was composed of a standard 5 % acrylamide stacking gel and a 7.5-12 % resolving gel. SDSPAGE gels were casted in 0.75 mm glass cassettes (Bio-Rad). The resolving layer was poured into the cassette and allowed to set for 20-30 mins and layered with 1 ml of isopropanol to provide an even top layer surface after solidification of the gel. The

isopropanol was discarded, and the stacking gel solution was then poured into the cassette and an appropriately sized comb was inserted. The stacking layer set for 20 mins.

Table 10. SDS-Page reagents

| Stacking gel | Resolving gel | SDS running buffer |
|---|--|--|
| 126 mM Tris pH 8.8 0.1 % SDS 12 % acrylamide (29:1) 0.15 % ammonium persulphate 0.07 % TEMED | 240 mM Tris pH 6.8 0.1 % SDS 4.3 % acrylamide (29.1) 0.23 % ammonium persulphate 0.07 % TEMED | 0.3 % (w/v) Tris-HCL 1.44 % (w/v) glycine 0.15 % (w/v) SDS |

Polyacrylamide gels were mixed in sterile 50 ml falcon tubes. Ammonium persulfate was freshly dissolved in water at 10% (w/v).

After the final incubation period the comb and gasket were carefully removed, and the cassette was inserted into a gel tank and sealed against the central column. 1x TGS was then added to the gel tank and wells were submerged in TGS buffer. A protein standard (ColorPlus marker p7709S, New England Biolabs) was loaded into the first well of each gel. Protein samples in loading buffer were then loaded into subsequent wells. The electrodes were connected to a BioRad power pack and a voltage of 90 V was applied until the protein front entered the resolving layer, at this point the voltage was increased to 130 V. Once the protein front had migrated through the acrylamide gel to ensure sufficient separation, the voltage was stopped. Careful notice was taken to ensure the protein front did not run off the gel. The gel tank was disconnected from the power pack and the cassettes removed. The gels used in this process were either used for staining with Coomassie blue, or the western blot protocol described in Materials and Methods, Section 2.8.5.

2.8.3 Coomassie staining of SDS-PAGE gels

SDS-PAGE gels were visualised following a 20-minute shaking incubation phase at room temperature with Coomassie brilliant blue stain (40 % (v/v) Methanol, 20 % (v/v) Glacial acetic acid, 0.1 % Coomassie brilliant blue R250), followed by a 20-minute shaking incubation phase with de-stain solution (10 % (v/v) methanol, 10 % (v/v) Acetic acid). Gels were then submerged overnight in sterile water, shaking at room temperature.

2.8.4 Semi-dry transfer of proteins to PVDF membranes

Proteins were separated via molecular mass by SDS-PAGE. The polyacrylamide gel containing the protein samples was removed from the cassette and the stacking layer was discarded. The resolving gel was removed from the cassette and placed in transfer buffer (0.0058 % w/v Tris base, 0.0029 % w/v glycine, 0.00004 % w/v SDS, 20 % v/v methanol). Four pieces of Whatman blotting paper (Thermo Fisher) was cut into 8x9 cm pieces and soaked in transfer buffer. PVDF western blotting membrane (Thermo Fisher) was wet thoroughly in methanol (Thermo Fisher) and then placed in transfer buffer to 10 mins. Two pieces of blotting paper was placed on the anode plate of a Trans-Blot Semi-Dry Transfer cell (BioRad), followed by the PVDF membrane, the polyacrylamide gel, and the final two pieces of blotting paper. To ensure that there were no significant air bubbles present between layers, a roller was used to roll out any excess air. The cathode plate was place on top and the apparatus was connected to a power pack. A voltage of 25 V was applied for 30 mins. Upon completion of the semi-dry transfer the PVDF membrane was removed for use in the immunoblotting procedure as detailed in Materials and Methods, Section 2.8.5.

2.8.5 Immunoblotting procedure

Following the completion of the semi-dry transfer protocol, the PVDF membrane was placed in 6 ml of blocking solution (5 % w/v Dried Skimmed Milk (Oxoid) and PBS/T (Phosphate Buffered Saline and 0.2 % Tween 20 [Sigma]) and incubated with shaking for 1 hour at room temperature. The membrane was briefly washed twice with PBS/T and placed in a 50 ml falcon tube with 6-12 ml of blocking solution containing the appropriate concentration of primary antibody, for details on primary antibodies used see Materials and Methods, Section 2.8.8. A 1-hour incubation with shaking at room temperature followed. The PVDF was carefully removed from the 50 ml falcon tube and rinsed briefly with PBS/T. The membrane was then incubated with PBS/T and washed via shaking for 15 mins, followed by another two 15 min washes, replacing the PBST/T each time. After the completion of the wash phases, the PVDF membrane was placed in a fresh 50 ml falcon tube containing 6-12 ml of blocking solution containing an appropriate concentration of secondary antibody conjugated to Horse-Radish Peroxidase, for details on secondary antibodies used see Materials and Methods, Section 2.8.8. A 30-minute incubation period with shaking at room temperature followed. The PVDF membrane was then washed with PBS/T as previously undertaken after the primary antibody straining. The membrane was then placed in PBS.

2.8.6 ECL detection (Enhanced Chemiluminescence)

The PVDF membrane was placed in a clean polyethylene terephthalate box and the ECL solutions, listed in the table below, were mixed in a 1:1 ration. The PBS used to incubate the PVDF membrane was discarded and the ECL solution was added and incubated for 1 min with constant shaking. The ECL solution was discarded and the membrane was removed and

placed in a Sharon wrap. The membrane was placed into the SYNGENE G: BOX gel doc system and blots were visualised.

The GeneSys Software (Version 1.6.5.0) was used to analyse blots and a Synoptics 6MP camera was used to capture images. To calculate the Ras2p band intensity relative to the Pgk1p loading control, ImageJ version 1.51n was used. Here the integrated intensity of the Ras2p band was calculated and divided by the integrated intensity of the Pgk1p band and normalised to the control strain.

Table 11. Recipes for ECL solutions

| Name | Recipe |
|------------|---|
| Solution 1 | 1 ml luminol 250 mM (3-aminophthalhydrazide from FLUKA No. 09253 0.44 ml p-coumaric acid 90 mM (Sigma No C9008) 10 ml 1 M Tris.HCL (pH 8.5) Water to 100 ml |
| Solution 2 | 64 μl 30% hydrogen peroxide 10 ml 1 M Tris.HCL (pH 8.5) Water to 100 ml |

2.8.7 Stripping of PVDF membrane

Following the completion of an ECL detection on a PVDF membrane, a loading control was required to ensure an even loading of protein to the gel. Here previously bound antibodies were required to be removed from the PVDF to allow for re-probing with a new antibody. The Restore Western Blot Stripping Buffer (ThermoScientific) solution and protocol was used. The PVDF membrane was carefully removed from the 50 ml falcon tube and rinsed briefly with PBS/T. The membrane was then incubated with PBS/T and washed via shaking for 15 mins, followed by another two 15 min washes replacing the PBST/T each time. After the completion of the wash phases, the PVDF was immersed in 10 ml of stripping buffer and incubated for 30

mins at room temperature with shaking. The stripping buffer was discarded and the PVDF membrane was washed with PBS/T as previously undertaken before addition of stripping buffer. Following the completion of the stripping protocol, the PVDF membrane was placed in 6 ml of blocking solution (5 % w/v Dried Skimmed Milk (Oxoid) and PBS/T (Phosphate Buffered Saline and 0.2 % Tween 20 [Sigma]) and incubated with shaking for 1 hour at room temperature before probing with a fresh primary antibody.

2.8.8 Antibodies used in study

Antibodies were used to perform western blot analysis. The antibodies used within this study are listed below.

Primary antibody used for Ras2p detection: Goat anti-Ras2 polyclonal IgG was purchased from Santa Cruz Biotechnology (Santa Cruz Biotechnology, Inc. Bergheimer Str. 89-2, 69115 Heidelberg, Germany) and was used at a dilution of 1/1000.

Secondary antibody for Ras2p detection: Anti-sheep IgG HRP (Sigma, catalogue number A3415) and was used at a dilution of 1/5000.

Primary antibody used for detection Pgk1p: Rabbit anti-Pgk1p (Supplied by Professor Mick Tuite a 1:10 000 dilution and was used as the loading control.

Secondary antibody used for detection Pgk1p: Anti-rabbit (Supplied by Professor Mick Tuite) a 1:500 dilution was used as the following loading control.

Primary antibody used for GFP detection: Mouse anti-GFP (Sigma, catalogue number 1181446000) used at a dilution of 1/1000.

Secondary antibody used for Porin and GFP detection: Anti-Mouse IgG HRP (Sigma, catalogue number #A4416) and was used at a dilution 1/5000.

2.9 Cell biology techniques

2.9.1 Absorbance assays for growth rate analysis of S. cerevisiae cells

A sterile inoculation loop was used to pick a fresh colony of yeast. The colony was inoculated into 5 ml of appropriate medium and grown overnight at 30 °C with shaking at 200 rpm. The optical density of the overnight culture was calculated by absorbance at OD_{600} using an Eppendorf Biophotometer plus. Cultures were diluted to an OD_{600} of 0.1 in 1 ml of the appropriate fresh medium in a sterile 24-well plate (Greiner). Alternatively, cultures were diluted to an OD_{600} of 0.1 in 500 μ l of the appropriate fresh medium in a sterile 48-well plate (Greiner). Growth was measured using a BMG LABTECH FLUOstar OPTIMA or a BMG LABTECH SPECTROstar Nano plate reader.

Table 12. The protocol setting used to measure growth rate

| Cycle Time | 1800 seconds |
|-------------------------|------------------------------|
| Flashes Per Well | 3 |
| Excitation | 600 nm |
| Shaking Frequency | 400 nm |
| Shaking Mode | Double Orbital |
| Additional Shaking Time | 30 Seconds before each cycle |
| Temperature | 30 °C |
| Positioning Delay | 0.5 seconds |

For the analysis and processing of the data generated by the plate reader, the BMG LABTECH MARS data analysis software was used. The data processed in this software was then

exported to Microsoft Excel for further analysis. Each growth curve assay displayed in this thesis is the sum of three biological repeats, each of which includes three technical repeats.

Doubling times for each strain were determined by separately plotting sequential 2-hour data sets individually, each overlapping by 30 minutes, with time in hours or mins (x-axis) against the OD_{600} (y-axis) using Microsoft Excel 2010. For each 2-hour plot, an exponential trend line equation was generated, $y = c e^{(b*x)}$, which is equivalent to $ln(y) = ln(c) + b e^{(b*x)}$, for which b represents the slope and ln(c) represents the y-axis intercept. The 2 hour plot with the highest x value (which represents the slope) in the exponential line equation was selected, and that x-value was used to generate the doubling time (hours) using the formula LN (2)/x.

2.9.2 Cell counting using a haemocytometer

To perform cells counts, a haemocytometer was used. An overnight culture was diluted 1/25 and log phase cultures were enumerated without dilution. A 50 μ L aliquot of culture was loaded onto the haemocytometer and counted under a light microscope using the 100x magnification. When counting budding yeast cells, cells with a bud size greater than one third the size of the mother cell were counted as two cells, if not, buds were not included in the cell count. Only cells existing within, or on the bottom or left-hand line of the box were counted. A minimum of 300 cells were counted when possible.

2.9.3 Viability assay

A sterile inoculation loop was used to pick a fresh colony of yeast. The colony was inoculated into 5 ml of appropriate medium and grown overnight at 30 °C with shaking at 200 rpm. The cell density of the overnight culture was measured using an Eppendorf Biophometer plus. Cells were diluted to an OD₆₀₀ of 0.1 in 5 ml of the appropriate fresh media. Cells were

incubated at 30 °C shaking at 200 rpm for 24 hours. The number of cells in a culture was counted under a microscope using a haemocytometer. Cells were diluted to 2 x 10^3 cells/ml and 150 μ l (300 cells) was plated on to the appropriate media. 300 cells from each sample was plated onto an agar plate, which, for 100 % viability, should lead to the growth of 300 colony forming units (CFU). Plates were incubated at 30 °C for 2-4 days before counting to ensure that slow growing strains had sufficient time to grow. The percentage viability was determined by the dividing the number of observed CFU's by the number of expected CFU's and multiplied by 100.

2.9.4 Di/Tri-peptide supplementation viability assay

A sterile inoculation loop was used to pick a fresh colony of yeast. The colony was inoculated into 5 ml of appropriate medium and grown overnight at 30 °C with shaking at 200 rpm. The cell density of the overnight culture was measured using an Eppendorf Biophometer plus. Cells were diluted to an OD_{600} of 0.1 in 5 ml of the appropriate fresh media. Cells were incubated at 30 °C shaking at 200 rpm for 24 hours. The number of cells in a culture was counted under a microscope using a haemocytometer. Cells were diluted to 2 x 10^3 cells/ml and 300 cells were plated onto either SD-URA or SD –URA with the addition of a specific dipeptide at a 1 mM concentration. The di-peptides used in this study; Leucine-Leucine (Sigma), Alanine-Leucine (Sigma), Tyrosine-Alanine (Sigma) or Histadine-Leucine (Sigma). Alternatively, cells were plated on media containing a mix of all the di-peptides listed above, added together at a 1 mM concentration. Plates were incubated at 30 °C for 2-4 days before counting to ensure that slow growing strains had sufficient time to grow. The percentage viability was determined by the dividing the number of observed CFU's by the number of expected CFU's and multiplied by 100.

2.9.5 Hydrogen Peroxide Sensitivity Assay

A sterile inoculation loop was used to pick a fresh colony of yeast. The colony was inoculated into 5 ml of appropriate medium and grown overnight at 30 °C with shaking at 200 rpm. The cell density of the overnight culture was measured using an Eppendorf Biophotometer plus. Overnight cultures were then diluted to OD_{600} 0.1 in 1 ml of the appropriate media. Cells were diluted to 1 x 10^7 cells/ml and were diluted 1000-fold over three serial dilutions. Each 1000-fold dilution of the sample was plated onto four different agar plates differing in concentration of hydrogen peroxide (H_2O_2). A 3 % percent working stock of hydrogen peroxide (v/v) was made from a 30 % hydrogen peroxide stock solution (v/v). From this stock, 1 mM, 2 mM, 3 mM, and 4 mM concentrations of hydrogen peroxide was added to 40 ml of agar media. Plates were dried and then incubated at 30 °C and checked after 48 and 72 hours. Following incubation, visual analysis was performed to observe the differences in growth. Images were taken on a scanner (CANOscan 4000), 48 hours after plating.

2.9.6 Copper Sensitivity Assay

A sterile inoculation loop was used to pick a fresh colony of yeast. The colony was inoculated into 5 ml of appropriate medium and grown overnight at 30 °C with shaking at 200 rpm. The cell density of the overnight culture was measured using an Eppendorf Biophotometer plus. Overnight cultures were then diluted to OD_{600} 0.1 in 1 ml of the appropriate media. Cells were diluted to 1 x 10^7 cells/ml and were diluted 1000-fold over three serial dilutions. Each 1000-fold dilution of the sample was plated onto four different agar plates differing in concentration of CuSO₄. A 100 mM working stock of CuSO₄ was made. From this stock, 1 mM, 1.5 mM, 2 mM and 3 mM concentrations of CuSO₄ was added to 40 ml of agar media. Plates were dried and then incubated at 30 °C and checked after 48 and 72 hours. Following

incubation, visual analysis was performed to observe the differences in growth. Images were taken on a scanner (CANOscan 4000), 48 hours after plating.

2.9.7 GFP-ATG8 autophagy assay

A sterile inoculation loop was used to pick a fresh colony of yeast. The colony was inoculated into 5 ml of appropriate medium and grown overnight at 30 °C with shaking at 200 rpm. The cell density of the overnight culture was measured using an Eppendorf Biophometer plus. Cells were diluted to an OD₆₀₀ of 0.1 in 5 ml of the appropriate fresh media. Cells were incubated at 30 °C shaking at 200 rpm for 24 hours. Following this, 1ml of culture was transferred to the nitrogen starvation media (Materials and Methods, Section 2.1.4) lacking ammonium sulphate to induce autophagy via nitrogen starvation and incubated at 30 °C with 200 rpm shaking for 6 hours. Total protein was extracted from cells pre- and post-induction of autophagy and subjected to western blotting (Materials and Methods, Section 2.8.5).

2.9.8 Chronological Ageing Assay

A sterile inoculation loop was used to pick a fresh colony of yeast. The colony was inoculated into 5 ml of appropriate medium and grown overnight at 30 °C with shaking at 200 rpm. The cell density of the overnight culture was measured using an Eppendorf Biophotometer plus. The overnight cultures were sub-cultured to a calculated OD₆₀₀ of 0.1 in 10 ml of appropriate medium in 100 ml conical flasks. Samples were incubated at 30 °C with shaking at 200 rpm. After 24 hours of incubation, an aliquot of the culture was taken to calculate the colony forming units (Materials and Methods, Section 2.9.9) and for flow cytometry analysis to measure levels of propidium iodide (Materials and Methods, Section 2.9.12) and dihydroethidium fluorescence (Materials and Methods, Section 2.9.11). Once the aliquot of culture was taken, samples were immediately returned to the incubator to minimise sample

exposure time outside of the incubation parameters. Aliquots of cells were taken from the same culture sequentially at 24-hour intervals for 6 days and colony forming unit counts and flow cytometry analysis were undertaken. The final measurement was taken after 12 days of sample incubation.

2.9.9 Clonogenic Survival Assay of wild type cells overexpressing $RAS2^{S225A}$, $RAS2^{S225E}$ or a plasmid control

An aliquot of 10 μ l of suspended cells was taken from the original culture and diluted in 990 μ l of sterile water. The diluted sample was further diluted by a 1/100 dilution in PBS. The sample was then inserted into a CASY cell counter (Scharfe Systems) and the number of cells in a culture was calculated. Serial dilutions were performed to ensure that 300 cells of each sample were plated onto each agar plate, which, for 100 % viability, should lead to the growth of 300 colony forming units (CFU). Plates were incubated at 30 °C for 48 hours before counting to ensure that slow growing strains had sufficient time to grow. The percentage viability was determined by the dividing the number of observed CFU's by the number of expected CFU's and multiplied by 100.

2.9.10 Flow Cytometry

To detect the presence of fluorescence within yeast cells a BD FACSCalibur flow cytometer was used, and the BD FACStation data management system was used for acquisition and data analysis of samples. The system uses an air-cooled argon-ion laser exciting fluorophore. The FACS counted and analysed 10,000 cells per sample and the flow rate was set to $^{\sim}60~\mu$ l/min. $^{\sim}2~x~10^6$ cells were diluted in 1 ml of 1 M PBS for FACS analysis.

2.9.11Flow cytometry to monitor DHE fluorescence to detect superoxide radicals

The dihydroethidium (DHE) dye (Invitrogen D23107) was used for the detection of superoxide radicals. The blue fluorescent DHE dye is oxidised by superoxide radicals to the red fluorescent form, hydroxyethidium. The 585 nm band pass filter (FL-2) placed in the light path before detection was used for red light detection. Approximately 2 x 106 cells were re-suspended in PBS containing 10µM DHE and incubated for 10-15 mins before FACS analysis.

2.9.12 Flow cytometry to detect Propidium Iodide uptake to assess necrosis

To check for the presence of necrotic cells in a population, 4 μ I of propidium iodide was added 30 secs before being placed into the FACS. Propidium iodide (PI) accumulates in cells when the plasma membrane is compromised and intercalates into nucleic acids. PI can therefor only penetrate necrotic cells and is excluded by viable cells that have an intact plasma membrane. When PI is bound to nucleic acids, the fluorescent excitation maximum is 35 nm and the emission maximum is 617 nm. Propidium iodide (PI) binds to DNA by intercalating between the bases, with little or no sequence preference, and with a stoichiometry of one dye per 4–5 base pairs of DNAs. PI also binds to RNA, necessitating treatment with nucleases to distinguish between RNA and DNA staining. Once the dye is bound to nucleic acids, its fluorescence is enhanced 20- to 30-fold, the fluorescence excitation maximum is shifted ~30–40 nm to the red, and this is relatively low, PI exhibits a sufficiently large Stokes shift to allow simultaneous detection of nuclear DNA. A baseline was set using an unlabelled control.

2.10 Fluorescence Microscopy of yeast cells

2.10.1 Fluorescence Microscopy

For the visualisation of fluorescent cells, an Olympus 1X81 inverted microscope was used. The light source was provided by a Cool LED pE4000 illumination system. All images were captured using an Andor's Zyla 4.2 PLUS sCMOS camera. The acquisition software used to obtain images was Micro-Manger, version 1.4.22. A single drop of Olympus Immoil-F30CC immersion oil was applied to the surface of the cover slip and an Olympus 60 x objective lens (NA = 1.35) was used to locate cells within a sample. An Olympus 100 x objective lens (NA = 1.4) was used to visualize individual cells. Cells with GFP-tagged proteins were observable using the GFP channel with excitation/emission wavelengths of 488/512 nm. DIC images were acquired using a halogen light source with identical settings to GFP imaging. To ensure images were representative of the whole population each microscopy experiment was repeated in triplicate. For the analysis and processing of images the ImageJ FIJI software was used. The counting of cells for phenotype characterisation was conducted by eye from images generated from fluorescent microscopy.

2.10.2 Sample Preparation

A sterile inoculation loop was used to pick a fresh colony of yeast. The colony was inoculated into 5 ml of appropriate low fluorescence selective medium and grown overnight at 30 °C with shaking at 200 rpm. The optical density of the overnight culture was measured using an Eppendorf Biophotometer plus. For stationary phase microscopy analysis, overnight cultures were diluted to an OD_{600} of 0.1 in 5 ml of fresh media and grown for 24 hours. For the analysis of cells in logarithmic phase of cell growth, cells were sub-cultured and grown to OD_{600} 0.7. A 3 μ l aliquot of the culture was placed on a microscope slide and covered with a 20 mm by 20

mm cover slip. A single drop of Olympus Immoil-F30CC immersion oil was added to the cover slip and examination under the microscope was carried out.

2.11 High Resolution Respirometry

The Oroboros O2K Oxygraph High Resolution Respirometer was used to determine the consumption of 02 from mitochondria in cell suspensions. The Datlab 4 software was used for the analysis and acquisition of data generated by the respirometer. The respirometer contained two chambers, each of which was maintained at 30 °C and held 2 ml of cells suspended in media without glucose. To calibrate the instrument, the medium from which the cells were grown in was used. An overnight liquid culture was diluted to a calculated OD₆₀₀ of 0.1 and cells were analysed at 24 hours post inoculation. To ensure that an equal volume of cells was present in each chamber, cells were counted using a haemocytometer. A 1/80 dilution was performed, and a full haemocytometer grid of cells was counted to calculate the number of yeast cells present in 1 ml of culture. The samples were diluted to a cell density of 10⁶ cells/ml into 3 ml of appropriate media. 2.5 ml of each diluted culture was inserted into one of the two chambers to ensure each chamber was full. The chamber stoppers were inserted into position and any residual liquid culture was aspirated away. The exact cell concentration was then entered into the Datlab4 software for an accurate oxygen flux/cell reading.

For the analysis of cells mitochondria, a series of drugs were introduced into the chamber using specifically engineered syringes, which target individual components of the electron transport chain. The following drugs: Triethiltyn bromide (TET) (Sigma-Aldrich), carbonylcyanidep-trifluoromethoxyphenylhydrazone (FCCP) (Fluka), and Antimycin A (AntA) (Sigma-Aldrich) were in added to each sample chamber. The sequence of drug addition was

as follows; a 0.2 mM final concentration TET was added to each chamber (8 μ l from a 50 mM stock solution in DMSO), followed by 0.012 mM FCCP (2 μ l of a 12 mM stock in ethanol) and finally 0.002 mM AntA (2 μ l of a 2 mM stock solution in ethanol). To facilitate the detection of a full respiratory drug response, a 5-minute interval was left between the additions of each drug.

Chapter 3

Yeast as a model organism to study the effects of *RAS2*, *RAS2*^{S225A} or *RAS2*^{S225} overexpression

3.1 Introduction

Ras proteins are small GTPases that act as molecular switches within cells that link extracellular stimuli to intracellular effectors. Ras proteins play a conserved role in the control of both cell growth and proliferation [211]. As a result, mutations that induce the constitutive activation of Ras proteins are often associated with changes in cell behaviour that can lead to disease, such as human cancer [41]. The localisation of Ras proteins are reported to be predominantly to the inner cytoplasmic surface of the plasma membrane, but they can also be observed on endomembrane's, such as the endoplasmic reticulum, and the mitochondrial outer membrane [65][57][212].

In recent years, the localisation and signalling of Ras on the plasma membrane has been extensively studied. It has been shown that Ras undergoes a series of posttranslational modifications that dictate its subcellular localisation. Firstly, farnesylation of the cysteine on the C-terminal CAAX motif targets Ras to the cytosolic surface of the ER where the AAX is proteolytically cleaved and the c- terminus methylated [51][53]. In the majority of Ras proteins cysteine residues close to the CAAX motif are palmitoylated, facilitating the translocation of Ras from the ER to the plasma membrane [60]. Evidence exists to suggest that Ras proteins can undergo phosphorylation events which regulate its activity. Whistler and Rine identified Ser⁴¹² as an important phosphorylation site on the yeast Ras2 protein where substitution of serine with alanine at this residue lead to increased cAMP levels and elevated ration of Ras2-GTP compared to total Ras2 [74][213]. Surprisingly, the phosphorylation of Ras2p in *S. cerevisiae* has not been studied regarding its regulation of intracellular localisation, despite significant evidence existing linking Ras phosphorylation to its localisation in humans. For example, the phosphorylation by PKC of the Serine¹⁸¹ residue

within K-Ras, promotes rapid dissociation of K-Ras from the inner leaflet of plasma membrane to other intracellular membranes, including the outer membrane of mitochondria [77].

While phosphorylation is an important posttranslational modification, little is known on its effect on Ras2 protein activation and localisation. This study aims to further investigate whether Ras2p phosphorylation provides a mechanism that regulates Ras2p trafficking inside the cell.

In the laboratory of Dr Campbell Gourlay, previous investigations using data obtained from the PhosphoPep version 2.0 project www.phosphopep.org/index.php, produced experimental information regarding putative Ras2 phosphorylation sites that are affected by the deletion of *SSN3* and *SIT4* respectively. Interestingly, the phosphorylation sites that were predicted to be affected upon the deletion of either *SSN3* or *SIT4* were found to be identical and focussed upon the serine residue at position 225 of Ras2p. We therefor sought to investigate whether modification of Serine²²⁵ lead to any changes in Ras2 protein localisation or activity within the cell and whether this was accompanied by any phenotypes in cells expressing either *RAS2*^{5225A} or *RAS2*^{5225E}.



Figure 13. Sequence alignment of the yeast Ras2 and Ras1.

Interestingly, an independent group identified the Ser²²⁶ residue in Ras1 to be an important residue for Ras1 phosphorylation, as mutating this residue to an alanine drastically diminishes the level of Ras1 phosphorylation [214]. Upon sequence alignment of yeast Ras1 and Ras2 (*Figure 13*) we show little sequence similarity outside of the GTPase domain. However, the serine site position in both Ras1 and Ras2 is similar suggesting that serine residues located around this position may play a conserved regulatory role within Ras proteins.

3.2 Construction of the *RAS2* mutant alleles- site-directed mutagenesis substitution of the putative Ras2p phosphorylation site Serine²²⁵ by Alanine or Glutamate

To investigate whether Serine²²⁵ phosphorylation is important for the localisation of Ras2p, growth and viability a site directed mutagenesis approach was adopted. The wild type *RAS2* gene was mutated at Serine²²⁵ where the serine was either substituted with alanine to produce a non-phosphoryatable residue or glutamate to produce phosphomimetic residue. Site-directed mutagenesis was previously undertaken by Eman Badr of the Gourlay Lab to replace Serine²²⁵ in the Ras2p with alanine or glutamate in the gateway donor vector PDON221. To confirm the correct introduction of the necessary mutations, samples were sent off for DNA Sequencing as described in Materials and Methods, Section 2.7.15. Expression vectors were generated from the donor vector by use of the gateway LR clonase reaction as described in Materials and Methods, Section 2.7.14. N-terminal tagged GFP vectors for the expression of GFP-Ras2p, GFP-Ras2p^{5225A} and GFP-Ras2p^{5225E} were generated to investigate fluorescently tagged protein localisation. Vectors expressing untagged *RAS2*, *RAS2*^{5225A} and *RAS2*^{5225E} were also generated to investigate growth and viability of cells expressing these constructs.

3.3 Expression of RAS2, RAS2^{S225A} and RAS2^{S225E} alleles in S. cerevisiae

The levels of wild type and mutant Ras2p were determined by western blot analysis as described in Materials and Methods, Section 2.8. To examine whether the expression of the Ras2p changed during different phases of cell growth, samples were prepared from log and stationary cultures. To ensure uniform protein loading, the levels of 3-PhosphoGlycerate Kinase, Pgk1p, in each strain were examined as a control. After probing for the Pgk1p, the membrane was stained with coomassie brilliant blue as a further control for protein loading. To calculate the Ras2p band intensity relative to the Pgk1p loading control, ImageJ version 1.51n was used. Here the integrated intensity of the Ras2p band was calculated and divided by the integrated intensity of the Pgk1p band and normalised to the control strain.

Firstly, the levels of wild type and mutant Ras2p were analysed in a wild type background. As expected, exponentially growing cells expressing either the wild type or *RAS2* mutant alleles presented an increase in Ras2p expression when compared to the wild type control (*Figure 14/15*). An increase in Ras2p expression was observed in cells overexpressing *RAS2*^{5225A} or *RAS2*^{5225E} when compared to the *RAS2* overexpression strain (*Figure 14/15*). Furthermore, in cells overexpressing *RAS2*^{5225A} or *RAS2*^{5225E} an increase in protein degradation products was observed when compared to the wild type control and cells overexpressing *RAS2* (*Figure 14*). As cells reached stationary phase of cell growth, 24 hours after inoculation, the levels of Ras2p in all overexpression strains were increased when compared to the wild type control (*Figure 16/17*). An increase in Ras2p expression was observed in wild type cells overexpressing *RAS2*^{5225A} or *RAS2*^{5225E} when compared to the *RAS2* overexpression strain (*Figure 16/17*). No significant difference in Ras2p degradation products was observed between wild type cells overexpressing *RAS2*, *RAS2*^{5225A} or *RAS2*^{5225A} or

RAS2, RAS2^{S225A}, RAS2^{S225E} or an empty plasmid were expressed in a $\Delta ras2$ strain to examine the affects that the mutants of RAS2 have on the levels of Ras2p produced in the absence of endogenous Ras2p. No Ras2p signal was detected in a $\Delta ras2$ strain expressing the empty plasmid backbone control, confirming the deletion of RAS2 in this background (Figure 18). No significant difference in the levels of Ras2p in strains were observed in cells overexpressing RAS2^{S225A} or RAS2^{S225E} when compared to the RAS2 overexpression strain (Figure 18/19).



Figure 14. A western blot showing the detection of Ras2p in cells overexpressing RAS2, RAS2^{S225A}, RAS2^{S225E} or an empty plasmid control in a wild type background.

Cells were grown in SD –URA media and sampled during exponential phase of cell growth. To ensure uniform protein loading, the levels of Pgk1p were detected after probing for Ras2p. This experiment was repeated three times and a representative data set is shown.






Figure 15. A bar chart representing the change in Ras2p band intensity relative to the Pgkp loading control of wild type cells overexpressing RAS2, RAS2^{S225A}, RAS2^{S225E} or empty plasmid control.

Cells were grown in –URA media and sampled during the exponential phase of growth. The data shown is an average of three biological repeats and the error bars represent the standard deviation.




Figure 16. A western blot showing the detection of Ras2p in cells over expressing RAS2, RAS2^{S225A}, RAS2^{S225E} or an empty plasmid control in a wild type background.

Cells were grown in SD – URA media and sampled during stationary phase of growth. To ensure uniform protein loading, the levels of Pgk1p were detected after probing for Ras2p. This experiment was repeated three times and a representative data set is shown.

Ras2p band intensity relative to the loading control




Figure 17. A bar chart representing the change in Ras2p band intensity relative to the Pgkp loading control of wild type cells overexpressing RAS2, RAS2^{S225A}, RAS2^{S225E} or an empty plasmid control.

Cells were grown in –URA media and sampled during stationary phase of growth. The data displayed is an average of three biological repeats and the error represent the standard deviation.




Figure 18. A western blot showing the detection of Ras2p in Δras2 cells over expressing RAS2, RAS2^{S225A}, RAS2^{S225E} or an empty plasmid control.

Cells were grown in SD –URA media and sampled during stationary phase of growth. To ensure uniform protein loading, the levels of Pgk1p were detected after probing for Ras2p. This experiment was repeated three times and a representative data set is shown.




Figure 19. A bar chart representing the change in Ras2p band intensity relative to the Pgkp loading control of Δ ras2 cells overexpressing RAS2, RAS2^{S225A}, RAS2^{S225E} or an empty plasmid control.

Cells were grown in –URA media and sampled during stationary phase of growth. The data displayed is an average of three biological repeats and the error represent the standard deviation

3.4 Analysis of the effects of phosphorylation of Serine²²⁵ upon Ras2p localisation

3.4.1 Microscopic analysis of wild type cells expressing GFP-Ras2p, GFP-Ras2p S225A or GFP-Ras2p S225E

We sought to determine the localisation of N-terminally GFP-tagged Ras2p, Ras2p^{S225A} and Ras2p^{S225E} to determine whether disruption of this site of phosphorylation would affect localisation. An N-terminal GFP-tag was preferred over a C-terminal GFP-tag, as a C-terminal GFP-tag will be cleaved during Ras2 protein processing and furthermore interfere with the C-terminal CAAX motif and hinder Ras2p membrane targeting. The localisation of Ras2p was examined upon overexpression of the mutant constructs in both stationary and logarithmic phases of cell growth. Plasmids expressing either GFP-Ras2p, GFP-Ras2p^{S225A} or GFP-Ras2p^{S225E} were transformed into wild type cells and an expression vector containing only the

GFP label was used as a control. During logarithmic phase of cell growth, a widespread/diffused GFP signal was observed in wild type cells overexpressing GFP from the control plasmid. In wild type cells overexpressing either GFP-Ras2p, GFP-Ras2p^{S225A} or GFP-Ras2p^{S225E} a strong plasma membrane localisation of fluorescently labelled Ras2p was seen (Figure 20).

During stationary phase of cell growth wild type cells overexpressing the control plasmid displayed widespread/diffused GFP signal throughout the cytoplasm of the cell (Figure 20). In wild type cells overexpressing either GFP-Ras2p, GFP-Ras2p^{S225A} or GFP-Ras2p^{S225E} a predominant localisation of GFP-Ras2p was observed at the plasma membrane (Figure 20). It was noted that these strains were also seen to localise GFP-Ras2p to intracellular foci which was not observed in the control strain. However, such an observation was noted infrequently. To quantify which was the predominant localisation of GFP-Ras2p, 100 cells for each strain were counted on three separate days and the number of cells displaying either plasma membrane, diffused/widespread and nuclear GFP-Ras2 localisation was calculated and represented as a percentage of the total number of cells counted. In both stationary and logarithmic phases of cell growth, wild type cells expressing the control plasmid displayed no nuclear or plasma membrane localisation of GFP (Figure 21/22). Whereas 70-80 % of wild type cells expressing either GFP-Ras2p, GFP-Ras2p^{S225A} or GFP-Ras2p^{S225E} displayed a predominant localisation at the plasma membrane with a small population of cells displaying a widespread/diffused GFP signal. No Nuclear localisation of GFP-Ras2p, GFP-Ras2p^{S225A} or GFP-Ras2p^{S225E} was observed (Figure 21/22). This data set suggest that GFP-Ras2p localises primarily to the plasma membrane in both log and stationary phase of growth regardless of the phosphorylation state of Serine²²⁵.




Figure 20. Images taken by fluorescent microscopy of wild type cells overexpressing either GFP-RAS2, GFP-RAS2^{S225A} or GFP-RAS2^{S225E} during logarithmic and stationary phase of cell growth.

The Fluorescent signal represents the presence of Ras2p within cells and a vector containing only the GFP probe was introduced into wild type cells as a control. Cells were cultured in SD – URA growth media. This experiment was repeated three times and a representative data set is shown. Scale bar – $10 \, \mu m$




Figure 21. Graphical representation of the localisation of GFP-Ras2p in wild type cells expressing either GFP-RAS2, GFP-RAS2^{5225A} or GFP-RAS2^{5225E} during logarithmic phase of cell growth.

A vector containing only the GFP probe was used as a control. Cells were cultured in SD –URA growth media. To quantify the localisation of GFP-Ras2p, 100 cells for each strain were counted on three separate days with a total 300 cells being counted and the number of cells displaying the different phenotypes observed was calculated and represented as a percentage of the total number of cells counted. The data represents an average of three biological repeats and error bars represents the standard deviation.




Figure 22. Graphical representation of the localisation of GFP-Ras2p in wild type cells expressing either GFP-RAS2, GFP-RAS2^{S225A} or GFP-RAS2^{S225E} during stationary phase of cell growth.

A vector containing only the GFP probe was used as a control. Cells were cultured in SD –URA growth media. To quantify the localisation of GFP-Ras2p 100 cells for each strain were counted on three separate days with a total 300 cells being counted and the number of cells displaying the different phenotypes observed was calculated and represented as a percentage of the total number of cells counted. The data represents an average of three biological repeats and error bars represents the standard deviation.

3.5 Analysis of the effects of phosphorylation of Serine²²⁵ upon the activation of Ras

3.5.1 Microscopic analysis of wild type cells expressing Ras2p, Ras2p^{S225A}, Ras2p^{S225E} co-expressed with an GFP-RBD probe

To investigate whether the modification of the Serine²²⁵ residue of Ras2p influences Ras activity a construct was introduced that expresses the Ras binding domain of human Raf1 fused to GFP [70]. The RBD domain binds to Ras proteins only in their GTP-bound state. The localisation of active-Ras proteins was analysed during the stationary and logarithmic phase

of growth. In these experiments a plasmid overexpressing Ras2p, Ras2p^{S225A} or Ras2p^{S225E} was introduced into wild type cells and their activity assessed by GFP-RBD localisation (*Figure 23*). In wild type actively growing yeast cells, the GFP-RBD signal is predominantly localised at both the plasma membrane and the nucleus as has previously been described [70]. During stationary phase, Ras activity is reduced as cells stop dividing and accordingly the probe was seen as a diffuse signal throughout the cell with a faint signal in the nucleus [70].

Interestingly, during logarithmic phase of growth wild type cells overexpressing either Ras2p^{5225A} or Ras2p^{5225E} showed very little plasma membrane or nuclear localisation of the GFP-RBD signal (*Figure 23/24*). Instead the GFP-RBD probe was observed to accumulate at the nuclear envelope (*Figure 23/24*). Such nuclear envelope localisation was never observed in either the control or Ras2p overexpression strains. This provides evidence that the modification of Serine²²⁵ leads to a change in the localisation of the active population of Ras when compared to the control and Ras2p overexpression strains during logarithmic growth. As the localisation of GTP-bound Ras2p dictates its interaction with its effector proteins and thus downstream signalling pathways, we hypothesize that the change in the localisation of the active Ras population observed in wild type cells overexpressing *RAS2*^{5225A} or *RAS2*^{5225E} may result in significant phenotypic changes when compared to the control and *RAS2* overexpression strains.

During stationary phase of cell growth, wild type cells expressing the control, or Ras2p overexpression plasmid presented an RBD-GFP probe signal that was predominantly seen as a diffused cytoplasmic signal with a faint nuclear signal (*Figure 23/25*). In a small percentage of cells, we observed the RBD-probe signal manifesting in intracellular foci, which was not observed during logarithmic growth (*Figure 23*).

Significant differences in RBD-GFP probe localisation was observed in wild type cells overexpressing Ras2p^{S225A} or Ras2p^{S225E} during stationary phase growth (*Figure 23/25*). In wild type cells overexpressing either Ras2p^{S225A} or Ras2p^{S225E}, we observed nuclear envelope localisation of the RBD-probe, which again was not seen in the control or Ras2p overexpression strain (*Figure 23/25*). An increase in the number of intracellular foci in these mutants was also observed when compared to the control strain (*Figure 25*). Here we suggest that the modification of Ras2^{S225} leads to changes in active Ras localisation in both logarithmic and stationary phases of cell growth.




Figure 23. Fluorescence microscopy images of wild type strains overexpressing RAS2, RAS2^{S225A}, RAS2^{S225E} or an empty plasmid backbone control using a GFP-RBD probe during logarithmic and stationary phase of growth.

Fluorescence signal represents the presence of active Ras within cells. Cells were cultured in SD-URA/-LEU growth media. This experiment was repeated three times and a representative data set is shown. Scale bar - $10 \mu m$.




Figure 24. Graphical representation of the localisation of active-Ras in wild type cells expressing either RAS2, RAS2^{S225A}, RAS2^{S225E} or an empty plasmid control during logarithmic phase of cell growth. Cells were cultured in SD –URA/-LEU growth media.

To quantify the localisation of active Ras 100 cells for each strain were counted on three separate days with a total 300 cells being counted and the number of cells displaying the different phenotypes observed was calculated and represented as a percentage of the total number of cells counted. The data represents an average of three biological repeats and error bars represents the standard deviation.




Figure 25. Graphical representation of the localisation of active-RAS in wild type cells expressing either RAS2, RAS2^{S225A}, RAS2^{S225E} or an empty plasmid control during stationary phase of cell growth.

Cells were cultured in SD –URA/-LEU growth media. To quantify the localisation of active Ras 100 cells for each strain were counted on three separate days with a total 300 cells being counted and the number of cells displaying the different phenotypes observed was calculated and represented as a percentage of the total number of cells counted. The data represents an average of three biological repeats and error bars represents the standard deviation.

3.6 Growth analysis of yeast cells overexpressing RAS2, RAS2^{S225A} or RAS2^{S225E}

To investigate the growth of yeast strains that overexpress the yeast *RAS2*^{S225A} or *RAS2*^{S225E} mutant alleles, growth and viability was compared to wild type cells overexpressing *RAS2* or an empty plasmid backbone control. The growth of *S. cerevisiae* in liquid culture is characterized into four distinct phases: lag, logarithmic (exponential), post-diauxic and stationary phase (*Figure 26*). Each growth phase reflects the availability of nutrients and the adaption to changes in nutrient levels or exposure to stress.




Figure 26. A diagram depicting the growth phases of S. cerevisiae cultivated in rich medium supplemented with glucose.

The optical density (OD) of yeast cells is measured at 600nm. The logarithmic (log) phase of growth represents fermentation of glucose. In log phase the presence of glucose suppresses mitochondrial respiratory function via the mechanism of glucose repression, and cells obtain their energy requirements from fermentative glycolysis resulting in the production of ethanol. The diauxic shift occurs when glucose levels become depleted and cells must shift their metabolism from fermentative growth to respiratory growth, and the aerobic utilisation of ethanol. The post-diauxic phase occurs when cells have fully shifted to respiratory growth and utilise oxidative phosphorylation to support cellular functions. Stationary phase represents a period of minimal growth because of nutrient depletion and high cell density. Solid colours indicate steady states, diagonal stripes transient states.

The lag phase represents the period during in which cells are adapting to new media addition or adaption to the environment and represents a period of minimal growth or time spent in the G_0 phase of the cell cycle. Cells transitioning into the exponential phase of growth represent actively proliferating cells which in our culture conditions cells preferentially use glucose to generate energy by fermentation and suppression of oxidative phosphorylation, the so called Crabtree effect [214].

The diauxic shifts represent a shift from glucose utilisation to the use of ethanol produced during fermentation and marks a period of glucose de-repression and upregulation of mitochondrial biogenesis to support the necessary oxidative phosphorylation. The stationary phase of cell growth represents a commitment to cell cycle exit and accumulation of storage carbohydrates [215]. The limited growth that can be detected during stationary phase requires a functional mitochondrial electron transport chain [215].

3.6.1 Overexpression of *RAS2*^{S225A} or *RAS2*^{S225E} in yeast cells leads to growth defects

The growth of *S. cerevisiae* can be influenced by several factors such as temperature, pH, and the availability of nutrients. To analyse the growth of yeast strains overexpressing *RAS2*, $RAS2^{S225A}$, $RAS2^{S225E}$ or an empty plasmid control, a growth assay was performed as described in Materials and Methods, Section 2.9.1. The growth of both a wild type strain and a $\Delta ras2$ strain expressing the RAS2 mutant alleles were analysed to determine whether the overexpression of either $RAS2^{S225A}$ or $RAS2^{S225E}$ affects cells in the presence of endogenous Ras2p.

In the presence of endogenous Ras2p the overexpression of either *RAS2*^{5225A} or *RAS2*^{5225E} led to a lower final OD, early transition into the post-diauxic phase of cell growth and extended lag phase when compared to the control strain (*Figure 27*). Furthermore, In the presence of endogenous Ras2p the overexpression of *RAS2*^{5225A} or *RAS2*^{5225E} led to a decrease in the exponential growth rate when compared to the control strain (*Figure 28*). The doubling times (growth rates) for a wild type control strain and a wild type strain overexpressing *RAS2* was approximately 180 minutes (*Figure 28*). Wild type cells expressing either *RAS2*^{5225A} or *RAS2*^{5225E} displayed a significant increase in doubling time to approximately 200 minutes (*Figure 28*).




Figure 27. Growth analysis of S. cerevisiae wild type cells overexpressing RAS2, RAS2^{S225A}, RAS2^{S225E} or empty plasmid control.

The growth analysis was carried out in SD –URA media as described in Materials and Methods (Section 2.9.1). This data represents an average of three biological repeats and error bars represent the standard deviation.




Figure 28. Growth rate analysis of S. cerevisiae wild type cells overexpressing RAS2 or RAS2^{S225A} or RAS2^{S225E}

The growth rate analysis was carried out as described in Materials and Methods (Section 2.9.1). The data represents an average of three biological repeats and error bars represents the standard deviation. A One-way ANOVA using a Dunnetts multiple comparison test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value \leq 0.05 and *** = adjusted p value \leq 0.001.

The alleles *RAS2*, *RAS2*^{S225A} or *RAS2*^{S225E} were overexpressed in a $\Delta ras2$ strain to determine whether the expression of these alleles would result in a growth phenotype in the absence of endogenous Ras2p. The overexpression of either *RAS2*^{S225A} or *RAS2*^{S225E} in a $\Delta ras2$ background led a lower final OD, early transition into the post-diauxic phase of cell growth and extended lag phase when compared to the control strain (*Figure 29*). Without the presence of endogenous Ras2p the overexpression of either *RAS2*^{S225A} or *RAS2*^{S225E} led to a decrease in the exponential growth rate when compared to the control strain (*Figure 30*). The doubling times (growth rates) for a $\Delta ras2$ control strain and a $\Delta ras2$ strain overexpressing *RAS2* was approximately 180 minutes (*Figure 30*). No significant difference in growth rate was observed

when RAS2 or an empty plasmid control was overexpressed in either wild type cells or a $\Delta ras2$ background. $\Delta ras2$ cells overexpressing either $RAS2^{5225A}$ or $RAS2^{5225E}$ displayed a significant increase in doubling time when compared to the $\Delta ras2$ control and RAS2 overexpression strain (Figure 30). In wild type cells, the overexpression of either $RAS2^{5225A}$ or $RAS2^{5225E}$ presented a doubling time of 200 minutes (Figure 29). In a $\Delta ras2$ background, the overexpression of $RAS2^{5225E}$ presented a doubling time of also 200 minutes with a doubling of 190 minutes observed in the $RAS2^{5225A}$ strain (Figure 30). Suggesting that the growth defects caused by the overexpression of $RAS2^{5225A}$ or $RAS2^{5225E}$ are dominant as defects occur irrespective of whether endogenous Ras2p is present.




Figure 29. Growth rate analysis of a S. cerevisiae Δ ras2 strain overexpressing RAS2, RAS2^{S225A}, RAS2^{S225E} or an empty plasmid control.

The growth analysis was carried out in SD –URA media as described in Materials and Methods (Section 2.9.1). The data represents an average of three biological repeats and error bars represents the standard deviation.




Figure 30. Growth rate analysis of S. cerevisiae Δ ras2 cells overexpressing RAS2, RAS2^{S225A}, RAS2^{S225E} or an empty plasmid control.

The growth rate analysis was carried out as described in Materials and Methods (Section 2.9.1). The data represents an average of three biological repeats and error bars represents the standard deviation. A One-way ANOVA using a Tukey multiple comparison test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value \le 0.05 and *** = adjusted p value \le 0.001.

3.6.2 Overexpression of either $RAS2^{S225A}$ or $RAS2^{S225E}$ in yeast cells leads to decreased cell viability

To determine whether the overexpression of either $RAS2^{S225A}$ or $RAS2^{S225E}$ affects viability in both a wild type and $\Delta ras2$ background, a viability assay was conducted. An overnight culture was re-inoculated to 2 x 10^3 cells/ml and incubated for 24 hours. 200 μ l (containing 300 cells) was plated onto selective, -URA agar plates. These were left to incubate at 30 °C for 36 hours and the colonies were then counted to allow quantification of colony forming units (CFUs). Viability of cells analysed from the inoculated culture represented the viability of cells, or cell death, during nutrient deprivation. Analysing viability of yeast cells under stresses such as nutrient deprivation can shed light on whether cells are functioning correctly. A stationary phase, after 24 hours of growth, wild type strain expressing a control plasmid, had approximately 40 % viability when grown in SD -URA medium.

The overexpression of *RAS2* in a wild type and $\Delta ras2$ background lead to an increase in cell viability when compared to the control strains (*Figure 31*). In cells overexpressing the empty plasmid control the loss of ras2 lead to no significant change in viability (*Figure 31*). The overexpression of either $RAS2^{S225A}$ or $RAS2^{S225E}$ in both a wild type and $\Delta ras2$ background lead to a two-fold reduction in colony forming efficiency when compared to wild type and $\Delta ras2$ background control strains (*Figure 31*). We can conclude that the overexpression of $RAS2^{S225A}$ or $RAS2^{S225E}$ leads to both perturbed growth and a reduction in viability when compared to the control strains in both a wild type and $\Delta ras2$ background.




Figure 31. A colony forming efficiency assay of S. cerevisiae wild type or Δras2 cells overexpressing RAS2, RAS2^{S225A}, RAS2^{S225E}or an empty plasmid control grown in SD –URA media

A) A colony forming efficiency assay of S. cerevisiae wild type cells overexpressing RAS2, RAS2^{S225A}, RAS2^{S225E} or an empty plasmid control grown in SD –URA media. A colony forming efficiency analysis was carried out as described in Materials and Methods (Section 2.9.3). A One-way ANOVA using a Dunnetts multiple comparison test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value \leq 0.05 and *** = adjusted p value \leq 0.001. B) A colony forming efficiency assay of S. cerevisiae Δ ras2 cells overexpressing RAS2, RAS2^{S225A}, RAS2^{S225E} or an empty plasmid control, grown in SD –URA. The colony forming efficiency analysis was carried out as described in Materials and Methods (Section 2.9.3). A One-way ANOVA using a Tukey multiple comparison test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value \leq 0.05 and *** = adjusted p value \leq 0.001.

3.6.3 Overexpression of *RAS2*^{S225A} or *RAS2*^{S225E} in a yeast cells leads to a sensitivity to oxidative stress

Ras activity has been linked to cells ability to adapt to environmental stress [216]. We investigated the effect of oxidative stress on wild type cells expressing *RAS2*, *RAS2*^{S225A}, *RAS2*^{S225E} using a spotting assay as described in Materials and Methods, Section 2.9.5.

On the control plate a reduction in growth was observed in wild type cells overexpressing either *RAS2*^{S225A} or *RAS2*^{S225} when compared to the control strain (*Figure 32*). This is

concordant with the phenotypes observed in the growth assay (*Figure 27*) and the viability assay (*Figure 31*). Interestingly, the overexpression of *RAS2* in wild type cells led to an increase in growth when compared to the wild type control in all conditions investigated (*Figure 32*). As the concentration of hydrogen peroxide increased, the growth of wild type cells overexpressing *RAS2*^{5225A} or *RAS2*^{5225E} decreased when compared to the wild type control and *RAS2* overexpression strains (*Figure 32*). At a hydrogen peroxide concentration of 3 mM, we observe growth in both the control strain and the *RAS2* overexpression strain, but growth was absent in wild type cells expressing either *RAS2*^{5225A} or *RAS2*^{5225E} (*Figure 32*). This suggests that the overexpression of either *RAS2*^{5225A} or *RAS2*^{5225E} leads to sensitivity to oxidative stress in wild type cells.




Figure 32. Spotting assay of wild type cells overexpressing RAS2, RAS2^{S225A,} RAS2^{S225E} or an empty plasmid control.

Cells were serially diluted from 2*10^6/ml to 2*10^3/ml and plated onto SD -URA plates supplemented with increasing concentrations of hydrogen peroxide.

To investigate whether the overexpression of either *RAS2*^{5225A} or *RAS2*^{5225E} in wild type cells leads to hydrogen peroxide sensitivity in liquid media, growth analysis was conducted when the media was supplement with 2 mM hydrogen peroxide. As previously observed, the expression of *RAS2*^{5225A} or *RAS2*^{5225E} in wild type cells leads to growth defects when grown in SD –URA media (*Figure 31*). However wild type cells overexpressing either *RAS2*^{5225A} or *RAS2*^{5225E} and grown in 2 mM hydrogen peroxide, presented a further significant increase in lag time and a decrease in final OD reached when compared to cells expressing *RAS2*^{5225A} or *RAS2*^{5225E} grown without the presence of hydrogen peroxide (*Figure 33*). Upon addition of hydrogen peroxide, we also observed a significant increase in doubling time when compared to wild type cells expressing *RAS2*^{5225A} or *RAS2*^{5225E} grown without the supplementation of hydrogen peroxide to the media (*Figure 34*).




Figure 33. Growth analysis of S. cerevisiae wild type cells overexpressing RAS2, RAS2^{S225A}, RAS2^{S225E} or an empty plasmid control.

A growth analysis of wild type cells overexpressing RAS2, RAS2^{S225A}, RAS2^{S225E} or an empty plasmid control was carried out in SD –URA or SD-URA + 2mM H_2O_2 media as described in Materials and Methods (Section 2.9.1). This data represents an average of three biological repeats and error bars represent the standard deviation.




Figure 34. Growth rate analysis of wild type cells overexpressing RAS2, RAS2^{S225A}, RAS2^{S225E} or an empty plasmid control.

A growth rate analysis of wild type cells overexpressing RAS2, RAS2^{S225E} or an empty plasmid control grown in either SD –URA or SD –URA+ 2mM H_2O_2 was carried out as described in Materials and Methods (Section 2.9.1). The data represents an average of three biological repeats and error bars represents the standard deviation. A One-way ANOVA using a Tukey multiple comparison test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value \leq 0.05 and *** = adjusted p value \leq 0.001.

3.6.4 Overexpression of $RAS2^{S225A}$ or $RAS2^{S225E}$ in yeast cells leads to copper sensitivity

We have previously shown that the overexpression of either *RAS2*^{S225A} or *RAS2*^{S225E} in wild type cells leads to oxidative stress sensitivity. We sought to investigate whether the overexpression of either *RAS2*^{S225A} or *RAS2*^{S225E} in wild type cells resulted in other environmental stress sensitivities, such as heavy metal ion stress. Here we supplemented copper sulphate (CuSO₄) at varying concentrations to the growth media and investigated the effect of heavy metal ion stress on the growth of wild type cells overexpressing *RAS2*,

RAS2^{S225A}, *RAS2*^{S225E} or an empty plasmid control using a spotting assay as described in Materials and Methods, Section 2.9.6.

On the control plate a reduction in growth was observed in wild type cells overexpressing either *RAS2*^{5225A} or *RAS2*⁵²²⁵ when compared to the control strain (*Figure 35*). As the concentration of CuSO₄ increased, the growth of wild type cells overexpressing *RAS2*^{5225A} or *RAS2*^{5225E} decreased when compared to the wild type control and *RAS2* overexpression strains (*Figure 35*). At a CuSO₄ concentration of 3 mM, we observe growth in both the control strain and the *RAS2* overexpression strain, but no growth was observed in wild type cells expressing either *RAS2*^{5225A} or *RAS2*^{5225E} (*Figure 35*). This suggests that the overexpression of either *RAS2*^{5225A} or *RAS2*^{5225E} leads to sensitivity to CuSO₄ in wild type cells.




Figure 35. Spotting assay of wild type cells overexpressing RAS2, RAS2^{S225A,} RAS2^{S225E} or an empty plasmid control.

Cells were serially diluted from 2*10^6/ml to 2*10^3/ml and plated onto SD -URA plates supplemented with increasing concentrations of copper sulphate. This experiment was completed three times and a representative result is shown.

3.7 Chronological ageing analysis of *S. cerevisiae* cells overexpressing *RAS2*^{5225A}

3.7.1 Overexpression of $RAS2^{S225A}$ in wild type cells reduces chronological life span

To further investigate the effects of the overexpression of the *RAS2*^{s225A} on both growth and viability a chronological ageing assay was conducted. Overnight cultures of wild type cells overexpressing the empty plasmid backbone control or *RAS2*^{s225A} mutant allele were grown and sub-cultured to a calculated OD₆₀₀ of 0.1 in SD –URA media. After 24 hours of incubation, an aliquot of the culture was taken to calculate the colony forming units (Materials and Methods, Section 2.9.9) and for flow cytometry analysis to measure levels of propidium iodide (Materials and Methods, Section 2.9.12) and dihydroethidium fluorescence (Materials and Methods, Section 2.9.11) to assess necrosis and superoxide production respectively. Aliquots of cells were taken from the same culture sequentially at 24-hour intervals for 6 days and colony forming unit counts and flow cytometry analysis were undertaken. The final measurement was taken after 12 days of sample incubation.




Figure 36. A chronological ageing assay of wild type cells over expressing RAS2^{5225A} or an empty plasmid control grown in SD –URA.

The chronological ageing assay was conducted as described in materials and method (Section 2.9.8). The data represents an average of three technical repeats and error bars represents the standard error of the mean.

After 24 hours of incubation the wild type control shows ~40 % viability compared to ~20 % in wild type cells overexpressing $RAS2^{S225A}$ (Figure 36). At day 2 we see an unexpected increase in viability in the wild type control but see a decrease in viability in cells overexpressing $RAS2^{S225A}$. Over time we observed an overall decrease in viability when compared to the first time point in both strains. At day 12, the $RAS2^{S225A}$ mutant was unable to form viable colonies whereas the control strain had a colony forming efficiency of ~18 %. Thus, under the conditions used the overexpression of $RAS2^{S225A}$ leads to a complete loss of viability after 12 days of incubation which was not observed in the wild type control (Figure 36).

3.7.2 Flow cytometry to analyse the levels of ROS in wild type cells expressing *RAS2*^{S225A}

To investigate the levels of cell death in cells overexpressing *RAS2*^{5225A}, fluorescence-activated cell sorting (FACS) was utilised. This flow cytometry-based technique was used to determine whether the overexpression of *RAS2*^{5225A} results in an increase in ROS. Increased levels of ROS within cells is indicative of cell stress or programmed cell death [217][155][218]. The dye dihydroethidium (DHE) was used to analyse ROS levels within cells. DHE is oxidised by superoxide radicals (O2⁻⁻). The reaction between superoxide and DHE leads to a fluorescence output that can be detected using a flow cytometer. ROS accumulation was measured using flow cytometry as described in Materials and Methods, Sections 2.9.11. A marker (M1) was set to incorporate the standard peak for the comparison of samples to a control sample grown without any ROS indicator dye. The M1 marker was set at the same fluorescence intensity position on the x axis of all subsequent samples. The second marker (M2) was set to the right-hand side of the M1 marker and incorporated any peaks that represented an increase in fluorescence intensity. The control had no value for the M2 marker as there was no increase fluorescence detected.




Figure 37. A bar chart presenting the percentage of DHE positive cells in wild type cells overexpressing RAS2^{S225A} or an empty plasmid control.

Strains were grown in SD-URA and measurements were taken over a 12-day period of continuous incubation. Cells were incubated with DHE in a 96 well plate for 15 minutes to measure superoxide production. The data displayed is an average of three biological repeats and error bars represent standard deviation

In both the wild type control and the $RAS2^{S225A}$ strain there was a very low percentage of DHE positive cells after the first day of growth suggesting a small proportion of ROS producing cells (Figure 37). Between days 2 to 6 there was an increase in the percentage of DHE positive in both strains. At day 6, the percentage of DHE positive cells rose to ~20% in both strains. At day 12 the percentage of DHE positive cells in the wild type control increased to 50 % and 55% in wild type cells overexpressing $RAS2^{S225A}$, respectively (Figure 37). This data set suggests that the overexpression of the $RAS2^{S225A}$ mutant does not lead to a loss of viability that correlates with an increase in ROS production, a phenotype commonly linked to forms of cell death in yeast [217].

3.7.3 Flow Cytometry to analyse the levels of necrosis in wild type cells expressing *RAS2*^{S225A}

To investigate the levels of necrosis in the wild type control and wild type cells overexpressing *RAS2*^{5225A} propidium iodide was used. Propidium iodide (PI) intercalates into double stranded nucleic acids when the cell membrane is compromised. PI can therefore only penetrate necrotic cells and is excluded by viable cells and so its uptake is a useful marker of this mode of cell death. A marker (M1) was set to incorporate the standard peak for the comparison of samples to a control sample grown without any Propidium Iodide. The M1 marker was set at the same fluorescence intensity position on the x axis of all subsequent samples. The second marker (M2) was set to the right-hand side of the M1 marker and incorporated any peaks that represented an increase in fluorescence intensity. The control had no value for the M2 marker as there was no increase fluorescence detected.

In both the wild type control and wild type cells overexpressing *RAS2*^{5225A} the percentage of PI positive cells was negligible at day 1 (*Figure 38*). Between days 1-4 there was a small increase in the percentage of PI positive cells from 1 to 10% in both strains. This was again expected, as the number of days of continuous growth increases the population of ageing cells in the culture will increase leading to an increase in cell death and hence an increase in the percentage of PI positive cells. At day 6 we observed a further increase in the percentage of PI positive cells in both strains, with the percentage of PI positive cells in the wild type control marginally exceeding that of the *RAS2*^{5225A} mutant strain. At day 12 a significant increase in PI positive cells is observed in the wild type control strain when compared to the *RAS2*^{5225A} strain. In the wild type control the percentage of PI positive cells reaches 50 % of the population with wild type cells overexpressing *RAS2*^{5225A} showing 40 % of the population

being PI positive (*Figure 38*). This data suggests that the overexpression of *RAS2*^{S225A} in wild type cells does not lead to a loss of viability that can be explained by an increase in necrosis.




Figure 38. A bar chart presenting the percentage of PI positive cells in wild type cells overexpressing RAS2^{S225A} or an empty plasmid control.

Strains were grown in SD-URA and measurements were taken over a 12-day period of continuous incubation Cells were incubated with PI in a 96 well plate for 15 minutes to measure cell death. The data displayed is an average of three technical repeats and error bars represent standard deviation.

3.8 The overexpression of either *RAS2*^{S225A} or *RAS2*^{S225E} in wild type cells presents no significant abnormalities in cells ability to regulate autophagy

In *S. cerevisiae*, Ras proteins mediate autophagy through the activity of PKA [219][167]. The RAS/cAMP/PKA pathway has been shown to be highly interconnected with the TOR pathways which is also involved in the regulation of autophagy in yeast [219][167][166]. Both Tor and Ras often control overlapping effectors, including effectors involved in autophagy. We aim to investigate whether the overexpression of either *RAS2*, *RAS2*^{S225A} or *RAS2*^{S225E} in a *GFP-ATG8* strain leads to changes in cells ability to regulate autophagy. Here we analyse the autophagy-

related ubiquitin-like protein Atg8 as a tool for monitoring and quantifying autophagy upon the overexpression *RAS2*, *RAS2*^{5225A} or *RAS2*^{5225E} in yeast cells (*Figure 39*).

Atg8 most commonly exists conjugated to the lipid phosphatidylethanolamine (PE). In S. cerevisiae, Atg8-PE conjugation is regulated by the nutritional status of the cells. During nutrient-rich conditions, Atg8 mainly exists in the unconjugated form but upon nitrogen starvation most of the Atg8 population conjugates to PE [220]. During nitrogen starvation Atg8-PE is recruited to the phagophore assembly site and localizes to both the inner and outer phagophore membranes, but is generally not detected on the surface of completed autophagosomes [220]. Upon autophagosome completion, Atg8-PE localised to the innerautophagosome membrane is transported to the vacuole where it is degraded by vacuolar proteases as part of the autophagic body [220]. The population of Atg8 present on the outer membrane of the autophagosome is released via the deconjugation of the Atg8-PE by a Atg4dependent cleave step [221]. GFP-Atg8 shows the same behaviour as Atg8, and autophagic flux can be followed by monitoring the vacuolar delivery and subsequent breakdown of GFP-Atg8. When autophagic flux is normal, GFP-Atg8 that is present inside the autophagosome is cleaved after the autophagic body membrane is lysed and the contents are exposed to the vascular hydrolases. The proteolysis of GFP-Atg8 liberates an intact GFP moiety, which accumulates in the vacuole as autophagy proceeds. The increase in free GFP levels can be detected and quantified by western blot analysis and correlated with the autophagic rate [222][223].

We transformed plasmids overexpressing either *RAS2*, *RAS2*^{S225A} or *RAS2*^{S225E} into a *GFP-ATG8* background to assess autophagic rate. An empty plasmid backbone was transformed into a *GFP-ATG8* background as a control. *ATG8–GFP* cells overexpressing either *RAS2*, *RAS2*^{S225A},

RAS2^{5225E}, or an empty plasmid control were grown in SD-URA for 24 hours to stationary phase. Following this, 1ml of culture was transferred to nitrogen starvation media (Materials and Methods, Section 2.1.4) to induce autophagy, and incubated at 30 °C with 200 rpm shaking for 6 hours (Materials and Methods, Section 2.9.7). Total protein was extracted from cells pre- and post-induction of autophagy and subjected to western blotting (Materials and Methods Section 2.8). We did not observe any significant differences in autophagic flux in *GFP-ATG8* strains overexpressing *RAS2*, *RAS2*^{5225A} or *RAS2*^{5225E} when compared to the control (*Figure 39*). In the absence of nitrogen starvation, no significant differences in the detection of GFP-ATG8 or GFP were observed between strains (*Figure 39*). In the presence of nitrogen starvation, a significant increase in GFP detection was detected in all strains but no significant difference in free GFP detection was noted between strains (*Figure 39*). As no significant differences in GFP liberation upon nitrogen starvation was observed when compared to the control strain, we propose that the overexpression of *RAS2*, *RAS2*^{5225A} or *RAS2*^{5225E} does not result in abnormalities in autophagic flux in wild type cells.




Figure 39. A western blot showing the detection of GFP in GFP-ATG8 cells overexpressing RAS2, RAS2^{S225A}, RAS2^{S225E} or an empty plasmid control.

Cells were grown in SD –URA media for 24 hours. 1ml of culture was transferred to nitrogen starvation media to induce autophagy via nitrogen starvation and incubated at 30°C with 200 RPM shaking for 6 hours. Total protein was extracted from cells pre- and post-induction of autophagy and subjected to western blotting. To ensure uniform protein loading, the levels of Pgk1p were detected after probing for Ras2p. This experiment was repeated three times and a representative data set is shown.

- 3.9 Analysis of the effects of the overexpression of *RAS2*^{S225A} or *RAS2*^{S225E} upon mitochondria morphology
- 3.9.1 Microscopic analysis of wild type cells overexpressing *RAS2*^{5225A}, *RAS2*^{5225E} or an empty plasmid control and co-expressed with a GFP-mitochondria probe

Ras activity has been linked to the regulation of mitochondrial function [224][218] [225]. To investigate the effect of the modification of Ras2^{S225} upon mitochondria morphology, wild type cells expressing either $RAS2^{S225A}$, $RAS2^{S225E}$ or an empty plasmid control were transformed with a GFP-mitochondria probe. During stationary phase of growth, no significant differences in mitochondrial inheritance or morphology was observed in wild type cells overexpressing $RAS2^{S225A}$ or $RAS2^{S225E}$ when compared to the control strain (Figure 40).




Figure 40. Images taken using fluorescence microscopy of wild type strains overexpressing RAS2^{S225A}, RAS2^{S225E} or an empty plasmid control co-expressed with a GFP-mitochondria probe during stationary phase of growth.

Fluorescence signal represents the presence of mitochondria within cells. The GFP mitochondria probe contains the first 69 amino acids of subunit 9 of the FO ATPase of Neurospora crassa [Su9(1–69)] which is a mitochondrial matrix targeting sequence and includes a processing site for the mitochondrial matrix processing peptidase (Westermann & Neupert 2000). Cells were cultured in SD –URA/-LEU growth media. This experiment was repeated three times and a representative data set is shown.

3.10 Respirometry to assess mitochondrial function in wild type cells overexpressing *RAS2*^{5225A} or *RAS2*^{5225E}

Our results indicate that the overexpression of either $RAS2^{S225A}$ or $RAS2^{S225E}$ in both a wild type and $\Delta ras2$ background can lead to a loss in viability that is not accompanied by an increase in either ROS accumulation or PI staining. One possibility is that cells overexpressing either $RAS2^{S225A}$ or $RAS2^{S225E}$ are in fact senescent or quiescent and that the loss of viability does not represent cell death, but rather an inability to divide. We noted no significant abnormalities in mitochondrial inheritance or morphology in cells overexpressing either $RAS2^{S225A}$ or $RAS2^{S225E}$, however we did not investigate mitochondrial activity. To address this, we measured respiration within wild type cells overexpressing $RAS2^{S225A}$ or $RAS2^{S225E}$.

A high-resolution respirometer was used to measure respiration by analysing the oxygen consumption of wild type cells overexpressing either *RAS2*^{S225A}, *RAS2*^{S225E} or an empty plasmid control. The oxygen consumption was measured as O₂ flow per cell (*Figure 41*). The drugs Triethiltyn bromide (TET), Carbonylcyanide p-trifluoromethoxyphenylhydrazone (FCCP), and Antimycin A (AntA) were used to investigate the functioning of individual components of the mitochondrial respiratory chain.




Figure 41. A typical respirometry profile generated from the Oroboros oxygraph-2k.

The blue line shows oxygen concentration and the red line represents the oxygen flux per cell (pmol/s*Mill). The black arrows indicate the steady state oxygen flux (Routine), the induced mitochondrial resting state (Leak), the maximal capacity of the electron transport system (ETS) and the non-mitochondrial oxygen flux (nmt). For the analyses of individual components of the respiratory chain specific drugs were added to the chambers. The drug TET was used to induce leak respiration, FCCP was used to inhibit ATP synthase and therefore allow maximal electron transport through the ETS and AntA was used to inhibit the ETS.

To measure 'Leak' respiration we used the drug TET, which inhibits ATP synthase complex V. ATP synthase produces energy in the form of ATP through the pumping of protons across the mitochondrial inner-membrane space (IMS) into the mitochondrial matrix. Inhibition of ATP synthase results in the accumulation of protons within the IMS, leading to an inhibition of the movement of electrons through the electron transport chain. The activity of ATP synthase therefore represents an integral control mechanism. Upon the addition of TET, any respiration that is detected when ATP synthase is inhibited does so because of protons moving freely across the IMM independently of the pump, and thus called leak respiration. If the leak respiration of a strain is higher than that of the control strain, we can conclude that

more respiration has been detected that is occurring independently of ATP synthase proton pumping activity and by association, ATP synthesis.

Mitochondrial membrane potential is a major regulator of electron passage, if the membrane potential is too high electrons cannot passage along the ETC as this requires proton pumping into the IMS, which becomes more difficult as the membrane potential is increased. The inhibition of ATP synthase stops election movement as the resulting affect is an increase in membrane potential. When a TET induced drop in respiration is not observed, it suggests that oxygen consumption and electron movement occurs independently of ATP synthase and therefor ATP is not synthesized as it requires the movement of protons through the pump; this is termed uncoupled respiration.

To measure the maximal capacity of the electron transport system (ETS) the drug FCCP was used. FCCP is a proton ionophore that forms pores in the IMM rendering it permeable and permitting the free flow of protons across it. The resulting effect if the disruption of the membrane potential provided by the proton gradient allowing the ETC to function at its maximal potential. As such, the higher the ETS detected, the higher the capacity of the ETC.

To measure the non-mitochondrial (nmt) origin of respiration the drug Antimycin A (AntA) was used. AntA inhibits cytochrome C reductase (complex III) through binding to the Qi site and preventing the transfer of electrons. Complex III is the third phase in the ETC and is oxidised at the Qi site, therefor inhibition of this site prevents re-oxidation by oxygen. As a result, any oxygen consumption detected after the addition of AntA is therefor of nmt origin.




Figure 42. A bar chart showing the routine, leak, ETS and NMT O2 flux values for wild type cells overexpressing RAS2^{S225A}, RAS2^{S225E} or an empty plasmid backbone control.

The data shown represents one experiment.

A significant reduction in routine respiration was observed upon the overexpression of RAS2^{5225E} in wild type cells when compared to the control strain (Figure 42). The overexpression of RAS2^{5225E} presented the most notable reduction, with a routine respiration of 0.2 (mt)[pmol/(s*Mill)], compared to 13.1 (mt)[pmol/(s*Mill)] in the wild type control (Figure 42). Our results indicate that the overexpression of either RAS2^{5225E} or RAS2^{5225E} in wild type cells results in a significant decrease in routine respiration when compared to the control strain. A significant decrease in leak respiration was also noted upon the overexpression of RAS2^{5225E} or RAS2^{5225E} when compared to the wild type control (Figure 42). Interestingly, leak respiration was not detected in wild type cells overexpressing RAS2^{5225E}. As the leak respiration of strains overexpressing RAS2^{5225E} or RAS2^{5225E} is lower than that of the control strain, we can conclude that the respiration detected in these strains is not occurring independently of ATP synthase proton pumping activity.

A significant decrease was observed in the maximal capacity of the electron transport system (ETS) in wild type cells overexpressing *RAS2*^{S225A} or *RAS2*^{S225E} when compared to the wild type control, therefor suggesting that the overexpression of either *RAS2*^{S225A} or *RAS2*^{S225E} causes a reduction in the overall capacity of the ETS (*Figure 42*).

Individual components of the ETC were further analysed to identify whether a component was affected by the overexpression of either *RAS2*^{S225A} or *RAS2*^{S225E}. This was completed by comparing the oxygen flux ratios between the Routine and ETS (R/E) and the Leak and ETS (L/E). The oxygen flux ratios from each strain were compared to the wild type expressing an empty plasmid backbone.

The ratio obtained from dividing the Routine respiration rate by the ETS respiration rate (R/E) defines how close to the maximal capacity the mitochondria are functioning during Routine respiration. The closer to 1 the R/E ratio is, the closer to maximum capacity the ETS is working in that strain. A higher R/E ratio could suggest more uncoupling of the ETC, an increase in ADP driven respiration or a limitation of the ETC components.

The ratio obtained from dividing the Leak respiration rate by the ETS respiration rate (L/E) was analysed to determine whether the ETC is uncoupled. The closer to 1 the L/E ratio is, the higher the levels of uncoupled respiration that are occurring independently of ATP synthase. Uncoupled respiration is not transformed into energy by phosphorylation of ADP.




Figure 43. The oxygen flux ratios between the Routine and ETS (R/E) and the Leak and ETS (L/E) are shown for wild type cells overexpressing RAS2^{S225A}, RAS2^{S225E} or an empty plasmid backbone control.

The data shown represents one experiment.

The increase in the R/E ratio observed in wild type cells overexpressing $RAS2^{S225A}$ suggests that the mitochondria in these cells are working closer to the maximal capacity when compared to the wild type control (*Figure 43*). To determine whether the increase in R/E was due to uncoupled respiration, the ratio for L/E was analysed. The L/E ratio was decreased in wild type cells overexpressing $RAS2^{S225A}$, which suggests a decrease in uncoupled respiration, when compared to wild type control (*Figure 43*). As the mitochondria in wild type cells overexpressing $RAS2^{S225A}$ are functioning close to their maximal capacity, we can conclude that wild type cells overexpressing $RAS2^{S225A}$ are neither necrotic nor apoptotic.

The decrease in the R/E ratio observed in wild type cells overexpressing *RAS2*^{S225E} suggests that the mitochondria in these cells are not functioning close to the maximal capacity when compared to the wild type control (*Figure 43*). To determine whether there is an increase in uncoupled respiration when compared to the control strain, the ratio for L/E was analysed. The L/E ratio was 0 in wild type cells overexpressing *RAS2*^{S225E}, which suggests there is no

uncoupled respiration present (*Figure 43*). We suggest that the overexpression of *RAS2*^{S225E} in wild type cells results in severe mitochondrial dysfunction, as opposed to repression. From the data generated in this study, we see no evidence of cell death markers even when respiration is minimal. We therefor conclude that the overexpression of either *RAS2*^{S225A} or *RAS2*^{S225E} results in a deficit of growth resumption that accounts for the loss of viability observed.

3.11 Sequence alignment between Ras2 and human N-Ras suggests that Serine²²⁵ is conserved in human N-Ras at Serine¹⁷³

We have shown that the Serine²²⁵ residue of the Ras2 protein is important for growth, viability, and the localisation of Ras. We hypothesized that this residue may be conserved in higher eukaryotes. To address this, sequence alignment between the Ras2 protein and the human N-Ras protein was performed (*Figure 44*). Remarkably, although significant sequence divergence between the yeast and human Ras proteins outside of the GTPase domain and C terminal CAAX box, we discovered that Ras2 Serine²²⁵ was conserved in human N-Ras at Serine¹⁷³ (*Figure 44*). The conservation of this serine residue in human Ras proteins may suggest an important role of this residue in higher eukaryotic systems. Plasmids overexpressing the wild type *NRAS* gene or plasmids containing the *NRAS* gene mutated at Serine⁵¹⁷³, where the serine was either substituted with alanine to produce a non-phosphoryatable residue or glutamate to produce phosphomimetic residue, were transformed into wild type cells and growth analysis was performed.



Figure 44. Sequence alignment of the Ras2 protein and human N-Ras shows that Serine²²⁵ of Ras2p (circled) is conserved in N-Ras at Serine¹⁷³.

3.11.1 The expression of *NRAS*, *NRAS*^{S173A} or *NRAS*^{S173E} induces growth defects in wild type cells

As sequence alignment revealed conservation of the yeast Ras2⁵²²⁵ phosphorylation site in the human Nras protein, constructs expressing human *NRAS* or human *NRAS* mutations at the equivalent phosphorylation site (Ser¹⁷³) were transformed into wild type cells. To analyse the growth of yeast strains overexpressing *NRAS*, *NRAS*^{5173A}, *NRAS*^{5173E} or an empty plasmid control, a growth assay was performed as described in Materials and Methods, Section 2.9.1. Overexpression of either *NRAS*, *NRAS*^{5173A} or *NRAS*^{5173E} in wild type cells resulted in severe growth defects when compared to the wild type control (*Figure 45*). The expression of either wild-type or mutated human *NRAS* led to an increase in lag time, early transition to diauxic growth and overall lower final biomass when compared to the control strain (*Figure 45*). The mutated forms of human *NRAS* were seen to perturb growth to a greater extent when

compared to the wild-type Human *NRAS* expressing strain. A significant increase in doubling time was observed upon the overexpression *NRAS*, *NRAS*^{S173A}, *NRAS*^{S173E} in wild type cells when compared to the control strain (*Figure 46*).




Figure 45. Growth analysis of S. cerevisiae wild type cells overexpressing RAS2, RAS2^{S225A}, RAS2^{S225E} or empty plasmid control.

The growth analysis was carried out in SD –URA media as described in Materials and Methods (Section 2.9.1). This data represents an average of three biological repeats and error bars represent the standard deviation.




Figure 46. Growth rate analysis of S. cerevisiae wild type cells overexpressing RAS2 or RAS2^{S225A} or RAS2^{S225E}.

The growth rate analysis was carried out as described in Materials and Methods (Section 2.9.1). The data represents an average of three biological repeats and error bars represents the standard deviation. A One-way ANOVA using a Dunnets multiple comparison test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value \le 0.05 and *** = adjusted p value \le 0.001.

3.11.2 Expression of NRAS, NRAS S173A or NRAS S173E in yeast cells leads to a reduction in viability

To determine whether the overexpression of either *NRAS*, *NRAS*^{S173A} or *NRAS*^{173E} led to changes in viability in wild type cells we performed a colony forming efficiency assay, as described in Materials and Methods, Section 2.9.3. The overexpression of either *NRAS*, *NRAS*^{S173A} or *NRAS*^{S173E} in wild type cells resulted in a significant reduction in viability when compared to the plasmid control in the wild type (*Figure 47*). Our data suggests that the overexpression of Human *NRAS* in yeast cells leads to a significant decrease in viability

regardless of the status of Ser¹⁷³. This data alone, therefor does not allow us to determine the significance of this residue without further studies.




Figure 47. A colony forming efficiency assay of S. cerevisiae wild type cells overexpressing NRAS, NRAS^{S173A}, NRAS^{S173E} or an empty plasmid control grown in SD –URA media.

A colony forming efficiency analysis was carried out as described in Materials and Methods (Section 2.9.3). This data represents three biological repeats and the error bars represent the standard deviation. A One-way ANOVA using a Dunnets multiple comparison test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value \leq 0.05 and *** = adjusted p value \leq 0.001.

3.12 Discussion of Results

Ras proteins are small GTPases that act as molecular switches within cells that link extracellular stimuli to intracellular effectors. Ras proteins play a conserved role in the control of both cell growth and proliferation [211]. As a result, mutations that induce the constitutive activation of Ras proteins are often associated with changes in cell behaviour that can lead to disease, such as human cancer [41]. The localisation of Ras proteins are reported to be predominantly to the inner cytoplasmic surface of the plasma membrane, but they can also be observed on endomembranes, such as the endoplasmic reticulum, and the mitochondrial outer membrane [65][57][212]. It has been shown that Ras undergoes a series of posttranslational modifications that dictate its subcellular localisation. Surprisingly, the phosphorylation of Ras2p in S. cerevisiae has not been studied in regards to its regulation of intracellular localisation, despite significant evidence existing linking phosphorylation to Ras localisation in humans [50][77]. While phosphorylation is an important posttranslational modification, little is known on its effect on Ras2 protein activation and localisation. Previous studies conducted by the Kent Fungal Lab, under the supervision of Dr Campbell Gourlay have identified the residue Ser²²⁵ of Ras2p as a potential phosphorylation site within the Ras2 protein of S. cerevisiae. The present study investigates further whether Ras2p phosphorylation provides a mechanism that regulates Ras2p trafficking inside the cell.

The data presented in this chapter suggests that the modification of the Ser²²⁵ residue of Ras2p is important for both localisation and activity of Ras proteins. We have shown that during both log and stationary phases of growth, the overexpression of either $RAS2^{S225A}$ or $RAS2^{S225E}$ in wild type cells results in significant changes in the localisation of active Ras populations when compared to the RAS2 overexpression strain and wild type control. Actively

growing wild type cells localise GTP-bound Ras to the plasma membrane and nucleus. In wild type cells, such localisation results in the activation of the cAMP/PKA pathway, which signals to the cell to initiate both growth and proliferation. We suggest that during exponential growth, wild type cells overexpressing either *RAS2*^{5225A} or *RAS2*^{5225E} sequester active Ras to the nuclear envelope with reduced activity seen at the plasma membrane and nucleus. We hypothesize that the miss-localisation and inappropriate activation of Ras at the nuclear envelope results in aberrant activation of the cAMP/PKA pathway.

Upon nutrient depletion, GTP-bound Ras populations present a widespread/diffused signal with a faint nuclear localisation within wild type cells. Interestingly, we show that the overexpression of RAS2^{5225A} or RAS2^{5225E} presents a nuclear envelope localisation of GTP-bound Ras which was not observed in either the control or RAS2 overexpression strains. We suggest that the overexpression of RAS2^{5225A} or RAS2^{5225E} leads to the miss localisation of active Ras to the nuclear envelope and an inappropriate activity during nutrient depletion, a time in which Ras activity should be minimal. We hypothesize that the resulting localisation of GTP-bound Ras caused by the overexpression of RAS2^{5225A} or RAS2^{5225E}, results in the inappropriate activation of PKA during a period of growth where its activity should be reduced.

The localisation of GFP-Ras2p, GFP-Ras2p^{S225A} or GFP-Ras2p^{S225E} was investigated using fluorescent microscopy. Surprisingly, no significant changes in the localisation of fluorescently labelled Ras2p was observed between wild type cells overexpressing *RAS2*, *RAS2*^{S225A} or *RAS2*^{S225E}. The predominant localisation of GFP-Ras2p was observed at the plasma membrane in both stationary and exponential phase of cell growth. As previously mentioned, the overexpression of *RAS2*^{S225A} or *RAS2*^{S225E} resulted in significant differences in the localisation

of active Ras population when compared to the control and *RAS2* overexpression strain. Therefor it was surprising that the overexpression of the mutant *RAS2* alleles failed to result in changes in GFP-Ras2p localisation. As the RBD domain binds to Ras proteins only in their GTP-bound state and does not differentiate between Ras1 and Ras2, we hypothesize that the modification of Ser²²⁵ results in the miss localisation of both Ras proteins when only in their GTP-bound state.

In the current study, the localisation of both active Ras and GFP-Ras2p was investigated exclusively in wild type cells. For future investigations, we believe it would be useful to study the localisation of active Ras populations and GFP-Ras2p in a $\Delta ras2$ background. Such investigations will reveal the effects of the overexpression of either *RAS2*, *RAS2*^{5225A} or *RAS2*^{5225E} on the localisation of active Ras populations in the absence of endogenous wild-type Ras2p. Similarly, we would like to investigate the localisation of GFP-Ras2p, GFP-Ras2p^{5225A} or GFP-Ras2p^{5225E} in a $\Delta ras2$ background to identify whether the presence of endogenous wild type Ras2p affects the localisation of GFP-Ras2p, GFP-Ras2p^{5225E}.

Western blot analysis confirmed that Ras2, Ras2p^{S225A} and Ras2p^{S225E} are being overexpressed in both a wild type and $\Delta ras2$ background. The overexpression of $RAS2^{S225A}$ or $RAS2^{S225E}$ in wild type cells during exponential phase of cell growth led to an increase in Ras2p protein expression when compared to the control and RAS2 overexpression strain. We hypothesize that this could be the result of an increase in the stability of the Ras2 protein, although it is not known whether this is due to an increase in mRNA levels, translation, or the stability of the protein itself. The overexpression of either $RAS2^{S225A}$ or $RAS2^{S225E}$ in a wild type background led to an increase Ras2p expression during stationary phase when compared to

the control and *RAS2* strain. Suggesting a putative role of Ser²²⁵ in the regulation of Ras2 protein expression or protein stability.

The overexpression of $RAS2^{S225A}$ or $RAS2^{S225E}$ resulted in significant growth defects when compared to the empty plasmid control in both wild type and $\Delta ras2$ backgrounds. Our findings show that $Ras2^{S225}$ is important for Ras function and furthermore that the growth defects induced by the overexpression of $RAS2^{S225A}$ or $RAS2^{S225E}$ are in fact dominant as growth defects manifest irrespective of whether endogenous Ras2p is present. Furthermore, we have identified the importance of $Ras2^{S225}$ in the maintenance of chronological lifespan. We show that the overexpression of $RAS2^{S225A}$ in wild type cells leads to a significant decrease in chronological life span when compared to the wild type, providing further evidence that the Ser^{225} residue is important for Ras function.

As Ras2p is involved in the regulation of antioxidant defences, we investigated whether the substitution of Ser²²⁵ of yeast Ras2 with glutamate or alanine led to changes in the cells ability to tolerate the addition of hydrogen peroxide to both liquid and solid media. The addition of H_2O_2 to liquid media resulted in significant growth defects in cells overexpressing *RAS2* mutant alleles when compared to the control strain. This effect was also recapitulated on solid media, with an increased sensitivity to peroxide observed in wild type cells overexpressing $RAS2^{S225A}$ or $RAS2^{S225E}$ when compared to the control strain. The inability of wild type cells overexpressing $RAS2^{S225A}$ or $RAS2^{S225E}$ to recover from this stress response is an indication that overexpression of either $RAS2^{S225A}$ or $RAS2^{S225E}$ alters the signalling properties of Ras and leads to a suppression of the oxidative stress response.

To investigate whether perturbed growth was accompanied by changes in culture viability a colony forming efficiency assay was performed. The expression of RAS2^{S225A} or RAS2^{S225E} in

both a wild type and $\Delta ras2$ background leads to a significant reduction in viability when compared to the control strain. The expression of *RAS2* did not appear to reduce viability in the $\Delta ras2$ background but interestingly increased viability when expressed in wild type cells. This reduction in viability only observed in cells overexpressing $RAS2^{S225A}$ or $RAS2^{S225E}$ suggests that the Ser²²⁵ of Ras2 is important for Ras function.

The findings within this chapter suggest that the modification of ser²²⁵ residue of Ras2 leads to growth defects, changes in the oxidative stress response and leads to a reduction in viability in wild type cells. We therefore investigate whether the overexpression of either *RAS2*^{5225A} in a wild type background leads to an increase in markers of cell death, such as ROS. Increased levels of ROS within cells is indicative of cell stress or programmed cell death [217][155][218]. Using FACS analysis with the dye dihydroethidium (DHE) we measured ROS levels in cells overexpressing *RAS2*^{5225A}. Interestingly our data indicated the overexpression of *RAS2*^{5225A} presented no significant increase in the percentage of DHE positive cells when compared to the wild type control. This data set suggests that the overexpression of the *RAS2*^{5225A} mutant does not lead to a loss of viability that correlates with an increase in ROS production, a phenotype commonly linked to forms of cell death in yeast [217].

With no significant elevation in cellular ROS levels in strains assayed, we performed a FACS analysis using the dye propidium iodide to determine whether wild type cells overexpressing RAS2^{5225A} showed increased levels of necrosis when compared to the wild type control. Our data suggests that the overexpression of RAS2^{5225A} presented no significant increase in the percentage of necrotic cells when compared to the wild type control. This data suggests that the overexpression of RAS2^{5225A} in wild type cells does not lead to a loss of viability that can be explained by an increase in necrosis.

In *S. cerevisiae*, Ras proteins mediate autophagy through the activity of PKA [219][167]. The RAS/cAMP/PKA pathway has been shown to be highly interconnected with the TOR pathways which is also involved in the regulation of autophagy in yeast [219][167][166]. Both Tor and Ras often control overlapping effectors, including effectors involved in autophagy. We investigated whether the overexpression of either *RAS2*, *RAS2*^{5225A} or *RAS2*^{5225E} led to changes in cells ability to regulate autophagy. We observed no significant differences in autophagic flux upon the overexpression of *RAS2*^{5225A} or *RAS2*^{5225E} when compared to the control strain, indicating that the overexpression of either *RAS2*^{5225A} or *RAS2*^{5225E} does not result in autophagic flux abnormalities.

We show that the expression of $RAS2^{S225A}$ or $RAS2^{S225E}$, in both a wild type and $\Delta ras2$ background results in a loss of viability but is not accompanied by elevated DHE or PI staining. An explanation is that cells expressing the mutant RAS2 alleles are in fact senescent or quiescent and that the loss of viability does not represent cell death, but rather an inability to divide. To address this, we investigated levels of respiration within wild type cells overexpressing $RAS2^{S225A}$ or $RAS2^{S225E}$. We can confirm that wild type cells overexpressing $RAS2^{S225E}$ are respiring suggesting these cells are not dead but have an inability to divide.

The findings in this chapter clearly suggest an important role of the Ser²²⁵ residue of Ras2 for both protein localisation and function. We hypothesized that this residue may be conserved in higher eukaryotes. To address this, sequence alignment between the Ras2 protein and the human N-Ras protein was performed. Interestingly, although significant sequence divergence between the yeast and human Ras proteins outside of the GTPase domain and C terminal CAAX box, we discovered that Ras2 Serine⁵²²⁵ was conserved in human N-Ras at Serine¹⁷³. As

sequence alignment revealed conservation of the yeast Ras2^{S225} phosphorylation site in the human Nras protein, constructs expressing human *NRAS* or human *NRAS* mutations at the equivalent phosphorylation site (Ser¹⁷³) were transformed into wild type cells. Growth analysis revealed that the overexpression of either *NRAS*, *NRAS*^{S173A} or *NRAS*^{S173E} in wild type cells resulted in severe growth defects and reduced viability when compared to the wild type control. However, it appears that the overexpression of human *NRAS* in the yeast system is inherently toxic and therefor the importance of the *NRAS*^{S173} is unknown and requires further investigation.

In this study we observed a loss in viability upon the overexpression of *RAS2*^{S225A} or *RAS2*^{S225E} that cannot be explained by cell death. We therefor propose that the loss of viability observed in these cells is not attributable to cell death but rather a cessation of cell growth. Future investigations will focus on determining the nature of the growth arrest driven by the miss localisation of active Ras and to determine under which conditions cells can re-engage in the cell cycle.

Chapter 4 Probing the Ras/cAMP/PKA pathway

4.1 Introduction

The Ras/cAMP/PKA pathway in *S. cerevisiae* plays a major role in the control of growth and metabolism in response to nutrients. The main positive regulator of the pathway is Cdc25, which in response to nutrients, activates the redundant small GTPases Ras1 and Ras2 [78]. GTP-bound Ras activates adenylate cyclase, stimulating the production of cAMP. An increase in cAMP results in the activation of Protein Kinase A (PKA) via the dissociation of the PKA regulatory subunit Bcy1 from the PKA catalytic subunit(s) encoded by *TPK1*, *TPK2* and *TPK3* [81][192]. Upon activation, PKA controls a number of essential cellular and physiological processes such as growth, resting state, glycogen and trehalose content, carbohydrate and nitrogen metabolism, stress tolerance and the expression of genes that are controlled by STRE-boxes in their promotors [226][154][216].

The production of cAMP plays an integral role in the transmission and coordination of nutrient signals into the cell. Extracellular glucose levels in the growth medium are coupled to intracellular cAMP concentrations that regulate appropriate responses [227][228]. Control of cAMP levels is essential for yeast cell adaption, for example the regulation has been shown to mediate glycogen storage, oxidative metabolism, response to heat shock as well as a commitment to cell death [228][229][230][147]. Ras activity and cAMP levels are also tightly linked to growth, for example the expression of ribosomal protein genes is increased upon cAMP elevation to support cell division [119]. The production of intracellular cAMP is tightly regulated through feedback loops and the action of the phosphodiesterases, which catalyse the degradation of cAMP [86][85]. *S. cerevisiae* contains two cAMP phosphodiesterases, *PDE1* and *PDE2*, which encode a low-affinity (Pde1) and a high-affinity cAMP phosphodiesterase (Pde2) [86][85]. Pde2 is an Mg2+ requiring, zinc-binding enzyme which controls the basal

cAMP levels in the cell and thereby protects it from changes in the extracellular environment [88].

Mutations that inhibit the production of cAMP, such as seen in $\Delta cdc25$ mutants, prevent progression through the cell cycle check point in late G1 called start, rendering cells arrested in G1 in a manner closely resembling the cell cycle arrest promoted by nutrient depletion [231][232]. While mutations that activate the Ras/cAMP pathway, such as activating mutations in the *RAS2* gene and *BCY1* mutations appear to present the opposite phenotype. Wild type cells perform G1 arrest in response to nutrient depletion [233], where cells carrying activating mutations in the Ras/cAMP pathway fail to accumulate as G1-arrested cells upon nutrient deprived conditions [115]. Cells with constitutive Ras/cAMP signalling, such as the ras^{val19} mutant, fail to adapt to nutrient depletion and rapidly lose viability [98].

We have shown that the overexpression of *RAS2*^{5225A} or *RAS2*^{5225E} in wild type cells lead to growth defects, reduced viability, sensitivity to both reactive oxygen species and copper and reduced respiration. We show that the overexpression of *RAS2*^{5225A} or *RAS2*^{5225E} results in the miss localisation of active Ras populations to the nuclear envelope during both log and stationary phases of growth. We hypothesize that such defects are a result of an early transition into a post-diauxic growth because of the miss localisation of active Ras populations to nuclear envelope. Previous studies have established a correlation between post-translational processing of Ras, its membrane localization, and its biological activity [234][235][61]. In *S. cerevisiae*, Ras proteins are localised predominantly in the cell in a membrane compartment, as are other components of the signal transduction pathway with which Ras interacts, including adenylyl cyclase and Cdc25 [236][237]. Mutation of the site of farnesylation in Ras blocks all post-translational processing, abolishes its biological activity,

and renders the protein predominantly cytoplasmic [78]. This has prompted models suggesting that post-translational modification of Ras is essential for its biological activity because it allows co-localization of Ras with other components of the signal transduction apparatus.

As the predominant plasma membrane localisation of active Ras during log phase growth was not observed in cells overexpressing either *RAS2*^{5225A} or *RAS2*^{5225E}, we sought to investigate whether the premature transition into reduced growth was induced through aberrant Ras/cAMP signalling. To address this, *RAS2*^{5225A} or *RAS2*^{5225E} mutant alleles were overexpressed in strains lacking different components of the RAS/cAMP/PKA pathway and growth and viability were conducted.

4.2 Growth analysis of the overexpression of $RAS2^{S225A}$ or $RAS2^{S225E}$ in a $\Delta pde2$ background

Pde2 is a high-affinity cAMP phosphodiesterase which catalyses the degradation of cAMP [86]. The deletion of *PDE2* leads to an elevation in intracellular cAMP, resulting in the over activation of PKA [238][165]. To investigate whether an increase in activation of the Ras/cAMP/PKA pathway in cells overexpressing $RAS2^{S225A}$ or $RAS2^{S225E}$ resulted in further changes in growth and viability, we overexpressed either $RAS2^{S225A}$ or $RAS2^{S225E}$ in a $\Delta pde2$ background and conducted both growth and viability assays.

4.2.1 Over expression of $RAS2^{S225A}$ or $RAS2^{S225E}$ in a $\Delta pde2$ background leads to growth defects

The growth of cells overexpressing $RAS2^{S225A}$, $RAS2^{S225E}$ or containing an empty plasmid control in a $\Delta pde2$ background was analysed using the growth assay described in Materials and Methods, Section 2.9.1. The growth of $\Delta pde2$ strains was compared to a wild type strain expressing an empty plasmid control. The overexpression of $RAS2^{S225A}$ or $RAS2^{S225E}$ in a $\Delta pde2$ background lead to a significant increase in lag time and reached a lower final biomass when compared to the control strain in both the wild type and pde2 deletion background (*Figure 48*). When compared to the wild type control, $\Delta pde2$ strains expressing an empty plasmid control displayed an early transition into the post-diauxic phase of cell growth and reached a lower final biomass after 24 hours of growth (*Figure 48*). When compared to the overexpression of either $RAS2^{S225A}$ or $RAS2^{S225E}$ in a wild type background (*Figure 28*), a significant increase in lag time and decrease in overall biomass was observed after 24 hours of growth when either $RAS2^{S225A}$ or $RAS2^{S225E}$ was overexpressed in a $\Delta pde2$ background (*Figure 48*).

No significant difference in growth rates was observed between wild type cells or $\Delta pde2$ cells expressing an empty plasmid control (*Figure 49*). Although, a significant decrease in growth rate was observed in strains overexpressing $RAS2^{5225A}$ or $RAS2^{5225E}$ in a pde2 deletion background when compared the wild type and $\Delta pde2$ control strain (*Figure 49*). When compared to the growth rate of wild type cells overexpressing either $RAS2^{5225A}$ or $RAS2^{5225E}$ (*Figure 29*), we observed a 60-minute decrease in growth rate when overexpressing $RAS2^{5225A}$ or $RAS2^{5225E}$ in a $\Delta pde2$ background. Our results imply that a loss in the ability to control the activation of the Ras/cAMP/PKA results in a further loss in fitness upon the overexpression of either $RAS2^{5225A}$ or $RAS2^{5225E}$, as supported by previous published observations, Leadsham et al 2010 [224].




Figure 48. Growth analysis of cells overexpressing RAS2^{S225A}, RAS2^{S225E} or empty plasmid control in Δ pde2 background.

Wild type cells expressing an empty plasmid control was assayed as an additional control. The growth analysis was carried out in SD –URA media as described in Materials and Methods (Section 2.9.1). The experiment was repeated three times and representative data set is shown. This data represents an average of three technical repeats and error bars represent the standard deviation.




Figure 49. Growth rate analysis of cells overexpressing RAS2^{S225A}, RAS2^{S225E} or an empty plasmid backbone control in Δ pde2 background.

Wild type cells expressing an empty plasmid control was assayed as an additional control. The growth rate analysis was carried out as described in Materials and Methods (Section 2.9.1). The experiment was repeated three times and representative data set is shown. The data represents an average of three technical repeats and error bars represents the standard deviation. A One-way ANOVA using a Dunnets multiple comparison test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value \leq 0.05 and *** = adjusted p value \leq 0.001.

4.2.2 The Overexpression of either $RAS2^{S225A}$ or $RAS2^{S225E}$ in a $\Delta pde2$ background leads to a further decrease in viability when compared to the overexpression of RAS2 mutants in wild type cells

To determine whether the overexpression of either $RAS2^{S225A}$ or $RAS2^{S225E}$ in a $\Delta pde2$ background lead to a reduction in viability, a viability assay was conducted as described in Materials and Methods, Section 2.9.3. The viability of cells overexpressing $RAS2^{S225A}$ or

 $RAS2^{S225E}$ in a $\Delta pde2$ background was compared to wild type cells expressing the $RAS2^{S225A}$ or $RAS2^{S225E}$ to attest whether the deletion of pde2 further attenuated viability.

An overnight culture was re-inoculated to 2 x 10^3 cells/ml and incubated for 24 hours. 300 cells were plated onto selective, -URA agar plates. These were left to incubate at 30 °C for 36 hours and the colonies were then counted to allow quantification of colony forming units (CFUs). Viability of cells analysed from the inoculated culture represented the viability of cells, or cell death, during nutrient deprivation.

A wild type strain expressing a control plasmid grown for 24 hours, had approximately 40 % viability when grown on SD -URA medium. The expression of an empty plasmid control in a $\Delta pde2$ background lead to no significant change in viability when compared to the wild type control strain (*Figure 50*). The overexpression of *RAS2*^{S225A} or *RAS2*^{S225E} in a $\Delta pde2$ background presented a significant reduction in viability when compared to the wild type and $\Delta pde2$ control strains (*Figure 50*). Upon the deletion of *PDE2*, cells overexpressing either *RAS2*^{S225A} or *RAS2*^{S225E} presented a significant decrease in viability when compared to wild type cells overexpressing *RAS2*^{S225A} or *RAS2*^{S225E} (*Figure 50*). Indicating that the deletion of *pde2* in wild type cells overexpressing *RAS2*^{S225A} or *RAS2*^{S225E} further attenuates viability.




Figure 50. A colony forming efficiency assay of S. cerevisiae wild type and $\Delta pde2$ cells overexpressing RAS2^{S225A}, RAS2^{S225E}or an empty plasmid control, grown in SD –URA. The colony forming efficiency analysis was carried out as described in Materials and Methods (Section 2.9.3). The data presented is the average of three biological repeats and error bars represent standard deviation. A One-way ANOVA using a Tukey multiple comparison test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value \leq 0.05 and *** = adjusted p value \leq 0.001.

4.3 Growth analysis of wild type cells co-expressing *PDE2* and the *RAS2* mutant alleles

4.3.1 The co-expression of *PDE2* in wild type cells overexpressing $RAS2^{S225E}$ rescues growth defects

We have previously observed that the overexpression of either $RAS2^{S225A}$ or $RAS2^{S225E}$ in a $\Delta pde2$ background further attenuates growth and viability when compared to the overexpression of $RAS2^{S225A}$ or $RAS2^{S225E}$ in wild type cells. We hypothesize that such observations are a result of an elevation in the activity of the Ras/cAMP/PKA pathway which

is further increased due to the cells inability to degrade cAMP in the absence of *PDE2*. We investigate whether reducing the activation of the Ras/cAMP/PKA through the overexpression of *PDE2*, will lead to differences in growth and viability in cells overexpressing either *RAS2*^{5225A} or *RAS2*^{5225E} mutant alleles. To analyse the growth of wild type cells co-expressing *PDE2* with *RAS2*^{5225A}, *RAS2*^{5225E} or an empty plasmid backbone, a growth assay was performed as described in Materials and Methods, Section 2.9.1. The growth of these strains was compared to a wild type strain expressing an empty plasmid control.

All strains overexpressing *PDE2* presented an early transition into post diauxic growth and reached a lower final biomass after 24 hours of growth when compared to the wild type control (*Figure 51*). Interestingly, the overexpression of *PDE2* in wild type cells overexpressing *RAS2*^{5225E} lead to no observable growth defects when compared to wild type cells coexpressing *PDE2* with the empty plasmid control. Wild type cells co-expressing *PDE2* with *RAS2*^{5225A} presented significant growth defects when compared to the wild type cells coexpressing *PDE2* with the empty plasmid control (*Figure 51*).

A decreased growth rate when compared to the wild type control was observed in all *PDE2* overexpression strains. An increase in growth rate was observed when *PDE2* was coexpressed with *RAS2*^{5225E} when compared to the *PDE2* overexpression control strain (*Figure 52*). However, no significant differences in growth rate were observed when *PDE2* was coexpressed with *RAS2*^{5225A} in wild type cells when compared to the *PDE2* overexpression control strain (*Figure 52*). Our data indicates that the overexpression of *PDE2* in wild type cells overexpressing either *RAS2*^{5225A} or *RAS2*^{5225E} results in a rescue of the growth rate defects.




Figure 51. Growth analysis of wild type cells co-expressing PDE2 with either RAS2^{S225A}, RAS2^{S225E} or empty plasmid control.

Wild type cells expressing an empty plasmid control was assayed as an additional control. The growth analysis was carried out in SD -URA/-LEU media as described in Materials and Methods (Section 2.9.1). The experiment was repeated three times and representative data set is shown. This data represents an average of three technical repeats and error bars represent the standard deviation.




Figure 52. Growth rate analysis of wild type cells overexpressing RAS2^{S225A}, RAS2^{S225E} or an empty plasmid backbone co-expressed with PDE2.

Wild type cells expressing an empty plasmid control was assayed as an additional control. The growth rate analysis was carried out as described in Materials and Methods (Section 2.9.1). The experiment was repeated three times and representative data set is shown. The data represents an average of three technical repeats and error bars represents the standard deviation. A One-way ANOVA using a Tukey multiple comparison test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value \leq 0.05 and *** = adjusted p value \leq 0.001.

4.3.2 The expression of *PDE2* in wild type cells overexpressing $RAS2^{S225A}$ or $RAS2^{S225E}$ rescues viability

To determine whether the overexpression of *PDE2* in wild type cells overexpressing *RAS2*^{S225A}, *RAS2*^{S225E} or an empty plasmid control resulted in a change in viability, a viability assay was conducted as described in Materials and Methods, Section 2.9.3.

The viability of wild type cells overexpressing *RAS2*^{S225A} or *RAS2*^{S225E} and *PDE2* was compared to wild type cells expressing the *RAS2* mutant alleles without *PDE2* overexpression. When compared to the wild type control, no significant differences in viability was observed when *PDE2* was overexpressed in wild type cells overexpressing *RAS2*^{S225A} or *RAS2*^{S225E} (*Figure 53*). Suggesting that overexpression of *PDE2* rescues viability when co-expressed with either *RAS2*^{S225A} or *RAS2*^{S225E}. In wild type cells overexpressing *RAS2*^{S225A} or *RAS2*^{S225E} only, the percentage of viable cells was significantly lower than when *PDE2* was co-overexpressed with *RAS2*^{S225A} or *RAS2*^{S225E} (*Figure 53*).




Figure 53. A colony forming efficiency assay of wild type cells overexpressing RAS2^{S225A}, RAS2^{S225E} or an empty plasmid backbone co-expressed with PDE2.

Cells were grown in SD-URA/-LEU or -URA. The colony forming efficiency analysis was carried out as described in Materials and Methods (Section 2.9.3). The data presented is the average of three biological repeats and error bars represent standard deviation. A One-way ANOVA using a Tukey multiple comparison test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value \le 0.05 and *** = adjusted p value \le 0.001.

4.4 Growth analysis of the effects of the deletion of *TPK1*, *TPK2* or *TPK3* on wild type cells overexpressing *RAS2*^{S225A} or *RAS2*^{S225E}

4.4.1 Deletion of *TPK2* or *TPK3* reduces growth defects in cells overexpressing *RAS2*^{S225A} or *RAS2*^{S225E}

PKA is a heterotetramer comprised of two regulatory subunits and two catalytic subunits [239]. In *S. cerevisiae, BCY1* encodes the regulatory subunit and the catalytic subunits are encoded by *TPK1, TPK2* and *TPK3*. [81][78]. The binding of two cAMP molecules to each regulatory subunit in the holoenzyme triggers the release of the catalytic subunits and their activation. The PKA subunits Tpk1, 2 and 3 share overlapping functions but also have been shown to be involved in the regulation of several separable processes. Tpk1 has been identified to play a role in the branched chain amino acid biosynthesis pathway, mitochondrial DNA stability and mitochondrial iron homeostasis [82]. Whereas Tpk2 has been shown to impact iron uptake, trehalase synthesis and water homeostasis [82][83]. However, constitutive PKA activity can prove deleterious, with the overexpression of *TPK3* shown to inhibit growth [84].

We have previously shown that the viability of wild type cells overexpressing either $RAS2^{S225A}$ or $RAS2^{S225E}$ can be significantly altered though either the deletion or overexpression of PDE2. Our results indicate that the overexpression of RAS2 mutant alleles results in an inability of cells to appropriately regulate the Ras/cAMP/PKA pathway. We sort to investigate whether the deletion of one or more of the TPK subunits in strains overexpressing $RAS2^{S225A}$ or $RAS2^{S225E}$ results in any significant changes in growth and viability.

To analyse the growth of cells overexpressing $RAS2^{S225A}$, $RAS2^{S225E}$ or an empty plasmid backbone control in a $\Delta tpk1$, $\Delta tpk2$ or $\Delta tpk3$ background, a growth assay was performed as

described in Materials and Methods, Section 2.9.1. The growth of $\Delta tpk1$, $\Delta tpk2$ or $\Delta tpk3$ strains was compared to a wild type strain containing an empty plasmid (Figure 54).

The overexpression of either $RAS2^{S225A}$ or $RAS2^{S225E}$ in a $\Delta tpk1$, $\Delta tpk2$ or $\Delta tpk3$ background presented an early transition into post diauxic growth and reached a lower final biomass after 24 hours of growth when compared to all strains expressing an empty plasmid control (*Figure 54*). Strains expressing either $RAS2^{S225A}$ or $RAS2^{S225E}$ in a $\Delta tpk1$ background presented the most severe growth defects when compared to control strains (*Figure 54*). When compared to the overexpression of $RAS2^{S225A}$ or $RAS2^{S225E}$ in wild type cells, the expression of RAS2 mutant alleles in a $\Delta tpk2$ or $\Delta tpk3$ background presented a reduction in the severity of the growth defects (*Figure 54*). In both a $\Delta tpk2$ or $\Delta tpk3$ background, the overexpression of either $RAS2^{S225A}$ or $RAS2^{S225E}$ displayed no significant changes in growth rate when compared to the wild type control (*Figure 55*). Whereas expression in a $\Delta tpk1$ background led to a decrease in growth rate when compared to the wild type control strain (*Figure 55*). This data suggests that the loss of either *TPK2* or *TPK3* in cells overexpressing $RAS2^{S225A}$ or $RAS2^{S225E}$ leads to a rescue of growth rate defects, indicating an involvement of the function of Tpk2 and Tpk3 in

the toxic effects on growth rate induced by the overexpression of either $RAS2^{S225A}$ or $RAS2^{S225E}$.




Figure 54. Growth analysis of cells overexpressing RAS2^{S225A}, RAS2^{S225E} or empty plasmid control in Δ tpk1 (A), Δ tpk2 (B) or Δ tpk3 (C)

Wild type cells expressing an empty plasmid control was assayed as an additional control. The growth analysis was carried out in SD –URA media as described in Materials and Methods (Section 2.9.1). The experiment was repeated three times and representative data set is shown. This data represents an average of three technical repeats and error bars represent the standard deviation.




Figure 55. Growth rate analysis of wild type cells overexpressing RAS2^{S225A}, RAS2^{S225E} or an empty plasmid backbone in Δ tpk1 (A), Δ tpke2 (B) or Δ tpk3 background (C).

Wild type cells expressing an empty plasmid control was assayed as an additional control. The growth rate analysis was carried out as described in Materials and Methods (Section 2.9.1). The experiment was repeated three times and representative data set is shown. The data represents an average of three technical repeats and error bars represents the standard deviation. A One-way ANOVA using a Dunnetts multiple comparison test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value \leq 0.05 and *** = adjusted p value \leq 0.001.

4.4.2 Analysis of viability in $\Delta tpk1$, $\Delta tpk2$ or $\Delta tpk3$ cells overexpressing $RAS2^{S225A}$ or $RAS2^{S225E}$

To determine whether the overexpression of either $RAS2^{S225A}$ or $RAS2^{S225E}$ in a $\Delta tpk1$, $\Delta tpk2$ or $\Delta tpk3$ background led to changes in viability, a viability assay was conducted as described in Materials and Methods, Section 2.9.3. The viability of cells overexpressing $RAS2^{S225A}$ or $RAS2^{S225E}$ in a tpk1, tpk2 or tpk3 single deletion background was compared to wild type or tpk1-3 deletion strains expressing an empty plasmid control. The viability of wild type cells overexpressing $RAS2^{S225A}$ or $RAS2^{S225E}$ was also compared to the viability observed upon the overexpression of $RAS2^{S225A}$ or $RAS2^{S225E}$ in a tpk1, tpk2 or tpk3 single deletion background.

An overnight culture was re-inoculated to 2 x 10³ cells/ml and incubated for 24 hours. 300 cells were plated onto selective, -URA agar plates. These were left to incubate at 30 °C for 36 hours and the colonies were then counted to allow quantification of colony forming units (CFUs). Viability of cells analysed from the inoculated culture represented the viability of cells, or cell death, during nutrient deprivation. After 24 hours of growth, a wild type strain expressing a control plasmid, had approximately 40 % viability when grown on SD -URA medium.

Upon the deletion of tpk1 in all strains, a reduction in viability was observed when compared to the wild type control (Figure 56). $\Delta tpk1$ cells expressing an empty plasmid control presented a significant decrease in viability when compared to the wild type control, suggesting a putative function of Tpk1 in the maintenance of viability under the growth conditions used. Interestingly, the expression of $RAS2^{S225A}$ in a $\Delta tpk1$ background lead to an increase in viability when compared to $\Delta tpk1$ cells expressing an empty plasmid control (Figure 56). However, no significant change in viability was observed when compared to wild

type cells overexpressing $RAS2^{S225A}$ (Figure 56). No significant changes in viability was observed when $RAS2^{S225E}$ was expressed in a $\Delta tpk1$ background when compared to the $\Delta tpk1$ control strain (Figure 56). A decrease in viability was seen in cells overexpressing $RAS2^{S225E}$ in a $\Delta tpk1$ background when compared to wild type strains overexpressing $RAS2^{S225E}$ (Figure 56). Our data suggests that Tpk1p and the Ras2p^{S225A} mutants are acting within different pathways, as loss of TPK1 leads to a loss in viability which can be improved upon the overexpression of $RAS2^{S225A}$. However, the loss of TPK1 increases the toxic effects on viability upon the overexpression of $RAS2^{S225E}$ when compared to the expression of $RAS2^{S225E}$ in wild type cells but not when compared to the $\Delta tpk1$ control, providing further evidence to suggest that Tpk1 and RAS2 mutant alleles are functioning independently. This observation aligns with the data shown in Figure 54, suggesting that the toxic effects induced by the overexpression of $RAS2^{S225E}$ are not mediated through Tpk1.

Upon the overexpression of $RAS2^{S225A}$ or $RAS2^{S225E}$ in a $\Delta tpk2$ background a decrease in viability was observed when compared to the wild type control and the $\Delta tpk2$ control strain (Figure 56). Interestingly, an increase in viability is observed in $\Delta tpk2$ cells expressing an empty plasmid control when compared to the wild type control suggesting that TPK2 has a putative function in reducing viability during the post diauxic shift under the growth conditions used (Figure 56). The overexpression of $RAS2^{S225A}$ or $RAS2^{S225E}$ in a $\Delta tpk2$ background results in no further decrease in viability when compared to the overexpression of $RAS2^{S225A}$ or $RAS2^{S225E}$ in a wild type background (Figure 56). We therefore propose that the loss in viability induced by the overexpression of RAS2 mutant alleles in cells does not depend on Tpk2 alone. Therefor the role of Tpk2 in exponential growth is separable from the observed loss of viability during stationary phase growth.

Upon the overexpression of RAS2^{S225A} or RAS2^{S225E} in Δtpk3 cells a significant decrease in viability is observed when compared to the wild type and $\Delta tpk3$ control strains (Figure 56). No significant difference in viability was observed between the wild type and Δtpk3 control strain (Figure 56). Indicating the deletion of tpk3 does not play an important function in maintenance of cell viability under the conditions used. Our data suggests that the deletion of tpk3 in cells overexpressing RAS2^{S225A} or RAS2^{S225E} does not rescue viability to wild type levels. However, a significant decrease in viability was observed upon the deletion of tpk3 in cells overexpressing RAS2^{S225E} when compared to wild type cells overexpressing either RAS2^{S225E}. However, no significant difference in viability was observed between the overexpression of $RAS2^{S225A}$ in a $\Delta tpk3$ or wild type background. Our data indicates that the loss of tpk3 in cells overexpressing RAS2^{S225E} results in a further attenuation of viability. However, the loss of tpk3 in cells overexpressing RAS2^{S225A} does not present any changes in viability when compared to expression of RAS2^{S225A} in wild type cells. Overall, we show the loss viability observed upon expression of the RAS mutant alleles used here cannot be attributed to the activity of any single PKA subunit.




Figure 56. A colony forming efficiency assay of S. cerevisiae wild type, Δ tpk1 (A), Δ tpk2 (B) or Δ tpk3 (C) cells overexpressing RAS2^{S225A}, RAS2^{S225E}or an empty plasmid control, grown in SD –URA.

The colony forming efficiency analysis was carried out as described in Materials and Methods (Section 2.9.3). The data presented is the average of three biological repeats and error bars represent standard deviation. A One-way ANOVA using a Tukey multiple comparison test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value \le 0.05 and *** = adjusted p value \le 0.001

4.5 Growth analysis of the double deletion of tpk1/tpk2, tpk3/tpk2 or tpk1/tpk3 on wild type cells overexpressing RAS2 mutant alleles

4.5.1 Overexpression of *RAS2* mutant alleles in tpk1-3 double deletion backgrounds leads to no rescue of growth defects

The deletion of *TPK1*, *TPK2* or *TPK3* in cells overexpressing *RAS2*^{S225A} or *RAS2*^{S225E} failed to result in a complete rescue of viability or growth. We hypothesized that the double deletion of different Tpk subunits in cells overexpressing the *RAS2* mutant alleles may result in a full restoration of viability to that of the wild type control.

To analyse the growth of cells overexpressing $RAS2^{S225A}$, $RAS2^{S225E}$ or an empty plasmid backbone control in a $\Delta tpk1/\Delta tpk2$, $\Delta tpk2/\Delta tpk3$ or $\Delta tpk1/\Delta tpk3$ background, a growth assay was performed as described in Materials and Methods, Section 2.9.1. The growth of mutant strains was compared to a wild type strain expressing an empty plasmid control.

The overexpression of $RAS2^{5225A}$ or $RAS2^{5225E}$ in all backgrounds presented an early transition into post diauxic growth and reached a lower final biomass after 24 hours of growth when compared to all strains expressing an empty plasmid control (*Figure 57*). When compared to the overexpression of $RAS2^{5225A}$ or $RAS2^{5225E}$ in wild type cells, the expression of RAS2 mutant alleles in a $\Delta tpk1/\Delta tpk2$ background presented a reduction in the severity of the growth defects previously observed when expressed in wild type cells (*Figure 57*). Strains expressing $RAS2^{5225A}$ or $RAS2^{5225E}$ in a $\Delta tpk3/\Delta tpk2$ background presented the most severe growth defects when compared to control strains (Figure 57). We observed a marginal decrease in growth rate when $RAS2^{5225A}$ was overexpressed in a tpk1/tpk2 when compared to the wild type control (*Figure 58*). No significant changes in growth rate were observed upon the overexpression of $RAS2^{5225A}$ or $RAS2^{5225E}$ in a $\Delta tpk1/\Delta tpk3$ background when compared to the

wild type control (*Figure 58*). However, a significant decrease in growth rate was observed upon the overexpression of $RAS2^{S225A}$ or $RAS2^{S225E}$ in $\Delta tpk2/\Delta tpk3$ background when compared to the wild type control (*Figure 58*). We suggest that the overlapping functions of either Tpk1 and Tpk2 or Tpk1 and Tpk3 is either responsible for the reduced growth rate or that the combined loss of these subunits can compensate for the toxic effects of the overexpression of $RAS2^{S225A}$ or $RAS2^{S225E}$ in wild type cells.




Figure 57. Growth analysis of cells overexpressing RAS2^{S225A}, RAS2^{S225E} or empty plasmid control in a Δ tpk1/ Δ tpk2 (A), Δ tpk1/ Δ tpk3 (B), or Δ tpk1/ Δ tpk3 (C).

Wild type cells expressing an empty plasmid control was assayed as an additional control. The growth analysis was carried out in SD –URA media as described in Materials and Methods (Section 2.9.1). The experiment was repeated three times and representative data set is shown. This data represents an average of three technical repeats and error bars represent the standard deviation.




Figure 58. Growth rate analysis of yeast cells overexpressing RAS2^{S225A}, RAS2^{S225E} or an empty plasmid backbone in a Δ tpk1/ Δ tpk2 (A), Δ tpk1/ Δ tpk3 (B) or Δ tpk1/ Δ tpk3 (C) background.

Wild type cells expressing an empty plasmid control was assayed as an additional control. The growth rate analysis was carried out as described in Materials and Methods (Section 2.9.1). The experiment was repeated three times and representative data set is shown. The data represents an average of three technical repeats and error bars represents the standard deviation. A One-way ANOVA using a Dunnets multiple comparison test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value \leq 0.05 and *** = adjusted p value \leq 0.001.

4.5.2 Analysis of viability in cells overexpressing $RAS2^{S225A}$ or $RAS2^{S225E}$ in a $\Delta tpk1/\Delta tpk3$ or $\Delta tpk1/\Delta tpk3$ background

As the overexpression of either $RAS2^{S225A}$ or $RAS2^{S225E}$ in a $\Delta tpk1$, $\Delta tpk2$ or $\Delta tpk3$ background did not result in a full rescue of viability to wild type levels, the RAS2 mutant alleles were expressed in backgrounds containing the double deletion of the genes encoding the Tpk subunits to investigate whether the combination of Tpk subunit deletions restored viability in wild type cells overexpressing the RAS2 mutant alleles. To determine whether the overexpression of either $RAS2^{S225A}$ or $RAS2^{S225E}$ in a $\Delta tpk1$ / $\Delta tpk2$, $\Delta tpk1$ / $\Delta tpk3$ or $\Delta tpk1$ / $\Delta tpk3$ background lead to a change in viability, a viability assay was conducted as described in Materials and Methods, Section 2.9.3. The viability of cells overexpressing $RAS2^{S225A}$ or $RAS2^{S225E}$ in Tpk subunit double deletion strains was compared to wild type and tpk1-3 double deletion strains expressing an empty plasmid as a control.

Cells overexpressing an empty plasmid control in a $\Delta tpk1/\Delta tpk2$ background presented no significant changes in viability when compared to the wild type control (*Figure 59*). The overexpression of $RAS2^{S225A}$ or $RAS2^{S225E}$ in a $\Delta tpk1/\Delta tpk2$ background showed a decrease in viability when compared to the wild type and $\Delta tpk1/\Delta tpk2$ control (*Figure 59*). However, no significant change in viability was observed when compared to wild type cells overexpressing *RAS2* mutant alleles. Our data suggests that deletion of both Tpk1 and Tpk2 in wild type cells expressing the mutant *RAS2* alleles does not result in the rescue of viability to wild type levels. This suggests that the toxicity observed through either the overexpression of *RAS2*^{S225A} or *RAS2*^{S225E} is not mediated through the combined functions of Tpk1 and Tpk2.

Cells expressing the control plasmid in a $\Delta tpk1/\Delta tpk3$ background showed a significant reduction in viability when compared to the wild type control with cells eliciting less than 5%

viability (Figure 59). This result suggests a putative role for both subunits in the maintenance of viability in stationary phase of growth under the conditions used. The expression of either $RAS2^{5225A}$ or $RAS2^{5225E}$ in a $\Delta tpk1/\Delta tpk3$ background did not lead to the formation of viable colonies, thus indicating that the deletion of both $\Delta tpk1$ and $\Delta tpk3$ in wild type cells overexpressing $RAS2^{5225A}$ or $RAS2^{5225E}$ prevents the formation of viable colonies (Figure 59). Upon the expression of an empty plasmid in a $\Delta tpk3/\Delta tpk2$ background, a small decrease in viability is observed when compared to the wild type control (Figure 59). Upon the expression of either $RAS2^{5225A}$ or $RAS2^{5225E}$ mutant alleles in a $\Delta tpk3/\Delta tpk2$ background, we see a significant decrease in viability when compared to the $\Delta tpk3/\Delta tpk2$ control strain (Figures 59). When compared to wild type cells expressing either $RAS2^{5225A}$ or $RAS2^{5225E}$, the deletion of $\Delta tpk3/\Delta tpk2$ in these strains leads to a further decrease in viability (Figure 59). Suggesting that the deletion of both tpk3 and tpk2 is important for the maintenance of viability in wild

type cells overexpressing RAS2^{S225A} or RAS2^{S225E} mutant alleles.




Figure 59. A colony forming efficiency assay of wild type, $\Delta tpk1/\Delta tpk2$ (A), $\Delta tpk1/\Delta tpk3$ (B) or $\Delta tpk3/\Delta tpk2$ (C) cells overexpressing RAS2^{S225A}, RAS2^{S225E}or an empty plasmid control, grown in SD –URA.

The colony forming efficiency analysis was carried out as described in Materials and Methods (Section 2.9.3). The data presented is the average of three biological repeats and error bars represent standard deviation. A One-way ANOVA using a Tukey multiple comparison test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value \leq 0.05 and *** = adjusted p value \leq 0.001.

4.6 Microscopic analysis of GFP-Tpk1p, GFP-Tpk2p or GFP-Tpk3p cells overexpressing *RAS2*^{5225A}, *RAS2*^{5225E} or an empty plasmid control

In the mammalian system, PKA anchor proteins (AKAPs) localise PKA holoenzymes to distinct subcellular localisations. Such targeting facilitates the spatio-temporal control of PKA signalling in order to phosphorylate specific localized effectors [240]. Considering the wide variety of PKA-controlled targets in *S. cerevisiae*, it is therefore not surprising that subcellular localisation of PKA subunits, as in multicellular organisms, occurs in the yeast system.

In *S. cerevisiae*, wild type cells grown on glucose localise Byc1 almost exclusively in the nucleus during exponential growth, while in stationary phase Bcy1 is distributed in both nuclear and cytoplasmic compartments [241]. In wild type yeast growing on glucose, GFP-Tpk1, GFP-Tpk2 and GFP-Tpk3 present a predominated localisation in the nucleus [242][241]. GFP-Tpk2 presents the strongest nuclear localisation with GFP-Tpk1 and GFP-Tpk3 showing a more even distribution over both the nuclear and cytoplasmic compartments. It was shown by Portela et al (2009), that wild type yeast cells grown to stationary phase showed a pronounced decrease in nuclear accumulation of all PKA subunits with GFP-Tpk2 and GFP-Tpk3 concentrated in extra-nuclear foci [242]. As it has been shown that PKA subunit localisation has been correlated to intracellular cAMP levels we sought to investigate whether the overexpression of *RAS2*^{5225A} or *RAS2*^{5225E} in wild type cells resulted in changes to the localisation of GFP-Tpk1, GFP-Tpk2 or GFP-Tpk3.

To attest whether the overexpression of *RAS2*^{S225A} or *RAS2*^{S225E} influenced the localisation of either GFP-Tpk1, GFP-Tpk2 or GFP-Tpk3, fluorescent microscopy was conducted as described in Methods and Materials (Section 2.10). The localisation of fluorescently labelled Tpk subunits was examined during both stationary and exponential phases of cell growth (*Figure 60*). An empty plasmid control was introduced to all fluorescently tagged strains as a control. In wild type cells grown on glucose, GFP-Tpk1 is reported to be mainly accumulated in the nucleus during exponential growth [242][241]. Our findings are concordant with literature and show that a GFP-Tpk1 strain expressing an empty plasmid control also presents a predominant nuclear localisation (*4.14A*). Such localisation of GFP-Tpk1 was also observed in cells overexpressing either *RAS2*^{S225A} or *RAS2*^{S225E} (*Figure 60/61*). No significant changes in the percentage of cells presenting nuclear localisation was observed upon the overexpression of

either *RAS2*^{S225A} or *RAS2*^{S225E} in a GFP-Tpk1 background when compared to the control strain (*Figure 60/61*). Our results suggest that the overexpression of either *RAS2*^{S225A} or *RAS2*^{S225E} does not affect GFP-Tpk1p localisation during exponential growth.

It has been shown that during stationary phase growth, a pronounced decrease in nuclear accumulation of all PKA subunit is observed. Our results are not in keeping with such an observation as the localisation of GFP-Tpk1 still presented a predominant nuclear localisation with no significant loss of nuclear accumulation of GFP-Tpk1 observed between log and stationary phases of growth in all strains (*Figure 60/61*). Portela et al (2009), assayed cells after 7 days of growth, whereas in this study our definition of stationary phase is growth after 24 hours. One explanation is that the 6-day time difference between the experiments conducted in this study and those conducted by Portela et al (2009), is the cause in the differences in localisation observed. The predominant localisation of GFP-Tpk1 in all strains assayed is a nuclear localisation with no significant differences in the percentage of cells presenting a nuclear localisation of GFP-Tpk1 observed upon the overexpression of *RAS2* mutant alleles when compared to the control (*Figure 60/61*). Our results indicate that the overexpression of either *RAS2*^{5225A} or *RAS2*^{5225E} does not affect GFP-Tpk1 localisation during stationary phase growth.




Figure 60. Images taken by fluorescent microscopy of GFP-Tpk1p cells overexpressing either RAS2^{S225A}, RAS2^{S225E} or an empty plasmid vector control during exponential and stationary phase of cell growth.

The fluorescent signal represents the presence of GFP-Tpk1 within cells. Cells were cultured in SD – URA growth media. This experiment was repeated three times and a representative data set is shown. Scale bar = $10~\mu m$




Figure 61. Graphical representation of the localisation of GFP-Tpk1p in cells expressing either RAS2^{S225A}, RAS2^{S225E} or an empty plasmid control during the logarithmic (A) or stationary (B) phase of cell growth.

Cells were cultured in SD –URA growth media. To quantify the localisation of GFP-Tpk1, 100 cells for each strain were counted on three separate days with a total 300 cells being counted and the number of cells displaying the different phenotypes observed was calculated and represented as a percentage of the total number of cells counted. The data represents an average of three biological repeats and error bars represents the standard deviation.

In wild type cells, GFP-Tpk2 is localised in the nucleus during logarithmic growth. Our data reflects current literature and presents GFP-Tpk2 localised to the nucleus in the GFP-Tpk2p control strain during log phase growth (*Figure 62/63*). We observed no significant change in GFP-Tpk2 localisation in cells expressing *RAS2*^{S225A} or *RAS2*^{S225E} when compared to the control,

suggesting that expression of either *RAS2*^{S225A} or *RAS2*^{S225E} does not affect GFP-Tpk2p localisation in actively growing cells (*Figure 62/63*).

It has been reported that during stationary phase of growth in wild type cells, GFP-Tpk2 presents a pronounced reduction in nuclear accumulation and GFP-Tpk2 localises to extranuclear foci. In this study we see a predominant nuclear localisation of GFP-Tpk2 in all strains examined (*Figure 62/63*), however we infrequently noted the presence of extra-nuclear foci. No significant difference in the percentage of cells presenting nuclear localisation of GFP-Tpk2 or the percentage extra-nuclear foci was observed upon the overexpression of either *RAS2*^{5225A} or *RAS2*^{5225E} in a GFP-Tpk2 background when compared to the control strain (*Figure 62/63*). We therefore propose that the overexpression of *RAS2*^{5225A} or *RAS2*^{5225E} does not affect GFP-Tpk2p localisation in stationary phase cells.




Figure 62. Images taken by fluorescent microscopy of GFP-Tpk2p cells overexpressing either RAS2^{S225A}, RAS2^{S225E} or an empty plasmid vector control during exponential and stationary phase of cell growth.

The fluorescent signal represents the presence of GFP-Tpk2p within cells. Cells were cultured in SD – URA growth media. This experiment was repeated three times and a representative data set is shown.




Figure 63. Graphical representation of the localisation of GFP-Tpk2p in cells expressing either RAS2^{S225A}, RAS2^{S225E} or an empty plasmid control during the logarithmic (A) or stationary (B) phase of cell growth.

Cells were cultured in SD –URA growth media. To quantify the localisation of GFP-Tpk2, 100 cells for each strain were counted on three separate days with a total 300 cells being counted and the number of cells displaying the different phenotypes observed was calculated and represented as a percentage of the total number of cells counted. The data represents an average three biological repeats and error bars represents the standard deviation.

In wild type yeast cells grown on glucose, GFP-Tpk3 accumulates in the nucleus during exponential growth and sequesters in extra-nuclear foci in stationary phase. During exponential growth, a predominant nuclear localisation of GFP-Tpk3 was observed in all strains examined with no difference in GFP-Tpk3p localisation upon the overexpression of RAS2^{S225A} or RAS2^{S225E} when compared to the control strain (Figure 64/65). We therefor

propose that the overexpression of either *RAS2*^{S225A} or *RAS2*^{S225E} does not lead to changes in GFP-Tpk3 localisation during exponential growth.

During stationary phase, all strains examined show a pronounced reduction in the percentage of cells with a nuclear localisation of GFP-Tpk3 and an increase in GFP-Tpk3 localising to the cytoplasmic compartment was observed (*Figure 64/65*). GFP-Tpk3 was seen to localise to extra-nuclear foci but again this was noted infrequently (*Figure 64/65*). The predominant localisation of GFP-Tpk3 in all strains was cytoplasmic with no significant differences in GFP-Tpk3 localisation observed upon the overexpression of *RAS2*^{5225A} or *RAS2*^{5225E} when compared to control strain noted (*4.18B*). We propose that the overexpression of *RAS2*^{5225A} or *RAS2*^{5225A} or *RAS2*^{5225E} does not result in the miss localisation of Tpk subunits in either exponential or stationary growth.




Figure 64. Images taken by fluorescent microscopy of GFP-Tpk3p cells overexpressing either RAS2^{S225A}, RAS2^{S225E} or an empty plasmid vector control during exponential and stationary phase of cell growth.

The fluorescent signal represents the presence of GFP-Tpk3p within cells. Cells were cultured in SD – URA growth media. This experiment was repeated three times and a representative data set is shown.




Figure 65. Graphical representation of the localisation of GFP-Tpk3p in cells expressing either RAS2^{S225A}, RAS2^{S225E} or an empty plasmid control during the logarithmic (A) or stationary (B) phase of cell growth.

Cells were cultured in SD –URA growth media. To quantify the localisation of GFP-Tpk3, 100 cells for each strain were counted on three separate days with a total 300 cells being counted and the number of cells displaying the different phenotypes observed was calculated and represented as a percentage of the total number of cells counted. The data represents an average three biological repeats and error bars represents the standard deviation.

4.7 Discussion

S. cerevisiae tolerates diverse environmental conditions through the coordinated regulation of growth, cell cycle progression and metabolic activities. The Ras/cAMP pathway is fundamental for the regulation and integration of these processes [147][136][243][216]. The reprogramming of cell metabolism at the diauxic shift, as well as adaptions during both the post-diauxic phase and entry into stationary phase, are negatively regulated by the Ras/cAMP/PKA pathway [216][154][244][153]. Therefore, mutations that activate the Ras/cAMP pathway, such as activating mutations in the RAS2 gene and BCY1 mutations fail to undergo correct diauxic reprogramming during nutrient depletion [233][115]. Cells with elevated cAMP levels rapidly lose viability in stationary phase as they fail to activate gene expression programmes that facilitate storage of carbohydrates, oxidative phosphorylation and upregulation of stress response mechanisms [233][115]. Conversely, cells with lower cAMP/PKA activity, such as seen in Δcdc25 mutants, exhibit physiological changes associated with nutrient limitation, including G₁ cell cycle arrest, accumulation of storage carbohydrates and increased resistance towards heat and depleted oxidative stress responses [231][232]. We have previously shown that the overexpression of RAS2^{S225A} or RAS2^{S225E} in wild type cells results in the miss localisation of active Ras populations to the nuclear envelope, resulting in significant defects in both growth and viability. We hypothesize that such defects are a result of the dysregulation of the cell cycle. We sought to investigate whether cessation of growth was caused through the aberrant signalling of Ras/cAMP/PKA pathway. To address this, RAS2^{S225A} or RAS2^{S225E} mutant alleles were overexpressed in strains lacking different components of the Ras/cAMP/PKA pathway.

The loss of *PDE2* in cells overexpressing *RAS2*^{S225A} or *RAS2*^{S225E} resulted in a further attenuation of viability and growth defects when compared to the overexpression of RAS2 mutant alleles in wild type cells. Our results imply that a loss in the ability to control intracellular cAMP levels and Ras/cAMP/PKA pathway activation, results in a further loss in fitness upon the overexpression of either RAS2^{S225A} or RAS2^{S225E}, as supported by previous published observations, Leadsham et al 2010 [224]. We hypothesize that such observations can be explained through an elevation in intracellular cAMP levels and increased activity of the Ras/cAMP/PKA pathway, which is further increased due to the cells inability to degrade cAMP in the absence of PDE2. To reduce the levels of intracellular cAMP and Ras/cAMP/PKA activation in wild type cells overexpressing RAS2^{S225A} or RAS2^{S225E} we co-expressed PDE2 and performed both a growth and viability assay. The overexpression of PDE2 in cells expressing either RAS2^{S225A} or RAS2^{S225E} resulted in a complete rescue of viability and growth rate to that of wild type levels. We suggest that the growth and viability defects observed are a result of increased levels of cAMP, and thus activation of PKA, which can be repressed via reducing cAMP levels via the co-expression of PDE2.

We hypothesize that the overexpression of either *RAS2*^{S225A} or *RAS2*^{S225E} in wild type cells results in an increase in the activation of the Ras/cAMP/PKA pathway. We therefore sought to investigate whether the deletion of the genes encoding downstream targets of cAMP, such as the PKA catalytic subunits *TPK1*, *TPK2* and *TPK3* in wild cells overexpressing *RAS2*^{S225A} or *RAS2*^{S225E} resulted in changes in growth and viability in a manner analogous to the deletion or overexpression of *PDE2*. Our results suggest that *TPK1* is epistatic with the expression of the *RAS2*^{S225A} mutant allele with respect to viability. We conclude this as expression of *RAS2*^{S225A} rescues viability defects upon loss of *TPK1* in wild type cells. Tpk2 function is responsible for the reduction in viability observed in the wild type but is not involved in the

loss of viability observed upon the overexpression of either *RAS2*^{5225A} or *RAS2*^{5225E} in wild type cells. We propose that Tpk3 contributes to the maintenance of viability in cells overexpressing *RAS2*^{5225A} or *RAS2*^{5225E} as loss of Tpk3 results in a further loss in viability. We suggest that the loss in viability upon the overexpression of *RAS2* mutant alleles cannot be attributed to the activity of any single Tpk, as the deletion of single Tpk subunits does not rescue the viability phenotype. We therefor investigated the effect of deleting combinations of the Tpk subunits in wild type cells overexpressing *RAS2*^{5225A} or *RAS2*^{5225E}. We suggest that the overlapping functions of either Tpk1 and Tpk2 or Tpk1 and Tpk3 is either responsible for the reduced growth rate or that the combined loss of these subunits can compensate for the toxic effects of the overexpression of *RAS2*^{5225A} or *RAS2*^{5225E} in wild type cells.

We conclude that the deletion of PKA subunits in wild type cells overexpressing *RAS2*^{5225A} or *RAS2*^{5225E} has pronounced effects on the growth rate but not viability. A possible explanation is that all three subunits contribute to the loss of viability, but the more likely explanation is that the complexity of PKA function means that the deletion of multiple subunits results in pleiotropic effects and the loss of viability observed upon the combined deletion of Tpk subunits are additive to the toxic effects of the overexpression *RAS2*^{5225A} or *RAS2*^{5225E}. The single or double deletion of the genes encoding the downstream targets of cAMP, such as the PKA catalytic subunits *TPK1*, *TPK2* and *TPK3* in wild cells overexpressing *RAS2*^{5225A} or *RAS2*^{5225E} did not result in changes in growth and viability analogous to the overexpression of *PDE2*. This observation does not wholly support our hypothesis that the effects of *RAS2*^{5225A} or *RAS2*^{5225E} overexpression are mediated via the PKA pathway. But as the overexpression of *PDE2* was sufficient to rescue viability in wild type cells overexpressing *RAS2* mutant alleles, we propose that the reduced growth phenotype is mediated by the dysregulated activation of PKA. However, the genetic approach of deleting Tpk subunits could not dissect the control of PKA

on the slow growth phenotype observed. We propose the following model (*Figure 66*) to explain the control of PKA on the phenotypes observed upon the overexpression of *RAS2*^{5225A} or *RAS2*^{5225E} in wild type cells. Further investigations will focus on whether there any environmental conditions, such as growth in nutrient rich media, which rescue cells overexpressing *RAS2* mutant alleles to resume normal growth.




Figure 66. A schematic demonstrating how the miss localisation of Ras $2p^{S225}$ to the nuclear envelope effects PKA activity.

The modification of RAS2^{S225} results in the miss localisation of active-Ras to the nuclear envelope during both log and stationary phase of growth. Miss localization of Ras to the nuclear envelope leads to an increased activation of PKA. The redundant functions of Tpk1 and Tpk2 or Tpk1 and Tpk3 are responsible for the reduction in growth rate defects and increased PKA activity drives a loss in viability that is attributed to a state of cell cycle dysregulation. Viability can be rescue upon the overexpression of PDE2 demonstrating that viability defects are dependent on PKA activity.

Chapter 5

The role of nutrient availability in the growth of $Ras2^{225}$ mutant strains

5.1 Introduction

In previous chapters we show that the overexpression of either *RAS2*^{S225A} or *RAS2*^{S225E} leads to Ras miss localisation and activation at the nuclear envelope. Such localisation results in growth defects and a loss of viability that we propose is attributable to a dysregulation of the cell cycle. We established that the slow growth phenotype observed is linked to elevated PKA activity, as overexpression of *PDE2* in strains overexpressing *RAS2*^{S225A} or *RAS2*^{S225E} rescued viability.

Investigations thus far involved the culturing of cells in minimal media to allow for the selection of plasmids used in this study. We consistently observed that overnight cultures of wild type cells exhibited a viability between 40-50 % suggesting that the media used is limiting. However, overexpression of *RAS2* led to an increase in viability in minimal media, suggesting that the media itself may not be limiting. It may be the case that the wild type strain used in this study is unable to access or forage for certain metabolites, leading to reduced viability, which can be corrected upon the overexpression of *RAS2*. This finding suggests an interplay between Ras activity, utilisation of available nutrition and cell fate. We sought to investigate whether changing the nutritional composition of growth media would enable cells overexpressing *RAS2* mutant alleles to resume growth in a manner analogous to the co-expression with *PDE2*.

In this chapter we focus on the effects of di/tri-peptide availability and uptake on cell fate within the context of Ras activation. Peptides are composed of sequences of amino acids and once catabolized provide the essential building blocks required for protein synthesis. In addition, certain peptides and amino acids can be utilized as a nitrogen source and can act as signalling molecules that alter cell behaviour. For example, the branched-chain amino acid

leucine, has been shown to control TORC1 activity [171][172]. TORC1 senses and responds to nutrients to promote cell growth and the inhibition of catabolic processes, such as autophagy. Branched-chain amino acids such as leucine function by affecting the 'nucleotide binding status of the Exit from G ₀ Complex' (EGOC) GTPase subunits Gtr1 and Gtr2 in *Saccharomyces cerevisiae*, promoting growth[173][174].

In mammals, amino acids exert a major role on the regulation of protein synthesis through the control of the kinases mTOR and Gcn2 [172][177]. The regulation of Gcn2 activity by amino acid availability relies on the capacity of Gcn2 to sense the increased levels of uncharged tRNAs upon amino acid scarcity [177]. Upon low levels of essential amino acids, Gcn2 phosphorylates the α -subunit of eukaryotic initiation factor 2 alpha (eIF2 α), resulting in the inhibition of protein synthesis. [178].

Due to the multifaceted role of amino acids and peptides in biological systems, it is therefore not surprising that microbes have evolved a multitude of mechanisms to facilitate peptide and amino acid uptake. The study of such mechanisms has been extensively examined in yeast, with amino acid uptake mechanisms presenting high conservation in mammals.

Saccharomyces cerevisiae has two distinct peptide transport mechanisms, a di-/tripeptides (the PTR system) and a tetra-/pentapeptides (the OPT) transport system [245][246][180]. The PTR family of peptide transporters transport a number of substrates, including amino acids, nitrates and di/tri-peptides [179]. PTR2 encodes an integral membrane protein (Ptr2p) involved in the physical translocation of peptides across the plasma membrane by the means of proton-motive force [180]. The transporter is specific for di-/tripeptides, with a preference for peptides containing hydrophobic amino acids. In S. cerevisiae the regulation of PTR2 expression is strongly affected by the composition of the extracellular environment.

In the absence of the preferred nitrogen sources PTR2 expression is induced [181] [182]. The import of di/tripeptides composed of basic or bulky hydrophobic N-terminal residues increases PTR2 expression via reducing cellular levels of Cup9p, the homeodomain-containing transcriptional repressor of PTR2. Specific di/tri-peptides function as both as ligands and regulators of the E3 ubiquitin ligase Ubr1p. Ubr1p mediates the Cup9p degradation system that is governed by the identity of N-terminal amino acids [183][184]. Most di/tripeptides are too small to be degraded by the proteasome and are assimilated as nutrients by intracellular peptidases. However, di/tripeptides with basic (Type 1: His, Lys, or Arg) and bulky (Type 2: Ile, Trp, Leu, Tyr, or Phe) N-terminal residues can compete with larger protein substrates and bind at the Type 1 and Type 2 Ubr1p substrate-binding sites. Once bound, Ubr1p-mediated degradation of Cup9p is allosterically activated via the release of the Ubr1p auto inhibitory domain, revealing a substrate-binding domain that binds an internal degron in Cup9p [185]. Relief of Cup9p repression of PTR2 results in enhanced PTR2 expression. A positive regulatory feedback loop is created where di/tripeptide uptake perpetuates Ubr1p-mediated Cup9p degradation, upregulating PTR2 expression and thus increased di/tripeptide uptake.

Although Ptr2p is the major transporter of di/tripeptides in *S. cerevisiae*, di/tripeptides can also be imported with a low efficacy by Dal5p, whose primary function is the import of nitrogen sources, such as allantoate and ureidosuccinate [186]. As aforementioned, the peptide transporters Opt1 and Opt2, which have partially overlapping functions, import peptides of 4–5 residues. In addition, Opt1 is a high affinity importer of glutathione, a "noncanonical" tripeptide [187]. In the same way as the Ptr2 transporter of di/tripeptides, the expression of *OTP2* is down-regulated by Cup9p, whereas the expression of *OPT1* is independent of Cup9p [187]. In addition to *PTR2* and *OPT2*, the N-end rule pathway also controls the expression of *DAL5*, but in a manner contrary to that of the other two

transporters: whereas Cup9p is a transcriptional repressor of *PTR2* and *OPT2*, Cup9p upregulates the expression of *DAL5* [179][187].

In this chapter we investigate how the availability and uptake of di/tripeptides interplays with entry and restore growth in cells overexpressing *RAS2*^{S225A} or *RAS2*^{S225E} mutant alleles grown in -URA

5.2 Growth on nutrient rich media rescues viability in wild type cells overexpressing *RAS2*^{5225A} or *RAS2*^{5225E}

In Chapter 3, we show that the viability of wild type cells overexpressing either *RAS2*^{5225A} or *RAS2*^{5225E} is significantly reduced after 24 hours of growth in minimal media. We sought to investigate whether growth on nutrient rich media, such as YPD, rescued viability in cells overexpressing *RAS2*^{5225A} or *RAS2*^{5225E}. To address this, a colony forming efficiency assay was performed. An overnight culture was re-inoculated to 2 x 10³ cells/ml and incubated for 24 hours. 300 cells were plated onto either selective -URA agar plates or YPD agar plates. These were left to incubate at 30 °C for 36 hours and the colonies were then counted to allow quantification of colony forming units (CFUs).

All strains re-plated onto YPD media presented a significant increase in viability when compared to strains grown on SD –URA (Figure 67). When compared to wild type cells overexpressing RAS2^{5225A} or RAS2^{5225E} grown on SD-URA, the re-plating of RAS2^{5225A} or RAS2^{5225E} strains onto nutrient rich agar resulted in a significant increase in colony forming efficiency (Figure 67). No significant differences in viability were observed between wild type cells overexpressing RAS2^{5225A}, RAS2^{5225E} or an empty plasmid control when grown on YPD (Figure 67). This data indicates that overexpression of either RAS2^{5225A} or RAS2^{5225E} in wild type cells does not lead to cell death but rather a cessation of proliferation. Cells were able to re-proliferate upon re-plating on nutrient rich agar, providing further evidence to suggest that overexpression of RAS2^{5225A} or RAS2^{5225E} leads to a cessation of growth as opposed to cell death in the yeast system.




Figure 67. A colony forming efficiency assay of S. cerevisiae wild type cells overexpressing RAS2^{S225A}, RAS2^{S225E}or an empty plasmid control grown in SD –URA media and plated on either SD-URA or YPD.

A colony forming efficiency analysis was carried out as described in Materials and Methods (Section 2.9.3). A One-way ANOVA using a Tukey multiple comparison test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value \leq 0.05 and *** = adjusted p value \leq 0.001

5.3 Determination of the component of YPD that allows *RAS2*^{S225A} or *RAS2*^{S225E} to escape growth cessation

5.3.1 Supplementation of Yeast Extract to minimal media rescues viability in wild type cells expressing $RAS2^{S225A}$ or $RAS2^{S225E}$

In order to determine which component of the nutrient rich media results in the exit from the reduced growth phenotype observed in cells overexpressing *RAS2*^{S225A} or *RAS2*^{S225E}, YPD was broken down into its constituent parts and these were individually added to the SD –URA agar at the same concentration as seen in YPD. A colony forming efficiency assay was performed as described in Materials and Methods Section 2.9.3, and after 24 hours of incubation in SD – URA media cells were plated onto either SD-URA or SD –URA + Yeast Extract solid media and the colony forming efficiency for each condition was calculated.

Upon growth on SD-URA media supplemented with yeast extract, a significant increase in viability was observed in all strains when compared to strains grown on SD-URA (*Figure 68*). Again, no significant changes in viability were observed in wild type cells overexpressing *RAS2*^{5225A} or *RAS2*^{5225E} alleles compared to the wild type control grown in SD –URA plus yeast extract (*Figure 68*). We therefor suggest that the supplementation of yeast extract to SD-URA media rescues viability in wild type cells overexpressing *RAS2*^{5225A} or *RAS2*^{5225E} mutant alleles enabling cells to resume normal growth.




Figure 68. A colony forming efficiency assay of S. cerevisiae wild type cells overexpressing RAS2^{5225A}, RAS2^{5225E}or an empty plasmid control grown in SD –URA media and plated on either SD-URA or SD-URA + Yeast Extract.

A colony forming efficiency analysis was carried out as described in Materials and Methods (Section 2.9.3). A One-way ANOVA using a Tukey multiple comparison test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value \leq 0.05 and *** = adjusted p value \leq 0.001

5.3.2 Increasing the glucose concentration in the growth media does not rescue viability in wild type cells overexpressing *RAS2*^{S225A} or *RAS2*^{S225E}

It has previously been established that the addition of glucose to nutrient starved cultures provides the stimulus for cells to exit a quiescent state and re-proliferate [247] [149][226][150]. To attest whether increasing the glucose concentration in the growth media would result in an increase in viability in cells overexpressing either *RAS2*^{5225A} or *RAS2*^{5225E} in a manner resembling that of the re-plating of cells on YPD, a colony forming efficiency assay was conducted. After 24 hours of growth in SD –URA, cells were plated on either SD-URA (2% glucose) or SD-URA (4% glucose). We observed no significant difference in colony forming efficiency in the wild type control when re-plated on SD-URA containing 4% glucose (*Figure 69*). No rescue in the viability to that of the wild type control was observed in *RAS2*^{5225A} or *RAS2*^{5225E} mutants when plated on media containing 4% glucose (*Figure 69*). We therefor conclude that increasing the availability of glucose in the growth media does not rescue viability in a manner resembling that of growth on YPD. We therefor conclude that the resumption of normal growth observed in cells overexpressing *RAS2*^{5225A} or *RAS2*^{5225E} is not glucose dependent.




Figure 69. A colony forming efficiency assay of S. cerevisiae wild type cells overexpressing RAS2^{5225A}, RAS2^{5225E}or an empty plasmid control grown in SD –URA media and plated on either SD-URA (2 % glucose) or SD-URA (4 % glucose).

A colony forming efficiency analysis was carried out as described in Materials and Methods (Section 2.9.3). A One-way ANOVA using a Tukey multiple comparison test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value \leq 0.05 and *** = adjusted p value \leq 0.001

5.3.3 Supplementation of Peptone to minimal media increases viability of wild type cells overexpressing *RAS2*^{S225A} or *RAS2*^{S225E}

As we have observed that the supplementation of yeast extract to SD-URA was sufficient to rescue the toxic effects on viability of expressing either *RAS2*^{S225A} or *RAS2*^{S255E} in wild type cells. We sort to investigate whether the supplementation of peptone, at the same concentration seen in YPD, to SD-URA media allow cells overexpressing *RAS2* mutant alleles to re-engage the cell cycle. To address this question, a colony forming efficiency assay was conducted as previously described and cells were plated on either SD-URA or SD-URA supplemented with peptone.

Upon growth on SD-URA media supplemented with peptone, a significant increase in viability was observed in all strains when compared to growth on SD-URA (*Figure 70*). Again, no significant changes in viability were observed in wild type cells overexpressing $RAS2^{S225A}$ or $RAS2^{S225E}$ mutant alleles when compared to the wild type control grown in SD –URA with the supplementation of peptone (*Figure 70*). We therefor propose that the supplementation of peptone to SD-URA media rescues viability in wild type cells overexpressing $RAS2^{S225A}$ or $RAS2^{S225E}$ and enables cells escape growth cessation.




Figure 70. A colony forming efficiency assay of S. cerevisiae wild type cells overexpressing RAS2^{S225A}, RAS2^{S225E}or an empty plasmid control grown in SD –URA media and plated on either SD-URA or SD-URA + Peptone.

A colony forming efficiency analysis was carried out as described in Materials and Methods (Section 2.9.3). A One-way ANOVA using a Tukey multiple comparison test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value \leq 0.05 and *** = adjusted p value \leq 0.001

5.4 Supplementation of Peptone to minimal media increases chronological life span of wild type cells overexpressing *RAS2*^{S225A}

We have previously shown that the overexpression of *RAS2*^{S225A} in wild type cells lead to a decrease in chronological life span. As the supplementation of peptone to the growth media was shown to rescue viability in wild type cells overexpressing *RAS2*^{S225A}, we sought to investigate whether supplementation of peptone to SD-URA media, at the same concentration found in YPD, would lead to an increase in the chronological lifespan of cells overexpressing *RAS2*^{S225A}. To test this hypothesis, a chronological life span assay was conducted as described in Materials and Methods, Section 2.9.8. Cells were grown in and then plated on SD-URA media or grown in SD-URA + Peptone and then plated on media containing SD-URA + Peptone.

All strains grown in the presence of peptone presented a significant increase in chronological lifespan when compared to strains grown without peptone supplementation (*Figure 71*). On day 1, the wild type control strain grown in the presence of peptone presented a significant increase in viability when compared to the control strain grown in SD-URA only (*Figure 71*). At day 12, the wild type control grown with peptone supplementation showed ~40 % of the culture still being able to form viable colonies compared to only ~20 % in the wild type control grown without peptone (*Figure 71*).

Wild type cells overexpressing $RAS2^{S225A}$ grown in SD-URA + peptone, presented a significant increase in viability after day 1 when compared to the $RAS2^{S225A}$ mutant grown in –URA media (Figure 71). After day 12, wild type cells overexpressing $RAS2^{S225A}$ were unable to form viable colonies, however when grown in media supplemented with peptone, ~20 % of cells were able to form viable colonies (Figure 71). We therefor propose that peptone supplementation

increases chronological lifespan in all strains and reduces the detrimental effects of the overexpression of *RAS2*^{S225A} on chronological lifespan in wild type cells.




Figure 71. A chronological ageing assay of wild type cells over expressing RAS2^{S225A} or an empty plasmid control grown in SD –URA and plated on SD-URA or grown in SD-URA + Peptone and plated on SD-URA + Peptone.

The chronological ageing assay was conducted as describe in materials and method (Section 2.9.8). The data represents an average of three biological repeats and error bars represents the standard error of the mean.

5.5 Supplementation of peptone to minimal media protects cells from necrosis

We have shown that the supplementation of peptone to SD –URA increases the chronological lifespan of all strains examined. We aimed to attest whether an increase in chronological lifespan was coupled with a decrease in cell death. To address this question, fluorescence-activated cell sorting (FACS) was employed to analyse the levels of cell death markers in wild type cells overexpressing $RAS2^{S225A}$ or an empty plasmid control when grown in either SD – URA or SD –URA + peptone. To investigate the levels of necrosis in the wild type control and wild type cells overexpressing $RAS2^{S225A}$ propidium iodide was used.

The supplementation of peptone to SD –URA significantly decreased the percentage of PI positive cells in all strains (*Figure 72*). No significant difference in the percentage of PI positive cells between wild type and the *RAS2*^{5225A} overexpression strain were observed after 12 days (*Figures 5.6B*). On day 12, cells grown without peptone supplementation presented ~40% of the cells being PI positive, whereas cells grown in the presence of peptone presented less than 2 % of the population being PI positive (*Figure 72*). After 12 days of growth in peptone supplemented media, no significant elevation in cell death was observed (*Figure 72*). We therefor conclude that peptone addition protects all strains examined from necrosis and that necrosis cannot explain the loss of viability observed in wild type or *RAS2*^{5225A} expressing cells during the chronological lifespan assay. However, we conclude that necrosis does account for a significant proportion of dead cells after day 6 of the chronological ageing assay and that this is prevented by peptone supplementation to the media.




Figure 72. A bar chart presenting the percentage of PI positive cells in wild type cells overexpressing RAS2^{5225A} or an empty plasmid control grown in -URA (A) or -URA + Peptone (B)

(A) A bar chart presenting the percentage of PI positive cells in wild type cells overexpressing RAS2^{S225A} or an empty plasmid control. Strains were grown in SD-URA and measurements were taken over a 12-day period of continuous incubation. Cells were incubated with PI in a 96 well plate for 15 minutes to measure cell death. The data displayed is an average of three biological repeats. (B) A bar chart presenting the percentage of PI positive cells in wild type cells overexpressing RAS2^{S225A} or an empty plasmid control. Strains were grown in SD-URA + Peptone and measurements were taken over a 12-day period of continuous incubation. Cells were incubated with PI in a 96 well plate for 15 minutes to measure cell death. The data displayed is an average of three biological repeats and error represent standard deviation.

5.6 Supplementation of peptone to minimal media retards ROS accumulation in cells

The supplementation of peptone to the growth media increased the chronological life span of all strains examined and reduced the levels of necrosis within the population. We therefor sort to attest whether the supplementation of peptone reduced the accumulation of ROS, a marker attributed to cell death, in all strains examined. To investigate the levels of cell death in cells overexpressing *RAS2*^{S225A} or an empty plasmid control, fluorescence-activated cell sorting (FACS) was utilised. This flow cytometry-based technique was used to determine

whether the overexpression of *RAS2*^{S225A} results in an increase in ROS. The dye dihydroethidium (DHE) was used to analyse superoxide levels within cells. During the first six days of incubation, the addition of peptone to the growth media reduced the percentage of DHE positive cells in all strains examined when compared to cells grown in SD –URA (Figure 73). Between days 1 and 4 in strains grown in the presence of peptone, less than 1 % of the cell population tested positive for elevated DHE (*Figure 73*). However, at day 12, the supplementation of peptone did not reduce the percentage of DHE positive cells when compared to the strains grown in SD –URA only (*Figure 73*). We propose that the addition of peptone to the growth media protects all strains examined from ROS accumulation during the first 6 days of incubation. We suggest that ROS accumulation cannot explain the loss in viability of cells until the last two time points of the chronological ageing assay, where elevated ROS contributes significantly.




Figure 73. A bar chart presenting the percentage of DHE positive cells in wild type cells overexpressing RAS2^{5225A} or an empty plasmid control grown in -URA (A) or -URA + Peptone (B)

A) A bar chart presenting the percentage of DHE positive cells in wild type cells overexpressing RAS2^{S225A} or an empty plasmid control. Strains were grown in SD-URA and measurements were taken over a 12-day period of continuous incubation. Cells were incubated with DHE in a 96 well plate for 15 minutes to measure superoxide production. The data displayed is an average of three biological repeats. (B) A bar chart presenting the percentage of DHE positive cells in wild type cells overexpressing RAS2^{S225A} or an empty plasmid control. Strains were grown in SD-URA + peptone and measurements were taken over a 12-day period of continuous incubation. Cells were incubated with DHE in a 96 well plate for 15 minutes to measure superoxide production. The data displayed is an average of three biological repeats and error bars represent standard deviation.

5.7 Supplementation of Peptone to minimal media protects cells from oxidative stress

We have previously shown that the overexpression of either *RAS2*^{S225A} or *RAS2*^{S225E} in wild type cells leads to an increase in hydrogen peroxide sensitivity when compared to the wild type control and *RAS2* overexpression strain. We have shown that the supplementation of peptone to minimal media resulted in increased chronological life span and overall decrease in cell death and stress in all strains examined. We sought to investigate whether the supplementation of peptone to SD –URA media containing different concentrations of

hydrogen peroxide would rescue the hydrogen peroxide sensitivity previously observed upon the overexpression of RAS2^{S225A} or RAS2^{S225E} in wild type cells. To investigate the effect of oxidative stress on wild type cells expressing RAS2, RAS2^{S225A}, RAS2^{S225E} or an empty plasmid control, a blotting assay was conducted as described in Materials and Methods, Section 2.9.5. On the SD -URA control plate, which did not contain H₂O₂ or peptone, a reduction in growth can be observed in cells expressing RAS2^{S225A} or RAS2^{S225E} when compared to the control strain (Figure 74). Upon the supplementation of peptone to the control plate, the reduced growth observed in cells overexpressing RAS2^{S225A} or RAS2^{S225E} is rescued (Figure 74). In the absence of peptone, as the concentration of hydrogen peroxide is increased, the growth of the wild type cells overexpressing RAS2^{S225A} or RAS2^{S225E} decreases (Figure 74). At a hydrogen peroxide concentration of 3 mM, we observed growth in both the control strain and the RAS2 overexpression strain, but growth was absent in wild type cells overexpressing either RAS2^{S225A} or RAS2^{S225E} (Figure 74). However, in the presence of peptone, all strains assayed grew on all concentrations of hydrogen peroxide (Figure 74). As the concentration of hydrogen peroxide was increased, we observed no significant decrease in growth across all strains (Figure 74). We therefor propose that peptone supplementation is protective against

peroxide stress in wild type cells overexpressing *RAS2*, *RAS2*^{S225A}, *RAS2*^{S225E} or an empty plasmid control.




Figure 74. Spotting assay of wild type cells overexpressing RAS2, RAS2^{S225A,} RAS2^{S225E} or an empty plasmid control grown on -URA (A) or -URA + Peptone (B) in the presence of hydrogen peroxide.

(A) Spotting assay of wild type cells overexpressing RAS2, RAS2^{S225A}, RAS2^{S225E} or an empty plasmid control. Cells were serially diluted from 2*10^6/ml to 2*10^3/ml and plated onto SD -URA plates supplemented with increasing concentrations of hydrogen peroxide. (B) Spotting assay of wild type cells overexpressing RAS2, RAS2^{S225A}, RAS2^{S225E} or an empty plasmid control. Cells were serially diluted from 2*10^6/ml to 2*10^3/ml and plated onto SD -URA plates containing peptone and supplemented with increasing concentrations of hydrogen peroxide.

5.8 Leucine supplementation does not rescue viability in wild type cells overexpressing *RAS2*^{5225A} or *RAS2*^{5225E}

Certain peptides and amino acids can be utilized as a nitrogen source and can act as signalling molecules that alter cell behaviour. For example, the branched-chain amino acid leucine, has been shown to control TORC1 activity [171][172]. TORC1 senses and responds to nutrients to promote cell growth and the inhibition of catabolic processes, such as autophagy. Branched-

chain amino acids such as leucine function by affecting the 'nucleotide binding status of the Exit from G₀ Complex' (EGOC) GTPase subunits Gtr1 and Gtr2 in *Saccharomyces* cerevisiae [173][174].

We hypothesize that growth on YPD and supplementation of either yeast extract or peptone to SD –URA media increases the concentration of amino acids within the media. As leucine concentrations have been positively correlated with cell growth, we investigated whether increasing the concentration of leucine in the media rescues viability in wild type cells overexpressing *RAS2*^{5225A} or *RAS2*^{5225E}. A colony forming efficiency assay was conducted as previously described in methods and materials, Section 2.9.3. Cells were plated on either SD-URA or SD-URA supplemented with 150 μg/ml of leucine. The normal levels of leucine required in the medium for the growth of *S. cerevisiae* are 30 μg/ml. A synthetic complete (SC) URA drop out mixture of amino acids from Formedium however contains 380 μg/ml leucine. We increased the levels of leucine further by adding an additional 150 μg/ml of leucine to the SD –URA media and investigated whether additional leucine supplementation resulted in pronounced changes in viability of wild type cells overexpressing *RAS2*^{5225A} or *RAS2*^{5225E} (Figure 75).

We observed no significant difference in colony forming efficiency in the wild type control when re-plated on SD-URA supplemented with 150 μ g/ml of leucine (Figure 75). No rescue in the viability to that of the wild type control was observed in $RAS2^{S225A}$ or $RAS2^{S225E}$ mutants when plated on media containing additional leucine (Figure 75). We therefor conclude that increasing the availability of leucine in the growth media does not rescue viability in a manner resembling that of growth on YPD. We therefor conclude that the exit from growth cessation observed in cells overexpressing $RAS2^{S225A}$ or $RAS2^{S225E}$ is not leucine dependent.




Figure 75. A colony forming efficiency assay of S. cerevisiae wild type cells overexpressing RAS2^{S225A}, RAS2^{S225E}or an empty plasmid control grown in SD –URA media and plated on either SD-URA or SD-URA + 150 μ g/ml of leucine.

A colony forming efficiency analysis was carried out as described in Materials and Methods (Section 2.9.3). A One-way ANOVA using a Tukey multiple comparison test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value \leq 0.05 and *** = adjusted p value \leq 0.001

5.9 Deletion of the di/tri-peptide transporter *PTR2* does not further attenuate viability in wild type cells overexpressing *RAS2*^{5225A} or *RAS2*^{5225E} mutant alleles

We suggest that the supplementation of either yeast extract or peptone to minimal media is sufficient to allow wild type cells expressing *RAS2*^{S225A} or *RAS2*^{S225E} to re-engage the cell cycle. We hypothesized that both peptone and yeast extract may share a common metabolite(s) to which the increase in the viability observed can be attributed to.

Peptone is produced by the enzymatic digest of proteins, producing water-soluble, protein hydrolysates of non-chemically defined nature, containing peptides, amino acids, and

inorganic salts, but devoid of lipids and sugars. Whereas yeast extract consists of the intracellular content of yeast cells upon removal of the cell wall. Upon the analysis of the two ingredients, we observed that both ingredients provide a source of di/tripeptides to the cells. We hypothesized that the increase in viability observed in wild type cells overexpressing the $RAS2^{S225A}$ or $RAS2^{S225E}$ mutant alleles upon the supplementation of either yeast extract or peptone to the media is a result of elevated intracellular levels of di/tri-peptides within cells. In S. cerevisiae, the uptake of di/tripeptides is predominantly performed by the transmembrane peptide transporter Ptr2p. We hypothesized that the deletion of PTR2 in wild type cells overexpressing RAS2^{S225A} or RAS2^{S225E} would further attenuate viability. To attest this hypothesis, plasmids overexpressing RAS2^{S225A}, RAS2^{S225E} or an empty plasmid control were introduced into a \(\Delta ptr2 \) background and a colony forming efficiency assay was performed as described in Materials and Methods, Section 2.9.3. The deletion of PTR2 in wild type cells expressing the empty plasmid control presented no significant changes in viability when compared to the wild type control (Figure 76). In wild type strains expressing either RAS2^{S225A} or RAS2^{S225E} the deletion of PTR2 resulted in ~20 % of cells within the population being able to form colony forming units (Figure 76), presenting no difference in viability when compared wild type cells overexpressing RAS2^{S225A} or RAS2^{S225E} mutant alleles (Figure 76). We therefor propose that the deletion of PTR2 does not further attenuate viability in wild type cells expressing either RAS2^{S225A} or RAS2^{S225E}.




Figure 76. A colony forming efficiency assay of S. cerevisiae wild type or $\Delta ptr2$ cells overexpressing RAS2^{S225A}, RAS2^{S225E} or an empty plasmid control grown in SD –URA media. A colony forming efficiency analysis was carried out as described in Materials and Methods (Section 2.9.3). A One-way ANOVA using a Dunnetts multiple comparison test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value ≤ 0.05 and *** = adjusted p value ≤ 0.001

5.10 Deletion of *CUP9* in wild type cells overexpressing *RAS2*^{5225A} or *RAS2*^{5225E} rescues growth defects

Expression of the *PTR2* peptide transporter is induced by dipeptides with destabilizing N-terminal residues. These dipeptides bind to Ubr1p, the ubiquitin ligase of the N-end rule pathway, and allosterically accelerate the Ubr1-dependent degradation of Cup9p, a transcriptional repressor of *PTR2*. Ubr1p targets Cup9p through its internal degron [185]. We have previously shown that deletion of *PTR2* presented no significant changes in viability in wild type cells overexpressing *RAS2*^{S225A} or *RAS2*^{S225E} mutant alleles. We hypothesized that increasing *PTR2* expression and thus increasing di/tri-peptide transport in wild type cells

overexpressing either $RAS2^{S225A}$ or $RAS2^{S225E}$ may enhance viability. To increase PTR2 expression, we deleted the gene encoding for the transcriptional repressor of PTR2, CUP9. Plasmids encoding either $RAS2^{S225A}$ or $RAS2^{S225E}$ or an empty plasmid control were introduced into a $\Delta cup9$ background and a growth analysis was conducted as described in Materials and Methods, Section 2.9.1.

We observed no significant growth defects in $\triangle cup9$ strains overexpressing $RAS2^{S225A}$ or $RAS2^{S225E}$ mutant alleles when compared to the wild type control (Figure 77) with no significant differences in growth rate observed (Figure 78). Deletion of CUP9 in wild type cells rescues the growth defects previously observed when overexpressing $RAS2^{S225A}$ or $RAS2^{S225E}$ in wild type cells.




Figure 77. Growth analysis of S. cerevisiae wild type and Δ cup9 cells overexpressing RAS2^{S225A}, RAS2^{S225E} or empty plasmid control.

The growth analysis was carried out in SD –URA media as described in Materials and Methods (Section 2.9.1). This data represents an average of three biological repeats and error bars represent the standard deviation.




Figure 78. Growth rate analysis of S. cerevisiae wild type or Δ cup9 cells overexpressing RAS2^{S225A}, RAS2^{S225E} or an empty plasmid control.

The growth rate analysis was carried out as described in Materials and Methods (Section 2.9.1). The data represents an average of three biological repeats and error bars represents the standard deviation. A One-way ANOVA using a Dunnets multiple comparison test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value \le 0.05 and *** = adjusted p value \le 0.001.

5.11 Deletion of *CUP9* in wild type cells expressing *RAS2* mutant alleles rescues viability

To determine whether the overexpression of either $RAS2^{S225A}$ or $RAS2^{S225E}$ affects viability in a $\Delta cup9$ background, a viability assay was conducted as described in Materials and Methods, Section 2.9.3 The deletion of CUP9 in wild type cells expressing a plasmid control presented no significant change in viability when compared to the wild type control (*Figure 79*). Interestingly, the overexpression of $RAS2^{S225E}$ in a $\Delta cup9$ background lead to a significant increase in viability when compared to the wild type control (*Figure 79*). Furthermore, the overexpression of $RAS2^{S225A}$ in a $\Delta cup9$ background lead to no significant changes in viability when compared to the wild type control (*Figure 79*). Our data suggests that the deletion of CUP9 in wild type cells overexpressing $RAS2^{S225A}$ or $RAS2^{S225E}$ prevents the toxic gain of function of the overexpression of either $RAS2^{S225A}$ or $RAS2^{S225E}$ in wild type cells and prevents cells from disengaging the cell cycle.




Figure 79. A colony forming efficiency assay of S. cerevisiae wild type or Δ cup9 cells overexpressing RAS2^{S225E} or an empty plasmid control grown in SD –URA media. A colony forming efficiency analysis was carried out as described in Materials and Methods (Section 2.9.3). The data represents an average of three biological repeats and error bars represents the standard deviation. A One-way ANOVA using a Dunnetts multiple comparison test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value ≤ 0.005 and *** = adjusted p value ≤ 0.001 .

5.12 Deletion of *UBR1* does not further attenuate viability in wild type cells overexpressing *RAS2*^{5225A} or *RAS2*^{5225E}

We have previously shown that the deletion of *CUP9* rescues the growth defects induced by the overexpression of either *RAS2*^{S225A} or *RAS2*^{S225E} in wild type cells. We hypothesize that deletion of *CUP9*, increases *PTR2* expression thus increasing the transportation of ditripeptides into the cell and restoring viability. As Ubr1p degrades cellular Cup9p, we hypothesize that the deletion of *UBR1* in wild type cells will increase the levels of cellular Cup9p and thus decrease the expression of *PTR2* which may further decrease viability in wild type cells overexpressing either *RAS2*^{S225A} or *RAS2*^{S225E}. To attest this hypothesis, plasmids

encoding $RAS2^{S225A}$, $RAS2^{S25E}$ or an empty plasmid control were introduced into a $\Delta ubr1$ strain and a colony forming efficiency assay was conducted as described in Materials and Methods, Section 2.9.3).

The expression of an empty plasmid control in a $\Delta ubr1$ background lead to no significant changes in viability when compared to the wild type control (*Figure 80*). The overexpression of either $RAS2^{S225A}$ or $RAS2^{S225E}$ in a UBR1 deletion strain lead to a decrease in viability when compared to the control strains (*Figure 80*). The viability of $\Delta ubr1$ strains expressing either $RAS2^{S225A}$ or $RAS2^{S225E}$ was ~20%, which mirrors that seen in wild type cells overexpressing the $RAS2^{S225A}$ or $RAS2^{S225E}$ mutant alleles (*Figure 30*). We therefor propose that the deletion of UBR1 in wild type cells overexpressing $RAS2^{S225A}$ or $RAS2^{S225E}$ does not lead to a further attenuation of viability.




Figure 80. A colony forming efficiency assay of S. cerevisiae wild type or Δ ubr1 cells overexpressing RAS2^{S225E}, RAS2^{S225E} or an empty plasmid control grown in SD –URA media. A colony forming efficiency analysis was carried out as described in Materials and Methods (Section 2.9.3). The data represents an average of three biological repeats and error bars represents the standard deviation. A One-way ANOVA using a Dunnetts multiple comparison test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value \leq 0.05 and *** = adjusted p value \leq 0.001.

5.13 The effects of di-peptide supplementation on the viability of wild type cells overexpressing the *RAS2* mutant alleles

We have shown that the deletion *of CUP9* in wild type cells overexpressing either *RAS2*^{S225A} or *RAS2*^{S225E} rescues both growth and viability. We hypothesize that the deletion of *CUP9*, relieves *PTR2* from repression and increases its expression. We propose that increased *PTR2* expression will lead to elevate di/tri-peptide uptake into cells which may result in the rescue of the growth defects observed in wild type cells overexpressing *RAS2*^{S225A} or *RAS2*^{S225E}.

It has been previously revealed that the regulation of *PTR2* expression in *S. cerevisiae* is also influenced by the extracellular environment. In particular di/tri-peptides have been identified to induce *PTR2* expression [185][182][179]. Furthermore, the import of di/tri-peptides comprised of basic or bulky hydrophobic N-terminal residues have also been shown to increase *PTR2* expression via the reduction of cellular levels of the *PTR2* repressor Cup9p [185].

In order to increase *PTR2* expression without the deletion of its repressor *CUP9* in wild type cells overexpressing *RAS2*^{5225A}, we proposed to utilize the positive regulatory feedback loop mediated by di/tri-peptide uptake by the supplementation of peptides containing bulky and basic N-terminal residues to the –URA growth media. We hypothesize that the supplementation of these specific di/tripeptides will upregulate *PTR2* expression and thus increase di/tri-peptide uptake and enable wild type cells overexpressing *RAS2*^{5225A} to exit growth cessation. To attest this hypothesis, a colony forming efficiency assay was performed as described in (Materials and Methods, Section 2.9.4) and after 24 hours of incubation in SD –URA media, cells were plated onto either SD-URA or SD –URA with the addition of a specific

di-peptide at a 1 mM concentration. After 36 hours of incubation the colony forming efficiency for each condition was calculated.

Surprisingly, no significant difference in viability was observed in all strains grown in the presence of any of the supplemented di-peptides (*Figure 81*). No increase in viability to that of the wild type was observed in the *RAS2*^{5225A} mutant upon supplementation of any of the di/tripeptides to the minimal media (*Figure 81*). We therefor conclude that the presence of either Leu-Leu, Ala-Leu, Tyro-Ala or His-Leu at a 1 mM concentration does increase viability in wild type cells overexpressing *RAS2*^{5225A} in the conditions used.




Figure 81. A colony forming efficiency assay of S. cerevisiae wild type cells overexpressing RAS2^{S225A} or an empty plasmid control grown in SD –URA media and plated on SD-URA supplemented with a di-peptide at a 1 mM concentration.

A colony forming efficiency analysis was carried out as described in Materials and Methods (Section 2.9.4). The data represents an average of three biological repeats and error bars represents the standard deviation.

The supplementation of either Leucine-Leucine, Alaline-Leucine, Tyrosine-Alaline or Histadine-Leucine dipeptides to the growth media at a 1 mM concentration did not rescue viability in wild type cells overexpressing *RAS2*5225A. We hypothesized that combining all the previously examined dipeptides together in the growth media may present changes in viability of the *RAS2*5225A mutant, which were not observed previously when dipeptides were supplemented to the growth media singularly. To attest this hypothesis, a colony forming efficiency assay was conducted as previously described in Materials and Methods, Section 2.9.4. Cells were plated onto SD –URA media containing the following dipeptides at a 1 mM concentration, Leucine-Leucine, Alaline-Leucine, Tyrosine-Alaline and Histadine-Leucine. The supplementation of the dipeptide mix did not result in a rescue of viability in wild type cells overexpressing *RAS2*5225A when compared to the wild type control (*Figure 82*). We conclude that the supplementation of the dipeptides examined in this study, either added singularly or combined together, failed to produce any significant changes in the viability of either the wild type control or the *RAS2*5225A mutant when compared to cells grown on SD-URA media.




Figure 82. A colony forming efficiency assay of S. cerevisiae wild type cells overexpressing RAS2^{S225A} or an empty plasmid control grown in SD –URA media and plated on SD-URA supplemented with the di-peptides; Leucine-Leucine, Alaline-Leucine, Tyrosine-Alaline and Histadine-Leucine at a 1 mM concentration.

A colony forming efficiency analysis was carried out as described in Materials and Methods (Section 2.9.1). The data represents an average of three biological repeats and error bars represents the standard deviation. A One-way ANOVA using a Dunnetts multiple comparison test was used to determine statistical significance. Non-significant = NS, * = adjusted p-value \leq 0.05 and *** = adjusted p value \leq 0.001.

5.14 Discussion

In previous chapters we suggest that the overexpression of either *RAS2*^{S225A} or *RAS2*^{S225E} leads to the miss localisation of active Ras to the nuclear envelope. Such localisation results in growth defects and a loss of viability that we believe to be attributable to deregulation in the cell cycle. We established that the slow growth phenotype observed is linked to elevated PKA activity, as overexpression of *PDE2* in strains overexpressing *RAS2*^{S225A} or *RAS2*^{S225E} rescued viability. We sought to investigate whether changing the nutrition availability would enable cells overexpressing *RAS2* mutant alleles to restore growth and viability in manner analogous to the co-expression with *PDE2*.

We show that the growth of wild type cells overexpressing RAS2^{S225A} or RAS2^{S225E} on nutrient rich media, such as YPD, rescued viability. We therefore propose that the overexpression of either RAS2^{S225A} or RAS2^{S225E} in wild type cells does not lead to cell death but rather a cessation of proliferation, as cells were able to re-proliferate upon re-plating on nutrient rich agar. This provides further evidence to suggest that the overexpression of RAS2^{S225A} or RAS2^{S225E} leads to a cessation of growth in the yeast system opposed to cell death. To determine which component of the nutrient rich media results in the reengaging of the cell cycle, YPD was broken down into its constituent parts and these were individually added to the SD –URA agar at the same concentration as seen in YPD. Viability assays were conducted and the supplementation of both yeast extract or peptone to SD –URA media resulted in a rescue of viability in wild type cells overexpressing RAS2^{S225A} or RAS2^{S225E}. Interestingly, increasing the availability of either glucose or leucine to cells overexpressing RAS2^{S225A} or RAS2^{S225E} did not lead to any changes in viability. This indicates that the nature of the slow growth phenotype seen upon overexpression of RAS2 mutant alleles is not mediated through glucose and leucine levels.

The effects of peptone supplementation were investigated further with regards to its effect on chronological life span, cell death and oxidative stress sensitivity. In wild type cells overexpressing *RAS2*^{5225A} or *RAS2*^{5225A}, the supplementation of peptone increased the chronological life span of cells and decreased the levels of both necrosis and ROS in the cell population.

We show that the supplementation of either yeast extract or peptone to minimal media is sufficient to allow wild type cells expressing *RAS2*^{S225A} or *RAS2*^{S225E} to restore growth. We hypothesized that both peptone and yeast extract may share a common metabolite(s) to

which the increase in the viability observed can be attributed to. Upon the analysis of the two ingredients, we observed that both ingredients provide a source of di/tripeptides to the cells. We hypothesized that the increase in viability observed in wild type cells overexpressing the *RAS2*^{5225A} or *RAS2*^{5225E} mutant alleles upon the supplementation of either yeast extract or peptone to the media is a result of elevated intracellular levels of di/tri-peptides within cells. In *S. cerevisiae*, the uptake of di/tripeptides is predominantly performed by the transmembrane peptide transporter Ptr2p. To reduce the intracellular levels of di/tripeptides, *PTR2* was deleted in cells overexpressing *RAS2* mutant alleles. Surprisingly, the deletion of *PTR2* presents no significant changes in viability. However, the deletion of *CUP9*, the transcriptional repressor of *PTR2*, rescued both growth and viability defects. We propose that the deletion of *CUP9* increases *PTR2* expression, increases peptide uptake and allowing cells to reengage in the cell cycle. This data indicates an interplay between Ras activity, utilisation of available nutrition and cell fate.

To further investigate the effects of di/tri-peptide uptake on the viability of cells overexpressing either *RAS2*^{S225A} or *RAS2*^{S225E}, the dipeptides; Leu-Leu, Ala-Leu, Tyro-Ala or His-Leu were supplemented to the growth media and viability assays conducted. However, no significant effects on cell viability were observed upon the addition of any of the di-peptides. We then hypothesised that the rescue of viability observed in cells overexpressing *RAS2*^{S225A} or *RAS2*^{S225E} may not be mediated by a single di-peptide but rather a combination. To attest this the dipeptides previously examined were added together in the growth media and viability assays were conducted. However, no change in viability was recorded in wild type cells overexpressing *RAS2* mutant alleles. We therefor propose that the rescue in viability

observed from growth on YPD, supplementation of either peptone or yeast and deletion of *CUP9* is not wholly attributable to an increase in di/tripeptide uptake.

Although unlikely, it is possible that the growth of wild type cells in nutrient rich media may result in a reduction of plasmid copy number. In this scenario, a reduction in copy number of either the plasmids expressing RAS2^{5225A} or RAS2^{5225E} in wild type cells could explain the increase in viability observed when grown in YPD media when compared to cells grown in SD –URA media. This is an important considerations and further investigations must be conducted to address this question. In the next chapter we investigate the global effects of the overexpression of either RAS2^{5225A} or RAS2^{5225E} in wild type cells via genome-wide transcriptome analysis.

Chapter 6 Transcriptome analysis of *RAS2*^{S225A} or *RAS2*^{S225E} overexpressing cells

6.1 Introduction

Quiescence in yeast cells is defined as a temporary non-proliferating cellular state. In *S. cerevisiae*, quiescent cells display a number of specific characteristics that differentiate them from proliferating cells: the overall transcription rate is substantially reduced [215]; the rate of overall protein synthesis is reduced to approximately 0.3 % of that observed in exponential cultures [248]; the expression of specific gene sets is severely downregulated e.g. genes encoding ribosomal proteins[249]; and chromosomes are condensed [250].

In previous chapters we suggest that the overexpression of either *RAS2*^{S225A} or *RAS2*^{S225E} in wild type cells leads to growth defects and a loss of viability that we propose to be attributable to a dysregulation in the cell cycle. We suggest that the slow growth phenotype is mediated through the Ras/cAMP/PKA pathway as suppression of this pathway, through the overexpression of *PDE2*, leads to a complete rescue of viability and growth. In addition, we show that increasing the nutrient availability to cells overexpressing *RAS2* mutant alleles, either through growth on nutrient rich media or through deletion of *CUP9*, also results in a rescue of the loss of viability phenotype. We therefore sought to investigate the gene expression patterns that govern the reduced growth phenotype observed using an RNA sequencing approach.

6.2 Illumina library preparation and RNA sequencing

After 24 hours of growth, total RNA was extracted in biological triplicate from wild type cells overexpressing *RAS2*^{5225A}, *RAS2*^{5225E} or containing an empty plasmid using the E.Z.N.A.TM Yeast RNA Kit as detailed in Materials and Methods, Section 2.7.4. After extraction, RNA purity was estimated using a NanoDrop ND-1000 spectrophotometer and sent to the Centre for Genome

Enabled Biology and Medicine (Aberdeen, UK) for library preparation and sequencing. Sequencing was performed on the Illumina NextSeq500 platform, producing 75bp single end reads.

Prior to library preparation the quality and quantification of RNA samples were evaluated with TapeStation (Agilent) and Qubit (Thermal Fisher) by Dr Jin Pu from the Centre for Genome Enabled Biology and Medicine (Aberdeen, UK). The samples with the minimum RIN of 8.0 were proceeded. The mRNA-Seq libraries were prepared using TruSeq™ Stranded mRNA Sample Preparation Kit (Ilumina) according to the manufacturer's instructions. Briefly, Poly-A RNA were purified from 500ng of total RNA with 1ul (1:100) ERCC spike (Thermal Fisher) as an internal control using RNA purification oligo(dT) beads, fragmented and retrotranscribed using random primers. Complementary-DNAs were end-repaired, and 3-adenylated, indexed adapters were then ligated. 15 cycles of PCR amplification were performed, and the PCR products were cleaned up with AMPure beads (Beckman Coulter). Libraries were validated for quality on Agilent DNA1000 Kit and quantified with the qPCR NGS Library Quantification kit (Roche). The final libraries were equimolar pooling and sequenced using the High Output 1X75 kit on the Illumina NextSeq 500 platform producing 75 bp single end reads. For each library a depth 20-30M reads were generated.

6.3 Quality control analysis of RNA-Seq reads

The analysis of RNA–Seq samples was performed using the Galaxy web platform (www.usegalaxy.org) [202]. The quality of the RNA sequencing reads was checked using the FASTQC v0.11.5 plug-in, using the default settings [203]. The FastQC plug-in provides a simplistic platform to perform quality control checks on raw sequencing data sourced from high throughput sequencing pipelines. FastQC delivers visual readouts of the quality of raw

sequencing data, providing information on basic statistics including the average sequence length, number of sequences and the number of poor-quality sequences. Importantly, FastQC produces a Phred score for each sample, providing information on the probability of a base being erroneous and provides an adapter content score, indicating the level of adapter contamination within the reads.

After the completion of the FastQC analysis, the information obtained was used to determine whether any trimming of the sequencing was necessary before deeper analysis. All samples with low quality ends (Phred score < 20) and adapter sequences were trimmed using the TrimGalore v0.4.3 plug-in [204]. After trimming, 98.8% of initial reads remained and FastQC v0.11.5 [203] was run again to confirm the quality. There were no Poly-A reads (more than 90% of the bases equal A), ambiguous reads (containing N) or low-quality reads (more than 50% of the bases with a Phred score < 20). After processing, the mean Phred score per read was 37.

6.4 FastQC output

6.4.1 Basic Statistics

The basic statistics output generated from the FastQC analysis indicated that there were no sequences flagged as poor quality after trimming across all samples (Table 6.1). The sequence length of the reads after trimming was between 40-52 bases and the average sequencing depth was 34 M across all samples with an average GC % of 41.

Table 13. Basic statistics output from FastQC analysis of the RNA sequencing reads generated from RNA isolated from wild type cells overexpressing RAS2^{5225A} (replicate 1). This table is representative of all the samples.

Basic Statistics

| Measure | Value |
|-----------------------------------|---|
| Filename | Trim Galore_ on data 67_ trimmed reads.gz |
| File type | Conventional base calls |
| Encoding | Sanger / Illumina 1.9 |
| Total Sequences | 34051638 |
| Sequences flagged as poor quality | 0 |
| Sequence length | 40-52 |
| %GC | 41 |

6.4.2 Phred Score

A Phred quality score is a measure of the quality of identification of the nucleobases generated by automated DNA sequencing [251]. The Phred scores provides an insight into the probability that a base within a sequencing read has been wrongly assigned, thereby providing an estimation of the quality of the sequencing reaction, and hence resulting reads.

A phred score resides on a logarithmic scale ranging from 1-40 where the higher the Phred score the lower the probability of the base being erroneous. A nucleotide base Phred score of 30 indicates a 1 in 1000 probability that the base was assigned incorrectly during the sequencing reaction. This translates to an accuracy of 99.9 % and therefore reads with a Phred score greater than 30 are considered good quality reads and progressed to next-generation sequencing applications such as RNA-Seq [251]. For the 9 samples investigated in this study, all samples produced Phred scores greater than 30, with the average Phred score being 35 (Figure 83)




Figure 83. The average Phred score for each base across the length of the sequencing read. This read was generated from the RNA isolated from wild type cells overexpressing RAS2^{S225A} (replicate 1). This graph is representative of all samples investigated.

6.4.3 N content

The N content indicates the number of ambiguous reads within a sample, i.e. the number of reads containing at least one base which was not assigned and hence denoted as N. There were no ambiguous reads in any of the 9 samples under investigation (Figure 84)




Figure 84. N content across all bases within the reads from RNA isolated from wild type cells overexpressing RAS2^{S225A} (Sample 1).

This graph is representative of all samples.

6.4.4 Adapter Content

The adapter content value provides a quantification of any contamination in reads caused by the presence of sequences originating from the library preparation. Contaminations caused by the presence of adapter sequences can result in alignment errors when aligning the reads to a reference genome since the adaptor sequences will not appear in the genome. Therefor trimming of reads is necessary to remove any adaptor sequences which could influence downstream applications. Post trimming, no adaptor sequences were detected in reads from all samples (Figure 85).




Figure 85. Adaptor content across bases within the reads of RNA isolated from wild type cells overexpressing RAS2^{S225A} (sample 1).
This graph is representative of all samples.

6.5 Principle Component Analysis

A principle component analysis (PCA) is a statistical procedure used for the exploration of large data sets. PCA is a valuable method for the visualisation of large data sets and is used to determine the degree of similarity between biological replicates, and how different they are to samples from other conditions. PCA was conducted within the DESeq2 package as part of the differential gene expression analysis [207].

The PCA reduces the dimensionality of the data sets by determining directions along which the most variation occurs thus simplifying very large data sets while retaining as much information as possible [252]. Within a PCA, the first principle component (PC1), is the direction along which most of variation occurs and the second principal component (PC2) covers as much of the remaining variation as possible [252]. Samples are plotted on a PCA graph based on the two principle components. Samples displaying clear clustering, indicates similarity between samples and large degrees of separation between samples indicates a low level of similarity.

In this study, biological replicates of the RNA sequenced from wild type cells overexpressing either *RAS2*^{S225A}, *RAS2*^{S225E} or an empty plasmid control cluster well along both the PC1 and PC2 axis, indicating that within the biological repeats there is a high degree of similarity (*Figure 86*). There is also a significant degree of separation between the clusters of the biological repeats suggesting differential gene expression between strains (*Figure 86*).




Figure 86. Principle component analysis of the RNA-Seq data obtained from wild type cells overexpressing RAS2^{S225A}, RAS2^{S225E} or an empty plasmid control.

6.6 Analysis of RNA-Seq reads using the Galaxy online platform

Processed reads were aligned with the reference *S. cerevisiae* genome S288C version R64-2-1_20150113 (SacCer3) using HISAT2 v2.1.0 with single-end reads and reverse strand settings, with all other settings set to default [205]. After the completion of the alignment, the number of mapped reads which overlapped CSD features in the genome, using the S288C version R64-2-1_20150113_features gtf annotation file, were determined using the featureCounts plug-in v1.6.3 with default settings [206]. Reads aligning to multiple positions or overlapping more than one gene were discarded, counting only reads aligning unambiguously to a single gene. Differential gene expression analysis between RNA extracted from wild type cells overexpressing *RAS2*^{5225A}, *RAS2*^{5225E} or an empty plasmid control were performed using DESeq2 v1.18.1 using default settings [207].

Using DESeq2, the expression levels of each gene in wild type cells overexpressing either

RAS2^{S225A} or RAS2^{S225E} was compared to samples generated from wild type cells overexpressing an empty plasmid control. The overexpression of either RAS2^{S225A} or RAS2^{S225E} led to a global response resulting in the significant differential expression of genes when compared to the wild type control. The overexpression of RAS2^{S225A} lead to the differential gene expression (false-discovery-rate adjusted p-value (q) \leq 0.05) of 4133 genes, with roughly equal numbers of genes up- and downregulated (2054 up and 2079 down) (Figure 87). 58 genes were strongly (log2 fold change >2) upregulated and 23 were strongly (log2 fold change <-1.5) downregulated. The overexpression of RAS2^{S225E} lead to the differential gene expression (false-discovery-rate adjusted p-value (q) \leq 0.05) of 5202 genes, with 2543 upregulated and 2659 down downregulated (Figure 88). 281 genes were strongly (log2 fold change >2) upregulated and 644 genes were strongly (log2 fold change <-1.5) downregulated. To identify the cellular pathways which these differentially expressed genes are within we conducted Gene Set Enrichment Analysis (GSEA; Broad Institute) [208]. The GSEA is a computational method which determines whether a prior defined gene set data presents statistically significant, concordant differences between two biological states.

To conduct a GSEA analysis, a list of significantly ($q \le 0.05$) differentially expressed genes, ranked from the most upregulated to the most downregulated were uploaded into the GSEA database and compared to a gene set data base (S288C version R64-2-1_20150113_features gtf annotation file). GSEA functions to identify whether the members of each gene set are randomly distributed within the ranked gene list or significantly overrepresented (enriched) at either end of the gene list. Gene sets are ranked using a normalised enrichment score (NES). A positive normalised enrichment score indicates that genes within a specific a gene set are located at the top of the ranked gene list whereas a negative normalised enrichment score indicates that genes within a specific gene set are located at the bottom of the ranked

gene list. From this information we can predict which biological processes or pathways are up- or downregulated between strains. The GSEA is a powerful form of analysis as an increase in the expression of 15 % of all genes associated with a pathway may have more effect than a single gene that has say a 10-fold increase in expression. The GSEA output provides enrichment profiles showing correlations with numerous overlapping gene sets, we were able to visualise networks of similar gene sets using the cytoscape 3.7.1 EnrichmentMap plug-in [253] (Figure 87).

6.7. GSEA analysis of cellular processes differentially regulated by the overexpression of *RAS2*^{S225A}

Interestingly, the overexpression of *RAS2*^{S225A} in wild type cells induced a significant upregulation in pathways involved in ribosomal biogenesis, transcription, translation, glucose transport and central metabolism (*Figure 87*). Such an observation was surprising as the pathways upregulated recapitulate those observed from exponentially growing cells [248][249][226][226].

However, such an observation can be explained upon the analysis of the pathways downregulated by the overexpression of *RAS2*^{S225A}. We observed a significant downregulation in cytoskeletal, microtubule and kinetochore dynamics and nuclear and cell division; chromosome condensation and segregation, cell cycle phase transition, mitosis and transcription factors associated with cell cycle phase progression (*Figure 87*). The resulting effect of the downregulation of the pathways are indicative of a cessation of proliferation. It may be the case that a loss of co-ordination between cytoplasmic and nuclear machinery occurs upon the overexpression of *RAS2*^{S225A} in that cells are primed for cell division but possess an inability to divide.




Figure 87. Global gene expression changes in wild type cells overexpressing RAS2^{S225A} when compared to a wild type control.

(A) DESeq2 was used to compare gene expression in wild type cells overexpressing RAS2^{S225A} to a wild type control and a volcano plot was generated of the \log_2 fold change against mean of normalised counts for each gene; red dots = significantly differentially expressed (q \leq 0.05) genes, grey dots = not significant. In total there were 4133 significantly differentially expressed genes. Normalised counts are the number of reads a gene has and therefor the higher the mean of normalised count, the greater the expression of that gene. (B) Gene set cluster map created using the cytoscape plug in showing the most upregulated and downregulated gene

sets as determined by GSEA analysis along with their cellular functions. Each circle represents a gene set and the lines between them corresponds to how much they overlap, the thicker the line the greater the genes they have in common.

6.7. GSEA analysis of cellular processes differentially regulated by the overexpression of *RAS2*^{S225E}

GSEA analysis revealed that the overexpression of *RAS2*^{5225E} in wild type cells elicits a similar pattern in the cellular pathways upregulated to that observed upon the overexpression of *RAS2*^{5225A}. We observed an upregulation in pathways involved in ribosomal biogenesis, transcription, translation, glucose transport and central metabolism (*Figure 88*). All of which can be attributed to an actively growing population of cells. The pathways downregulated mimicked those seen upon overexpression of *RAS2*^{5225A} with chromosome condensation and segregation, cell cycle phase transition, mitosis and transcription factors associated with cell cycle phase progression and chromatin remodelling all downregulated (*Figure 88*). This data suggests that both *RAS2*^{5225E} and *RAS2*^{5225A} lead to similar changes in the regulation of cell processes that may explain why cells enter a quiescent state.




Figure 88. Global gene expression changes in wild type cells overexpressing RAS2^{S225E} when compared to a wild type control.

(A) DESeq2 was used to compare gene expression in wild type cells overexpressing RAS2^{S225E} to a wild type control and a volcano plot was generated of the \log_2 fold change against mean of normalised counts for each gene; red dots = significantly differentially expressed ($q \le 0.05$) genes, grey dots = not significant. In total there were 5202 significantly differentially expressed genes. Normalised counts are the number of reads a gene has and therefor the higher the mean of normalised count, the greater the expression of that gene. (B) Gene set cluster map generated by cytoscape showing the most upregulated and downregulated gene sets as

determined by GSEA analysis along with their cellular functions. Each circle represents a gene set and the lines between them corresponds to how much they overlap, the thicker the line the greater the genes they have in common.

6.8 Further analysis of the gene sets enriched upon overexpression of *RAS2*^{5225A} in wild type cells

Following GSEA analysis we sought to visualise networks of similar gene sets using the cytoscape plug in (Figure 89). We sought to identify which processes within these gene set networks were up- or downregulated. To achieve this, we used the normalised enrichment score (NES) to identify which processes and to what extent genes in these pathways were either up- or downregulated when compared to the wild type control. Upon the overexpression of $RAS2^{5225A}$ in wild type cells we observed an increase in ribosomal biogenesis, transcription, and translation. Here we observed that gene sets involved in; cytoplasmic translation (NES = 2.29), cytosolic ribosome (NES = 2.29), ribosome biogenesis (NES = 2.07), translation elongation (NES = 2.43), preribosome (NES = 2.19) and ribosome assembly (NES = 2.18) were all significantly upregulated (Figure 89). A full list of the genes within the gene set networks that regulate the processes detailed below can be found in the appendix.




Figure 89. Gene sets shown to be upregulated upon the overexpression of RAS2^{S225A}when compared to the wild type control. (A), cytosolic ribosomes (B), ribosome biogenesis (6), translation elongation (D), preribosome (E) and ribosome assembly (F).

Vertical black lines represent individual genes in the significantly differentially expressed ranked gene list from upregulated (left) to downregulated (right). An increase in the enrichment score is seen if there are many genes towards the beginning of the ranked list (upregulated) in the gene set. When the green line climbs rapidly and peaks near the start of the graph (as shown here) it can be concluded that that gene set is overall upregulated. NES = normalised enrichment score, positive NES shows enrichment in the upregulated group of genes.

The gene sets significantly downregulated upon the overexpression of $RAS2^{S225A}$, indicated by a negative normalised enrichment score (NES), included condensation of chromosomes (NES = - 2.22), kinetochore dynamics (NES = -2.31), sister chromatid segregation (NES = -2.08), regulation of mitotic metaphase anaphase transition (NES = -2.08), the U2 spliceosome complex (NES = -2.33) and microtubule based processes (NES = -1.93) (Figure 90). A list of the genes within the gene set networks that regulate the processes detailed below can be found in the appendix.




Figure 90. Gene sets shown to be downregulated upon the overexpression of RAS2^{5225A} when compared to the wild type control. Chromosome condensation (A), kinetochore and microtububle based processes (B), sister chromatid segregation (C), the regulation of mitotic-metaphase-anaphase transition (D), U2 Type splicesomal complex (E) and microtubule based processes (F).

Vertical black lines represent individual genes in the significantly differentially expressed ranked gene list from upregulated (left) to downregulated (right). An increase in the enrichment score is seen if there are many genes towards the beginning of the ranked list (upregulated) in the gene set. When the green line climbs rapidly and peaks near the start of the graph (as shown here) it can be concluded that that gene set is overall upregulated. NES = normalised enrichment score, positive NES shows enrichment in the upregulated group of genes.

6.9 Further analysis of the gene sets enriched upon overexpression of *RAS2*^{S225E} in wild type cells

Upon the overexpression of $RAS2^{S225E}$ in wild type cells we observed a similar gene enrichment profile when compared to the $RAS2^{S225A}$ mutant. Here we observed gene sets involved in cytoplasmic translation (NES = 2.41), cytosolic ribosomes (NES = 2.67), ribosome biogenesis (NES = 2.76), translation elongation (NES = 2.53), preribosome (NES = 2.89) and ribosome assembly (NES = 2.58) were all significantly upregulated (Figure 91). When compared wild type cells overexpressing $RAS2^{S225A}$, the normalised enrichment score for each of the above processes is higher in cells overexpressing $RAS2^{S225E}$. A list of the genes within the gene set networks that regulate the processes detailed below can be found in the appendix.




Figure 91. Gene sets shown to be upregulated upon the overexpression of RAS2^{S225E} when compared to the wild type control. Cytoplasmic translation (A), cytosolic ribosomes (B), preribosome (C), ribosome biogenesis (D), translation elongation (E), and ribosome assembly (F).

Vertical black lines represent individual genes in the significantly differentially expressed ranked gene list from upregulated (left) to downregulated (right). An increase in the enrichment score is seen if there are many genes towards the beginning of the ranked list (upregulated) in the gene set. When the green line climbs rapidly and peaks near the start of the graph (as shown here) it can be concluded that that gene set is overall upregulated. NES = normalised enrichment score, positive NES shows enrichment in the upregulated group of genes.

The gene sets significantly downregulated upon the overexpression of $RAS2^{S225E}$, indicated by a negative normalised enrichment score (NES), included; condensation of chromosomes (NES = -2.55), nuclear division (NES = -1.84), sister chromatid segregation (NES = -2.19), organelle fission (NES = -1.90), chromosome segregation (NES = -2.30) and microtubule based processes (NES = -2.16) (Figure 92).




Figure 92. Gene sets shown to be downregulated upon the overexpression of RAS2^{S225E} when compared to the wild type control. Chromosome segregation (A), chromosome condensation (B), organelle fission (C), sister chromatid segregation (D), nuclear division (E) and microtubule based processes (D).

Vertical black lines represent individual genes in the significantly differentially expressed ranked gene list from upregulated (left) to downregulated (right). An increase in the enrichment score is seen if there are many genes towards the beginning of the ranked list (upregulated) in the gene set. When the green line climbs rapidly and peaks near the start of the graph (as shown here) it can be concluded that that gene set is overall upregulated. NES = normalised enrichment score, positive NES shows enrichment in the upregulated group of genes.

6.10 Discussion

In previous chapters we suggest that the overexpression of either *RAS2*^{S225A} or *RAS2*^{S225E} in wild type cells leads to growth defects and a loss of viability that we propose to be attributable to a dysregulation of the cell cycle. We propose that the slow growth phenotype is mediated through the Ras/cAMP/PKA pathway and that nutrient availability, or indeed the cells ability to acquire nutrition, appears to play an important role.

Through genome-wide transcriptome analysis of wild type cells overexpressing either *RAS2*^{5225A} or *RAS2*^{5225E} we sought to investigate the gene expression patterns that may govern the slower growth phenotype. Of particular interest was to ascertain whether mutant Ras2 expression led to changes in gene expression patterns that might be regarded as hallmarks of cell quiescence. Quiescence in yeast cells is typically defined as a temporary non-proliferating cellular state characterised by reduced protein synthesis and chromosome condensation. In addition, a number of phenotypes have been described within quiescent yeast cells such as fragmented mitochondria, presence of actin bodies, chromosome condensation, formation of P-bodies, stress granules and proteasome storage granules and nuclear localisation of heat-shock proteins [254]. Crucially however, quiescent cells are capable of responding to environmental signals such as the presence of carbon and quickly re-engage the cell cycle [109].

Upon the transition of cells into the quiescent state, the coordinated downregulation of ribosome synthesis contributes to a dramatic ~300-fold reduction in protein synthesis rates [255][256]. Ribosomal protein synthesis represents 15 % of total translation and ribosome RNA transcription represents 60 % of the total transcription. It is therefore not surprising that the first global downregulation of genes upon transition into quiescence is the shutdown of

the transcription of genes encoding for the proteins in both subunits of the ribosome [255]. As protein synthesis requires a significant amount of energy such down regulation may be crucial for the survival of non-dividing or quiescent cell populations.

Unexpectedly, the overexpression of either RAS2^{S225A} or RAS2^{S225E} in wild type cells resulted in a significant upregulation of transcription, translation, and ribosomal biogenesis. Such an observation was unexpected as the pathways upregulated recapitulate those observed within exponentially growing cells. We suggest that the overexpression of RAS2^{S225A} in wild type cells results in a transition into a quiescence like phenotype. However, quiescence is not hallmarked by an upregulation in either transcriptional or translational machinery [215][151][254]. So, does the expression of RAS2^{S225A} or RAS2^{S225E} lead to quiescence at all? The cell-based assays conducted in this study show that overexpression of RAS2^{S225A} or *RAS2*^{S225A} leads to both a significant reduction in viability and a reduced level of respiration. This is not concordant with the status of an actively growing population. However, upon analysis of the pathways downregulated upon the overexpression of these RAS2 alleles we observe the downregulation of processes that govern cell division such as chromosome condensation and segregation, cell cycle phase transition, mitosis and transcription factors associated with cell cycle phase progression. The resulting effect of the downregulation of the pathways represent the fact that these cells are not engaged in the cell cycle and may provide an explanation for the loss in viability observed. But can a reduction in these pathways explain the inability of cells to resume normal growth upon exposure to fresh growth media?

We hypothesize that the upregulation of transcription, translation and ribosomal biogenesis may be a result of increased PKA activity, as cells with enhanced PKA functions fail to undergo transcriptional reprogramming upon entry in diauxic growth [257]. However, constitutive PKA

activity is usually correlated with a significant loss of viability that is attributed to cell death, as in seen cells expressing the *ras*^{val19} mutant [98]. The overexpression of either *RAS2*^{S225A} or *RAS2*^{S225E} also results in a loss of viability but which is accompanied by cell death. We therefore propose that the overexpression of either *RAS2*^{S225A} or *RAS2*^{S225E} in wild type cells leads to an unreported slow growth phenotype that is characterized by an upregulation of transcriptional and translational machinery and a downregulation of nuclear and cellular division.

Chapter 7 Final Discussion

Ras proteins are small GTPases that act as molecular switches within cells that link extracellular stimuli to intracellular effectors. Ras proteins play a conserved role in the control of both cell growth and proliferation [211]. As a result, mutations that induce the constitutive activation of Ras proteins are often associated with changes in cell behaviour that can lead to disease, such as human cancer [41]. The localisation of Ras proteins are reported to be predominantly to the inner cytoplasmic surface of the plasma membrane, but they can also be observed on endomembrane's, such as the endoplasmic reticulum, and the mitochondrial outer membrane [65][57][212].

In recent years, the localisation and signalling of Ras on the plasma membrane has been extensively studied. It has been revealed that Ras undergoes a series of posttranslational modifications that dictate its subcellular localisation. Evidence exists to suggest that Ras proteins can undergo phosphorylation events which regulate its activity. Whistler and Rine identified Ser⁴¹² as an important phosphorylation site on the yeast Ras2 protein where substitution of serine with alanine at this residue lead to increased cAMP levels and elevated ration of Ras2-GTP compared to total Ras2 [74][213]. Surprisingly, the phosphorylation of Ras2p in *S. cerevisiae* has not been studied in regards to its regulation of intracellular localisation, despite significant evidence existing linking Ras phosphorylation to its localisation in humans [77]. This study aims to further investigate whether Ras2p phosphorylation provides a mechanism that regulates Ras2p trafficking inside the cell.

7.1 Modification of the Ser²²⁵ residue of Ras2p is important for localisation, activity, and function of Ras proteins

The data presented in this thesis suggests that the modification of the Ser²²⁵ residue of Ras2p is important for both localisation and activity of Ras proteins. We have shown that during both log and stationary phases of growth, the overexpression of either *RAS2*^{5225A} or *RAS2*^{5225E} in wild type cells results in significant changes in the localisation of active Ras populations. Actively growing wild type cells localise GTP-bound Ras to the plasma membrane and nucleus. In wild type cells, such localisation results in the activation of the cAMP/PKA pathway, which signals to the cell to initiate both growth and proliferation. We suggest that during exponential growth, wild type cells overexpressing either *RAS2*^{5225A} or *RAS2*^{5225E} sequester active Ras to the nuclear envelope with reduced activity seen at the plasma membrane and nucleus. Furthermore, we suggest that the overexpression of *RAS2*^{5225A} or *RAS2*^{5225E} also leads to the miss localisation of active Ras to the nuclear envelope and an inappropriate activity during stationary phase of growth. This finding therefor highlights the important role of Ras2 protein phosphorylation on both the modulation of protein activity and localisation.

The findings within this thesis propose that the modification of Ras2⁵²²⁵ is also important for Ras protein function. As modification of Ras2⁵²²⁵ leads to growth defects, changes in the oxidative stress response and leads to a reduction in viability in wild type cells. We show that the reduction of viability observed upon the overexpression of *RAS2* mutant alleles does not represent cell death but rather an inability to divide. We therefor propose that the overexpression of *RAS2* mutant alleles leads to a cessation of growth in wild type cells. Looked at together, we clearly suggest a novel role of the Ser²²⁵ residue of Ras2p for the localisation of GTP-bound Ras and propose a link between subcellular localisation of active Ras and growth cessation. Such findings provide important insights on how targeting phosphorylation

sites, such as Ras2^{S225}, can be exploited to prevent growth in cells where uncontrolled proliferation leads to disease.

7.2 Overexpression of *RAS2*^{S225A} or *RAS2*^{S225E} results in aberrant Ras/cAMP/PKA signalling and entry into state of reduced growth

We suggest that the overexpression of either RAS2^{S225A} or RAS2^{S225E} leads to the miss localisation of active Ras to the nuclear envelope. Such localisation results in growth defects and a loss of viability that we believe to be attributable to a dysregulation in the cell cycle. We sought to investigate whether the dysregulation of the cell cycle was caused through the aberrant signalling of Ras/cAMP/PKA pathway. We established that the slow growth phenotype observed is linked to elevated PKA activity, as overexpression of PDE2 in strains overexpressing RAS2^{S225A} or RAS2^{S225E} rescued viability. This observation was interesting as we initially hypothesized that the slow growth phenotype was a result of decreased PKA signalling. As mutations that inhibit the production of cAMP and thus reduce PKA activation, prevent progression through the cell cycle check point and render cells arrested in G1. Such a scenario would provide an explanation for the reduced growth phenotype observed upon overexpression of RAS2 mutant alleles [231][232]. Typically, mutations that activate the Ras/cAMP/PKA pathway, such as activating mutations in the RAS2 gene and BCY1 mutations fail to accumulate as G1-arrested cells upon nutrient deprived conditions resulting in a decrease in viability that is strongly correlated to cell death [115]. Whereas, we show that overexpression of RAS2^{S225A} or RAS2^{S225E} leads to enhanced PKA activity resulting in a reduction of viability that is not attributable to cell death but rather to a cessation of growth. We believe the answer lies within the localisation of active Ras, overexpression of RAS2 mutant alleles sequesters active Ras to the nuclear envelope as opposed to the inner leaflet of the plasma membrane. We hypothesize that Ras signalling from the nuclear envelope to PKA may result in the activation of effectors that elicit a change in gene expression that promotes a loss in co-ordination of growth control and environmental sensing that promotes growth cessation.

As evidence for this we show that increasing the level of nutrition available enabled cells overexpressing *RAS2* mutant alleles to escape quiescence in manner analogous to the coexpression with *PDE2*. Such a result may suggest that such cells are either incapable of taking up sufficient levels of nutrition, which yeast perceives as growth factors, or indeed that cells do not sense available nutrition. We propose that increasing the nutrient availability to cells overexpressing *RAS2* mutant alleles either through growth on nutrient rich media or through deletion of *CUP9* results in a rescue of the viability phenotype. This finding would tend to suggest to us that Ras mutant induced growth cessation occurs because of an inability to take up nutrition from the environment. Evidence for a role for Ras in this respect is further provided by our finding that *RAS2* overexpression improves viability on minimal media. Overall, our data suggests a link between Ras proteins, nutrient uptake, and growth cessation.

7.3 Genome-wide transcriptome analysis of wild type cells overexpressing RAS2^{S225A} or RAS2^{S225E}

We show that the overexpression of either *RAS2*^{S225A} or *RAS2*^{S225E} in wild type cells leads to growth defects and a loss of viability that we propose to be attributable to cell quiescence. We suggest that the slow growth phenotype is mediated through the Ras/cAMP/PKA pathway and that nutrient availability, or indeed the cells ability to acquire nutrition, appears to play an important role. Through genome-wide transcriptome analysis of wild type cells overexpressing either *RAS2*^{S225A} or *RAS2*^{S225E} we sought to investigate the gene expression

patterns that may govern the slow growth phenotype. Of interest was to ascertain whether mutant Ras2 expression led to changes in gene expression patterns that might be regarded as hallmarks of cell quiescence.

Unexpectedly, the overexpression of either RAS2^{S225A} or RAS2^{S225E} in wild type cells resulted in a significant upregulation of transcription, translation, and ribosomal biogenesis. Such an observation was unexpected as the pathways upregulated recapitulate those observed within exponentially growing cells [255]. However, upon analysis of the pathways downregulated upon the overexpression of these RAS2 alleles we observe the downregulation of processes that govern cell division such as chromosome condensation and segregation, cell cycle phase transition, mitosis and transcription factors associated with cell cycle phase progression. The resulting effect of the downregulation of the pathways represent the fact that these cells are not engaged in the cell cycle and may provide an explanation for the loss in viability observed. We hypothesize that the upregulation of transcription, translation and ribosomal biogenesis may be a result of increased PKA activity, as cells with enhanced PKA functions fail to undergo transcriptional reprogramming upon entry in diauxic growth [257]. However, constitutive PKA activity is usually correlated with a significant loss of viability that is attributed to cell death, as in seen cells expressing the ras^{val19} mutant [98]. The overexpression of either RAS2^{S225A} or RAS2^{S225E} also results in a loss of viability but which is not accompanied by cell death. We therefore propose that the overexpression of either RAS2^{S225A} or RAS2^{S225E} in wild type cells leads to an unreported slow phenotype that is characterized by an upregulation of transcriptional and translational machinery and a downregulation of nuclear and cellular division at a time when nutrient levels have depleted. Why mutant Ras cells are no longer able to re-engage growth when given fresh media of the same composition is unclear but

RNA-Seq data not included in this thesis suggests the deletion of *CUP9* in a *RAS2*^{S225A} background may reinstate cellular growth via the upregulation of a number of transporters that facilitate nutrient uptake.

7.4 Sequence alignment between Ras2 and human N-Ras suggests that Serine²²⁵ is conserved in human N-Ras at Serine⁵¹⁷³

We have shown that the Serine²²⁵ of the Ras2 protein is important for growth, viability, and the localisation and activity of Ras proteins. We hypothesized that this residue may be conserved in higher eukaryotes. To address this, sequence alignment between the Ras2 protein and the human N-Ras protein was performed (*Figure 93*). Interestingly, although significant sequence divergence between the yeast and human Ras proteins outside of the GTPase domain and C terminal CAAX box, we discovered that Ras2 Serine²²⁵ was conserved in human N-Ras at Serine¹⁷³ along with conservation of the surrounding region. The conservation of this serine residue in human Ras proteins may suggest an important role of this residue in higher eukaryotic systems, which could be exploited as a potential target for anti-Ras cancer therapy.



Figure 93. Sequence alignment of the Ras2 protein and human N-Ras shows that Serine²²⁵ of Ras2p (circled) is conserved in N-Ras at Serine¹⁷³

Interestingly, an independent group identified the Ser²²⁶ residue in Ras1 to be an important residue for Ras1 phosphorylation, as mutating this residue to an alanine drastically diminishes the level of Ras1 phosphorylation [214]. Upon sequence alignment of yeast Ras1 and Ras2 (*Figure 13*) we show little sequence similarity outside of the GTPase domain. However, the serine site position in both Ras1 and Ras2 is similar suggesting that serine residues located around this position may play a conserved regulatory role within Ras proteins.

7.5 Targeting Ras membrane interaction as an anti-Ras cancer therapy

Investigations have estimated that ~50 % of all tumours are a result of mutations involved in the constitutive activation of Ras signalling [26]. Intensive sequencing of the cancer genome has revealed that, despite the identification of over 600 validated cancer genes (COSMIC v80; http://cancer.sanger.ac.uk/cosmic), Ras oncogenes still constitute the most frequently mutated oncogene family in human cancers [258]. Despite decades of intensive effort, a

clinically effective anti-Ras therapy remains elusive, prompting the widely held perception that Ras proteins are 'undruggable' [259][260].

Initial approaches for the development of Ras inhibitors were guided by understanding the biochemical defects of mutant Ras proteins; HRAS, KRAS4A, KRAS4B and NRAS [261]. Unsuccessful attempts to develop anti-Ras drugs resulted from the misconception that the four Ras oncoproteins were identical in function [260]. With an ever increasing appreciation that different Ras proteins play unique roles in cancer, research has shifted its focus to KRAS, the isoform most frequently mutated in human cancer [262]. Sequence analyses have revealed the importance of the amino acids at positions 12, 13 and 61 in Ras proteins, mutations that cause the alternation of residues can lead to the over-activation of Ras via GAP impairment [41]. Mutations at these residues impair intrinsic and GAP-stimulated GTP hydrolysis rates and/or increase intrinsic exchange rates, favouring stimulus-independent formation of active Ras-GTP. As such, the earliest attempts of anti-Ras therapy centred on the formulation of small-molecule antagonists of GTP binding. Unfortunately, the picomolar affinity of Ras for GTP and the millimolar cellular concentrations of GTP render such attempts unsuccessful [262]. Small molecule mimetics of GAP activation on mutant Ras proteins was also unsuccessful due to the lack of well-defined hydrophobic pockets on the surface of Ras proteins [261]. As such many regarded Ras proteins as not tractable. This perception led to the pursuit of indirect strategies to target proteins that promote Ras membrane interaction. With the recognition that Ras oncogenic activity is dependent on its association with the inner leaflet of the plasma membrane, and the subsequent identification of posttranslational modifications that modulate this association, came the next targeted anti-Ras therapy. Ras is synthesized in the cytosol and undergoes a series of posttranslational modification's that

promote its membrane association [263]. The initial modification is farnesyltransferase-catalyzed covalent addition of a farnesyl moiety to the cysteine residue of the CAAX motif. Followed by the proteolytic removal of the last three amino acids by Rec1 [263]. Lastly, isoprenylcysteine carboxyl methyltransferase (ICMT) facilitates methyl transfer to the C-terminal amino acid to negate the negative charge and prevent plasma membrane repulsion [263]. As the association of Ras proteins with the plasma membrane is essential for their function, targeting this requirement can be viewed as the functional equivalent not of turning off the defective switch that is oncogenic Ras, but of removing it and thereby destroying the circuit.

Due to the important role of the farnesyl lipid modification for posttranslational modifications and for Ras oncogenic activity, numerous farnyltransferase inhibitors were developed such as Ionafarnib and tipifarnib but disappointingly displayed no efficacy in the clinic. However, targeting other posttranslational modifications of Ras, such as phosphorylation, still display some promise as effective anti-Ras therapies [263][260][264]. Of these, phosphorylation of KRAS4B on serine¹⁸¹ can alter subcellular localisation of Ras, displacing the modified GTPase from the plasma membrane, and converting KRAS4B from growth-promoting to a growth-suppressing protein [77][265][266].

Like the phosphorylation of the Serine¹⁸¹ of KRAS4B, the modification of the phosphorylation site of Serine²²⁵ of Ras2p also alters the subcellular localisation of Ras proteins, displacing GTP-bound Ras from the plasma membrane to the nuclear envelope. Such localisation is correlated with a transition into a quiescence-like state that can be viewed as growth-supressing. We therefor hypothesize that modification of the equivalent serine residue in the NRAS oncoprotein, Serine¹⁷³, may also alter the subcellular localisation of Ras proteins and

convert NRAS from growth-promoting to a growth-suppressing protein. Providing more promise, is that the Serine¹⁷³ residue of NRAS is in the variable domain of the protein, which makes this putative phosphorylation site an attractive drug target due to its accessibility.

Cosmic, the 'Catalogue of Somatic Mutations in Cancer' is an expert-curated database encompassing the wide variety of somatic mutation mechanisms causing human cancer. COSMIC contains details on millions of mutations across thousands of different cancer types. Hand-curation of key cancer genes provide in-depth detail on mutation distributions and effects, whilst semi-automated curation of cancer genomes provides broad somatic annotations toward target discovery. The COSMIC data provides details on the site and frequency of specific mutations.

Here we used the COSMIC data to investigate whether mutations located at the residue Ser¹⁷³ of NRAS were recorded (*Figure 94*). Interestingly, we observed that mutations have been found around the conserved serine residues, but mutations were not recorded at Ser¹⁷³. It would thus be interesting to investigate whether modification of the residues surrounding NRAS^{S173} lead to changes in Ras localisation.




Figure 94. A graphical representation of the location and frequency of mutations surrounding the Ser^{173} of NRAS.

Mutations at NRAS^{S173} were absent but mutations were observed surrounding the conserved serine residue suggesting that these residues may be important for localisation and activity of Ras proteins.

7.6 Conclusions and future investigations

The work presented in this thesis suggests that the modification of the Ser²²⁵ residue of Ras2p is important for both localisation and activity of Ras proteins in yeast cells. We show that the miss localisation of active Ras proteins to the nuclear envelope of cells results in significant growth defects that are mediated through aberrant the Ras/cAMP/PKA signalling pathway. We suggest that enhanced PKA activity stimulated from active Ras populations on the nuclear envelope results in a decrease in viability which we attribute to premature cell cycle arrest, a phenotype previously not correlated with enhanced PKA activity. RNA-Seq analysis suggests that the slow growth phenotype does not recapitulate canonical quiescent transcription profiles but instead is characterised by an upregulation of transcriptional and translational machinery and a downregulation of nuclear and cellular division. The slow growth phenotype can be repressed through increasing nutrient availability to cells either through growth on

nutrient rich media or through deletion of *CUP9*. Sequence alignment between yeast Ras2 and human NRas, revealed that the Ser²²⁵ residue of Ras2 is conserved in human NRas at Serine¹⁷³. If modification of *NRAS*¹⁷³ in human cells results in the miss localisation of activated oncoproteins and induction in cell growth cessation. We suggest that this mechanism could be exploited as a potential anti-Ras cancer therapeutic if the precise nature of the effects of Ras redirection can be identified.

Further Work

- In cancer, a single mutation in just one copy of a gene can be enough to induce tumorigenesis. Dominant genes show their effect even if there is just one mutation in one copy of that gene pair [267]. This thesis has shown that the overexpression of either *RAS2*^{5225A} or *RAS2*^{5225E} in the presence of wild type *RAS2* resulted in a dominant phenotype. However, many of the experiments presented here have been conducted solely in a wild type background. While this thesis aimed to examine the effect of mutated *RAS2* expression in a system closely resembling that present in the human condition i.e. one wild type and one mutated gene. Limitations of this experimental design are that the effect of mutated Ras2 protein expression alone is not known, and therefor whether the presence of the wild type Ras2 protein confounds the phenotype observed upon the overexpression of either *RAS2*^{5225A} or *RAS2*^{5225E} in *S. cerevisiae*. To address this, all experiments investigating the expression of either *RAS2*^{5225A} or *RAS2*^{5225E} should be conducted in both wild type and Δ*ras2* yeast cells.
- We have observed significant differences in viability between yeast cells overexpressing RAS2, RAS2^{S225A} or RAS2^{S225E} and NRAS, NRAS^{S173A} or NRAS^{S173E}; therefore, it would be interesting to investigate if similar growth defects and changes

in localisation of Ras and active Ras occur in a mammalian system. To address this, we would like to express *NRAS*, *NRAS*^{S173A} or *NRAS*^{S173E} in a human neuroblastoma cell line and conduct growth and viability assays. The human oncogene *NRAS* is linked to haematological malignancies particularly acute leukaemia [197][268]. Our data could therefore provide valuable information which might assist in developing new strategies for cancer treatment.

- We have shown that the reduction in viability induced by the overexpression of *RAS2*^{5225A} or *RAS2*^{5225E} in wild type cells can be reversed through the co-expression of *PDE2*. As aforementioned, Pde2 is a high-affinity cAMP phosphodiesterase which catalyses the degradation of cAMP[86]. The resulting effect of the overexpression of *PDE2*, is a decrease in intracellular levels of cAMP. We hypothesize that the overexpression of *RAS2*^{5225A} or *RAS2*^{5225E} in wild type cells leads to increase in intracellular cAMP levels and increased PKA activity. To attest this hypothesis, we would like to measure the intracellular levels of cAMP in wild type cells overexpressing *RAS2*^{5225A} or *RAS2*^{5225E} and compare levels to a wild type control. This would be achieved through a metabolite extraction protocol and measuring cAMP concentrations within cells.
- To investigate the global effects of the overexpression of either *RAS2*^{S225A} or *RAS2*^{S225E} in wild type cells we conducted a genome-wide transcriptome analysis. We have observed the global transcriptional changes induced upon the overexpression of *RAS2*^{S225A} or *RAS2*^{S225E} when compared to the wild type. It would be interesting to extract the RNA from wild type cells overexpressing wild type *RAS2* and perform RNA-Seq analysis to observe the changes in gene expression when the Serine²²⁵ is not

- mutated. Such analysis would allow us to determine the genes up/downregulated and the gene sets enriched upon the modification of *RAS2*⁵²²⁵.
- We observed that the overexpression of *RAS2*^{S225A} or *RAS2*^{S225E} in wild type cells had a dramatic effect on a wide array of cellular processes. By performing ribosomal profiling, we could observe a global profile of ribosomes in the cell allowing us to identify if they are being utilised for translation. In cells overexpressing either *RAS2*^{S225A} or *RAS2*^{S225E} we would anticipate that there should be an increase in 80S ribosomes, and polysomes if the overexpression of *RAS2* mutant alleles in the system is contributing to translation.
- Other lines of investigation would be to investigate whether the phosphorylation of Ras2⁵²²⁵ resulted in changes to the phosphorylation status of nearby serine residues – such as serine²²⁴. Furthermore, we would like to examine whether mutating both serine²²⁵ and serine²²⁴ would lead to a further attenuation of growth and viability in yeast cells overexpressing these mutant alleles.
- It would be interesting to investigate why the loss of *CUP9* in cells overexpressing either *RAS2*^{S225A} or *RAS2*^{S225E} restore normal cell growth. Such insight could be achieved through comparing RNA-Seq data from wild type cells overexpressing *RAS2* mutant alleles to the expression of *RAS2* mutant alleles in a Δ*cup9* background. Such analysis would allow us to determine the genes up/downregulated and the gene sets enriched upon the deletion of *CUP9* in cells overexpressing *RAS2*^{S225A} or *RAS2*^{S225E}.

References

- 1. Mager WH, and Winderickx J (**2005**). Yeast as a model for medical and medicinal research. **Trends Pharmacol Sci**. 26(5): 265–273. doi: 10.1016/j.tips.2005.03.004.
- 2. Goffeau A, Barrell BG, Bussey H, Davis RW, Dujon B, Feldmann H, Galibert F, Hoheisel JD, Jacq C, Johnston M, Louis EJ, Mewes HW, Murakami Y, Philippsen P, Tettelin H, and Oliver SG (1996). Life with 6000 Genes. Science (80-). 274(October): 546–567. 8849441.
- 3. Connelly C, Dietrich F, Andre B, Dow S, Boeke J, Bakkoury M, Gentalen E, Foury F, Shoemaker D, Anderson K, Benito R, Bussey H, Chu A, Friend S, Winzeler E, Liang H, Davis K, Astromoff A, and Bangham R (1999). Functional Characterization of the S. cerevisiae Genome by Gene Deletion and Parallel Analysis. Science (80-). 285(5429): 901–906.
- 4. Guri G, Chu AM, Li N, Carla C, Linda R, Steeve V, Dow S, Lucau-danila A, Anderson K, Arkin AP, Astromoff A, Bakkoury M El, Bangham R, Benito R, Brachat S, Andre B, Jaramillo DF, Kelly DE, Kelly SL, and Ko P (2002). Functional profiling of the Saccharomyces cerevisiae genome. Nature. 418(6896): 387–391.
- 5. Lequin S, Chassagne D, Bellat J-P, Huh W, Falvo J V, Gerke LC, Carroll AS, Howson RW, Weissman JS, and Shea EKO (**2003**). Global analysis of protein localization in budding yeast. **Nature**. 425(6959): 686–691.
- 6. Chemical C, Plant R, Plant P, Biol M, Ghaemmaghami S, Huh W, and Bower K (**2003**). Global analysis of protein expression in yeast. **Nature**. 108(1997): 737–741.
- 7. Foury F (**1997**). Human genetic diseases: A cross-talk between man and yeast. **Gene**. 195(1): 1–10. doi: 10.1016/S0378-1119(97)00140-6.
- 8. Heinicke S, Livstone MS, Lu C, Oughtred R, Kang F, Angiuoli S V., White O, Botstein D, and Dolinski K (2007). The Princeton Protein Orthology Database (P-POD): A comparative genomics analysis tool for biologists. **PLoS One**. 2(8). doi: 10.1371/journal.pone.0000766.
- 9. Laurent JM, Young JH, Kachroo AH, and Marcotte EM (**2016**). Efforts to make and apply humanized yeast. **Brief Funct Genomics**. 15(2): 155–163. doi: 10.1093/bfgp/elv041.
- 10. Zabrocki P, Pellens K, Vanhelmont T, Vandebroek T, Griffioen G, Wera S, Van Leuven F, and Winderickx J (**2005**). Characterization of α -synuclein aggregation and synergistic toxicity with protein tau in yeast. **FEBS J**. 272(6): 1386–1400. doi: 10.1111/j.1742-4658.2005.04571.x.
- 11. Bourne HR, Sanders DA, and McCormick F (1990). The GTPase superfamily: a conserved switch for diverse cell functions. **Nature**. 348(6297): 125–32. doi: 10.1038/348125a0.
- 12. Biou V, and Cherfils J (**2004**). Structural Principles for the Multispecificity of Small GTP-Binding Proteins. **Biochemistry**. 43(22): 6833–6840. doi: 10.1021/bi049630u.
- 13. Seabra MC, and Wasmeier C (**2004**). Controlling the location and activation of Rab GTPases. **Curr Opin Cell Biol**. 16(4): 451–457. doi: 10.1016/j.ceb.2004.06.014.
- 14. M Zerial, and H McBride (2001). Rab proteins as membrane organizers. Nat Rev Mol Cell

- Biol. 2(2): 107-17.
- 15. Memon AR (**2004**). Erratum: The role of ADP-ribosylation factor and SAR1 in vesicular trafficking in plants (Biochimica et Biophysica Acta (2004) 1664 (9-30) PII: S0005-2736(04)00098-7 and DOI: 10.1016/j.bbamem.2004.04.005). **Biochim Biophys Acta Biomembr**. 1665(1–2): 201. doi: 10.1016/j.bbamem.2004.08.007.
- 16. Ridley AJ (**2001**). Rho GTPases in cell migration. **J Cell Sci**. 114(July): 2713–2722. doi: 10.4161/sgtp.28997.
- 17. Ridley AJ (**2001**). Rho family proteins- coordinating cell responses. **Trends Cell Biol**. 11(12): 471–477.
- 18. Weis K (**2004**). Regulating Access to the Genome. **Cell**. 112(4): 441–451. doi: 10.1016/s0092-8674(03)00082-5.
- 19. Li H-Y, Cao K, and Zheng Y (**2003**). Ran in the spindle checkpoint: a new function for a versatile GTPase. **Trends Cell Biol**. 13(11): 553–557. doi: 10.1016/j.tcb.2003.09.003.
- 20. Boguski MS, and Frank B (**1993**). Proteins regulating Ras and its relatives. **Nature**. 366(December): 643–653.
- 21. Cox AD, and Der CJ (**2010**). Ras history: The saga continues. **Small GTPases**. 1(1): 2–27. doi: 10.4161/sgtp.1.1.12178.
- 22. Wennerberg K (**2005**). The Ras superfamily at a glance. **J Cell Sci**. 118(5): 843–846. doi: 10.1242/jcs.01660.
- 23. Bourne HR, DA S, and F. M (1991). The GTPase superfamily: conserved structure and molecular mechanism. Nature. 10: 117–27. 1898771.
- 24. Milburn M V, Tong L, Devos AM, Brunger A, Yamaizumi Z, Nishimura S, and Kim S (**1990**). Molecular switch for signal transduction: Structural differences between active and inactive forms of protooncogenic ras proteins. **Science (80-)**. 247(9): 939–945.
- 25. Almoh SC, Rapp G, Wilson K, Petratos K, Lentfer A, Wittinghofer A, Kabsch W, Pai EF, Petskoh GA, and Goody RS (**2000**). Time-resolved X-ray crystallographic study of the conformational change in Ha-Ras p21 protein on GTP hydrolysis. **Nature**. 345(May 1990): 309–315.
- 26. Bos JL, Rehmann H, and Wittinghofer A (**2007**). Review GEFs and GAPs: Critical Elements in the Control of Small G Proteins. **Cell**. 129: 865–877. doi: 10.1016/j.cell.200.
- 27. Rooij J De, and Bos JL (1997). Minimal Ras-binding domain of Raf1 can be used as an activation-specific probe for Ras. **Oncogene**. 14: 623–625.
- 28. Kataoka T, Powers S, Cameron S, Fasano O, Goldfarb M, Broach J, and Wigler M (1985). Functional homology of mammalian and yeast RAS genes. **Cell**. 40(1): 19–26. doi: 10.1016/0092-8674(85)90304-6.
- 29. Arozarena I, Calvo F, and Crespo P (**2011**). Ras, an actor on many Stages: Posttranslational modifications, Localization, and Site-Specified Events. **Genes and Cancer**. 2(3): 182–194. doi: 10.1177/1947601911409213.

- 30. Papageorge AG, Defeo-Jones D, Robinson P, Temeles G, and Scolnick EM (**1984**). Saccharomyces cerevisiae synthesizes proteins related to the p21 gene product of ras genes found in mammals. **Mol Cell Biol**. 4(1): 23–29. doi: 10.1128/mcb.4.1.23.
- 31. Wolfe KH (**2015**). Origin of the yeast whole-genome duplication. **PLoS Biol**. 13(8): 1–7. doi: 10.1371/journal.pbio.1002221.
- 32. Kataoka T, Powers S, McGill C, Fasano O, Strathern J, Broach J, and Wigler M (**1984**). Genetic analysis of yeast RAS1 and RAS2 genes. **Cell**. 37(2): 437–45. doi: 10.1016/0092-8674(84)90374-x.
- 33. Breviario D, Hinnebusch AG, and Dhar R (**1988**). Multiple regulatory mechanisms control the expression of the RAS1 and RAS2 genes of Saccharomyces cerevisiae. **EMBO J**. 7(6): 1805–1813. doi: 10.1002/j.1460-2075.1988.tb03012.x.
- 34. Tatchell K, Robinson LC, and Breitenbach M (1985). RAS2 of Saccharomyces cerevisiae is required for gluconeogenic growth and proper response to nutrient limitation. **Proc Nadl Acad Sci USA**. 82: 3785–3789.
- 35. Lisziewicz J, Brown J, Breviariol D, Sreenath T, Ahmed N, Koller R, and Dhar R (**1990**). Transcriptional regulatory elements of the RAS2 gene of Saccharomyces cerevisiae. **Nucleic Acids Res**. 18(14): 4167–4174.
- 36. Fraenkel DG (**1985**). On ras gene function in yeast. **Proc Natl Acad Sci**. 82(14): 4740–4744. doi: 10.1073/pnas.82.14.4740.
- 37. Marshall MS, Gibbs JB, Scolnick EM, and Sigal IS (1987). Regulatory function of the Saccharomyces cerevisiae RAS C-terminus. **Mol Cell Biol**. 7(7): 2309–2315. doi: 10.1128/mcb.7.7.2309.
- 38. Gibbs JB, Schaber MD, Allard WJ, Sigal IS, and Scolnick EM (**1988**). Purification of ras GTPase activating protein from bovine brain. **Proc Natl Acad Sci**. 85(14): 5026–5030. doi: 10.1073/pnas.85.14.5026.
- 39. Wang Y (**2001**). Alternative splicing of the K-RAS gene in mouse tissues and cell lines. **Exp Lung Res**. 27: 255–267.
- 40. Matallanas D, Arozarena I, Berciano MT, Aaronson DS, Pellicer A, Lafarga M, and Crespo P (2003). Differences on the Inhibitory Specificities of H-Ras, K-Ras, and N-Ras (N17) Dominant Negative Mutants Are Related to Their Membrane Microlocalization. J Biol Chem. 278(7): 4572–4581. doi: 10.1074/jbc.M209807200.
- 41. Campbell PM, and Der CJ (**2004**). Oncogenic Ras and its role in tumor cell invasion and metastasis. **Semin Cancer Biol**. 14(2): 105–114. doi: 10.1016/j.semcancer.2003.09.015.
- 42. Karnoub AE, and Weinberg RA (**2008**). Ras oncogenes: Split personalities. **Nat Rev Mol Cell Biol**. 9(7): 517–531. doi: 10.1038/nrm2438.
- 43. Rudolph J, and Stokoe D (**2014**). Selective inhibition of mutant ras protein through covalent binding. **Angew Chemie Int Ed**. 53(15): 3777–3779. doi: 10.1002/anie.201400233.
- 44. Monahan AM, Callanan JJ, and Nally JE (**2008**). Proteomic analysis of post-translational modifications. **Microbiology**. 76(11): 4952–4958.

- 45. Fujiyama A, Matsumoto K, and Tamanoi F (**1987**). A novel yeast mutant defective in the processing of ras proteins: assessment of the effect of the mutation on processing steps. **EMBO J**. 6(1): 223–228.
- 46. Fujiyama A, and Tamanoi F (**1986**). Processing and fatty acid acylation of RAS1 and RAS2 proteins in Saccharomyces cerevisiae. **Proc Natl Acad Sci**. 83(5): 1266–1270. doi: 10.1073/pnas.83.5.1266.
- 47. Hancock JF, Cadwaller K, Paterson H, and Marshall CJ (**2003**). A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins. **Trends Cell Biol**. 2(3): 73. doi: 10.1016/0962-8924(92)90064-t.
- 48. Casey PJ, Solski PA, Der CJ, and Buss JE (**2006**). P21Ras Is Modified By a Farnesyl Isoprenoid. **Proc Natl Acad Sci**. 86(21): 8323–8327. doi: 10.1073/pnas.86.21.8323.
- 49. Rowell CA, Kowalczyk JJ, Lewis MD, and Garcia AM (**1997**). Direct Demonstration of Geranylgeranylation and Farnesylation of Ki-Ras in Vivo. **J Biol Chem**. 272(22): 14093–14097. doi: 10.1074/jbc.272.22.14093.
- 50. Choy E, Chiu VK, Silletti J, Feoktistov M, Morimoto T, Michaelson D, Ivanov IE, and Philips MR (**1999**). Endomembrane Trafficking of Ras. **Cell**. 98(1): 69–80. doi: 10.1016/S0092-8674(00)80607-8.
- 51. Schmidt WK, Tam A, Fujimura-Kamada K, and Michaelis S (**2002**). Endoplasmic reticulum membrane localization of Rce1p and Ste24p, yeast proteases involved in carboxyl-terminal CAAX protein processing and amino-terminal a-factor cleavage. **Proc Natl Acad Sci**. 95(19): 11175–11180. doi: 10.1073/pnas.95.19.11175.
- 52. Winter-Vann AM, and Casey PJ (**2005**). Post-prenylation-processing enzymes as new targets in oncogenesis. **Nat Rev Cancer**. 5(5): 405–412. doi: 10.1038/nrc1612.
- 53. Choy E, Chiu VK, Silletti J, Feoktistov M, Morimoto T, Michaelson D, Ivanov IE, and Philips MR (1999). Endomembrane trafficking of ras: The CAAX motif targets proteins to the ER and Golgi. Cell. 98(1): 69–80. doi: 10.1016/S0092-8674(00)80607-8.
- 54. Laude AJ, and Prior IA (**2008**). Palmitoylation and localisation of RAS isoforms are modulated by the hypervariable linker domain. **J Cell Sci**. 121(4): 421–427. doi: 10.1242/jcs.020107.
- 55. Eisenberg S, Laude AJ, Beckett AJ, Mageean CJ, Aran V, Hernandez-Valladares M, Henis YI, and Prior IA (**2013**). The role of palmitoylation in regulating Ras localization and function. **Biochem Soc Trans**. 41(1): 79–83. doi: 10.1042/BST20120268.
- 56. Rocks O (2005). An Acylation Cycle Regulates Localization and Activity of Palmitoylated Ras Isoforms. Science (80-). 307(5716): 1746–1752. doi: 10.1126/science.1105654.
- 57. Chiu VK, Bivona T, Hach A, Sajous JB, Silletti J, Wiener H, Johnson RL, Cox AD, and Philips MR (**2002**). Ras signalling on the endoplasmic reticulum and the Golgi. **Nat Cell Biol**. 4(5): 343–350. doi: 10.1038/ncb783.
- 58. Shih TY, Weeks MO, Young HA, and Scolnick EM (1979). Identification of a sarcoma virus-coded phosphoprotein in nonproducer cells transformed by Kirsten or Harvey murine sarcoma virus. Virology. 96(1): 64–79. doi: 10.1016/0042-6822(79)90173-9.

- 59. Hancock JF, Magee AI, Childs JE, and Marshall CJ (1989). All ras proteins are polyisoprenylated but only some are palmitoylated. **Cell**. 57(7): 1167–1177. doi: 10.1016/0092-8674(89)90054-8.
- 60. Dong X, Mitchell DA, Lobo S, Zhao L, Bartels DJ, and Deschenes RJ (**2003**). Palmitoylation and Plasma Membrane Localization of Ras2p by a Nonclassical Trafficking Pathway in Saccharomyces cerevisiae. **Mol Cell Biol**. 23(18): 6574–6584. doi: 10.1128/MCB.23.18.6574.
- 61. Schafer WR, and Rine J (1992). PROTEIN PRENYLATION:.
- 62. Goodman LE, Judd SR, Farnsworth CC, Powers S, Gelb MH, Glomset JA, and Tamanoi F (1990). Mutants of Saccharomyces cerevisiae defective in the farnesylation of Ras proteins. **Proc Natl Acad Sci.** 87(24): 9665–9669. doi: 10.1073/pnas.87.24.9665.
- 63. Belotti F, Tisi R, Paiardi C, Rigamonti M, Groppi S, and Martegani E (**2012**). Localization of Ras signaling complex in budding yeast. **Biochim Biophys Acta Mol Cell Res**. 1823(7): 1208–1216. doi: 10.1016/j.bbamcr.2012.04.016.
- 64. Vanoni M, Vavassori M, Frascotti G, Martegani E, and Alberghina L (**1990**). Overexpression of the CDC25 gene, an upstream element of the ras/adenylyl cyclase pathway in Saccharomyces cerevisiae, allows immunological identification and characterization of its gene product. **Biochem Biophys Res Commun**. 172(1): 61–69. doi: 10.1016/S0006-291X(05)80173-1.
- 65. Sobering AK, Romeo MJ, Vay HA, and Levin DE (**2003**). A Novel Ras Inhibitor, Eri1, Engages Yeast Ras at the Endoplasmic Reticulum. **Mol Cell Biol**. 23(14): 4983–4990. doi: 10.1128/mcb.23.14.4983-4990.2003.
- 66. Dong J, and Bai X (**2011**). The membrane localization of Ras2p and the association between Cdc25p and Ras2-GTP are regulated by protein kinase A (PKA) in the yeast *Saccharomyces cerevisiae*. **FEBS Lett**. 585(8): 1127–1134. doi: 10.1016/j.febslet.2011.03.057.
- 67. Belotti F, Tisi R, Paiardi C, Groppi S, and Martegani E (**2011**). PKA-dependent regulation of Cdc25 RasGEF localization in budding yeast. **FEBS Lett**. 585(24): 3914–3920. doi: 10.1016/j.febslet.2011.10.032.
- 68. Broggi S, Martegani E, and Colombo S (**2013**). Nuclear Ras2-GTP controls invasive growth in Saccharomyces cerevisiae. **PLoS One**. 8(11): e79274. doi: 10.1371/journal.pone.0079274.
- 69. Broggi S, Martegani E, and Colombo S (**2013**). Live-cell imaging of endogenous Ras-GTP shows predominant Ras activation at the plasma membrane and in the nucleus in Saccharomyces cerevisiae. **Int J Biochem Cell Biol**. 45(2): 384–394. doi: 10.1016/j.biocel.2012.10.013.
- 70. Leadsham JE, Miller K, Ayscough KR, Colombo S, Martegani E, Sudbery P, and Gourlay CW (2009). Whi2p links nutritional sensing to actin-dependent Ras-cAMP-PKA regulation and apoptosis in yeast. J Cell Sci. 122(Pt 5): 706–15. doi: 10.1242/jcs.042424.
- 71. Oliveira A, and Sauer U (**2012**). The importance of post-translational modifications in regulating Saccharomyces Cerevisiae metabolism. **FEMS Yeast Res**. 12(2): 104–117.
- 72. Cohen P (2002). The origins of protein phosphorylation. Nat Cell Biol. 4(5): 127–130.

- 73. Vlastaridis P, and Grigoris D (**2017**). Estimating the total number of phosphoproteins and phosphorylation sites in eukaryotic proteomes. **Gigascience**. 6(2): 1–11.
- 74. Whistler JL, and Rine J (1997). Ras2 and Ras1 protein phosphorylation is Saccharomyces cerevisiae. J Biol Chem. 272(30): 18790–18800. doi: 10.1074/jbc.272.30.18790.
- 75. Cobitz AR, Yim EH, Brown WR, Perou CM, and Tamanoi F (2006). Phosphorylation of RAS1 and RAS2 proteins in Saccharomyces cerevisiae. **Proc Natl Acad Sci.** 86(3): 858–862. doi: 10.1073/pnas.86.3.858.
- 76. Gibbs J, Ellis R, and Scolnick E (**1984**). Autophosphorylation of v-Ha-ras p21 is modulated by amino acid residue 12. **PNAS**. 81(9): 2674–2678.
- 77. Bivona TG, Quatela SE, Bodemann BO, Ahearn IM, Soskis MJ, Mor A, Miura J, Wiener HH, Wright L, Saba SG, Yim D, Fein A, Pérez De Castro I, Li C, Thompson CB, Cox AD, and Philips MR (**2006**). PKC regulates a farnesyl-electrostatic switch on K-Ras that promotes its association with Bcl-XL on mitochondria and induces apoptosis. **Mol Cell**. 21(4): 481–493. doi: 10.1016/j.molcel.2006.01.012.
- 78. Toda T, Uno I, Ishikawa T, Powers S, Kataoka T, Broek D, Cameron S, Broach J, Matsumoto K, and Wigler M (1985). In yeast, RAS proteins are controlling elements of adenylate cyclase. **Cell**. 40(1): 27–36. doi: 10.1016/0092-8674(85)90305-8.
- 79. Cazzaniga P, Pescini D, Besozzi D, Mauri G, Colombo S, and Martegani E (**2008**). Modeling and stochastic simulation of the Ras / cAMP / PKA pathway in the yeast Saccharomyces cerevisiae evidences a key regulatory function for intracellular guanine nucleotides pools. **J Biotechnol**. 133: 377–385. doi: 10.1016/j.jbiotec.2007.09.019.
- 80. Toda T, Cameron S, Sass P, Zoller M, Scott JD, McMullen B, Hurwitz M, Krebs EG, and Wigler M (1987). Cloning and characterization of BCY1, a locus encoding a regulatory subunit of the cyclic AMP-dependent protein kinase in Saccharomyces cerevisiae. **Mol Cell Biol**. 7(4): 1371–1377. doi: 10.1128/mcb.7.4.1371.
- 81. Toda T, Cameron S, Sass P, Zoller M, and Wigler M (**1987**). Three different genes in S. cerevisiae encode the catalytic subunits of the cAMP-dependent protein kinase. **Cell**. 50(2): 277–87. doi: 10.1016/0092-8674(87)90223-6.
- 82. Robertson LS, Causton HC, Young RA, and Fink GR (**2000**). The yeast A kinases differentially regulate iron uptake and respiratory function. **Proc Natl Acad Sci.** 97(11): 5984–5988. doi: 10.1073/pnas.100113397.
- 83. Robertson LS, and Fink GR (1998). The three yeast A kinases have specific signaling functions in pseudohyphal growth. **Genetic**. 95(November): 13783–13787.
- 84. Akada R, Yamamoto J, and Yamashita I (**1997**). Screening and identification of yeast sequences that cause growth inhibition when overexpressed. **Mol Gen Genet**. 254(3): 267–74. doi: 10.1007/s004380050415.
- 85. Nikawa J, Sass P, and Wigler M (**1987**). Cloning and characterization of the low-affinity cyclic AMP phosphodiesterase gene of Saccharomyces cerevisiae. **Mol Cell Biol**. 7(10): 3629–3636. doi: 10.1128/mcb.7.10.3629.
- 86. Sass P, Field J, Nikawa J, Toda T, and Wigler M (1986). Cloning and characterization of

- the high-affinity cAMP phosphodiesterase of Saccharomyces cerevisiae. **Proc Natl Acad Sci**. 83(24): 9303–9307. doi: 10.1073/pnas.83.24.9303.
- 87. Wilson RB, and Tatchell K (1988). SRA5 Encodes the Low-KM Cyclic AMP phosphodiesterase of Saccharomyces cerevisiae. Mol Cell Biol. 8(1): 505–510.
- 88. Suoranta K, and Londesborough J (1984). Purification of intact and nicked forms of a zinc-containing, Mg2+-dependent, low K(m) cyclic AMP phosphodiesterase from bakers' yeast. J Biol Chem. 259(11): 6964–6971.
- 89. Wilson RB, Renault G, Jacquet M, and Tatchell K (**1993**). The pde2 gene of Saccharomyces cerevisiae is allelic to rcal and encodes a phosphodiesterase which protects the cell from extracellullar cAMP. **FEBS Lett**. 325(3): 191–195. doi: 10.1016/0014-5793(93)81071-7.
- 90. Damak F, Boy-marcotte E, Le-roscouet D, Guilbaud R, and Jacquet M (1991). SDC25, a CDC25-Like gene Which Contains a RAS-Activating Domain and Is a Dispensable Gene of Saccharomyces cerevisiae. Mol Cell Biol. 11(1): 202–212.
- 91. Robinson L, Gibbs J, Marshall M, Sigal I, and Tatchell K (1987). CDC25: a component of the RAS-adenylate cyclase pathway in Saccharomyces cerevisiae. Science (80-). 235(4793): 1218–1221. doi: 10.1126/science.3547648.
- 92. Jones S, Vignais ML, and Broach JR (**1991**). The CDC25 protein of Saccharomyces cerevisiae promotes exchange of guanine nucleotides bound to ras. **Mol Cell Biol**. 11(5): 2641–2646. doi: 10.1128/mcb.11.5.2641.
- 93. Tanaka K, Matsumoto K, and Toh-E A (1989). IRA1, an inhibitory regulator of the RAS-cyclic AMP pathway in Saccharomyces cerevisiae. **Mol Cell Biol**. 9(2): 757–768. doi: 10.1128/mcb.9.2.757.
- 94. Tanaka K, Nakafuku M, Tamanoi F, Kaziro Y, Matsumoto K, and Toh-e A (**1990**). IRA2, a second gene of Saccharomyces cerevisiae that encodes a protein with a domain homologous to mammalian ras GTPase-activating protein. **Mol Cell Biol**. 10(8): 4303–4313. doi: 10.1128/mcb.10.8.4303.
- 95. Tanaka K, Nakafuku M, Satoh T, Marshall MS, Gibbs JB, Matsumoto K, Kaziro Y, and Tohe A (**1990**). S. cerevisiae genes IRA1 and IRA2 encode proteins that may be functionally equivalent to mammalian ras GTPase activating protein. **Cell**. 60(5): 803–807. doi: 10.1016/0092-8674(90)90094-U.
- 96. DeFeo-Jones D, Tatchell K, Robinson L, Sigal I, Vass W, Lowy D, and Scolnick E (**1985**). Mammalian and yeast ras gene products: biological function in their heterologous systems. **Science (80-)**. 228(4696): 179–184. doi: 10.1126/science.3883495.
- 97. Jacquet E, Parrini M, Bernardi A, Martegani E, and Parmeggiana A (**1994**). Properties of the catalytic domain of Cdc25, A yeast GDP/GTP exchange factor: Comparison of its activity on full-length and C-terminal truncated Ras2 proteins. **Biochem Biophys Res Commun**. 199(2): 497–503.
- 98. Mitts MR, Bradshaw-rouse J, and Heideman W (1991). Interactions between Adenylate Cyclase and the Yeast GTPase-Activating Protein IRAI. 11(9): 4591–4598.

- 99. Martegani E, Baroni MD, Frascotti G, and Alberghina L (**1986**). Molecular cloning and transcriptional analysis of the start gene CDC25 of Saccharomyces cerevisiae . **EMBO J**. 5(9): 2363–2369. doi: 10.1002/j.1460-2075.1986.tb04505.x.
- 100. Munder T, and Küntzel H (1989). Glucose-induced cAMP signaling in Saccharomyces cerevisiae is mediated by the CDC25 protein. **FEBS Lett**. 242(2): 341–345. doi: 10.1016/0014-5793(89)80498-3.
- 101. Schomerus C, Munder T, and Kuntzel H (**1990**). Site-directed mutagenesis of the Saccharomyces cerevisiae CDC25 gene: effects on mitotic growth and cAMP signalling. **MGG Mol Gen Genet**. 223(3): 426–432. doi: 10.1007/BF00264449.
- 102. Goldberg D, Segal M, and Levitzki A (1994). Cdc25 is not the signal receiver for glucose induced cAMP response in S. cerevisiae. **FEBS Lett**. 356(2–3): 249–254. doi: 10.1016/0014-5793(94)01273-3.
- 103. Rudoni S, Colombo S, Coccetti P, and Martegani E (**2001**). Role of guanine nucleotides in the regulation of the Ras/cAMP pathway in Saccharomyces cerevisiae. **Biochim Biophys Acta Mol Cell Res**. 1538(2–3): 181–189. doi: 10.1016/S0167-4889(01)00067-2.
- 104. Garreau H, Geymonat M, Renault G, and Jacquet M (1996). Membrane-anchoring domains of Cdc25p, a Saccharomyces cerevisiae ras exchange factor. Biol cell. 86(2–3): 93–102. 8893498.
- 105. Gross E, Goldberg D, and Levitzki A (**1992**). Phosphorylation of the S. cerevisiae Cdc25 in response to glucose results in its dissociation from Ras. **Nature**. 360(6406): 762–5. doi: 10.1038/360762a0.
- 106. Jian D, Aili Z, Xiaojia B, Huansheng Z, and Yun H (**2010**). Feedback regulation of Ras2 guanine nucleotide exchange factor (Ras2-GEF) activity of Cdc25p by Cdc25p phosphorylation in the yeast Saccharomyces cerevisiae. **FEBS Lett**. 584(23): 4745–4750. doi: 10.1016/j.febslet.2010.11.006.
- 107. Li Y, and Wang Y (**2013**). Ras protein/cAMP-dependent protein kinase signaling is negatively regulated by a deubiquitinating enzyme, Ubp3, in yeast. **J Biol Chem**. 288(16): 11358–11365. doi: 10.1074/jbc.M112.449751.
- 108. Phan VT, Ding VW, Li F, Chalkley RJ, Burlingame A, and Mccormick F (**2010**). The RasGAP Proteins Ira2 and Neurofibromin Are Negatively Regulated by Gpb1 in Yeast and ETEA in Humans. **Mol Cell Biol**. 30(9): 2264–2279. doi: 10.1128/MCB.01450-08.
- 109. Zaman S, Lippman SI, Zhao X, and Broach JR (**2008**). How Saccharomyces Responds to Nutrients . **Annu Rev Genet**. 42(1): 27–81. doi: 10.1146/annurev.genet.41.110306.130206.
- 110. Santangelo GM (2006). Glucose Signaling in Saccharomyces cerevisiae. Microbiol Mol Biol Rev. 70(1): 253–282. doi: 10.1128/MMBR.70.1.253.
- 111. Xue Y, and Hirsch JP (**1996**). GPR1 encodes a putative G protein-coupled receptor that associates with the Gpa2p G α subunit and functions in a Ras-independent pathway. **EMBO** J. 17(7): 1996–2007.
- 112. Kraakman L, Lemaire K, Ma P, Teunissen a W, Donaton MC, Van Dijck P, Winderickx J, de Winde JH, and Thevelein JM (1999). A Saccharomyces cerevisiae G-protein coupled

- receptor, Gpr1, is specifically required for glucose activation of the cAMP pathway during the transition to growth on glucose. **Mol Microbiol**. 32(5): 1002–12. 10361302.
- 113. Nakafuku M, Obara T, Kaibuchi K, Miyajima I, Miyajima A, Itoh H, Nakamura S, Arai K, Matsumoto K, and Kaziro Y (1988). Isolation of a second yeast Saccharomyces cerevisiae gene (GPA2) coding for guanine nucleotide-binding regulatory protein: studies on its structure and possible functions. **Proc Natl Acad Sci U S A**. 85(5): 1374–1378. doi: 10.1073/pnas.85.5.1374.
- 114. Lemaire K, Van De Velde S, Van Dijck P, and Thevelein JM (**2004**). Glucose and sucrose act as agonist and mannose as antagonist ligands of the G protein-coupled receptor Gpr1 in the yeast Saccharomyces cerevisiae. **Mol Cell**. 16(2): 293–299. doi: 10.1016/j.molcel.2004.10.004.
- 115. Colombo S, Ma P, Cauwenberg L, Winderickx J, Crauwels M, Teunissen A, Nauwelaers D, De Winde JH, Gorwa MF, Colavizza D, and Thevelein JM (1998). Involvement of distinct G-proteins, Gpa2 and Ras, in glucose- and intracellular acidification-induced cAMP signalling in the yeast Saccharomyces cerevisiae. EMBO J. 17(12): 3326–3341. doi: 10.1093/emboj/17.12.3326.
- 116. Dechant R, Binda M, Lee SS, Pelet S, Winderickx J, and Peter M (**2010**). Cytosolic pH is a second messenger for glucose and regulates the PKA pathway through V-ATPase. **EMBO J**. 29(15): 2515–2526. doi: 10.1038/emboj.2010.138.
- 117. Colombo S, Ronchetti D, Thevelein JM, Winderickx J, and Martegani E (**2004**). Activation state of the Ras2 protein and glucose-induced signaling in Saccharomyces cerevisiae. **J Biol Chem**. 279(45): 46715–22. doi: 10.1074/jbc.M405136200.
- 118. Rubio-Texeira M, Van Zeebroeck G, Voordeckers K, and Thevelein JM (**2010**). Saccharomyces cerevisiae plasma membrane nutrient sensors and their role in PKA signaling. **FEMS Yeast Res**. 10(2): 134–149. doi: 10.1111/j.1567-1364.2009.00587.x.
- 119. Klein C, and Struhl K (**1994**). Protein kinase A mediates growth-regulated expression of yeast ribosomal protein genes by modulating RAP1 transcriptional activity. **Mol Cell Biol**. 14(3): 1920–1928. doi: 10.1128/mcb.14.3.1920.
- 120. Neuman-Silberberg FS, Bhattacharya S, and Broach JR (1995). Nutrient availability and the RAS/cyclic AMP pathway both induce expression of ribosomal protein genes in Saccharomyces cerevisiae but by different mechanisms. **Mol Cell Biol**. 15(6): 3187–3196. doi: 10.1128/mcb.15.6.3187.
- 121. Wade JT, Hall DB, and Strahl K (**2004**). The transcription factor Ifh1 is a key regulator of yeast ribosomal protein genes. **Nature**. 432(7020): 1054–1058. doi: 10.1038/nature03175.
- 122. Hall DB, Wade JT, and Struhl K (**2006**). An HMG Protein, Hmo1, Associates with Promoters of Many Ribosomal Protein Genes and throughout the rRNA Gene Locus in Saccharomyces cerevisiae. **Mol Cell Biol**. 26(9): 3672–3679. doi: 10.1128/mcb.26.9.3672-3679.2006.
- 123. Martin DE, Soulard A, and Hall MN (2004). TOR regulates ribosomal protein gene expression via PKA and the Forkhead Transcription Factor FHL1. Cell. 119(7): 969–979. doi: 10.1016/j.cell.2004.11.047.

- 124. Schawalder SB, Kabani M, Howald I, Choudhury U, Werner M, and Shore D (**2004**). Growth-regulated recruitment of the essential yeast ribosomal protein gene activator Ifh1. **Nature**. 432(7020): 1058–1061. doi: 10.1038/nature03200.
- 125. Howard SC, Hester A, and Herman PK (**2003**). The Ras/PKA Signaling Pathway May Control RNA Polymerase II Elongation via the Spt4p/Spt5p Complex in Saccharomyces cerevisiae. **Genetics**. 165(3): 1059–1070.
- 126. Garrett S, Menold MM, and Broach JR (1991). The Saccharomyces cerevisiae YAK1 gene encodes a protein kinase that is induced by arrest early in the cell cycle. **Mol Cell Biol**. 11(8): 4045–4052. doi: 10.1128/mcb.11.8.4045.
- 127. Lee P, Paik SM, Shin CS, Huh WK, and Hahn JS (**2011**). Regulation of yeast Yak1 kinase by PKA and autophosphorylation-dependent 14-3-3 binding. **Mol Microbiol**. 79(3): 633–646. doi: 10.1111/j.1365-2958.2010.07471.x.
- 128. Lee P, Cho BR, Joo HS, and Hahn JS (**2008**). Yeast Yak1 kinase, a bridge between PKA and stress-responsive transcription factors, Hsf1 and Msn2/Msn4. **Mol Microbiol**. 70(4): 882–895. doi: 10.1111/j.1365-2958.2008.06450.x.
- 129. Boy-Marcotte E, Perrot M, Bussereau F, Boucherie H, and Jacquet M (1998). Msn2p and Msn4p control a large number of genes induced at the diauxic transition which are repressed by cyclic AMP in Saccharomyces cerevisiae. J Bacteriol. 180(5): 1044–1052.
- 130. Reinders A, Bürckert N, Boller T, Wiemken A, and De Virgilio C (1998). Saccharomyces cerevisiae cAMP-dependent protein kinase controls entry into stationary phase through the Rim15p protein kinase. Genes Dev. 12(18): 2943–2955. doi: 10.1101/gad.12.18.2943.
- 131. Cytryńska MI, Frajnt M, and Jakubowicz T (**2001**). Saccharomyces cerevisiae pyruvate kinase Pyk1 is PKA phosphorylation substrate in vitro. **FEMS Microbiol Lett**. 203(2): 223–227. doi: 10.1016/S0378-1097(01)00354-8.
- 132. Vaseghi S, Macherhammer F, Zibek S, and Reuss M (**2001**). Signal transduction dynamics of the protein kinase-A/phosphofructokinase-2 system in Saccharomyces cerevisiae. **Metab Eng**. 3(2): 163–172. doi: 10.1006/mben.2000.0179.
- 133. Gancedos C (1983). Fructose 2,6-Bisphosphate Activates the cAMP-dependent Phosphorylation of Yeast Fructose-1,6-bisphosphatase in Vitro. J Biol Chem. 10(August 1982): 4–6.
- 134. Lin K, Rath VL, Dai SC, Fletterick RJ, and Hwang PK (1996). A protein phosphorylation switch at the conserved allosteric site in GP. Science (80-). 273(5281): 1539–1541. doi: 10.1126/science.273.5281.1539.
- 135. Hardy TA, and Roach PJ (**1993**). Control of yeast glycogen synthase-2 by COOH-terminal phosphorylation. **J Biol Chem**. 268(32): 23799–23805.
- 136. Busti S, Coccetti P, Alberghina L, and Vanoni M (**2010**). Glucose signaling-mediated coordination of cell growth and cell cycle in Saccharomyces Cerevisiae. **Sensors**. 10(6): 6195–6240. doi: 10.3390/s100606195.
- 137. Wang XW, and Zhang YJ (**2014**). Targeting mTOR network in colorectal cancer therapy. **World J Gastroenterol**. 20(15): 4178–4188. doi: 10.3748/wjg.v20.i15.4178.

- 138. Peeper DS, Upton TM, Ladha MH, Neuman E, Zalvide J, Bernards R, DeCaprio JA, and Ewen ME (1997). Ras signalling linked to the cell-cycle machinery by the retinoblastoma protein. Nature. 386(6621): 177–181. doi: 10.1038/386177a0.
- 139. Pruitt K, and Der CJ (**2001**). Ras and Rho regulation of the cell cycle and oncogenesis. **Cancer Lett**. 171(1): 1–10. doi: 10.1016/S0304-3835(01)00528-6.
- 140. Downward J (**2004**). Cell cycle: Routine role for Ras. **Curr Biol**. 7(4): R258–R260. doi: 10.1016/s0960-9822(06)00116-3.
- 141. Lord PG, and Wheals AE (1983). Rate of cell cycle initiation of yeast cells when cell size is not a rate-determining factor. J Cell Sci. 59: 183–201.
- 142. Hartwell L., and Unger M. (1977). Unequal division in Saccharomyces Cerevisiae and its implications for the control of cell division. J Cell Biol. 75: 422–435.
- 143. Vanoni M, Vai M, Popolo L, and Alberghina L (1983). Structural heterogeneity in populations of the budding yeast Saccharomyces cerevisiae. J Bacteriol. 156(3): 1282–1291.
- 144. Johnston GC, Ehrhardt CW, Lorincz A, and Carter BLA (1979). Regulation of cell size in the yeast Saccharomyces cerevisiae. J Bacteriol. 137(1): 1–5.
- 145. Baroni MD, Monti P, Lilia B, and Comparata B (**1994**). Repression of growth-regulated G1 cyclin expression by cyclic AMP in budding yeast. **Nature**. 371: 339–342.
- 146. Tokiwa G, Tyerst M, Volpe T, and Futchert B (1994). Inhibition of G1 cyclin activity by the Ras/cAMP pathway in yeast. Nature. 371(September): 342–345.
- 147. Mizunuma M, Tsubakiyama R, Ogawa T, Shitamukai A, Kobayashi Y, Inai T, Kume K, and Hirata D (**2013**). Ras/cAMP-dependent protein kinase (PKA) regulates multiple aspects of cellular events by phosphorylating the whi3 cell cycle regulator in budding yeast. **J Biol Chem**. 288(15): 10558–10566. doi: 10.1074/jbc.M112.402214.
- 148. Wood MD, and Sanchez Y (**2010**). Deregulated Ras signaling compromises DNA damage checkpoint recovery in S. cerevisiae. **Cell Cycle**. 9(16): 3353–3363. doi: 10.4161/cc.9.16.12713.
- 149. Gray J V, Petsko GA, Johnston GC, Ringe D, Singer RA, and Werner-washburne M (2004). "Sleeping Beauty": Quiescence in Saccharomyces cerevisiae. Microbiol Mol Biol Rev. 68(2): 187–206. doi: 10.1128/MMBR.68.2.187.
- 150. Laporte D, Lebaudy A, Sahin A, Pinson B, Ceschin J, Daignan-Fornier B, and Sagot I (2011). Metabolic status rather than cell cycle signals control quiescence entry and exit. J Cell Biol. 192(6): 949–957. doi: 10.1083/jcb.201009028.
- 151. Coller HA, Sang L, and Roberts JM (**2006**). A new description of cellular quiescence. **PLoS Biol**. 4(3): 0329–0349. doi: 10.1371/journal.pbio.0040083.
- 152. Matson JP, and Cook JG (**2017**). Cell cycle proliferation decisions: the impact of single cell analyses. **FEBS J**. 284(3): 362–375. doi: 10.1111/febs.13898.
- 153. Smets B, Ghillebert R, De Snijder P, Binda M, Swinnen E, De Virgilio C, and Winderickx J (2010). Life in the midst of scarcity: Adaptations to nutrient availability in Saccharomyces cerevisiae. .

- 154. Thevelein JM, and de Winde JH (1999). Novel sensing mechanisms and targets for the cAMP-protein kinase A pathway in the yeast Saccharomyces cerevisiae. **Mol Microbiol**. 33(5): 904–18. 10476026.
- 155. Gourlay CW, Du W, and Ayscough KR (**2006**). Apoptosis in yeast Mechanisms and benefits to a unicellular organism. **Mol Microbiol**. 62(6): 1515–1521. doi: 10.1111/j.1365-2958.2006.05486.x.
- 156. Carmona-Gutierrez D, Eisenberg T, Büttner S, Meisinger C, Kroemer G, and Madeo F (**2010**). Apoptosis in yeast: Triggers, pathways, subroutines. **Cell Death Differ**. 17(5): 763–773. doi: 10.1038/cdd.2009.219.
- 157. Fröhlich KU, Fussi H, and Ruckenstuhl C (2007). Yeast apoptosis-From genes to pathways. **Semin Cancer Biol**. 17(2): 112–121. doi: 10.1016/j.semcancer.2006.11.006.
- 158. Gourlay CW, and Ayscough KR (**2006**). Actin-Induced Hyperactivation of the Ras Signaling Pathway Leads to Apoptosis in Saccharomyces cerevisiae. **Mol Cell Biol**. 26(17): 6487–6501. doi: 10.1128/mcb.00117-06.
- 159. Pentland DR, Piper-Brown E, Mühlschlegel FA, and Gourlay CW (**2018**). Ras signalling in pathogenic yeasts. **Microb Cell**. 5(2): 63/73.
- 160. Santos J, Leão C, and Sousa MJ (**2013**). Ammonium-dependent shortening of CLS in yeast cells starved for essential amino acids is determined by the specific amino acid deprived, through different signaling pathways. **Oxid Med Cell Longev**. 2013. doi: 10.1155/2013/161986.
- 161. Santos J, Sousa MJ, and Leão C (**2012**). Ammonium is toxic for aging yeast cells, inducing death and shortening of the chronological lifespan. **PLoS One**. 7(5). doi: 10.1371/journal.pone.0037090.
- 162. Narasimhan ML, Damsz B, Ibeas I, Yun D, Coca MA, Pardo M, Hasegawa PM, and Lafayette W (**2001**). A Plant defence response effector induces microbial apoptosis. **Mol Cell**. 8(October): 921–930.
- 163. Fröhlich E, Madeo F, Sigrist SJ, Grey M, Ligr M, Fröhlich K-U, and Wolf DH (**2002**). Oxygen Stress: A Regulator of Apoptosis in Yeast. **J Cell Biol**. 145(4): 757–767. doi: 10.1083/jcb.145.4.757.
- 164. Silva RD, Sotoca R, Johansson B, Ludovico P, Sansonetty F, Silva MT, Peinado JM, and Côrte-Real M (**2005**). Hyperosmotic stress induces metacaspase- and mitochondria-dependent apoptosis in Saccharomyces cerevisiae. **Mol Microbiol**. 58(3): 824–834. doi: 10.1111/j.1365-2958.2005.04868.x.
- 165. Lastauskiene E, Zinkevičiene A, and Čitavičius D (**2014**). Ras/PKA signal transduction pathway participates in the regulation of Saccharomyces cerevisiae cell apoptosis in an acidic environment. **Biotechnol Appl Biochem**. 61(1): 3–10. doi: 10.1002/bab.1183.
- 166. Chen Y, and Klionsky DJ (**2010**). The regulation of autophagy unanswered questions. **J Cell Sci**. 124(2): 161–170. doi: 10.1242/jcs.064576.
- 167. Stephan JS, Yeh Y-Y, Ramachandran V, Deminoff SJ, and Herman PK (**2009**). The Tor and PKA signaling pathways independently target the Atg1/Atg13 protein kinase complex to

- control autophagy. **Proc Natl Acad Sci**. 106(40): 17049–17054. doi: 10.1073/pnas.0903316106.
- 168. Jacinto E, and Lorberg A (2008). TOR regulation of AGC kinases in yeast and mammals. Biochem J. 410(1): 19–37. doi: 10.1042/bj20071518.
- 169. Noda T, Ohsumi Y, and Tor (**1998**). Tor, a Phosphatidylinositol Kinase Homologue, Controls Autophagy in yeast. **J Biol Chem**. 273(7): 3963–3966.
- 170. Zaman S, Lippman SI, Schneper L, Slonim N, and Broach JR (**2009**). Glucose regulates transcription in yeast through a network of signaling pathways. **Mol Syst Biol**. 5(245): 1–14. doi: 10.1038/msb.2009.2.
- 171. Kingsbury JM, Sen ND, and Cardenas ME (**2015**). Branched-Chain Aminotransferases Control TORC1 Signaling in Saccharomyces cerevisiae. **PLoS Genet**. 11(12): 1–24. doi: 10.1371/journal.pgen.1005714.
- 172. Stracka D, Jozefczuk S, Rudroff F, Sauer U, and Hall MN (**2014**). Nitrogen source activates TOR (Target of Rapamycin) complex 1 via glutamine and independently of Gtr/Rag proteins. **J Biol Chem**. 289(36): 25010–25020. doi: 10.1074/jbc.M114.574335.
- 173. Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-peled L, and Sabatini DM (2008). The Rag GTPases bind raptor and nediate amino acid signaling in mTORC1. Science (80-). 320(5882): 1496–1501. doi: 10.1126/science.1157535.The.
- 174. Binda M, Péli-Gulli MP, Bonfils G, Panchaud N, Urban J, Sturgill TW, Loewith R, and De Virgilio C (**2009**). The Vam6 GEF Controls TORC1 by Activating the EGO Complex. **Mol Cell**. 35(5): 563–573. doi: 10.1016/j.molcel.2009.06.033.
- 175. Rebsamen M, Pochini L, Stasyk T, De Araújo MEG, Galluccio M, Kandasamy RK, Snijder B, Fauster A, Rudashevskaya EL, Bruckner M, Scorzoni S, Filipek PA, Huber KVM, Bigenzahn JW, Heinz LX, Kraft C, Bennett KL, Indiveri C, Huber LA, and Superti-Furga G (2015). SLC38A9 is a component of the lysosomal amino acid sensing machinery that controls mTORC1. Nature. 519(7544): 477–481. doi: 10.1038/nature14107.
- 176. Wang S, Tsun Z-Y, Wolfson R, Shen K, Wyant GA, Plovanich ME, Yuan ED, Jones TD, Chantranupong L, Comb W, Wang T, Bar-Peled L, Zoncu R, Straub C, Kim C, Park J, Sabatini BL, and Sabatini DM (2015). The amino acid transporter SLC38A9 is a key component of a lysosomal membrane complex that signals arginine sufficiency to mTORC1. Science (80-). 347(6218): 188–194. doi: 10.1126/science.1257132.
- 177. Averous J, Lambert-Langlais S, Mesclon F, Carraro V, Parry L, Jousse C, Bruhat A, Maurin AC, Pierre P, Proud CG, and Fafournoux P (2016). GCN2 contributes to mTORC1 inhibition by leucine deprivation through an ATF4 independent mechanism. Sci Rep. 6(June): 1–10. doi: 10.1038/srep27698.
- 178. Berlanga JJ, Santoyo J, and De Haro C (**1999**). Characterization of a mammalian homolog of the GCN2 eukaryotic initiation factor 2α kinase. **Eur J Biochem**. 265(2): 754–762. doi: 10.1046/j.1432-1327.1999.00780.x.
- 179. Cai H, Hauser M, Naider F, and Becker JM (2007). Differential regulation and substrate preferences in two peptide transporters of Saccharomyces cerevisiae. **Eukaryot Cell**. 6(10): 1805–1813. doi: 10.1128/EC.00257-06.

- 180. Perry JR, Basrai MA, Steiner H-Y, Naider F, and Becker " JM (1994). Isolation and Characterization of a Saccharomyces cerevisiae Peptide Transport Gene. Mol Cell Biol. 14(1): 104–115.
- 181. Alagramam K, Naider F, and Becker JM (1995). A recognition component of the ubiquitin system is required for peptide transport in Saccharomyces cerevisiae. **Mol Microbiol**. 15(2): 225–34. doi: 10.1111/j.1365-2958.1995.tb02237.x.
- 182. Island MD, Naider F, and Becker JM (1987). Regulation of dipeptide transport in Saccharomyces cerevisiae by micromolar amino acid concentrations. J Bacteriol. 169(5): 2132–2136. doi: 10.1128/jb.169.5.2132-2136.1987.
- 183. Varshavsky A (**1997**). The N-end rule pathway of protein degradation. **Genes to Cells**. 2(1): 13–28. doi: 10.1046/j.1365-2443.1997.1020301.x.
- 184. Varshavsky A (1996). The N-end rule: Functions, mysteries, uses. **Proc Natl Acad Sci U S A**. 93(22): 12142–12149. doi: 10.1073/pnas.93.22.12142.
- 185. Du F, Navarro-Garcia F, Xia Z, Tasaki T, and Varshavsky A (**2002**). Pairs of dipeptides synergistically activate the binding of substrate by ubiquitin ligase through dissociation of its autoinhibitory domain. **Proc Natl Acad Sci U S A**. 99(22): 14110–14115. doi: 10.1073/pnas.172527399.
- 186. Homann OR, Cai H, Becker JM, and Lindquist SL (**2005**). Harnessing Natural Diversity to Probe Metabolic Pathways. **PLoS Genet**. 1(6): e80. doi: 10.1371/journal.pgen.0010080.
- 187. Wiles AM, Cai H, Naider F, and Becker JM (2006). Nutrient regulation of oligopeptide transport in Saccharomyces cerevisiae. **Microbiology**. 152(10): 3133–3145. doi: 10.1099/mic.0.29055-0.
- 188. Martinelli E, De Palma R, Orditura M, De Vita F, and Ciardiello F (**2009**). Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy. **Clin Exp Immunol**. 158(1): 1–9. doi: 10.1111/j.1365-2249.2009.03992.x.
- 189. Normanno N, Tejpar S, Morgillo F, De Luca A, Van Cutsem E, and Ciardiello F (**2009**). Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. **Nat Rev Clin Oncol**. 6(9): 519–527. doi: 10.1038/nrclinonc.2009.111.
- 190. Schulze WX, Deng L, and Mann M (2005). Phosphotyrosine interactome of the ErbBreceptor kinase family. **Mol Syst Biol**. 1(1): E1–E13. doi: 10.1038/msb4100012.
- 191. Downward J (**2003**). Targeting RAS signalling pathways in cancer therapy. **Nat Rev Cancer**. 3(1): 11–22. doi: 10.1038/nrc969.
- 192. Herrmann C (**2003**). Ras-effector interactions: After one decade. **Curr Opin Struct Biol**. 13(1): 122–129. doi: 10.1016/S0959-440X(02)00007-6.
- 193. KOLCH W (**2000**). Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. **Biochem J**. 351(2): 289–305. doi: 10.1042/bj3510289.
- 194. Yung Y, Dolginov Y, Yao Z, Rubinfeld H, Michael D, Hanoch T, Roubini E, Lando Z, Zharhary D, and Seger R (1997). Detection of ERK activation by a novel monoclonal antibody. FEBS Lett. 408(3): 292–296. doi: 10.1016/S0014-5793(97)00442-0.

- 195. Scheid MP, and Woodgett JR (**2001**). Phosphatidylinositol 3' Kinase Signaling in Mammary Tumorigenesis. **J Mammary Gland Biol Neoplasia**. 6(1): 83–99. doi: 10.1023/A:1009520616247.
- 196. Hancock JF, Apolloni A, Yan J, Lane A, and Roy S (**2002**). Ras Isoforms Vary in Their Ability to Activate Raf-1 and Phosphoinositide 3-Kinase. **J Biol Chem**. 273(37): 24052–24056. doi: 10.1074/jbc.273.37.24052.
- 197. Rajalingam K, Schreck R, Rapp UR, and Albert Š (**2007**). Ras oncogenes and their downstream targets. **Biochim Biophys Acta Mol Cell Res**. 1773(8): 1177–1195. doi: 10.1016/j.bbamcr.2007.01.012.
- 198. Powers S, Kataoka T, Fasano O, Goldfarb M, Strathem J, Broach J, and Wigler M (1984). Genes in S. cerevisiae encoding proteins with domains homologous to the mammalian ras proteins. **Cell**. 36(3): 607–612. doi: 10.1016/0092-8674(84)90340-4.
- 199. DeFeo-Jones D, Scolnick E, Koller R, and Dhar R (**1983**). Ras-related gene sequences identified and isolated from Saccharomyces cerevisiae. **Nature**. 306(5944): 707–709. doi: 10.1038/306707a0.
- 200. Clark S., McGrath J., and Levinson A. (1985). Expression of Normal and Activated Human Ha-ras cDNAs in Saccharomyces cerevisiae. Mol Cell Biol. 5(10): 2746–2752.
- 201. Fujiyama A, Matsumoto K, and Tamanoi F (1987). A novel yeast mutant defective in the processing of ras proteins: assessment of the effect of the mutation on processing steps. **EMBO J.** 6(1): 223–8. 3556161.
- 202. Afgan E, Baker D, Batut B, van den Beek M, Bouvier D, Cech M, Chilton J, Clements D, Coraor N, Grüning BA, Guerler A, Hillman-Jackson J, Hiltemann S, Jalili V, Rasche H, Soranzo N, Goecks J, Taylor J, Nekrutenko A, and Blankenberg D (**2018**). The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2018 update. **Nucleic Acids Res.** 46(W1): W537–W544. doi: 10.1093/nar/gky379.
- 203. (2010). AS FASTQC: A quality control tool for high throughput sequence data. .
- 204. Krueger F (2012) Trim Galore!: A wrapper tool around Cutadapt and FastQC to consistently apply quality and adapter trimming to FastQ files, with some extra functionality for MspI-digested RRBS-type (Reduced Representation Bisufite-Seq) libraries. .
- 205. Kim D, Langmead B, and Salzberg SL (**2015**). HISAT: a fast spliced aligner with low memory requirements. 12(4). doi: 10.1038/nmeth.3317.
- 206. Liao Y, Smyth GK, and Shi W (**2014**). FeatureCounts: An efficient general purpose program for assigning sequence reads to genomic features. **Bioinformatics**. 30(7): 923–930. doi: 10.1093/bioinformatics/btt656.
- 207. Love MI, Huber W, and Anders S (**2014**). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. **Genome Biol**. 15(12): 1–21. doi: 10.1186/s13059-014-0550-8.
- 208. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette M a, Paulovich A, Pomeroy SL, Golub TR, Lander ES, and Mesirov JP (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. **Proc Natl**

- Acad Sci U S A. 102(43): 15545–50. doi: 10.1073/pnas.0506580102.
- 209. Gueldener U (**2002**). A second set of loxP marker cassettes for Cre-mediated multiple gene knockouts in budding yeast. **Nucleic Acids Res**. 30(6): 23e 23. doi: 10.1093/nar/30.6.e23.
- 210. von der Haar T (**2007**). Optimized protein extraction for quantitative proteomics of yeasts. **PLoS One**. 2(10). doi: 10.1371/journal.pone.0001078.
- 211. Marshall M (1995). Interactions between Ras and Raf: key regulatory proteins in cellular transformation. **Mol Reprod Dev**. 42(4): 493–9. doi: 10.1002/mrd.1080420418.
- 212. Omerovic J, and Prior IA (2009). Compartmentalized signalling: Ras proteins and signalling nanoclusters. **FEBS J**. 276(7): 1817–1825. doi: 10.1111/j.1742-4658.2009.06928.x.
- 213. Xiaojia B, and Jian D (**2010**). Serine214 of Ras2p plays a role in the feedback regulation of the Ras-cAMP pathway in the yeast Saccharomyces cerevisiae. **FEBS Lett**. 584(11): 2333–2338. doi: 10.1016/j.febslet.2010.04.011.
- 214. Jin X, Starke S, Li Y, Sethupathi S, Kung G, Dodhiawala P, and Wang Y (**2016**). Nitrogen starvation-induced phosphorylation of Ras1 protein and its potential role in nutrient signaling and stress response. **J Biol Chem**. 291(31): 16231–16239. doi: 10.1074/jbc.M115.713206.
- 215. Herskowitz I (1988). Life cycle of the budding yeast Saccharomyces cerevisiae. **Microbiol Rev**. 52(4): 536–553.
- 216. Conrad M, Schothorst J, Kankipati HN, Van Zeebroeck G, Rubio-Texeira M, and Thevelein JM (**2014**). Nutrient sensing and signaling in the yeast *Saccharomyces cerevisiae*. **FEMS Microbiol Rev**. 38(2): 254–299. doi: 10.1111/1574-6976.12065.
- 217. Carmona-Gutierrez D et al. (2018). Guidelines and recommendations on yeast cell death nomenclature. **Microb Cell**. 5(1): 4–31. doi: 10.15698/mic2018.01.607.
- 218. Rinnerthaler M, Büttner S, Laun P, Heeren G, Felder TK, Klinger H, Weinberger M, Stolze K, Grousl T, Hasek J, Benada O, Frydlova I, Klocker A, Simon-Nobbe B, Jansko B, Breitenbach-Koller H, Eisenberg T, Gourlay CW, Madeo F, Burhans WC, and Breitenbach M (2012). Yno1p/Aim14p, a NADPH-oxidase ortholog, controls extramitochondrial reactive oxygen species generation, apoptosis, and actin cable formation in yeast. **Proc Natl Acad Sci U S A**. 109(22): 8658–8663. doi: 10.1073/pnas.1201629109.
- 219. Cebollero E, and Reggiori F (**2009**). Regulation of autophagy in yeast Saccharomyces cerevisiae. **Biochim Biophys Acta Mol Cell Res**. 1793(9): 1413–1421. doi: 10.1016/j.bbamcr.2009.01.008.
- 220. Nakatogawa H, Ichimura Y, and Ohsumi Y (**2007**). Atg8, a Ubiquitin-like Protein Required for Autophagosome Formation, Mediates Membrane Tethering and Hemifusion. **Cell**. 130(1): 165–178. doi: 10.1016/j.cell.2007.05.021.
- 221. Kirisako T, Ichimura Y, Okada H, Kabeya Y, Mizushima N, Yoshimori T, Ohsumi M, Takao T, Noda T, and Ohsumi Y (**2000**). The Reversible Modification Regulates the Membrane-Binding State of Apg8/Aut7 Essential for Autophagy and the Cytoplasm to Vacuole Targeting Pathway. **J Cell Biol**. 151(2): 263–276. doi: 10.1083/jcb.151.2.263.

- 222. Cheong H, and Klionsky DJ (**2008**). Chapter 1 Biochemical Methods to Monitor Autophagy-Related Processes in Yeast. pp 1–26.
- 223. Shintani T, and Klionsky DJ (**2004**). Cargo Proteins Facilitate the Formation of Transport Vesicles in the Cytoplasm to Vacuole Targeting Pathway. **J Biol Chem**. 279(29): 29889–29894. doi: 10.1074/jbc.M404399200.
- 224. Leadsham JE, and Gourlay CW (**2010**). CAMP/PKA signaling balances respiratory activity with mitochondria dependent apoptosis via transcriptional regulation. **BMC Cell Biol**. 11(1): 92. doi: 10.1186/1471-2121-11-92.
- 225. Guaragnella N, Coyne LP, Chen XJ, and Giannattasio S (**2018**). Mitochondria-cytosol-nucleus crosstalk: Learning from Saccharomyces cerevisiae. **FEMS Yeast Res**. 18(8): 1–15. doi: 10.1093/femsyr/foy088.
- 226. de Virgilio C (**2012**). The essence of yeast quiescence. **FEMS Microbiol Rev**. 36(2): 306–339. doi: 10.1111/j.1574-6976.2011.00287.x.
- 227. Eraso P, and Gancedo JM (1985). Use of glucose analogues to study the mechanism of glucose-mediated cAMP increase in yeast. **FEBS Lett**. 191(1): 51–54. doi: 10.1016/0014-5793(85)80991-1.
- 228. FRANÇOIS J, ERASO P, and GANCEDO C (1987). Changes in the concentration of cAMP, fructose 2,6-bisphosphate and related metabolites and enzymes in Saccharomyces cerevisiae during growth on glucose. **Eur J Biochem**. 164(2): 369–373. doi: 10.1111/j.1432-1033.1987.tb11067.x.
- 229. BROACH J (**1991**). RAS genes in Saccharomyces cerevisiae: signal transduction in search of a pathway. **Trends Genet**. 7(1): 28–33. doi: 10.1016/0168-9525(91)90018-L.
- 230. Taylor WE, and Young ET (**1990**). CAMP-dependent phosphorylation and inactivation of yeast transcription factor ADR1 does not affect DNA binding. **Proc Natl Acad Sci U S A**. 87(11): 4098–4102. doi: 10.1073/pnas.87.11.4098.
- 231. Matsumoto K, Uno I, Oshima Y, and Ishikawa T (**1982**). Isolation and characterization of yeast mutants deficient in adenylate cyclase and cAMP-dependent protein kinase. **Proc Natl Acad Sci U S A**. 79(7 I): 2355–2359. doi: 10.1073/pnas.79.7.2355.
- 232. Toda T, Uno I, Ishikawa T, Powers S, Kataoka T, Broek D, Cameron S, Broach J, Matsumoto K, and Wigler M (1985). In yeast, RAS proteins are controlling elements of adenylate cyclase. **Cell**. 40(1): 27–36. doi: 10.1016/0092-8674(85)90305-8.
- 233. Kelliher CM, Foster MW, Motta FC, Deckard A, Soderblom EJ, Arthur Moseley M, and Haase SB (2018). Layers of regulation of cell-cycle gene expression in the budding yeast Saccharomyces cerevisiae. **Mol Biol Cell**. 29(22): 2644–2655. doi: 10.1091/mbc.E18-04-0255.
- 234. Clarke S, Vogel JP, Deschenes RJ, and Stock J (1988). Posttranslational modification of the Ha-ras oncogene protein: evidence for a third class of protein carboxyl methyltransferases [published erratum appears in Proc Natl Acad Sci U S A 1988 Oct;85(20):7556]. Proc Natl Acad Sci U S A. 85(13): 4643–4647.
- 235. Fujiyama A, and Tamanoi F (1990). RAS2 Protein of Saccharomyces cerevisiae

- undergoes removal of methionine at N terminus and removal of three amino acids at C terminus. J Biol Chem. 265(6): 3362–3368.
- 236. Engelberg D, Simchen G, and Levitzki A (**1990**). In vitro reconstitution of cdc25 regulated S. cerevisiae adenylyl cyclase and its kinetic properties. **EMBO J**. 9(3): 641–651. doi: 10.1002/j.1460-2075.1990.tb08156.x.
- 237. Mitts MR, Grant DB, and Heideman W (1990). Adenylate cyclase in Saccharomyces cerevisiae is a peripheral membrane protein. **Mol Cell Biol**. 10(8): 3873–3883. doi: 10.1128/mcb.10.8.3873.
- 238. Hlavatá L, Aguilaniu H, Pichová A, and Nyström T (**2003**). The oncogenic RAS2val19 mutation locks respiration, independently of PKA, in a mode prone to generate ROS. **EMBO** J. 22(13): 3337–3345. doi: 10.1093/emboj/cdg314.
- 239. Johnson KE, Cameron S, Toda T, Wigler M, and Zoller MJ (1987). Expression in Escherichia coli of BCY1, the regulatory subunit of cyclic AMP-dependent protein kinase from Saccharomyces cerevisiae. Purification and characterization. J Biol Chem. 262(18): 8636–8642.
- 240. Edwards AS, and Scott JD (**2000**). A-kinase anchoring proteins: Protein kinase A and beyond. **Curr Opin Cell Biol**. 12(2): 217–221. doi: 10.1016/S0955-0674(99)00085-X.
- 241. Griffioen G, Branduardi P, Ballarini A, Anghileri P, Norbeck J, Baroni MD, and Ruis H (**2001**). Nucleocytoplasmic Distribution of Budding Yeast Protein Kinase A Regulatory Subunit Bcy1 Requires Zds1 and Is Regulated by Yak1-Dependent Phosphorylation of Its Targeting Domain. **Mol Cell Biol**. 21(2): 511–523. doi: 10.1128/mcb.21.2.511-523.2001.
- 242. Tudisca V, Recouvreux V, Moreno S, Boy-Marcotte E, Jacquet M, and Portela P (**2010**). Differential localization to cytoplasm, nucleus or P-bodies of yeast PKA subunits under different growth conditions. **Eur J Cell Biol**. 89(4): 339–348. doi: 10.1016/j.ejcb.2009.08.005.
- 243. Tamaki H (**2007**). Glucose-stimulated cAMP-protein kinase a pathway in yeast Saccharomyces cerevisiae. **J Biosci Bioeng**. 104(4): 245–250. doi: 10.1263/jbb.104.245.
- 244. Steyfkens F, Zhang Z, Van Zeebroeck G, and Thevelein JM (2018). Multiple Transceptors for Macro- and Micro-Nutrients Control Diverse Cellular Properties Through the PKA Pathway in Yeast: A Paradigm for the Rapidly Expanding World of Eukaryotic Nutrient Transceptors Up to Those in Human Cells. Front Pharmacol. 9: 191. doi: 10.3389/fphar.2018.00191.
- 245. Wiles AM, Cai H, Naider F, Becker JM, and Jeffrey Becker jbecker CM Nutrient regulation of oligopeptide transport in Saccharomyces cerevisiae. doi: 10.1099/mic.0.29055-0.
- 246. Hauser M, Narita V, Donhardt AM, Naider F, and Becker JM (**2001**). Multiplicity and regulation of genes encoding peptide transporters in *Saccharomyces cerevisiae*. **Mol Membr Biol**. 18(1): 105–112. doi: 10.1080/09687680010029374.
- 247. Thevelein JM, Cauwenberg L, Colombo S, De Winde JH, Donation M, Dumortier F, Kraakman L, Lemaire K, Ma P, Nauwelaers D, Rolland F, Teunissen A, Van Dijck P, Versele M, Wera S, and Winderickx J (2000). Nutrient-induced signal transduction through the protein kinase A pathway and its role in the control of metabolism, stress resistance, and growth in

- yeast. **Enzyme Microb Technol**. 26(9–10): 819–825. doi: 10.1016/S0141-0229(00)00177-0.
- 248. Fuge EK, Braun EL, and Werner-Washburne M (1994). Protein synthesis in long-term stationary-phase cultures of Saccharomyces cerevisiae. J Bacteriol. 176(18): 5802–5813. doi: 10.1128/jb.176.18.5802-5813.1994.
- 249. Werner-Washburne M, Braun EL, Crawford ME, and Peck VM (1996). Stationary phase in Saccharomyces cerevisiae. **Mol Microbiol**. 19(6): 1159–66. doi: 10.1111/j.1365-2958.1996.tb02461.x.
- 250. Piñon R (**1978**). Folded chromosomes in non-cycling yeast cells: evidence for a characteristic g0 form. **Chromosoma**. 67(3): 263–74. doi: 10.1007/bf02569039.
- 251. Ewing B, Ewing B, Hillier L, Hillier L, Wendl MC, Wendl MC, Green P, and Green P (2005). Base-Calling of Automated Sequencer Traces Using. **Genome Res**. (206): 175–185. doi: 10.1101/gr.8.3.175.
- 252. Lever J, Krzywinski M, and Altman N (**2017**). Points of Significance: Principal component analysis. **Nat Methods**. 14(7): 641–642. doi: 10.1038/nmeth.4346.
- 253. Merico D, Isserlin R, Stueker O, Emili A, and Bader GD (**2010**). Enrichment map: A network-based method for gene-set enrichment visualization and interpretation. **PLoS One**. 5(11). doi: 10.1371/journal.pone.0013984.
- 254. Sagot I, and Laporte D (**2019**). The cell biology of quiescent yeast-a diversity of individual scenarios. doi: 10.1242/jcs.213025.
- 255. Boucherie H (1985). Protein synthesis during transition and stationary phases under glucose limitation in Saccharomyces cerevisiae. J Bacteriol. 161(1): 385–392.
- 256. Ju Q, and Warner JR (**1994**). Ribosome synthesis during the growth cycle of Saccharomyces cerevisiae. **Yeast**. 10(2): 151–157. doi: 10.1002/yea.320100203.
- 257. Thevelein J, Bonini B, Castermans D, Haesendonckx S, Kriel J, Louwet W, Thayumanavan P, Popova Y, Rubio-Texeira M, Schepers W, Vandormael P, Zeebroeck G, Verhaert P, Versele M, and Voordeckers K (2008). Novel mechanisms in nutrient activation of the yeast Protein Kinase A pathway. Acta Microbiol Immunol Hung. 55(2): 75–89. doi: 10.1556/AMicr.55.2008.2.1.
- 258. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, and Kinzler KW (2013). Cancer genome landscapes. Science (80-). 340(6127): 1546–1558. doi: 10.1126/science.1235122.
- 259. Stephen AG, Esposito D, Bagni RG, and McCormick F (**2014**). Dragging ras back in the ring. **Cancer Cell**. 25(3): 272–281. doi: 10.1016/j.ccr.2014.02.017.
- 260. Cox AD, Fesik SW, Kimmelman AC, Luo J, and Der CJ (**2014**). Drugging the undruggable RAS: Mission Possible? **Nat Rev Drug Discov**. 13(11): 828–851. doi: 10.1038/nrd4389.
- 261. Lazo JS, and Sharlow ER (**2016**). Drugging Undruggable Molecular Cancer Targets. **Annu Rev Pharmacol Toxicol**. 56(1): 23–40. doi: 10.1146/annurev-pharmtox-010715-103440.
- 262. Tsai FD, Lopes MS, Zhou M, Court H, Ponce O, Fiordalisi JJ, Gierut JJ, Cox AD, Haigis KM, and Philips MR (2015). K-Ras4A splice variant is widely expressed in cancer and uses a hybrid

- membrane-targeting motif. **Proc Natl Acad Sci U S A**. 112(3): 779–784. doi: 10.1073/pnas.1412811112.
- 263. Ahearn IM, Haigis K, Bar-Sagi D, and Philips MR (**2012**). Regulating the regulator: Post-translational modification of RAS. **Nat Rev Mol Cell Biol**. 13(1): 39–51. doi: 10.1038/nrm3255.
- 264. Cox AD, Der CJ, and Philips MR (2015). Targeting RAS membrane association: Back to the future for anti-RAS drug discovery? Clin Cancer Res. 21(8): 1819–1827. doi: 10.1158/1078-0432.CCR-14-3214.
- 265. Plowman SJ, Ariotti N, Goodall A, Parton RG, and Hancock JF (**2008**). Electrostatic Interactions Positively Regulate K-Ras Nanocluster Formation and Function. **Mol Cell Biol**. 28(13): 4377–4385. doi: 10.1128/mcb.00050-08.
- 266. Sung PJ, Tsai FD, Vais H, Court H, Yang J, Fehrenbacher N, Foskett JK, and Philips MR (2013). Phosphorylated K-Ras limits cell survival by blocking Bcl-xL sensitization of inositol trisphosphate receptors. **Proc Natl Acad Sci U S A**. 110(51): 20593–20598. doi: 10.1073/pnas.1306431110.
- 267. Hanahan D, and Weinberg R (**2000**). The Hallmarks of Cancer. **Cell**. 1(100): 0092–8674. 10647931.
- 268. Mandalà M, Merelli B, and Massi D (**2014**). Nras in melanoma: Targeting the undruggable target. **Crit Rev Oncol Hematol**. 92(2): 107–122. doi: 10.1016/j.critrevonc.2014.05.005.

Appendix

RAS2^{S225A} vs EV- Cytoplasmic Translation- Upregulated

| Gene Name | Rank in Gene List | Rank Metric Score | Running Enrichment Score |
|--------------|-------------------|-------------------|-----------------------------|
| RPPO | 25 | 2.342 | 0.0779 |
| TMA19 | 56 | 1.975 | 0.1413 |
| RPL30 | 121 | 1.675 | 0.1857 |
| RPL29 | 140 | 1.606 | 0.2388 |
| SSB1 | 195 | 1.461 | 0.278 |
| SSA1 | 220 | 1.406 | 0.3225 |
| SSB2 | 224 | 1.403 | 0.3721 |
| THS1 | 278 | 1.315 | 0.4062 |
| TMA7 | 311 | 1.265 | 0.4437 |
| RPL28 | 373 | 1.181 | 0.4711 |
| RPG1 | 404 | 1.133 | 0.5044 |
| <u>TIF11</u> | 426 | 1.1 | 0.5387 |
| <u>SSZ1</u> | 523 | 1.001 | 0.5511 |
| <u>TIF35</u> | 531 | 0.993 | 0.585 |
| TIF3 | 535 | 0.989 | 0.6197 |
| HYP2 | 596 | 0.918 | 0.6379 |
| TRM7 | 771 | 0.778 | 0.6231 |
| TAE1 | 1061 | 0.585 | 0.5732 |
| RBG1 | 1112 | 0.558 | 0.5809 |
| PRT1 | 1175 | 0.525 | 0.5846 |
| HCR1 | 1262 | 0.483 | 0.5808 |
| FES1 | 1388 | 0.428 | 0.5655 |
| FUN12 | 1803 | 0.267 | 0.4736 |
| CLU1 | 1941 | 0.213 | 0.4476 |
| TIF34 | 2035 | 0.16 | 0.4305 |
| TMA46 | 2238 | -0.234 | 0.3894 |
| RPM2 | 3373 | -0.601 | 0.1329 |
| MTG2 | 3405 | -0.614 | 0.1473 |
| AFG3 | 3551 | -0.679 | 0.1361 |

Cytosolic Ribosome

| Gene Name | Rank in Gene List | Rank Metric Score | Running Enrichment Score |
|--------------|-------------------|-------------------|-----------------------------|
| RPPO | 25 | 2.342 | 0.0505 |
| ASC1 | 49 | 2.05 | 0.0944 |
| RPS12 | 79 | 1.818 | 0.1312 |
| RPS5 | 85 | 1.784 | 0.1731 |
| RPS3 | 120 | 1.677 | 0.2053 |
| <u>RPL30</u> | 121 | 1.675 | 0.2458 |
| <u>RPS31</u> | 138 | 1.615 | 0.2809 |
| RPL29 | 140 | 1.606 | 0.3195 |
| RPL39 | 179 | 1.513 | 0.3467 |
| RPL5 | 208 | 1.425 | 0.3743 |
| RPL3 | 232 | 1.381 | 0.4021 |
| RPL38 | 257 | 1.345 | 0.4287 |
| <u>RPS20</u> | 279 | 1.313 | 0.4553 |
| RPL25 | 294 | 1.286 | 0.4829 |
| RPL32 | 300 | 1.278 | 0.5126 |
| RPS13 | 305 | 1.273 | 0.5424 |
| RLI1 | 318 | 1.253 | 0.5697 |
| SIS1 | 327 | 1.246 | 0.5979 |
| RPS2 | 363 | 1.193 | 0.6182 |
| RPL28 | 373 | 1.181 | 0.6445 |
| YEF3 | 378 | 1.174 | 0.6719 |
| <u>RPL10</u> | 452 | 1.072 | 0.6799 |
| NAT1 | 571 | 0.946 | 0.6738 |
| HYP2 | 596 | 0.918 | 0.6901 |
| MAP1 | 605 | 0.909 | 0.7101 |
| SQT1 | 678 | 0.848 | 0.7129 |
| ARD1 | 709 | 0.825 | 0.7255 |
| SNL1 | 1030 | 0.605 | 0.6615 |
| FES1 | 1388 | 0.428 | 0.5841 |
| NAT5 | 1632 | 0.33 | 0.5323 |
| NMD3 | 1733 | 0.293 | 0.5148 |
| FUN12 | 1803 | 0.267 | 0.5043 |
| LSG1 | 1943 | 0.212 | 0.4753 |
| <u>JJJ1</u> | 2216 | -0.226 | 0.4139 |
| HEF3 | 2692 | -0.367 | 0.3061 |
| RQC1 | 3116 | -0.5 | 0.2142 |
| RRP14 | 3137 | -0.507 | 0.2215 |
| BUD27 | 3546 | -0.676 | 0.1376 |

Pre-ribosome

| Gene Name | Rank in Gene List | Rank Metric Score | Running Enrichment Score |
|--------------|-------------------|-------------------|-----------------------------|
| SNU13 | 23 | 2.41 | 0.025 |
| RPPO | 25 | 2.342 | 0.0547 |
| RPS5 | 85 | 1.784 | 0.0627 |
| NOP58 | 100 | 1.74 | 0.0814 |
| KRR1 | 103 | 1.73 | 0.103 |
| RPS3 | 120 | 1.677 | 0.1204 |
| HCA4 | 148 | 1.59 | 0.1339 |
| RPL3 | 232 | 1.381 | 0.1308 |
| NIP7 | 242 | 1.365 | 0.146 |
| YVH1 | 249 | 1.355 | 0.1618 |
| EMG1 | 283 | 1.307 | 0.1702 |
| <u>NOP13</u> | 285 | 1.303 | 0.1866 |
| RPS13 | 305 | 1.273 | 0.1981 |
| ENP1 | 317 | 1.256 | 0.2114 |
| RLI1 | 318 | 1.253 | 0.2274 |
| NOP56 | 357 | 1.203 | 0.2332 |
| RPS2 | 363 | 1.193 | 0.2472 |
| RPL28 | 373 | 1.181 | 0.2601 |
| MRT4 | 411 | 1.123 | 0.2651 |
| UTP13 | 430 | 1.095 | 0.2746 |
| NOP1 | 431 | 1.094 | 0.2886 |
| <u>MAK16</u> | 498 | 1.034 | 0.2853 |
| NOC2 | 525 | 0.999 | 0.2915 |
| NEW1 | 534 | 0.991 | 0.3021 |
| DIM1 | 560 | 0.958 | 0.3081 |
| UTP4 | 564 | 0.953 | 0.3195 |
| HAS1 | 579 | 0.936 | 0.328 |
| IMP3 | 597 | 0.918 | 0.3354 |
| RRS1 | 598 | 0.917 | 0.3472 |
| UTP10 | 608 | 0.903 | 0.3564 |
| RPF2 | 629 | 0.886 | 0.3627 |
| CBF5 | 634 | 0.881 | 0.373 |
| NSA2 | 640 | 0.876 | 0.3829 |
| PRP43 | 652 | 0.866 | 0.3912 |
| SQT1 | 678 | 0.848 | 0.3958 |
| DBP3 | 696 | 0.833 | 0.4022 |

| CIC1 | 708 | 0.827 | 0.41 |
|--------------|------|-------|--------|
| NOP7 | 717 | 0.821 | 0.4185 |
| UTP14 | 739 | 0.806 | 0.4235 |
| DBP5 | 759 | 0.787 | 0.4288 |
| NUG1 | 790 | 0.768 | 0.4311 |
| MAK21 | 803 | 0.757 | 0.4378 |
| IPI1 | 807 | 0.755 | 0.4466 |
| RRP1 | 832 | 0.737 | 0.45 |
| KRE33 | 847 | 0.727 | 0.4558 |
| ROK1 | 866 | 0.715 | 0.4605 |
| SLX9 | 889 | 0.701 | 0.4639 |
| BFR2 | 896 | 0.696 | 0.4713 |
| UTP21 | 925 | 0.677 | 0.4729 |
| CGR1 | 1001 | 0.626 | 0.4621 |
| UTP6 | 1031 | 0.605 | 0.4626 |
| <u>SAS10</u> | 1045 | 0.596 | 0.4669 |
| SPB1 | 1072 | 0.578 | 0.4678 |
| FCF1 | 1132 | 0.548 | 0.46 |
| CKB2 | 1159 | 0.534 | 0.4604 |
| NOP2 | 1193 | 0.517 | 0.4587 |
| ERB1 | 1205 | 0.512 | 0.4625 |
| RIX7 | 1219 | 0.507 | 0.4657 |
| CKB1 | 1231 | 0.5 | 0.4693 |
| NSA1 | 1251 | 0.489 | 0.4708 |
| NOG1 | 1255 | 0.486 | 0.4763 |
| NOP9 | 1324 | 0.455 | 0.465 |
| RRP12 | 1334 | 0.452 | 0.4686 |
| UTP7 | 1366 | 0.441 | 0.4664 |
| RRP36 | 1394 | 0.425 | 0.4651 |
| NOP4 | 1422 | 0.413 | 0.4636 |
| NOG2 | 1466 | 0.397 | 0.4579 |
| DBP8 | 1488 | 0.388 | 0.4576 |
| CKA2 | 1528 | 0.364 | 0.4525 |
| BUD20 | 1536 | 0.361 | 0.4554 |
| RSA3 | 1543 | 0.359 | 0.4584 |
| PWP2 | 1566 | 0.351 | 0.4574 |
| UTP22 | 1602 | 0.34 | 0.453 |
| SSF1 | 1687 | 0.31 | 0.4359 |
| RRP7 | 1699 | 0.306 | 0.4371 |
| NMD3 | 1733 | 0.293 | 0.4326 |
| TIF6 | 1786 | 0.276 | 0.4231 |
| NOP6 | 1787 | 0.275 | 0.4266 |

| FUN12 | 1803 | 0.267 | 0.4262 |
|-------------|------|--------|--------|
| RRP5 | 1819 | 0.261 | 0.4258 |
| UTP23 | 1828 | 0.258 | 0.4271 |
| CMS1 | 1839 | 0.254 | 0.4278 |
| SQS1 | 1871 | 0.239 | 0.4231 |
| UTP5 | 1885 | 0.235 | 0.4229 |
| RLP24 | 1887 | 0.234 | 0.4256 |
| UTP15 | 1906 | 0.227 | 0.424 |
| RRP9 | 1909 | 0.227 | 0.4264 |
| NOP15 | 1981 | 0.198 | 0.4111 |
| YTM1 | 2015 | 0.179 | 0.4052 |
| UTP18 | 2117 | -0.189 | 0.3823 |
| RLP7 | 2137 | -0.196 | 0.3801 |
| DIP2 | 2158 | -0.205 | 0.3777 |
| TSR1 | 2162 | -0.206 | 0.3795 |
| CRM1 | 2184 | -0.215 | 0.377 |
| <u>JJJ1</u> | 2216 | -0.226 | 0.3722 |
| NOP16 | 2232 | -0.232 | 0.3714 |
| SPB4 | 2319 | -0.258 | 0.3531 |
| UTP20 | 2386 | -0.28 | 0.3402 |
| ENP2 | 2464 | -0.303 | 0.3248 |
| NOP19 | 2586 | -0.335 | 0.2988 |
| UTP30 | 2642 | -0.352 | 0.2895 |
| RRP15 | 2662 | -0.358 | 0.2893 |
| UTP11 | 2710 | -0.375 | 0.2823 |
| MRD1 | 2754 | -0.386 | 0.2765 |
| LAS1 | 2803 | -0.4 | 0.2696 |
| EBP2 | 2806 | -0.4 | 0.2742 |
| LTV1 | 2974 | -0.451 | 0.2381 |
| KRI1 | 2995 | -0.458 | 0.239 |
| ECM1 | 3114 | -0.5 | 0.2158 |
| DBP6 | 3234 | -0.544 | 0.193 |
| MDN1 | 3321 | -0.579 | 0.1788 |
| CKA1 | 3440 | -0.627 | 0.1573 |
| IMP4 | 3634 | -0.722 | 0.1182 |

Ribosome Assembly

| Gene Name | Rank in Gene List | Rank Metric Score | Running Enrichment Score |
|--------------|-------------------|-------------------|-----------------------------|
| RPP0 | 25 | 2.342 | 0.0885 |
| REX4 | 91 | 1.75 | 0.1433 |
| RPS31 | 138 | 1.615 | 0.1972 |
| IPI3 | 143 | 1.598 | 0.2608 |
| NSR1 | 180 | 1.508 | 0.3129 |
| RPL5 | 208 | 1.425 | 0.3638 |
| RPL3 | 232 | 1.381 | 0.414 |
| YVH1 | 249 | 1.355 | 0.4648 |
| RPL25 | 294 | 1.286 | 0.5059 |
| MRT4 | 411 | 1.123 | 0.5229 |
| RPL10 | 452 | 1.072 | 0.5564 |
| RPF2 | 629 | 0.886 | 0.549 |
| SQT1 | 678 | 0.848 | 0.5715 |
| <u>MAK21</u> | 803 | 0.757 | 0.5717 |
| <u>IPI1</u> | 807 | 0.755 | 0.6014 |
| RIA1 | 815 | 0.75 | 0.63 |
| RSA4 | 1222 | 0.505 | 0.5509 |
| RSA1 | 1519 | 0.368 | 0.4933 |
| RSA3 | 1543 | 0.359 | 0.5021 |
| SSF1 | 1687 | 0.31 | 0.4796 |
| RRP7 | 1699 | 0.306 | 0.4893 |
| FUN12 | 1803 | 0.267 | 0.4748 |
| LSG1 | 1943 | 0.212 | 0.4493 |
| SPB4 | 2319 | -0.258 | 0.3678 |
| MRD1 | 2754 | -0.386 | 0.2771 |
| MDN1 | 3321 | -0.579 | 0.1617 |
| MRH4 | 3681 | -0.753 | 0.1042 |

Ribosome Biogenesis

| Gene Name | Rank in Gene List | Rank Metric Score | Running Enrichment Score |
|-----------|-------------------|-------------------|-----------------------------|
| SNU13 | 23 | 2.41 | 0.0107 |
| RPPO | 25 | 2.342 | 0.0266 |
| RPS5 | 85 | 1.784 | 0.0238 |
| REX4 | 91 | 1.75 | 0.0346 |
| NOP58 | 100 | 1.74 | 0.0446 |

| KRR1 | 103 | 1.73 | 0.056 |
|--------------|-----|-------|--------|
| RPS3 | 120 | 1.677 | 0.0635 |
| RPL30 | 121 | 1.675 | 0.075 |
| RPS31 | 138 | 1.615 | 0.0821 |
| IPI3 | 143 | 1.598 | 0.0921 |
| HCA4 | 148 | 1.59 | 0.102 |
| NSR1 | 180 | 1.508 | 0.1045 |
| TSR2 | 194 | 1.463 | 0.1113 |
| SSB1 | 195 | 1.461 | 0.1213 |
| RPS15 | 201 | 1.446 | 0.13 |
| RPL5 | 208 | 1.425 | 0.1383 |
| EFG1 | 213 | 1.417 | 0.1471 |
| SSB2 | 224 | 1.403 | 0.1542 |
| RPL3 | 232 | 1.381 | 0.1619 |
| GSP1 | 235 | 1.379 | 0.171 |
| RRB1 | 236 | 1.374 | 0.1804 |
| NIP7 | 242 | 1.365 | 0.1886 |
| YVH1 | 249 | 1.355 | 0.1964 |
| RPS20 | 279 | 1.313 | 0.198 |
| EMG1 | 283 | 1.307 | 0.2063 |
| RPL25 | 294 | 1.286 | 0.2126 |
| <u>RPS13</u> | 305 | 1.273 | 0.2188 |
| ENP1 | 317 | 1.256 | 0.2247 |
| RLI1 | 318 | 1.253 | 0.2333 |
| <u>NOP56</u> | 357 | 1.203 | 0.2319 |
| RPS2 | 363 | 1.193 | 0.2388 |
| SRD1 | 400 | 1.139 | 0.2374 |
| GAR1 | 402 | 1.136 | 0.245 |
| MRT4 | 411 | 1.123 | 0.2507 |
| UTP13 | 430 | 1.095 | 0.2537 |
| NOP1 | 431 | 1.094 | 0.2612 |
| RPL10 | 452 | 1.072 | 0.2635 |
| ESF1 | 481 | 1.051 | 0.2635 |
| MAK5 | 482 | 1.051 | 0.2708 |
| MAK16 | 498 | 1.034 | 0.2741 |
| SSZ1 | 523 | 1.001 | 0.2748 |
| NOC2 | 525 | 0.999 | 0.2815 |
| NEW1 | 534 | 0.991 | 0.2863 |
| <u>DIM1</u> | 560 | 0.958 | 0.2865 |
| UTP4 | 564 | 0.953 | 0.2923 |
| HAS1 | 579 | 0.936 | 0.2951 |
| NHP2 | 585 | 0.931 | 0.3003 |

| SKI6 | 588 | 0.927 | 0.3062 |
|--------------|------|-------|--------|
| IMP3 | 597 | 0.918 | 0.3104 |
| RRS1 | 598 | 0.917 | 0.3168 |
| <u>ZUO1</u> | 604 | 0.91 | 0.3218 |
| UTP10 | 608 | 0.903 | 0.3272 |
| RAI1 | 622 | 0.89 | 0.33 |
| RPF2 | 629 | 0.886 | 0.3346 |
| CBF5 | 634 | 0.881 | 0.3397 |
| NSA2 | 640 | 0.876 | 0.3444 |
| PRP43 | 652 | 0.866 | 0.3476 |
| RPP1 | 676 | 0.849 | 0.3476 |
| SQT1 | 678 | 0.848 | 0.3532 |
| <u>RRP46</u> | 681 | 0.845 | 0.3585 |
| DBP3 | 696 | 0.833 | 0.3606 |
| <u>TMA20</u> | 715 | 0.823 | 0.3617 |
| NOP7 | 717 | 0.821 | 0.3671 |
| PWP1 | 728 | 0.813 | 0.3702 |
| FYV7 | 738 | 0.806 | 0.3734 |
| UTP14 | 739 | 0.806 | 0.379 |
| DBP9 | 750 | 0.798 | 0.3819 |
| NUG1 | 790 | 0.768 | 0.3772 |
| FAP7 | 793 | 0.763 | 0.382 |
| <u>MAK21</u> | 803 | 0.757 | 0.3849 |
| <u>IPI1</u> | 807 | 0.755 | 0.3893 |
| RIA1 | 815 | 0.75 | 0.3927 |
| RRP1 | 832 | 0.737 | 0.3937 |
| <u>KRE33</u> | 847 | 0.727 | 0.3951 |
| ROK1 | 866 | 0.715 | 0.3954 |
| RNT1 | 888 | 0.701 | 0.3949 |
| SLX9 | 889 | 0.701 | 0.3997 |
| <u>RRP42</u> | 895 | 0.696 | 0.4032 |
| BFR2 | 896 | 0.696 | 0.408 |
| NUP85 | 898 | 0.694 | 0.4126 |
| SRM1 | 917 | 0.682 | 0.4127 |
| UTP21 | 925 | 0.677 | 0.4155 |
| RRP43 | 933 | 0.673 | 0.4184 |
| <u>RRP40</u> | 936 | 0.669 | 0.4225 |
| CGR1 | 1001 | 0.626 | 0.4104 |
| UTP6 | 1031 | 0.605 | 0.4071 |
| SAS10 | 1045 | 0.596 | 0.4079 |
| YAR1 | 1054 | 0.59 | 0.4099 |
| RRP3 | 1070 | 0.579 | 0.4101 |

| SPB1 | 1072 | 0.578 | 0.4138 |
|--------|------|-------|--------|
| GRC3 | 1097 | 0.566 | 0.4115 |
| RCM1 | 1128 | 0.549 | 0.4076 |
| FCF1 | 1132 | 0.548 | 0.4106 |
| PUF6 | 1166 | 0.531 | 0.4058 |
| POP7 | 1178 | 0.524 | 0.4066 |
| NOP2 | 1193 | 0.517 | 0.4066 |
| SYO1 | 1204 | 0.512 | 0.4076 |
| ERB1 | 1205 | 0.512 | 0.4111 |
| RIX7 | 1219 | 0.507 | 0.4113 |
| RSA4 | 1222 | 0.505 | 0.4142 |
| CAM1 | 1226 | 0.5 | 0.4169 |
| MTR4 | 1250 | 0.489 | 0.4144 |
| NSA1 | 1251 | 0.489 | 0.4178 |
| NOG1 | 1255 | 0.486 | 0.4203 |
| HCR1 | 1262 | 0.483 | 0.4221 |
| MPP6 | 1304 | 0.466 | 0.4148 |
| NOP9 | 1324 | 0.455 | 0.4131 |
| RRP12 | 1334 | 0.452 | 0.4139 |
| UTP7 | 1366 | 0.441 | 0.409 |
| PUS7 | 1381 | 0.432 | 0.4084 |
| RRP36 | 1394 | 0.425 | 0.4082 |
| NOP4 | 1422 | 0.413 | 0.4042 |
| REX3 | 1445 | 0.404 | 0.4013 |
| RNA1 | 1448 | 0.403 | 0.4036 |
| NOG2 | 1466 | 0.397 | 0.4019 |
| DBP8 | 1488 | 0.388 | 0.3992 |
| RSA1 | 1519 | 0.368 | 0.3941 |
| BUD20 | 1536 | 0.361 | 0.3925 |
| RSA3 | 1543 | 0.359 | 0.3934 |
| RNH70 | 1555 | 0.356 | 0.393 |
| URB2 | 1565 | 0.352 | 0.3932 |
| PWP2 | 1566 | 0.351 | 0.3956 |
| TRM112 | 1598 | 0.341 | 0.39 |
| UTP22 | 1602 | 0.34 | 0.3916 |
| MTR3 | 1631 | 0.33 | 0.3867 |
| RRP4 | 1668 | 0.313 | 0.3796 |
| SSF1 | 1687 | 0.31 | 0.3771 |
| RRP7 | 1699 | 0.306 | 0.3764 |
| NMD3 | 1733 | 0.293 | 0.3699 |
| SDA1 | 1774 | 0.28 | 0.3616 |
| LTO1 | 1784 | 0.276 | 0.3612 |

| TIF6 | 1786 | 0.276 | 0.3628 |
|-------------|------|--------|--------|
| NOP6 | 1787 | 0.275 | 0.3647 |
| FUN12 | 1803 | 0.267 | 0.3627 |
| RRP8 | 1816 | 0.262 | 0.3615 |
| RRP5 | 1819 | 0.261 | 0.3628 |
| UTP23 | 1828 | 0.258 | 0.3625 |
| SQS1 | 1871 | 0.239 | 0.3534 |
| UTP5 | 1885 | 0.235 | 0.3516 |
| RLP24 | 1887 | 0.234 | 0.353 |
| LCP5 | 1888 | 0.234 | 0.3546 |
| UTP15 | 1906 | 0.227 | 0.3518 |
| RRP9 | 1909 | 0.227 | 0.3529 |
| FCF2 | 1913 | 0.224 | 0.3536 |
| NOP53 | 1934 | 0.216 | 0.35 |
| LSG1 | 1943 | 0.212 | 0.3494 |
| NOP15 | 1981 | 0.198 | 0.3413 |
| REX2 | 1994 | 0.192 | 0.3395 |
| NGL2 | 2014 | 0.179 | 0.3359 |
| YTM1 | 2015 | 0.179 | 0.3371 |
| SEN1 | 2039 | 0.153 | 0.3323 |
| TMA23 | 2056 | -0.159 | 0.3293 |
| NIC96 | 2098 | -0.183 | 0.32 |
| SAC3 | 2115 | -0.189 | 0.3172 |
| UTP18 | 2117 | -0.189 | 0.3183 |
| RLP7 | 2137 | -0.196 | 0.3147 |
| NUP49 | 2138 | -0.197 | 0.3161 |
| DIP2 | 2158 | -0.205 | 0.3126 |
| TSR1 | 2162 | -0.206 | 0.3133 |
| PUS5 | 2169 | -0.208 | 0.3132 |
| CRM1 | 2184 | -0.215 | 0.3111 |
| <u>JJJ1</u> | 2216 | -0.226 | 0.3047 |
| NOP16 | 2232 | -0.232 | 0.3024 |
| RMP1 | 2243 | -0.236 | 0.3015 |
| POP6 | 2262 | -0.242 | 0.2986 |
| SPB4 | 2319 | -0.258 | 0.286 |
| YAE1 | 2371 | -0.274 | 0.2748 |
| UTP20 | 2386 | -0.28 | 0.2731 |
| YRB2 | 2408 | -0.288 | 0.2697 |
| LSM7 | 2422 | -0.293 | 0.2684 |
| MRM2 | 2448 | -0.3 | 0.264 |
| ENP2 | 2464 | -0.303 | 0.2623 |
| RAT1 | 2488 | -0.309 | 0.2585 |

| NOP19 | 2586 | -0.335 | 0.2359 |
|--------|------|--------|--------|
| UTP30 | 2642 | -0.352 | 0.2242 |
| RRP15 | 2662 | -0.358 | 0.2218 |
| UTP11 | 2710 | -0.375 | 0.2124 |
| POP1 | 2717 | -0.376 | 0.2134 |
| RIO2 | 2752 | -0.385 | 0.2073 |
| MRD1 | 2754 | -0.386 | 0.2098 |
| RSP5 | 2785 | -0.393 | 0.2048 |
| LAS1 | 2803 | -0.4 | 0.2032 |
| EBP2 | 2806 | -0.4 | 0.2054 |
| BCP1 | 2807 | -0.4 | 0.2082 |
| RRP6 | 2921 | -0.435 | 0.1822 |
| LTV1 | 2974 | -0.451 | 0.1719 |
| KRI1 | 2995 | -0.458 | 0.17 |
| RRP17 | 3012 | -0.465 | 0.1691 |
| HIT1 | 3049 | -0.478 | 0.1631 |
| PAF1 | 3094 | -0.492 | 0.1552 |
| ECM1 | 3114 | -0.5 | 0.1538 |
| RRP14 | 3137 | -0.507 | 0.1517 |
| TSR3 | 3142 | -0.508 | 0.1541 |
| SNU66 | 3221 | -0.539 | 0.1378 |
| DBP6 | 3234 | -0.544 | 0.1385 |
| DIS3 | 3240 | -0.546 | 0.141 |
| MDN1 | 3321 | -0.579 | 0.1245 |
| LRP1 | 3332 | -0.581 | 0.1259 |
| SPT5 | 3358 | -0.591 | 0.1236 |
| NUP116 | 3447 | -0.63 | 0.1053 |
| MOT1 | 3514 | -0.658 | 0.0929 |
| TOR2 | 3521 | -0.663 | 0.096 |
| RRP45 | 3569 | -0.69 | 0.0887 |
| IMP4 | 3634 | -0.722 | 0.0772 |
| MRH4 | 3681 | -0.753 | 0.0706 |
| TOR1 | 3689 | -0.757 | 0.0741 |
| NUP1 | 3707 | -0.774 | 0.0751 |
| TOM1 | 3754 | -0.812 | 0.0689 |
| SNM1 | 3878 | -0.92 | 0.0436 |
| DBP7 | 3933 | -0.984 | 0.0366 |
| NME1 | 4005 | -1.098 | 0.0259 |

RAS2^{S225A} vs EV- Cell Cycle- Downregulated

| Gene Name | Rank in Gene List | Rank Metric Score | Running Enrichment Score |
|-------------|-------------------|-------------------|-----------------------------|
| KIN4 | 938 | 0.667 | -0.1891 |
| MAD2 | 1015 | 0.615 | -0.1701 |
| HHT2 | 1155 | 0.536 | -0.1714 |
| LTE1 | 1301 | 0.467 | -0.1784 |
| CDC20 | 1424 | 0.413 | -0.1831 |
| TPD3 | 1718 | 0.298 | -0.2367 |
| BMH1 | 1961 | 0.205 | -0.2835 |
| CTF3 | 2277 | -0.246 | -0.3456 |
| CDC55 | 2383 | -0.279 | -0.3543 |
| RTS1 | 2598 | -0.339 | -0.3861 |
| IPL1 | 2720 | -0.377 | -0.3927 |
| FIN1 | 2941 | -0.442 | -0.4196 |
| MPS1 | 3205 | -0.534 | -0.4514 |
| BUB3 | 3224 | -0.54 | -0.4228 |
| BUD2 | 3250 | -0.55 | -0.3953 |
| <u>ULP2</u> | 3297 | -0.571 | -0.3717 |
| GAC1 | 3368 | -0.599 | -0.3522 |
| MAD1 | 3406 | -0.614 | -0.3238 |
| DOC1 | 3489 | -0.65 | -0.3042 |
| SWM1 | 3524 | -0.664 | -0.2719 |
| CEP3 | 3570 | -0.69 | -0.2408 |
| BFA1 | 3733 | -0.791 | -0.2322 |
| BIR1 | 3826 | -0.874 | -0.2013 |
| DMA2 | 3895 | -0.934 | -0.1609 |
| CDH1 | 3970 | -1.039 | -0.1155 |
| CHL4 | 3982 | -1.053 | -0.0539 |
| CTF19 | 4076 | -1.374 | 0.0074 |

Condensed Chromosome

| Gene Name | Rank in Gene List | Rank Metric Score | Running Enrichment Score |
|---------------|-------------------|-------------------|-----------------------------|
| <u>SPO16</u> | 406 | 1.13 | -0.0782 |
| RFA3 | 635 | 0.881 | -0.1173 |
| <u>REC104</u> | 710 | 0.825 | -0.1192 |
| RFA2 | 765 | 0.783 | -0.117 |
| MEI4 | 799 | 0.76 | -0.11 |
| MCD1 | 805 | 0.755 | -0.0962 |
| SMC3 | 965 | 0.646 | -0.1228 |
| YCS4 | 1000 | 0.627 | -0.1187 |

| PDS5 | 1011 | 0.619 | -0.1089 |
|---------------|------|--------|---------|
| MAD2 | 1015 | 0.615 | -0.0973 |
| MCM16 | 1028 | 0.606 | -0.0882 |
| SMC6 | 1179 | 0.524 | -0.115 |
| SMC1 | 1192 | 0.517 | -0.1077 |
| MTW1 | 1228 | 0.5 | -0.1064 |
| HSK3 | 1229 | 0.5 | -0.0964 |
| NSE5 | 1383 | 0.431 | -0.1258 |
| DUO1 | 1473 | 0.393 | -0.1401 |
| DAD1 | 1581 | 0.347 | -0.1597 |
| CSM1 | 1622 | 0.333 | -0.163 |
| YCG1 | 1689 | 0.309 | -0.1732 |
| STU2 | 1741 | 0.29 | -0.1801 |
| IRR1 | 1751 | 0.287 | -0.1766 |
| SMC4 | 1797 | 0.271 | -0.1824 |
| LRS4 | 1872 | 0.239 | -0.196 |
| TOP2 | 1956 | 0.208 | -0.2124 |
| NSE1 | 2172 | -0.209 | -0.2616 |
| CTF3 | 2277 | -0.246 | -0.2825 |
| ZIP1 | 2300 | -0.252 | -0.283 |
| KRE29 | 2459 | -0.302 | -0.3162 |
| CST9 | 2483 | -0.307 | -0.3158 |
| PLC1 | 2512 | -0.316 | -0.3164 |
| CBF2 | 2556 | -0.328 | -0.3205 |
| MEC3 | 2581 | -0.334 | -0.3198 |
| RTS1 | 2598 | -0.339 | -0.317 |
| MCM22 | 2600 | -0.34 | -0.3105 |
| NUF2 | 2644 | -0.352 | -0.3142 |
| DAM1 | 2698 | -0.369 | -0.32 |
| IPL1 | 2720 | -0.377 | -0.3177 |
| ASK1 | 2863 | -0.419 | -0.3446 |
| PPH3 | 2912 | -0.432 | -0.3479 |
| FIN1 | 2941 | -0.442 | -0.346 |
| CSE4 | 2956 | -0.446 | -0.3406 |
| <u>REC102</u> | 2958 | -0.446 | -0.3319 |
| RED1 | 3163 | -0.518 | -0.3722 |
| MCM21 | 3166 | -0.52 | -0.3624 |
| MPS1 | 3205 | -0.534 | -0.3611 |
| BUB3 | 3224 | -0.54 | -0.3548 |
| DAD3 | 3225 | -0.541 | -0.3441 |
| ZIP2 | 3378 | -0.603 | -0.3698 |
| AME1 | 3445 | -0.63 | -0.3736 |

| SCM3 | 3460 | -0.636 | -0.3644 |
|---------------|------|--------|---------|
| NNF1 | 3469 | -0.641 | -0.3536 |
| NSE4 | 3501 | -0.653 | -0.3482 |
| <u>ECM11</u> | 3503 | -0.655 | -0.3354 |
| <u>REC107</u> | 3531 | -0.666 | -0.3289 |
| CEP3 | 3570 | -0.69 | -0.3245 |
| <u>REC114</u> | 3656 | -0.741 | -0.3309 |
| CTF13 | 3668 | -0.748 | -0.3187 |
| MMS21 | 3753 | -0.812 | -0.3233 |
| MND1 | 3765 | -0.823 | -0.3097 |
| <u>RAD51</u> | 3795 | -0.85 | -0.2999 |
| REC8 | 3796 | -0.85 | -0.283 |
| BIR1 | 3826 | -0.874 | -0.2727 |
| <u>UBC9</u> | 3861 | -0.901 | -0.2632 |
| SLK19 | 3917 | -0.963 | -0.2577 |
| MIF2 | 3925 | -0.975 | -0.24 |
| OKP1 | 3929 | -0.979 | -0.2212 |
| DSN1 | 3941 | -0.998 | -0.204 |
| <u>SPO13</u> | 3950 | -1.009 | -0.1859 |
| DMC1 | 3963 | -1.029 | -0.1684 |
| CHL4 | 3982 | -1.053 | -0.1518 |
| NDC80 | 3988 | -1.059 | -0.132 |
| <u>KRE28</u> | 4004 | -1.091 | -0.1139 |
| BRN1 | 4016 | -1.125 | -0.0942 |
| TFC3 | 4037 | -1.199 | -0.0753 |
| CTF19 | 4076 | -1.374 | -0.0573 |
| SPC24 | 4095 | -1.573 | -0.0304 |
| MEI5 | 4099 | -1.652 | 0.0017 |

Kinetechore

| Gene Name | Rank in Gene List | Rank Metric Score | Running Enrichment Score |
|-------------|-------------------|-------------------|-----------------------------|
| MAD2 | 1015 | 0.615 | -0.2262 |
| MCM16 | 1028 | 0.606 | -0.206 |
| MTW1 | 1228 | 0.5 | -0.2358 |
| HSK3 | 1229 | 0.5 | -0.2167 |
| <u>DU01</u> | 1473 | 0.393 | -0.2615 |
| DAD1 | 1581 | 0.347 | -0.2745 |
| CSM1 | 1622 | 0.333 | -0.2716 |
| STU2 | 1741 | 0.29 | -0.2896 |
| LRS4 | 1872 | 0.239 | -0.3124 |

| CRM1 | 2184 | -0.215 | -0.3807 |
|-------------|------|--------|---------|
| CTF3 | 2277 | -0.246 | -0.3939 |
| PLC1 | 2512 | -0.316 | -0.4394 |
| CBF2 | 2556 | -0.328 | -0.4375 |
| RTS1 | 2598 | -0.339 | -0.4346 |
| MCM22 | 2600 | -0.34 | -0.4219 |
| WIP1 | 2638 | -0.351 | -0.4175 |
| NUF2 | 2644 | -0.352 | -0.4053 |
| DAM1 | 2698 | -0.369 | -0.4042 |
| IPL1 | 2720 | -0.377 | -0.395 |
| CNN1 | 2767 | -0.388 | -0.3914 |
| ASK1 | 2863 | -0.419 | -0.3988 |
| FIN1 | 2941 | -0.442 | -0.4008 |
| CSE4 | 2956 | -0.446 | -0.3872 |
| MCM21 | 3166 | -0.52 | -0.4188 |
| MPS1 | 3205 | -0.534 | -0.4077 |
| BUB3 | 3224 | -0.54 | -0.3914 |
| DAD3 | 3225 | -0.541 | -0.3708 |
| MAD1 | 3406 | -0.614 | -0.3916 |
| AME1 | 3445 | -0.63 | -0.3768 |
| NNF1 | 3469 | -0.641 | -0.358 |
| CEP3 | 3570 | -0.69 | -0.3562 |
| CTF13 | 3668 | -0.748 | -0.3514 |
| BIR1 | 3826 | -0.874 | -0.3566 |
| SLK19 | 3917 | -0.963 | -0.3419 |
| MIF2 | 3925 | -0.975 | -0.3064 |
| OKP1 | 3929 | -0.979 | -0.2696 |
| CBF1 | 3939 | -0.996 | -0.2338 |
| <u>DSN1</u> | 3941 | -0.998 | -0.1958 |
| CHL4 | 3982 | -1.053 | -0.1654 |
| NDC80 | 3988 | -1.059 | -0.1261 |
| KRE28 | 4004 | -1.091 | -0.0881 |
| CTF19 | 4076 | -1.374 | -0.053 |
| SPC24 | 4095 | -1.573 | 0.0027 |

Microtubule based processes

| Gene Name | Rank in Gene List | Rank Metric Score | Running Enrichment Score |
|--------------|-------------------|-------------------|-----------------------------|
| ACT1 | 353 | 1.214 | -0.063 |
| <u>SPC29</u> | 379 | 1.169 | -0.0455 |

| SPC98 | 646 | 0.872 | -0.0938 |
|-------|------|--------|---------|
| CRN1 | 672 | 0.853 | -0.0828 |
| CMD1 | 713 | 0.824 | -0.076 |
| CLB4 | 725 | 0.814 | -0.0622 |
| RHO2 | 769 | 0.78 | -0.057 |
| TUB4 | 890 | 0.7 | -0.0726 |
| ESP1 | 1022 | 0.61 | -0.0928 |
| LDB18 | 1041 | 0.597 | -0.0851 |
| CLB1 | 1096 | 0.566 | -0.0871 |
| LIA1 | 1127 | 0.549 | -0.0834 |
| ARP1 | 1191 | 0.517 | -0.0885 |
| HSK3 | 1229 | 0.5 | -0.0876 |
| TVP38 | 1232 | 0.498 | -0.0779 |
| CDC28 | 1377 | 0.434 | -0.1049 |
| DUO1 | 1473 | 0.393 | -0.1205 |
| DYN2 | 1505 | 0.377 | -0.1205 |
| NDC1 | 1574 | 0.349 | -0.1304 |
| DAD1 | 1581 | 0.347 | -0.1248 |
| STU2 | 1741 | 0.29 | -0.1584 |
| BUD6 | 1815 | 0.262 | -0.1712 |
| HCM1 | 1895 | 0.231 | -0.1861 |
| BER1 | 1929 | 0.219 | -0.1899 |
| DSK2 | 1935 | 0.216 | -0.1868 |
| MYO2 | 1991 | 0.193 | -0.1965 |
| DYN1 | 2157 | -0.205 | -0.2333 |
| NAP1 | 2164 | -0.207 | -0.2306 |
| ATS1 | 2341 | -0.264 | -0.269 |
| RRD1 | 2375 | -0.274 | -0.2716 |
| KIP3 | 2435 | -0.297 | -0.2802 |
| BBP1 | 2494 | -0.311 | -0.2883 |
| CBF2 | 2556 | -0.328 | -0.2968 |
| SPO1 | 2578 | -0.333 | -0.2953 |
| RTS1 | 2598 | -0.339 | -0.2931 |
| SFI1 | 2627 | -0.347 | -0.293 |
| NUF2 | 2644 | -0.352 | -0.2898 |
| CLB3 | 2653 | -0.355 | -0.2846 |
| DAM1 | 2698 | -0.369 | -0.288 |
| SPC42 | 2699 | -0.369 | -0.2805 |
| IPL1 | 2720 | -0.377 | -0.2779 |
| SHE1 | 2753 | -0.386 | -0.278 |
| ASK1 | 2863 | -0.419 | -0.2965 |
| KIP2 | 2866 | -0.42 | -0.2885 |

| FIN1 | 2941 | -0.442 | -0.2979 |
|-------------|------|--------|---------|
| BNI1 | 2962 | -0.447 | -0.2938 |
| NIP100 | 2972 | -0.45 | -0.2869 |
| MLP2 | 2998 | -0.46 | -0.2838 |
| CDC5 | 3007 | -0.462 | -0.2764 |
| POM34 | 3090 | -0.491 | -0.2868 |
| CLB5 | 3092 | -0.491 | -0.2771 |
| MPS1 | 3205 | -0.534 | -0.2941 |
| DAD3 | 3225 | -0.541 | -0.2878 |
| GPA1 | 3229 | -0.543 | -0.2775 |
| SHP1 | 3235 | -0.544 | -0.2677 |
| JNM1 | 3246 | -0.549 | -0.2591 |
| NDL1 | 3262 | -0.554 | -0.2516 |
| STU1 | 3369 | -0.599 | -0.2657 |
| AME1 | 3445 | -0.63 | -0.2716 |
| NUM1 | 3562 | -0.687 | -0.2864 |
| CDC31 | 3573 | -0.691 | -0.2749 |
| CDC14 | 3604 | -0.705 | -0.268 |
| ASE1 | 3808 | -0.859 | -0.301 |
| BIR1 | 3826 | -0.874 | -0.2875 |
| KAR3 | 3828 | -0.876 | -0.27 |
| UBC9 | 3861 | -0.901 | -0.2596 |
| IRC15 | 3867 | -0.91 | -0.2424 |
| DMA2 | 3895 | -0.934 | -0.2301 |
| MPS2 | 3908 | -0.953 | -0.2138 |
| SLK19 | 3917 | -0.963 | -0.1962 |
| MIF2 | 3925 | -0.975 | -0.1782 |
| OKP1 | 3929 | -0.979 | -0.1591 |
| DSN1 | 3941 | -0.998 | -0.1416 |
| DYN3 | 3953 | -1.012 | -0.1237 |
| CDH1 | 3970 | -1.039 | -0.1066 |
| NDC80 | 3988 | -1.059 | -0.0894 |
| MPS3 | 4049 | -1.261 | -0.0787 |
| CTF19 | 4076 | -1.374 | -0.0572 |
| SPC24 | 4095 | -1.573 | -0.0298 |
| <u>CIK1</u> | 4096 | -1.59 | 0.0025 |

Sister Chromatid Segregation

| Gene Name | Rank in Gene List | Rank Metric Score | Running Enrichment Score |
|--------------|-------------------|-------------------|-----------------------------|
| POL30 | 166 | 1.548 | -0.0072 |
| MCD1 | 805 | 0.755 | -0.1489 |
| TOF1 | 879 | 0.705 | -0.1516 |
| KIN4 | 938 | 0.667 | -0.1513 |
| SMC3 | 965 | 0.646 | -0.1436 |
| YCS4 | 1000 | 0.627 | -0.1383 |
| PDS5 | 1011 | 0.619 | -0.1272 |
| MAD2 | 1015 | 0.615 | -0.1145 |
| ESP1 | 1022 | 0.61 | -0.1026 |
| MCM16 | 1028 | 0.606 | -0.0906 |
| HHT2 | 1155 | 0.536 | -0.1101 |
| SMC1 | 1192 | 0.517 | -0.1077 |
| CTF18 | 1215 | 0.509 | -0.102 |
| LTE1 | 1301 | 0.467 | -0.1128 |
| CDC20 | 1424 | 0.413 | -0.1341 |
| CHL1 | 1508 | 0.376 | -0.1464 |
| YCG1 | 1689 | 0.309 | -0.1843 |
| MRC1 | 1708 | 0.304 | -0.1821 |
| TPD3 | 1718 | 0.298 | -0.1778 |
| IRR1 | 1751 | 0.287 | -0.1794 |
| SMC4 | 1797 | 0.271 | -0.1846 |
| BMH1 | 1961 | 0.205 | -0.2206 |
| DYN1 | 2157 | -0.205 | -0.2644 |
| CTF3 | 2277 | -0.246 | -0.2885 |
| POL2 | 2313 | -0.257 | -0.2916 |
| APC2 | 2322 | -0.26 | -0.2879 |
| CDC55 | 2383 | -0.279 | -0.2967 |
| ELG1 | 2404 | -0.286 | -0.2954 |
| SGS1 | 2469 | -0.303 | -0.3046 |
| RTS1 | 2598 | -0.339 | -0.3289 |
| MCM22 | 2600 | -0.34 | -0.3217 |
| IPL1 | 2720 | -0.377 | -0.3429 |
| GPN2 | 2765 | -0.388 | -0.3454 |
| CTF8 | 2825 | -0.411 | -0.351 |
| <u>RDH54</u> | 2843 | -0.415 | -0.3461 |
| MMS22 | 2888 | -0.425 | -0.3477 |
| TOP1 | 2931 | -0.44 | -0.3485 |
| FIN1 | 2941 | -0.442 | -0.3411 |

| CSE4 | 2956 | -0.446 | -0.3348 |
|--------------|------|--------|---------|
| ESC2 | 3000 | -0.46 | -0.3353 |
| APC1 | 3076 | -0.486 | -0.3433 |
| SCC2 | 3095 | -0.492 | -0.337 |
| <u>MCM21</u> | 3166 | -0.52 | -0.3429 |
| MPS1 | 3205 | -0.534 | -0.3407 |
| BUB3 | 3224 | -0.54 | -0.3333 |
| BUD2 | 3250 | -0.55 | -0.3275 |
| <u>ULP2</u> | 3297 | -0.571 | -0.3264 |
| CSM3 | 3360 | -0.594 | -0.3287 |
| GAC1 | 3368 | -0.599 | -0.3173 |
| <u>ECO1</u> | 3382 | -0.605 | -0.3073 |
| RMI1 | 3400 | -0.613 | -0.2981 |
| MAD1 | 3406 | -0.614 | -0.2859 |
| SRC1 | 3454 | -0.635 | -0.2837 |
| DOC1 | 3489 | -0.65 | -0.2779 |
| SWM1 | 3524 | -0.664 | -0.2717 |
| <u>RAD30</u> | 3535 | -0.667 | -0.2596 |
| CEP3 | 3570 | -0.69 | -0.2529 |
| BFA1 | 3733 | -0.791 | -0.2758 |
| REC8 | 3796 | -0.85 | -0.2725 |
| SOH1 | 3818 | -0.869 | -0.2587 |
| BIR1 | 3826 | -0.874 | -0.2413 |
| KAR3 | 3828 | -0.876 | -0.2224 |
| IRC15 | 3867 | -0.91 | -0.2118 |
| SCC4 | 3880 | -0.922 | -0.1946 |
| <u>DMA2</u> | 3895 | -0.934 | -0.1776 |
| TOP3 | 3902 | -0.946 | -0.1584 |
| <u>DSN1</u> | 3941 | -0.998 | -0.146 |
| <u>SPO13</u> | 3950 | -1.009 | -0.1258 |
| CDH1 | 3970 | -1.039 | -0.1078 |
| CHL4 | 3982 | -1.053 | -0.0875 |
| BRN1 | 4016 | -1.125 | -0.071 |
| MPS3 | 4049 | -1.261 | -0.0513 |
| CTF19 | 4076 | -1.374 | -0.0276 |
| <u>CIK1</u> | 4096 | -1.59 | 0.0025 |

U2 Splicesome Complex

| Gene Name | Rank in Gene List | Rank Metric Score | Running Enrichment Score |
|---------------|-------------------|-------------------|-----------------------------|
| <u>PRP11</u> | 633 | 0.882 | -0.1141 |
| PRP39 | 1358 | 0.443 | -0.2712 |
| NTR2 | 1486 | 0.389 | -0.2841 |
| CWC22 | 1520 | 0.368 | -0.2749 |
| SMB1 | 1611 | 0.337 | -0.2811 |
| <u>SPP382</u> | 1710 | 0.302 | -0.291 |
| PRP16 | 2132 | -0.195 | -0.3853 |
| SNU56 | 2303 | -0.253 | -0.4151 |
| CWC25 | 2335 | -0.263 | -0.4104 |
| CEF1 | 2377 | -0.276 | -0.4075 |
| CWC24 | 2402 | -0.286 | -0.3999 |
| LUC7 | 2492 | -0.31 | -0.4072 |
| <u>SNU71</u> | 2592 | -0.337 | -0.4156 |
| SNP1 | 2626 | -0.347 | -0.4074 |
| CWC15 | 2873 | -0.421 | -0.448 |
| LEA1 | 2900 | -0.43 | -0.4341 |
| CWC27 | 2920 | -0.435 | -0.4183 |
| PRP45 | 2982 | -0.455 | -0.4119 |
| SYF1 | 3060 | -0.481 | -0.4082 |
| CUS1 | 3080 | -0.487 | -0.3899 |
| CLF1 | 3084 | -0.489 | -0.3676 |
| YHC1 | 3143 | -0.51 | -0.3578 |
| YJU2 | 3322 | -0.579 | -0.3743 |
| MUD1 | 3339 | -0.584 | -0.3507 |
| PRP9 | 3361 | -0.594 | -0.3279 |
| SLU7 | 3372 | -0.601 | -0.3021 |
| <u>SNT309</u> | 3391 | -0.608 | -0.2778 |
| SMD2 | 3443 | -0.63 | -0.2607 |
| NAM8 | 3451 | -0.633 | -0.2326 |
| HSH49 | 3457 | -0.635 | -0.2039 |
| PRP40 | 3467 | -0.64 | -0.1759 |
| CWC2 | 3505 | -0.656 | -0.1541 |
| PRP22 | 3693 | -0.764 | -0.1641 |
| SMD1 | 3789 | -0.844 | -0.1477 |
| PRP18 | 3802 | -0.854 | -0.1104 |
| <u>CWC21</u> | 3819 | -0.869 | -0.0734 |
| PRP2 | 3924 | -0.974 | -0.0531 |
| CWC23 | 3951 | -1.01 | -0.0119 |
| SYF2 | 3986 | -1.056 | 0.0295 |

RAS2^{S225E} vs EV- Cytoplasmic Translation- Upregulated

| Gene Name | Rank in Gene List | Rank Metric Score | Running Enrichment Score |
|-----------|-------------------|-------------------|-----------------------------|
| RPPO | 17 | 3.703 | 0.0675 |
| RPL30 | 22 | 3.58 | 0.1352 |
| TMA19 | 35 | 3.425 | 0.1983 |
| SSB2 | 98 | 2.756 | 0.2387 |
| SSB1 | 100 | 2.735 | 0.2909 |
| SSA1 | 122 | 2.54 | 0.3353 |
| TMA7 | 132 | 2.496 | 0.3813 |
| RPL28 | 216 | 2.164 | 0.4062 |
| RPL29 | 236 | 2.101 | 0.4427 |
| THS1 | 274 | 2.01 | 0.4738 |
| TIF35 | 281 | 1.996 | 0.5108 |
| SSZ1 | 289 | 1.967 | 0.547 |
| RPG1 | 295 | 1.936 | 0.5831 |
| TIF3 | 410 | 1.68 | 0.5926 |
| TIF11 | 453 | 1.616 | 0.6152 |
| TRM7 | 663 | 1.312 | 0.599 |
| RBG1 | 827 | 1.161 | 0.5889 |
| PRT1 | 848 | 1.143 | 0.6068 |
| HYP2 | 858 | 1.134 | 0.6267 |
| CLU1 | 1250 | 0.815 | 0.5649 |
| RBG2 | 1444 | 0.68 | 0.5397 |
| FUN12 | 1495 | 0.657 | 0.5424 |
| FES1 | 1606 | 0.601 | 0.5321 |
| SLH1 | 1714 | 0.546 | 0.5214 |
| TIF34 | 1762 | 0.527 | 0.5222 |
| TAE1 | 1810 | 0.501 | 0.5224 |
| MTF2 | 1826 | 0.491 | 0.5289 |
| HCR1 | 2033 | 0.4 | 0.4957 |
| TIF5 | 2391 | 0.235 | 0.4296 |
| GIR2 | 2418 | 0.225 | 0.4287 |
| SRO9 | 3107 | -0.451 | 0.3012 |
| MTG2 | 3375 | -0.581 | 0.2594 |
| RPM2 | 3503 | -0.65 | 0.2467 |
| TMA46 | 3726 | -0.784 | 0.2178 |
| AFG3 | 4181 | -1.13 | 0.1495 |
| RDN5-1 | 4548 | -1.548 | 0.1067 |

Cytosolic Ribosome

| Gene Name | Rank in Gene List | Rank Metric Score | Running Enrichment Score |
|-----------|-------------------|-------------------|-----------------------------|
| RPP0 | 17 | 3.703 | 0.0459 |
| RPL30 | 22 | 3.58 | 0.0927 |
| RPS3 | 31 | 3.465 | 0.1372 |
| RPS12 | 42 | 3.291 | 0.179 |
| ASC1 | 53 | 3.165 | 0.2191 |
| RPL3 | 61 | 3.052 | 0.2583 |
| YEF3 | 66 | 3.013 | 0.2976 |
| RPS31 | 85 | 2.857 | 0.3321 |
| RPS5 | 95 | 2.81 | 0.3676 |
| RPS2 | 156 | 2.38 | 0.3874 |
| RPS13 | 174 | 2.314 | 0.4148 |
| RPL39 | 199 | 2.233 | 0.4397 |
| RPL28 | 216 | 2.164 | 0.4654 |
| RPL25 | 219 | 2.155 | 0.4936 |
| RPL29 | 236 | 2.101 | 0.5184 |
| RPL10 | 238 | 2.096 | 0.5461 |
| RPS20 | 256 | 2.061 | 0.5701 |
| RLI1 | 261 | 2.053 | 0.5967 |
| RPL32 | 271 | 2.021 | 0.6218 |
| RPL5 | 280 | 1.998 | 0.6468 |
| RPL38 | 284 | 1.984 | 0.6726 |
| NAT1 | 556 | 1.456 | 0.6382 |
| MAP1 | 626 | 1.35 | 0.6425 |
| SIS1 | 757 | 1.215 | 0.6328 |
| ARD1 | 765 | 1.207 | 0.6475 |
| ARX1 | 822 | 1.163 | 0.6519 |
| HYP2 | 858 | 1.134 | 0.66 |
| SQT1 | 951 | 1.047 | 0.6557 |
| SNL1 | 1081 | 0.935 | 0.6426 |
| NMD3 | 1105 | 0.913 | 0.6501 |
| GCN20 | 1362 | 0.735 | 0.6091 |
| CDC48 | 1461 | 0.675 | 0.5987 |
| FUN12 | 1495 | 0.657 | 0.6009 |
| NAT5 | 1570 | 0.615 | 0.5944 |
| FES1 | 1606 | 0.601 | 0.5954 |
| LSG1 | 1616 | 0.595 | 0.6016 |
| GCN1 | 2111 | 0.36 | 0.5084 |
| REI1 | 2132 | 0.353 | 0.5091 |
| YGR054W | 2166 | 0.341 | 0.5071 |
| TIF5 | 2391 | 0.235 | 0.4658 |
| PAT1 | 2414 | 0.226 | 0.4644 |

| RQC1 | 2553 | -0.169 | 0.4393 |
|-------------|------|--------|--------|
| <u>JJJ1</u> | 3714 | -0.776 | 0.2196 |
| RRP14 | 4240 | -1.182 | 0.1312 |
| BUD27 | 4246 | -1.19 | 0.146 |
| RDN5-1 | 4548 | -1.548 | 0.1069 |

Pre-ribosome

| Gene Name | Rank in Gene List | Rank Metric Score | Running Enrichment Score |
|--------------|-------------------|-------------------|-----------------------------|
| <u>SNU13</u> | 11 | 4.043 | 0.0243 |
| RPPO | 17 | 3.703 | 0.0475 |
| RPS3 | 31 | 3.465 | 0.0676 |
| NIP7 | 60 | 3.074 | 0.0821 |
| RPL3 | 61 | 3.052 | 0.1021 |
| <u>NOP58</u> | 78 | 2.895 | 0.1178 |
| KRR1 | 94 | 2.814 | 0.1332 |
| RPS5 | 95 | 2.81 | 0.1516 |
| UTP13 | 130 | 2.504 | 0.1611 |
| NOP13 | 150 | 2.401 | 0.173 |
| RPS2 | 156 | 2.38 | 0.1876 |
| RPS13 | 174 | 2.314 | 0.1993 |
| NEW1 | 178 | 2.295 | 0.2138 |
| YVH1 | 204 | 2.212 | 0.2232 |
| EMG1 | 210 | 2.189 | 0.2365 |
| RPL28 | 216 | 2.164 | 0.2497 |
| NOP1 | 218 | 2.157 | 0.2636 |
| UTP10 | 250 | 2.068 | 0.2709 |
| ENP1 | 254 | 2.066 | 0.2838 |
| RLI1 | 261 | 2.053 | 0.2961 |
| <u>NOP56</u> | 263 | 2.044 | 0.3093 |
| ROK1 | 292 | 1.959 | 0.3165 |
| NOC2 | 305 | 1.906 | 0.3265 |
| NUG1 | 336 | 1.845 | 0.3325 |
| CBF5 | 345 | 1.818 | 0.3428 |
| HAS1 | 356 | 1.804 | 0.3526 |
| NSA2 | 376 | 1.756 | 0.3603 |
| HCA4 | 378 | 1.753 | 0.3716 |
| NOG1 | 382 | 1.744 | 0.3824 |
| CIC1 | 394 | 1.708 | 0.3914 |
| KRE33 | 404 | 1.699 | 0.4007 |
| RIX7 | 443 | 1.632 | 0.4037 |

| <u>UTP4</u> | 469 | 1.593 | 0.4091 |
|--------------|------|-------|--------|
| <u>PRP43</u> | 475 | 1.589 | 0.4185 |
| UTP14 | 489 | 1.56 | 0.4261 |
| DBP3 | 502 | 1.547 | 0.4338 |
| <u>DIM1</u> | 504 | 1.544 | 0.4437 |
| MRT4 | 511 | 1.54 | 0.4526 |
| UTP21 | 513 | 1.538 | 0.4625 |
| RPF2 | 515 | 1.535 | 0.4723 |
| <u>IPI1</u> | 540 | 1.484 | 0.4772 |
| MAK21 | 562 | 1.442 | 0.4824 |
| <u>MAK16</u> | 577 | 1.417 | 0.4889 |
| RRP12 | 638 | 1.339 | 0.4855 |
| NOP7 | 644 | 1.332 | 0.4932 |
| SPB1 | 687 | 1.284 | 0.4932 |
| BFR2 | 696 | 1.272 | 0.4999 |
| NOP2 | 754 | 1.217 | 0.4964 |
| SAS10 | 779 | 1.198 | 0.4994 |
| UTP6 | 781 | 1.195 | 0.507 |
| RRP1 | 788 | 1.19 | 0.5136 |
| ARX1 | 822 | 1.163 | 0.5145 |
| SLX9 | 826 | 1.161 | 0.5215 |
| DBP5 | 850 | 1.14 | 0.5244 |
| IMP3 | 857 | 1.134 | 0.5306 |
| PWP2 | 895 | 1.091 | 0.5303 |
| NOG2 | 900 | 1.089 | 0.5366 |
| RRS1 | 947 | 1.054 | 0.5342 |
| ERB1 | 948 | 1.053 | 0.5411 |
| SQT1 | 951 | 1.047 | 0.5476 |
| RRP36 | 982 | 1.015 | 0.5482 |
| NSA1 | 984 | 1.012 | 0.5546 |
| RRP5 | 1025 | 0.979 | 0.5529 |
| UTP7 | 1033 | 0.976 | 0.5579 |
| TIF6 | 1041 | 0.967 | 0.5628 |
| YTM1 | 1045 | 0.964 | 0.5685 |
| NOP4 | 1096 | 0.92 | 0.5645 |
| NMD3 | 1105 | 0.913 | 0.5688 |
| NOP12 | 1190 | 0.859 | 0.5575 |
| NOP9 | 1193 | 0.857 | 0.5627 |
| CKB1 | 1194 | 0.856 | 0.5683 |
| UTP5 | 1264 | 0.804 | 0.5597 |
| BUD20 | 1279 | 0.797 | 0.5621 |
| NOP15 | 1285 | 0.794 | 0.5662 |

| NOC4 | 1303 | 0.78 | 0.5679 |
|---------|------|--------|--------|
| SSF1 | 1349 | 0.744 | 0.5637 |
| UTP15 | 1414 | 0.697 | 0.5554 |
| MPP10 | 1480 | 0.668 | 0.5466 |
| DBP8 | 1493 | 0.659 | 0.5485 |
| FUN12 | 1495 | 0.657 | 0.5526 |
| UTP22 | 1519 | 0.645 | 0.5522 |
| ARB1 | 1532 | 0.641 | 0.554 |
| ECM16 | 1581 | 0.611 | 0.5483 |
| RLP24 | 1719 | 0.542 | 0.5242 |
| NAN1 | 1727 | 0.54 | 0.5263 |
| CKB2 | 1736 | 0.536 | 0.5282 |
| RRP9 | 1743 | 0.534 | 0.5305 |
| SOF1 | 1776 | 0.521 | 0.5275 |
| BMS1 | 1888 | 0.467 | 0.5081 |
| UTP25 | 1981 | 0.42 | 0.4923 |
| SQS1 | 2031 | 0.4 | 0.485 |
| NOC3 | 2032 | 0.4 | 0.4877 |
| TSR1 | 2035 | 0.397 | 0.4899 |
| DIP2 | 2076 | 0.377 | 0.4843 |
| UTP23 | 2083 | 0.374 | 0.4855 |
| DBP10 | 2119 | 0.358 | 0.4808 |
| NOP14 | 2124 | 0.357 | 0.4823 |
| REI1 | 2132 | 0.353 | 0.4832 |
| CGR1 | 2146 | 0.348 | 0.4829 |
| FCF1 | 2156 | 0.344 | 0.4833 |
| CMS1 | 2184 | 0.328 | 0.48 |
| UTP20 | 2192 | 0.325 | 0.4807 |
| BUD21 | 2219 | 0.312 | 0.4775 |
| RSA3 | 2245 | 0.3 | 0.4744 |
| UTP9 | 2249 | 0.295 | 0.4758 |
| RRP7 | 2315 | 0.269 | 0.4644 |
| YBL028C | 2332 | 0.264 | 0.4629 |
| HMO1 | 2339 | 0.261 | 0.4634 |
| BRX1 | 2361 | 0.251 | 0.4608 |
| RCL1 | 2374 | 0.241 | 0.46 |
| AFG2 | 2389 | 0.236 | 0.4587 |
| MRD1 | 2423 | 0.223 | 0.4535 |
| NOB1 | 2464 | 0.201 | 0.4467 |
| DRS1 | 2520 | 0.158 | 0.4366 |
| CKA2 | 2522 | 0.158 | 0.4375 |
| LAS1 | 2561 | -0.172 | 0.4309 |
| | | | |

| LOC1 | 2589 | -0.193 | 0.4268 |
|-------|------|--------|--------|
| RPF1 | 2636 | -0.222 | 0.4189 |
| UTP30 | 2802 | -0.303 | 0.3876 |
| BUD22 | 2838 | -0.324 | 0.3827 |
| NOP6 | 2930 | -0.365 | 0.3667 |
| UTP11 | 3076 | -0.434 | 0.3403 |
| LTV1 | 3291 | -0.541 | 0.3006 |
| ECM1 | 3450 | -0.627 | 0.2728 |
| NOP19 | 3453 | -0.628 | 0.2765 |
| NOP16 | 3659 | -0.74 | 0.24 |
| IMP4 | 3699 | -0.762 | 0.2371 |
| JJJ1 | 3714 | -0.776 | 0.2394 |
| EBP2 | 3720 | -0.781 | 0.2435 |
| RRP15 | 3808 | -0.837 | 0.2314 |
| DBP6 | 4227 | -1.172 | 0.1547 |
| KRI1 | 4409 | -1.365 | 0.1272 |
| CKA1 | 4487 | -1.446 | 0.1211 |

Ribosome assembly

| Gene Name | Rank in Gene List | Rank Metric Score | Running Enrichment Score |
|--------------|-------------------|-------------------|-----------------------------|
| RPPO | 17 | 3.703 | 0.0826 |
| RPL3 | 61 | 3.052 | 0.145 |
| NSR1 | 64 | 3.03 | 0.215 |
| RPS31 | 85 | 2.857 | 0.2774 |
| REX4 | 147 | 2.407 | 0.3212 |
| IPI3 | 185 | 2.274 | 0.3667 |
| YVH1 | 204 | 2.212 | 0.4145 |
| RPL25 | 219 | 2.155 | 0.4618 |
| RPL10 | 238 | 2.096 | 0.507 |
| RPL5 | 280 | 1.998 | 0.5453 |
| RIA1 | 402 | 1.7 | 0.5608 |
| MRT4 | 511 | 1.54 | 0.5752 |
| RPF2 | 515 | 1.535 | 0.6103 |
| IPI1 | 540 | 1.484 | 0.64 |
| <u>MAK21</u> | 562 | 1.442 | 0.6694 |
| RSA4 | 636 | 1.342 | 0.6861 |
| SQT1 | 951 | 1.047 | 0.6483 |
| RSA1 | 1223 | 0.832 | 0.614 |
| RIX1 | 1237 | 0.824 | 0.6306 |

| SSF1 | 1349 | 0.744 | 0.6259 |
|-------|------|--------|--------|
| FUN12 | 1495 | 0.657 | 0.6125 |
| LSG1 | 1616 | 0.595 | 0.6026 |
| BMS1 | 1888 | 0.467 | 0.5598 |
| DRS2 | 2081 | 0.375 | 0.5305 |
| RSA3 | 2245 | 0.3 | 0.5052 |
| RRP7 | 2315 | 0.269 | 0.4978 |
| MAK11 | 2353 | 0.255 | 0.4964 |
| BRX1 | 2361 | 0.251 | 0.5009 |
| TIF5 | 2391 | 0.235 | 0.5006 |
| MRD1 | 2423 | 0.223 | 0.4996 |
| DRS1 | 2520 | 0.158 | 0.4843 |
| RPF1 | 2636 | -0.222 | 0.4667 |
| MRH4 | 3713 | -0.774 | 0.2718 |

Ribosome Biogenesis

| Gene Name | Rank in Gene List | Rank Metric Score | Running Enrichment Score |
|--------------|-------------------|-------------------|-----------------------------|
| SNU13 | 11 | 4.043 | 0.0125 |
| RPPO | 17 | 3.703 | 0.0249 |
| <u>RPL30</u> | 22 | 3.58 | 0.0371 |
| RPS3 | 31 | 3.465 | 0.0481 |
| NIP7 | 60 | 3.074 | 0.0535 |
| RPL3 | 61 | 3.052 | 0.0646 |
| NSR1 | 64 | 3.03 | 0.0753 |
| NOP58 | 78 | 2.895 | 0.0831 |
| <u>RPS31</u> | 85 | 2.857 | 0.0923 |
| KRR1 | 94 | 2.814 | 0.1009 |
| RPS5 | 95 | 2.81 | 0.1111 |
| SSB2 | 98 | 2.756 | 0.1208 |
| SSB1 | 100 | 2.735 | 0.1305 |
| UTP13 | 130 | 2.504 | 0.1337 |
| REX4 | 147 | 2.407 | 0.1391 |
| RPS2 | 156 | 2.38 | 0.1461 |
| RPS13 | 174 | 2.314 | 0.1511 |
| RRB1 | 176 | 2.298 | 0.1592 |
| NEW1 | 178 | 2.295 | 0.1674 |
| IPI3 | 185 | 2.274 | 0.1744 |
| GSP1 | 202 | 2.229 | 0.1792 |
| YVH1 | 204 | 2.212 | 0.1871 |

| EMG1 | 210 | 2.189 | 0.194 |
|--------------|-----|-------|--------|
| NOP1 | 218 | 2.157 | 0.2004 |
| RPL25 | 219 | 2.155 | 0.2083 |
| RPL10 | 238 | 2.096 | 0.2122 |
| UTP10 | 250 | 2.068 | 0.2175 |
| ENP1 | 254 | 2.066 | 0.2244 |
| RPS20 | 256 | 2.061 | 0.2317 |
| RLI1 | 261 | 2.053 | 0.2383 |
| NOP56 | 263 | 2.044 | 0.2456 |
| RPL5 | 280 | 1.998 | 0.2496 |
| SSZ1 | 289 | 1.967 | 0.2551 |
| ROK1 | 292 | 1.959 | 0.2618 |
| NOC2 | 305 | 1.906 | 0.2663 |
| SKI6 | 308 | 1.903 | 0.2728 |
| TSR2 | 314 | 1.893 | 0.2786 |
| ESF1 | 330 | 1.85 | 0.2823 |
| NUG1 | 336 | 1.845 | 0.288 |
| CBF5 | 345 | 1.818 | 0.2929 |
| EFG1 | 349 | 1.814 | 0.2989 |
| HAS1 | 356 | 1.804 | 0.3043 |
| MAK5 | 358 | 1.803 | 0.3106 |
| NSA2 | 376 | 1.756 | 0.3135 |
| HCA4 | 378 | 1.753 | 0.3197 |
| NOG1 | 382 | 1.744 | 0.3254 |
| NHP2 | 390 | 1.72 | 0.3303 |
| RIA1 | 402 | 1.7 | 0.3342 |
| <u>KRE33</u> | 404 | 1.699 | 0.3402 |
| GAR1 | 426 | 1.658 | 0.3419 |
| RIX7 | 443 | 1.632 | 0.3445 |
| <u>SYO1</u> | 448 | 1.627 | 0.3496 |
| UTP4 | 469 | 1.593 | 0.3513 |
| RNT1 | 473 | 1.59 | 0.3564 |
| <u>PRP43</u> | 475 | 1.589 | 0.362 |
| UTP14 | 489 | 1.56 | 0.365 |
| DBP3 | 502 | 1.547 | 0.3682 |
| DIM1 | 504 | 1.544 | 0.3736 |
| <u>RPS15</u> | 506 | 1.544 | 0.379 |
| MRT4 | 511 | 1.54 | 0.3838 |
| UTP21 | 513 | 1.538 | 0.3892 |
| RPF2 | 515 | 1.535 | 0.3946 |
| RAI1 | 538 | 1.491 | 0.3955 |
| IPI1 | 540 | 1.484 | 0.4007 |

| PUF6 | 541 | 1.484 | 0.4061 |
|--------------|------|-------|--------|
| MTR4 | 560 | 1.444 | 0.4076 |
| MAK21 | 562 | 1.442 | 0.4127 |
| MAK16 | 577 | 1.417 | 0.4149 |
| RRP3 | 613 | 1.37 | 0.4127 |
| PWP1 | 625 | 1.351 | 0.4153 |
| RSA4 | 636 | 1.342 | 0.4182 |
| RRP12 | 638 | 1.339 | 0.4228 |
| NOP7 | 644 | 1.332 | 0.4267 |
| <u>ZUO1</u> | 676 | 1.292 | 0.425 |
| DBP2 | 678 | 1.292 | 0.4295 |
| BMT6 | 682 | 1.289 | 0.4335 |
| SPB1 | 687 | 1.284 | 0.4374 |
| DBP9 | 690 | 1.281 | 0.4417 |
| BFR2 | 696 | 1.272 | 0.4453 |
| PUS7 | 738 | 1.237 | 0.4413 |
| NOP2 | 754 | 1.217 | 0.4426 |
| RRP43 | 764 | 1.209 | 0.4452 |
| SAS10 | 779 | 1.198 | 0.4466 |
| UTP6 | 781 | 1.195 | 0.4508 |
| RRP1 | 788 | 1.19 | 0.4539 |
| ARX1 | 822 | 1.163 | 0.4513 |
| NUP85 | 825 | 1.161 | 0.4551 |
| SLX9 | 826 | 1.161 | 0.4593 |
| <u>URB2</u> | 840 | 1.15 | 0.4608 |
| IMP3 | 857 | 1.134 | 0.4617 |
| <u>RRP42</u> | 874 | 1.112 | 0.4624 |
| RCM1 | 893 | 1.094 | 0.4627 |
| PWP2 | 895 | 1.091 | 0.4664 |
| DHR2 | 898 | 1.09 | 0.47 |
| NOG2 | 900 | 1.089 | 0.4738 |
| BMT5 | 904 | 1.087 | 0.4771 |
| RPP1 | 907 | 1.086 | 0.4806 |
| RRS1 | 947 | 1.054 | 0.4764 |
| ERB1 | 948 | 1.053 | 0.4803 |
| SQT1 | 951 | 1.047 | 0.4837 |
| RRP36 | 982 | 1.015 | 0.4812 |
| NSA1 | 984 | 1.012 | 0.4846 |
| RRP5 | 1025 | 0.979 | 0.4799 |
| <u>TMA20</u> | 1032 | 0.976 | 0.4823 |
| UTP7 | 1033 | 0.976 | 0.4858 |
| FAP7 | 1040 | 0.967 | 0.4881 |

| TIF6 | 1041 | 0.967 | 0.4916 |
|----------------|------|-------|--------|
| YTM1 | 1045 | 0.964 | 0.4945 |
| SDA1 | 1047 | 0.96 | 0.4978 |
| NOP4 | 1096 | 0.92 | 0.4912 |
| SRD1 | 1104 | 0.913 | 0.4931 |
| NMD3 | 1105 | 0.913 | 0.4964 |
| RRP4 | 1130 | 0.892 | 0.4947 |
| <u>RRP46</u> | 1139 | 0.888 | 0.4963 |
| <u>NUP159</u> | 1144 | 0.886 | 0.4987 |
| <u>RRP40</u> | 1155 | 0.882 | 0.4998 |
| NOP12 | 1190 | 0.859 | 0.4959 |
| NOP9 | 1193 | 0.857 | 0.4987 |
| SRM1 | 1222 | 0.834 | 0.4959 |
| RSA1 | 1223 | 0.832 | 0.4989 |
| FCF2 | 1232 | 0.827 | 0.5003 |
| RIX1 | 1237 | 0.824 | 0.5025 |
| <u>RNH70</u> | 1259 | 0.806 | 0.5011 |
| UTP5 | 1264 | 0.804 | 0.5032 |
| REX3 | 1268 | 0.801 | 0.5055 |
| BUD20 | 1279 | 0.797 | 0.5063 |
| <u>NOP15</u> | 1285 | 0.794 | 0.5082 |
| NOC4 | 1303 | 0.78 | 0.5075 |
| SSF1 | 1349 | 0.744 | 0.5009 |
| URB1 | 1397 | 0.707 | 0.4938 |
| <u>TIF4631</u> | 1410 | 0.699 | 0.4938 |
| UTP15 | 1414 | 0.697 | 0.4957 |
| GLC7 | 1426 | 0.691 | 0.496 |
| POP7 | 1456 | 0.678 | 0.4925 |
| MPP10 | 1480 | 0.668 | 0.4901 |
| DBP8 | 1493 | 0.659 | 0.49 |
| FUN12 | 1495 | 0.657 | 0.4922 |
| YAR1 | 1505 | 0.652 | 0.4927 |
| UTP22 | 1519 | 0.645 | 0.4924 |
| ARB1 | 1532 | 0.641 | 0.4923 |
| FYV7 | 1547 | 0.633 | 0.4917 |
| ECM16 | 1581 | 0.611 | 0.4871 |
| NSP1 | 1582 | 0.61 | 0.4893 |
| SGD1 | 1598 | 0.603 | 0.4884 |
| LSG1 | 1616 | 0.595 | 0.4871 |
| RNA1 | 1699 | 0.553 | 0.4721 |
| LCP5 | 1711 | 0.547 | 0.4718 |
| RLP24 | 1719 | 0.542 | 0.4724 |

| NAN1 | 1727 | 0.54 | 0.4729 |
|--------|------|-------|---------|
| RRP9 | 1743 | 0.534 | 0.4717 |
| LSM6 | 1761 | 0.527 | 0.4701 |
| SOF1 | 1776 | 0.521 | 0.4691 |
| CAM1 | 1791 | 0.515 | 0.4681 |
| RVB2 | 1792 | 0.514 | 0.47 |
| MTR3 | 1803 | 0.504 | 0.4698 |
| MPP6 | 1823 | 0.493 | 0.4676 |
| RRP8 | 1829 | 0.491 | 0.4684 |
| TMA108 | 1846 | 0.48 | 0.4668 |
| | 1888 | 0.467 | 0.46 |
| BMS1 | 1981 | 0.42 | 0.4425 |
| UTP25 | | | |
| SQS1 | 2031 | 0.4 | 0.4339 |
| NOC3 | 2032 | 0.4 | 0.4353 |
| HCR1 | 2033 | 0.4 | 0.4368 |
| TSR1 | 2035 | 0.397 | 0.438 |
| NGL2 | 2058 | 0.386 | 0.4349 |
| DIP2 | 2076 | 0.377 | 0.4327 |
| DRS2 | 2081 | 0.375 | 0.4333 |
| UTP23 | 2083 | 0.374 | 0.4344 |
| GRC3 | 2086 | 0.373 | 0.4354 |
| DBP10 | 2119 | 0.358 | 0.4301 |
| NOP14 | 2124 | 0.357 | 0.4305 |
| REI1 | 2132 | 0.353 | 0.4304 |
| CGR1 | 2146 | 0.348 | 0.429 |
| FCF1 | 2156 | 0.344 | 0.4284 |
| UTP20 | 2192 | 0.325 | 0.4223 |
| BUD21 | 2219 | 0.312 | 0.4181 |
| RSA3 | 2245 | 0.3 | 0.414 |
| UTP9 | 2249 | 0.295 | 0.4144 |
| NOP8 | 2285 | 0.279 | 0.4082 |
| RRP7 | 2315 | 0.269 | 0.4032 |
| MAK11 | 2353 | 0.255 | 0.3965 |
| BRX1 | 2361 | 0.251 | 0.3959 |
| RCL1 | 2374 | 0.241 | 0.3943 |
| RTC6 | 2386 | 0.237 | 0.3929 |
| AFG2 | 2389 | 0.236 | 0.3934 |
| TIF5 | 2391 | 0.235 | 0.394 |
| MRD1 | 2423 | 0.223 | 0.3884 |
| NOB1 | 2464 | 0.201 | 0.3809 |
| GEP3 | 2476 | 0.196 | 0.3793 |
| | 2470 | 0.130 | 0.57 95 |

| Г <u></u> | 0500 | 10.450 | 100710 |
|-----------|------|--------|--------|
| DRS1 | 2520 | 0.158 | 0.3719 |
| RAT1 | 2540 | -0.13 | 0.3684 |
| JIP5 | 2545 | -0.152 | 0.3681 |
| LAS1 | 2561 | -0.172 | 0.3657 |
| NIC96 | 2570 | -0.181 | 0.3647 |
| POP4 | 2586 | -0.192 | 0.3623 |
| LOC1 | 2589 | -0.193 | 0.3626 |
| RPF1 | 2636 | -0.222 | 0.3539 |
| DIS3 | 2637 | -0.222 | 0.3547 |
| RSP5 | 2647 | -0.226 | 0.3536 |
| CSL4 | 2665 | -0.233 | 0.351 |
| PUS5 | 2711 | -0.26 | 0.3426 |
| REX2 | 2728 | -0.271 | 0.3403 |
| UTP30 | 2802 | -0.303 | 0.3263 |
| FAL1 | 2833 | -0.319 | 0.3213 |
| BUD22 | 2838 | -0.324 | 0.3216 |
| SPT5 | 2846 | -0.326 | 0.3214 |
| LTO1 | 2917 | -0.358 | 0.3082 |
| NOP6 | 2930 | -0.365 | 0.307 |
| SAC3 | 3000 | -0.401 | 0.2942 |
| HIT1 | 3022 | -0.409 | 0.2914 |
| LSM7 | 3026 | -0.411 | 0.2922 |
| UTP11 | 3076 | -0.434 | 0.2837 |
| NUP120 | 3100 | -0.448 | 0.2806 |
| TOM1 | 3175 | -0.483 | 0.267 |
| HRR25 | 3224 | -0.506 | 0.259 |
| TOR2 | 3252 | -0.52 | 0.2553 |
| NUP49 | 3256 | -0.522 | 0.2565 |
| LTV1 | 3291 | -0.541 | 0.2515 |
| RMP1 | 3446 | -0.625 | 0.2219 |
| ECM1 | 3450 | -0.627 | 0.2236 |
| NOP19 | 3453 | -0.628 | 0.2255 |
| MTR2 | 3510 | -0.653 | 0.2163 |
| BUD23 | 3594 | -0.704 | 0.2017 |
| POP6 | 3607 | -0.709 | 0.2018 |
| NUP116 | 3628 | -0.724 | 0.2003 |
| YAE1 | 3644 | -0.734 | 0.1998 |
| RIO2 | 3657 | -0.74 | 0.2 |
| NOP16 | 3659 | -0.74 | 0.2025 |
| RRP45 | 3696 | -0.761 | 0.1979 |
| TMA23 | 3698 | -0.762 | 0.2004 |
| IMP4 | 3699 | -0.762 | 0.2032 |
| 11VII T | 3033 | 0.102 | 0.2002 |

| MRH4 | 3713 | -0.774 | 0.2033 |
|-------|------|--------|--------|
| JJJ1 | 3714 | -0.776 | 0.2062 |
| EBP2 | 3720 | -0.781 | 0.208 |
| YRB2 | 3786 | -0.821 | 0.1975 |
| TOR1 | 3799 | -0.83 | 0.1981 |
| RRP15 | 3808 | -0.837 | 0.1995 |
| DBP7 | 3827 | -0.848 | 0.1988 |
| MOT1 | 3875 | -0.878 | 0.1923 |
| PAF1 | 3903 | -0.894 | 0.19 |
| RRP17 | 3935 | -0.922 | 0.187 |
| SNU66 | 3972 | -0.95 | 0.183 |
| TSR3 | 4108 | -1.055 | 0.1589 |
| SNM1 | 4207 | -1.152 | 0.1428 |
| DBP6 | 4227 | -1.172 | 0.1432 |
| RRP14 | 4240 | -1.182 | 0.145 |
| LRP1 | 4369 | -1.317 | 0.1233 |
| NUP1 | 4382 | -1.33 | 0.1257 |
| KRI1 | 4409 | -1.365 | 0.1253 |
| RNP1 | 4508 | -1.479 | 0.1104 |
| NME1 | 4925 | -2.497 | 0.0335 |

Translation Elongation

| Gene Name | Rank in Gene List | Rank Metric Score | Running Enrichment Score |
|-------------|-------------------|-------------------|-----------------------------|
| EFT1 | 18 | 3.69 | 0.0853 |
| TEF2 | 29 | 3.473 | 0.1669 |
| TEF1 | 39 | 3.308 | 0.2447 |
| EFT2 | 56 | 3.152 | 0.3174 |
| YEF3 | 66 | 3.013 | 0.3881 |
| SSB2 | 98 | 2.756 | 0.4483 |
| SSB1 | 100 | 2.735 | 0.514 |
| EFB1 | 126 | 2.524 | 0.5698 |
| RPS2 | 156 | 2.38 | 0.6213 |
| STM1 | 200 | 2.233 | 0.6666 |
| TEF4 | 248 | 2.07 | 0.7071 |
| <u>SSZ1</u> | 289 | 1.967 | 0.7466 |
| <u>ZUO1</u> | 676 | 1.292 | 0.7015 |
| HYP2 | 858 | 1.134 | 0.693 |
| GCN20 | 1362 | 0.735 | 0.6114 |
| TUF1 | 1708 | 0.549 | 0.5565 |
| CAM1 | 1791 | 0.515 | 0.5527 |

| GCN1 | 2111 | 0.36 | 0.4983 |
|------|------|--------|--------|
| SUA5 | 2151 | 0.346 | 0.499 |
| OAZ1 | 2300 | 0.275 | 0.4764 |
| DHH1 | 3517 | -0.658 | 0.2521 |
| CTK2 | 3535 | -0.665 | 0.2647 |
| CTK1 | 3555 | -0.676 | 0.2772 |
| CTK3 | 4091 | -1.042 | 0.1967 |

RAS2^{S225E} vs EV- Chromosome Segredatation- Downregulated

| Gene Name | Rank in Gene List | Rank Metric Score | Running Enrichment Score |
|--------------|-------------------|-------------------|-----------------------------|
| NDJ1 | 266 | 2.036 | -0.0401 |
| SCP160 | 322 | 1.864 | -0.0387 |
| RFC5 | 551 | 1.462 | -0.075 |
| TPD3 | 587 | 1.4 | -0.0726 |
| RFC4 | 729 | 1.243 | -0.0927 |
| POL30 | 906 | 1.086 | -0.121 |
| SMC3 | 1001 | 1.002 | -0.1333 |
| <u>INO80</u> | 1249 | 0.815 | -0.1778 |
| <u>SPO16</u> | 1275 | 0.798 | -0.1775 |
| KIN3 | 1317 | 0.769 | -0.1806 |
| GLC7 | 1426 | 0.691 | -0.1978 |
| CDC48 | 1461 | 0.675 | -0.2001 |
| <u>SPO22</u> | 1539 | 0.637 | -0.2114 |
| HOP1 | 1732 | 0.539 | -0.2467 |
| FOB1 | 1765 | 0.526 | -0.2496 |
| TOF1 | 1833 | 0.486 | -0.2599 |
| KIN4 | 1914 | 0.458 | -0.273 |
| SMC4 | 1918 | 0.457 | -0.2705 |
| CHL1 | 1923 | 0.451 | -0.2683 |
| SMC6 | 1940 | 0.442 | -0.2685 |
| LRS4 | 1997 | 0.415 | -0.2771 |
| LTE1 | 2057 | 0.386 | -0.2864 |
| DCC1 | 2087 | 0.372 | -0.2898 |
| CDC20 | 2243 | 0.3 | -0.3191 |
| BUR2 | 2259 | 0.289 | -0.3202 |
| MND2 | 2305 | 0.274 | -0.3275 |
| MAD2 | 2358 | 0.252 | -0.3363 |

| HDA3 | 2379 | 0.24 | -0.3387 |
|---------------|------|--------|---------|
| NPA3 | 2412 | 0.227 | -0.3437 |
| PAT1 | 2414 | 0.226 | -0.3423 |
| RFC2 | 2450 | 0.21 | -0.348 |
| PPH21 | 2467 | 0.201 | -0.3499 |
| CDC28 | 2494 | 0.186 | -0.3539 |
| MCK1 | 2576 | -0.185 | -0.3691 |
| MMS22 | 2587 | -0.193 | -0.3698 |
| STS1 | 2590 | -0.193 | -0.3689 |
| IRR1 | 2690 | -0.248 | -0.3872 |
| SLI15 | 2734 | -0.274 | -0.3941 |
| DMA1 | 2753 | -0.283 | -0.3958 |
| MCD1 | 2778 | -0.291 | -0.3987 |
| MAD3 | 2797 | -0.3 | -0.4003 |
| SPC72 | 2801 | -0.303 | -0.3989 |
| RAD61 | 2813 | -0.309 | -0.399 |
| CTF4 | 2835 | -0.322 | -0.4011 |
| CTF18 | 2851 | -0.329 | -0.4019 |
| RTS1 | 2871 | -0.337 | -0.4035 |
| ESP1 | 2918 | -0.359 | -0.4104 |
| HFM1 | 2950 | -0.375 | -0.4141 |
| SMC2 | 2973 | -0.388 | -0.416 |
| IML3 | 2991 | -0.398 | -0.4167 |
| GPN2 | 3014 | -0.407 | -0.4184 |
| CIN8 | 3031 | -0.413 | -0.4189 |
| CEP3 | 3055 | -0.426 | -0.4207 |
| <u>RTT102</u> | 3065 | -0.43 | -0.4196 |
| YPI1 | 3083 | -0.437 | -0.4201 |
| ELG1 | 3091 | -0.442 | -0.4185 |
| SGS1 | 3097 | -0.446 | -0.4165 |
| RED1 | 3145 | -0.467 | -0.4229 |
| CDC55 | 3160 | -0.478 | -0.4225 |
| DAD2 | 3202 | -0.496 | -0.4274 |
| NUP170 | 3203 | -0.496 | -0.4241 |
| HRR25 | 3224 | -0.506 | -0.4247 |
| SCC2 | 3234 | -0.51 | -0.4231 |
| BUB1 | 3237 | -0.511 | -0.42 |
| GIP3 | 3273 | -0.53 | -0.4235 |
| CTF3 | 3335 | -0.557 | -0.4321 |
| MCM21 | 3383 | -0.585 | -0.4377 |
| STH1 | 3463 | -0.632 | -0.4494 |
| SIZ1 | 3475 | -0.637 | -0.4474 |

| HHT2 | 3483 | -0.641 | -0.4444 |
|--------------|------|--------|---------|
| RMI1 | 3486 | -0.641 | -0.4405 |
| APC1 | 3491 | -0.644 | -0.437 |
| IES6 | 3519 | -0.658 | -0.438 |
| BUB2 | 3522 | -0.66 | -0.4339 |
| MTW1 | 3541 | -0.667 | -0.4331 |
| WIP1 | 3570 | -0.685 | -0.4341 |
| IRC15 | 3630 | -0.725 | -0.4412 |
| BIM1 | 3655 | -0.74 | -0.441 |
| POL2 | 3663 | -0.744 | -0.4374 |
| MAD1 | 3668 | -0.746 | -0.4332 |
| ZIP1 | 3712 | -0.774 | -0.4367 |
| <u>RDH54</u> | 3721 | -0.782 | -0.433 |
| FIN1 | 3746 | -0.795 | -0.4325 |
| <u>DU01</u> | 3753 | -0.801 | -0.4283 |
| BMH1 | 3760 | -0.806 | -0.4241 |
| RSC2 | 3771 | -0.813 | -0.4206 |
| CNN1 | 3779 | -0.816 | -0.4165 |
| PDS5 | 3787 | -0.822 | -0.4124 |
| <u>RAD30</u> | 3815 | -0.843 | -0.4121 |
| SRC1 | 3849 | -0.863 | -0.413 |
| CSE4 | 3850 | -0.863 | -0.4072 |
| KIP1 | 3898 | -0.89 | -0.4107 |
| AMA1 | 3943 | -0.924 | -0.4134 |
| SHP1 | 3970 | -0.947 | -0.4122 |
| TOP1 | 4017 | -0.983 | -0.4149 |
| SPC25 | 4040 | -1.001 | -0.4126 |
| CBF2 | 4045 | -1.003 | -0.4066 |
| DMA2 | 4092 | -1.044 | -0.4089 |
| NUD1 | 4095 | -1.047 | -0.4022 |
| CDC5 | 4118 | -1.065 | -0.3995 |
| DAM1 | 4122 | -1.071 | -0.3928 |
| BFA1 | 4124 | -1.075 | -0.3858 |
| <u>SG01</u> | 4134 | -1.086 | -0.3803 |
| BUD2 | 4152 | -1.097 | -0.3763 |
| DAD4 | 4162 | -1.105 | -0.3707 |
| SCC4 | 4166 | -1.108 | -0.3638 |
| MPS1 | 4193 | -1.145 | -0.3613 |
| REC8 | 4214 | -1.16 | -0.3575 |
| CSM4 | 4250 | -1.195 | -0.3566 |
| GLC8 | 4255 | -1.201 | -0.3493 |
| SWM1 | 4258 | -1.203 | -0.3415 |

| <u>ULP2</u> | 4259 | -1.203 | -0.3334 |
|--------------|------|--------|---------|
| SFH1 | 4288 | -1.227 | -0.3308 |
| NBL1 | 4289 | -1.228 | -0.3225 |
| ASK1 | 4298 | -1.243 | -0.3157 |
| SPC34 | 4310 | -1.255 | -0.3095 |
| AME1 | 4312 | -1.257 | -0.3012 |
| CTF8 | 4332 | -1.281 | -0.2964 |
| ZIP2 | 4381 | -1.33 | -0.2971 |
| PDS1 | 4421 | -1.38 | -0.2957 |
| BUB3 | 4453 | -1.408 | -0.2925 |
| CSM3 | 4466 | -1.422 | -0.2853 |
| <u>ECO1</u> | 4584 | -1.599 | -0.2982 |
| <u>VIK1</u> | 4608 | -1.627 | -0.2918 |
| CDH1 | 4620 | -1.641 | -0.283 |
| IPL1 | 4627 | -1.657 | -0.273 |
| TOP3 | 4650 | -1.701 | -0.266 |
| BIR1 | 4652 | -1.703 | -0.2547 |
| SCM3 | 4680 | -1.76 | -0.2482 |
| DMC1 | 4685 | -1.776 | -0.2371 |
| CDC14 | 4713 | -1.823 | -0.2302 |
| NFI1 | 4723 | -1.852 | -0.2195 |
| BRN1 | 4746 | -1.899 | -0.2112 |
| CHL4 | 4748 | -1.91 | -0.1985 |
| DAD3 | 4765 | -1.943 | -0.1886 |
| GAC1 | 4766 | -1.946 | -0.1754 |
| NNF1 | 4771 | -1.964 | -0.163 |
| CBF1 | 4792 | -2.026 | -0.1533 |
| <u>CTF19</u> | 4845 | -2.194 | -0.149 |
| NDC80 | 4847 | -2.199 | -0.1344 |
| KAR3 | 4849 | -2.21 | -0.1197 |
| MIF2 | 4858 | -2.23 | -0.1062 |
| OKP1 | 4876 | -2.305 | -0.0941 |
| SLK19 | 4886 | -2.343 | -0.0801 |
| MPS3 | 4919 | -2.483 | -0.0698 |
| SOH1 | 4931 | -2.508 | -0.0551 |
| <u>DSN1</u> | 4950 | -2.595 | -0.0412 |
| <u>SPO13</u> | 4960 | -2.647 | -0.0251 |
| <u>CIK1</u> | 5039 | -3.286 | -0.0187 |
| SPC24 | 5081 | -4.182 | 0.0012 |

Condensed Chromosome

| Gene Name | Rank in Gene List | Rank Metric Score | Running Enrichment Score |
|--------------|-------------------|-------------------|-----------------------------|
| NSE5 | 761 | 1.212 | -0.14 |
| REC104 | 914 | 1.08 | -0.1595 |
| SMC3 | 1001 | 1.002 | -0.1666 |
| <u>SPO16</u> | 1275 | 0.798 | -0.2131 |
| GLC7 | 1426 | 0.691 | -0.2361 |
| <u>SPO22</u> | 1539 | 0.637 | -0.2521 |
| PSY2 | 1584 | 0.61 | -0.2548 |
| HOP1 | 1732 | 0.539 | -0.2787 |
| SMC4 | 1918 | 0.457 | -0.3111 |
| RFA2 | 1921 | 0.452 | -0.307 |
| SMC6 | 1940 | 0.442 | -0.3061 |
| LRS4 | 1997 | 0.415 | -0.3131 |
| TOP2 | 2144 | 0.348 | -0.3388 |
| RFA3 | 2190 | 0.326 | -0.3445 |
| NSE3 | 2225 | 0.308 | -0.3482 |
| RAD17 | 2248 | 0.297 | -0.3496 |
| MAD2 | 2358 | 0.252 | -0.3689 |
| NSE1 | 2510 | 0.173 | -0.3973 |
| PLC1 | 2573 | -0.184 | -0.4079 |
| IRR1 | 2690 | -0.248 | -0.4286 |
| MCD1 | 2778 | -0.291 | -0.443 |
| RAD61 | 2813 | -0.309 | -0.4467 |
| RTS1 | 2871 | -0.337 | -0.4547 |
| RFA1 | 2886 | -0.34 | -0.4541 |
| SMC2 | 2973 | -0.388 | -0.4674 |
| IML3 | 2991 | -0.398 | -0.4668 |
| CIN8 | 3031 | -0.413 | -0.4704 |
| CEP3 | 3055 | -0.426 | -0.4707 |
| SMT3 | 3073 | -0.433 | -0.4698 |
| RED1 | 3145 | -0.467 | -0.4792 |
| DAD2 | 3202 | -0.496 | -0.4854 |
| HRR25 | 3224 | -0.506 | -0.4845 |
| BUB1 | 3237 | -0.511 | -0.4818 |
| STU2 | 3272 | -0.53 | -0.4832 |
| CTF3 | 3335 | -0.557 | -0.49 |
| MCM21 | 3383 | -0.585 | -0.4935 |
| MTW1 | 3541 | -0.667 | -0.5182 |
| MEC3 | 3598 | -0.706 | -0.5223 |
| PPH3 | 3603 | -0.708 | -0.516 |
| ZIP1 | 3712 | -0.774 | -0.5298 |
| FIN1 | 3746 | -0.795 | -0.5283 |

| <u>DUO1</u> | 3753 | -0.801 | -0.5215 |
|---------------|------|--------|---------|
| PDS5 | 3787 | -0.822 | -0.5198 |
| CSE4 | 3850 | -0.863 | -0.5235 |
| SPC25 | 4040 | -1.001 | -0.5512 |
| CBF2 | 4045 | -1.003 | -0.5419 |
| CTF13 | 4064 | -1.019 | -0.5352 |
| DAM1 | 4122 | -1.071 | -0.5358 |
| <u>SGO1</u> | 4134 | -1.086 | -0.5271 |
| DAD4 | 4162 | -1.105 | -0.5213 |
| MPS1 | 4193 | -1.145 | -0.5158 |
| REC8 | 4214 | -1.16 | -0.5081 |
| NSE4 | 4220 | -1.165 | -0.4974 |
| ASK1 | 4298 | -1.243 | -0.5002 |
| SPC34 | 4310 | -1.255 | -0.4898 |
| AME1 | 4312 | -1.257 | -0.4773 |
| ZIP2 | 4381 | -1.33 | -0.4775 |
| <u>REC107</u> | 4385 | -1.336 | -0.4647 |
| <u>REC114</u> | 4394 | -1.347 | -0.4527 |
| UBC9 | 4427 | -1.385 | -0.4451 |
| SAE3 | 4438 | -1.397 | -0.433 |
| <u>REC102</u> | 4445 | -1.404 | -0.4201 |
| BUB3 | 4453 | -1.408 | -0.4073 |
| <u>RAD51</u> | 4510 | -1.482 | -0.4036 |
| GMC2 | 4559 | -1.556 | -0.3975 |
| IPL1 | 4627 | -1.657 | -0.3942 |
| BIR1 | 4652 | -1.703 | -0.3818 |
| SCM3 | 4680 | -1.76 | -0.3695 |
| DMC1 | 4685 | -1.776 | -0.3524 |
| BRN1 | 4746 | -1.899 | -0.3453 |
| CHL4 | 4748 | -1.91 | -0.3262 |
| TFC3 | 4754 | -1.921 | -0.3078 |
| DAD3 | 4765 | -1.943 | -0.2903 |
| NNF1 | 4771 | -1.964 | -0.2715 |
| KRE28 | 4796 | -2.036 | -0.2557 |
| MMS21 | 4806 | -2.052 | -0.2369 |
| CTF19 | 4845 | -2.194 | -0.2224 |
| NDC80 | 4847 | -2.199 | -0.2004 |
| MND1 | 4851 | -2.22 | -0.1786 |
| MIF2 | 4858 | -2.23 | -0.1573 |
| OKP1 | 4876 | -2.305 | -0.1375 |
| SLK19 | 4886 | -2.343 | -0.1157 |
| DSN1 | 4950 | -2.595 | -0.1021 |

| <u>ECM11</u> | 4952 | -2.599 | -0.0762 |
|--------------|------|--------|---------|
| <u>SPO13</u> | 4960 | -2.647 | -0.0509 |
| MEI5 | 5042 | -3.347 | -0.0333 |
| SPC24 | 5081 | -4.182 | 0.0012 |

Microtubule Based Processes

| Gene Name | Rank in Gene List | Rank Metric Score | Running Enrichment Score |
|-----------|-------------------|-------------------|-----------------------------|
| ACT1 | 180 | 2.293 | -0.013 |
| CMD1 | 324 | 1.862 | -0.023 |
| LDB18 | 681 | 1.291 | -0.0813 |
| CLB4 | 795 | 1.184 | -0.092 |
| CRN1 | 810 | 1.172 | -0.0831 |
| LIA1 | 967 | 1.027 | -0.104 |
| ARP1 | 1133 | 0.891 | -0.1281 |
| CDC48 | 1461 | 0.675 | -0.1868 |
| TVP38 | 1661 | 0.574 | -0.2208 |
| NDC1 | 1690 | 0.559 | -0.2208 |
| BUD6 | 1724 | 0.541 | -0.222 |
| RRD2 | 2067 | 0.381 | -0.2867 |
| DSK2 | 2183 | 0.33 | -0.3064 |
| DYN2 | 2216 | 0.313 | -0.3096 |
| BER1 | 2296 | 0.276 | -0.3227 |
| CDC28 | 2494 | 0.186 | -0.3602 |
| CDC15 | 2736 | -0.276 | -0.4057 |
| DMA1 | 2753 | -0.283 | -0.4061 |
| SPC72 | 2801 | -0.303 | -0.4124 |
| ATS1 | 2804 | -0.305 | -0.4098 |
| CLB5 | 2829 | -0.318 | -0.4114 |
| RTS1 | 2871 | -0.337 | -0.4162 |
| ESP1 | 2918 | -0.359 | -0.4218 |
| KAR1 | 2939 | -0.37 | -0.4221 |
| YHR127W | 2995 | -0.399 | -0.4291 |
| JNM1 | 3007 | -0.404 | -0.4273 |
| CIN8 | 3031 | -0.413 | -0.4277 |
| PAC11 | 3052 | -0.425 | -0.4275 |
| DAD2 | 3202 | -0.496 | -0.4523 |
| HRR25 | 3224 | -0.506 | -0.4515 |
| BUB1 | 3237 | -0.511 | -0.4487 |
| SPC97 | 3260 | -0.524 | -0.4479 |

| STU2 | 3272 | -0.53 | -0.4448 |
|---------------|------|--------|---------|
| NBP1 | 3322 | -0.552 | -0.449 |
| CLB3 | 3354 | -0.567 | -0.4496 |
| HCM1 | 3356 | -0.568 | -0.4441 |
| BNI1 | 3387 | -0.586 | -0.4442 |
| SPC110 | 3396 | -0.593 | -0.4398 |
| RRD1 | 3412 | -0.606 | -0.4368 |
| KIP3 | 3490 | -0.643 | -0.4457 |
| NUM1 | 3500 | -0.646 | -0.441 |
| SWE1 | 3578 | -0.692 | -0.4495 |
| ABM1 | 3587 | -0.699 | -0.4441 |
| MLP2 | 3599 | -0.707 | -0.4392 |
| IRC15 | 3630 | -0.725 | -0.4379 |
| BIM1 | 3655 | -0.74 | -0.4353 |
| <u>NIP100</u> | 3666 | -0.745 | -0.4299 |
| FIN1 | 3746 | -0.795 | -0.4377 |
| <u>DU01</u> | 3753 | -0.801 | -0.4309 |
| KIP1 | 3898 | -0.89 | -0.4508 |
| SHP1 | 3970 | -0.947 | -0.4555 |
| GPA1 | 3976 | -0.954 | -0.4469 |
| SPC25 | 4040 | -1.001 | -0.4495 |
| CBF2 | 4045 | -1.003 | -0.4402 |
| DMA2 | 4092 | -1.044 | -0.4389 |
| NUD1 | 4095 | -1.047 | -0.4288 |
| KIP2 | 4102 | -1.052 | -0.4195 |
| NDL1 | 4105 | -1.054 | -0.4093 |
| CDC5 | 4118 | -1.065 | -0.401 |
| DAM1 | 4122 | -1.071 | -0.3909 |
| <u>SGO1</u> | 4134 | -1.086 | -0.3822 |
| DAD4 | 4162 | -1.105 | -0.3765 |
| STU1 | 4185 | -1.132 | -0.3696 |
| MPS1 | 4193 | -1.145 | -0.3595 |
| ASK1 | 4298 | -1.243 | -0.3678 |
| SPC34 | 4310 | -1.255 | -0.3574 |
| AME1 | 4312 | -1.257 | -0.345 |
| MPS2 | 4328 | -1.272 | -0.3353 |
| ASE1 | 4342 | -1.294 | -0.3249 |
| BBP1 | 4358 | -1.304 | -0.3148 |
| <u>POM34</u> | 4372 | -1.321 | -0.3042 |
| <u>UBC9</u> | 4427 | -1.385 | -0.3011 |
| CDC31 | 4484 | -1.442 | -0.2978 |
| SPC42 | 4543 | -1.532 | -0.2941 |

| SHE1 | 4581 | -1.596 | -0.2855 |
|-------------|------|--------|---------|
| VIK1 | 4608 | -1.627 | -0.2744 |
| CDH1 | 4620 | -1.641 | -0.2601 |
| IPL1 | 4627 | -1.657 | -0.2447 |
| BIR1 | 4652 | -1.703 | -0.2324 |
| DYN3 | 4693 | -1.797 | -0.2224 |
| CDC14 | 4713 | -1.823 | -0.2079 |
| DAD3 | 4765 | -1.943 | -0.1986 |
| CTF19 | 4845 | -2.194 | -0.1924 |
| NDC80 | 4847 | -2.199 | -0.1706 |
| KAR3 | 4849 | -2.21 | -0.1486 |
| MIF2 | 4858 | -2.23 | -0.1278 |
| OKP1 | 4876 | -2.305 | -0.1081 |
| SLK19 | 4886 | -2.343 | -0.0864 |
| MPS3 | 4919 | -2.483 | -0.0679 |
| DSN1 | 4950 | -2.595 | -0.0479 |
| <u>CIK1</u> | 5039 | -3.286 | -0.0325 |
| SPC24 | 5081 | -4.182 | 0.0012 |

Nuclear Division

| Gene Name | Rank in Gene List | Rank Metric Score | Running Enrichment Score |
|--------------|-------------------|-------------------|-----------------------------|
| YVH1 | 204 | 2.212 | -0.0308 |
| RCK1 | 228 | 2.127 | -0.0248 |
| NDJ1 | 266 | 2.036 | -0.0221 |
| SCP160 | 322 | 1.864 | -0.0241 |
| WTM1 | 396 | 1.708 | -0.0305 |
| BFR1 | 398 | 1.706 | -0.0221 |
| PSE1 | 452 | 1.619 | -0.0248 |
| TPD3 | 587 | 1.4 | -0.0453 |
| KAR4 | 616 | 1.362 | -0.0442 |
| MSH2 | 661 | 1.314 | -0.0466 |
| AMN1 | 673 | 1.296 | -0.0424 |
| CLB4 | 795 | 1.184 | -0.0613 |
| <u>SPO23</u> | 816 | 1.168 | -0.0595 |
| POL30 | 906 | 1.086 | -0.0723 |
| REC104 | 914 | 1.08 | -0.0683 |
| SMC3 | 1001 | 1.002 | -0.081 |
| RCK2 | 1181 | 0.864 | -0.1134 |
| MSH5 | 1197 | 0.855 | -0.1122 |
| <u>SPO16</u> | 1275 | 0.798 | -0.124 |

| CPR1 | 1294 | 0.788 | -0.1237 |
|--------|------|--------|---------|
| GLC7 | 1426 | 0.691 | -0.1471 |
| TRS85 | 1487 | 0.661 | -0.1561 |
| KAP104 | 1511 | 0.649 | -0.1576 |
| SPO22 | 1539 | 0.637 | -0.1599 |
| RTT101 | 1559 | 0.622 | -0.1607 |
| PSY2 | 1584 | 0.61 | -0.1625 |
| BRE1 | 1667 | 0.572 | -0.1765 |
| HOP1 | 1732 | 0.539 | -0.1869 |
| CDC10 | 1819 | 0.497 | -0.2021 |
| TOF1 | 1833 | 0.486 | -0.2023 |
| MRE11 | 1840 | 0.484 | -0.2011 |
| RAD50 | 1855 | 0.478 | -0.2016 |
| RAD1 | 1908 | 0.46 | -0.21 |
| KIN4 | 1914 | 0.458 | -0.2087 |
| SMC4 | 1918 | 0.457 | -0.207 |
| RFA2 | 1921 | 0.452 | -0.2051 |
| CHL1 | 1923 | 0.451 | -0.2031 |
| LRS4 | 1997 | 0.415 | -0.216 |
| DOT1 | 2020 | 0.405 | -0.2185 |
| RME1 | 2025 | 0.403 | -0.2173 |
| MLH1 | 2039 | 0.396 | -0.2179 |
| LTE1 | 2057 | 0.386 | -0.2195 |
| CDC42 | 2060 | 0.385 | -0.218 |
| CDC7 | 2062 | 0.384 | -0.2162 |
| DCC1 | 2087 | 0.372 | -0.2193 |
| TOP2 | 2144 | 0.348 | -0.229 |
| RFA3 | 2190 | 0.326 | -0.2366 |
| SHS1 | 2194 | 0.324 | -0.2356 |
| CDC20 | 2243 | 0.3 | -0.244 |
| RAD17 | 2248 | 0.297 | -0.2433 |
| BUR2 | 2259 | 0.289 | -0.2439 |
| XRS2 | 2269 | 0.286 | -0.2443 |
| MND2 | 2305 | 0.274 | -0.2501 |
| SKI8 | 2345 | 0.258 | -0.2568 |
| MAD2 | 2358 | 0.252 | -0.258 |
| NPA3 | 2412 | 0.227 | -0.2678 |
| SKP1 | 2429 | 0.221 | -0.27 |
| PPH21 | 2467 | 0.201 | -0.2765 |
| CDC28 | 2494 | 0.186 | -0.2809 |
| HAC1 | 2511 | 0.171 | -0.2834 |
| MCK1 | 2576 | -0.185 | -0.2956 |

| MMS22 | 2587 | -0.193 | -0.2967 |
|-------|------|--------|---------|
| KEL1 | 2674 | -0.239 | -0.3131 |
| IRR1 | 2690 | -0.248 | -0.315 |
| SNF3 | 2694 | -0.251 | -0.3143 |
| RIM8 | 2706 | -0.258 | -0.3153 |
| FPR3 | 2722 | -0.268 | -0.317 |
| CDC15 | 2736 | -0.276 | -0.3183 |
| SPO12 | 2748 | -0.28 | -0.3191 |
| DMA1 | 2753 | -0.283 | -0.3185 |
| PDR16 | 2760 | -0.286 | -0.3183 |
| MCD1 | 2778 | -0.291 | -0.3204 |
| STE20 | 2790 | -0.298 | -0.3211 |
| MAD3 | 2797 | -0.3 | -0.3209 |
| RAD10 | 2798 | -0.301 | -0.3193 |
| SPC72 | 2801 | -0.303 | -0.3182 |
| RAD61 | 2813 | -0.309 | -0.3189 |
| CLB5 | 2829 | -0.318 | -0.3204 |
| CTF4 | 2835 | -0.322 | -0.3198 |
| MLH3 | 2845 | -0.326 | -0.32 |
| CTF18 | 2851 | -0.329 | -0.3194 |
| RAD52 | 2867 | -0.336 | -0.3208 |
| RTS1 | 2871 | -0.337 | -0.3197 |
| RFA1 | 2886 | -0.34 | -0.3209 |
| ESP1 | 2918 | -0.359 | -0.3254 |
| HFM1 | 2950 | -0.375 | -0.3299 |
| SMC2 | 2973 | -0.388 | -0.3325 |
| NDT80 | 2976 | -0.39 | -0.3309 |
| IML3 | 2991 | -0.398 | -0.3318 |
| SAC3 | 3000 | -0.401 | -0.3314 |
| GPN2 | 3014 | -0.407 | -0.3321 |
| KEL2 | 3019 | -0.409 | -0.3308 |
| CIN8 | 3031 | -0.413 | -0.331 |
| CEP3 | 3055 | -0.426 | -0.3336 |
| RMR1 | 3057 | -0.426 | -0.3316 |
| YPI1 | 3083 | -0.437 | -0.3346 |
| NPR3 | 3085 | -0.439 | -0.3326 |
| ELG1 | 3091 | -0.442 | -0.3314 |
| SGS1 | 3097 | -0.446 | -0.3302 |
| RED1 | 3145 | -0.467 | -0.3375 |
| CDC55 | 3160 | -0.478 | -0.3379 |
| GIC2 | 3166 | -0.482 | -0.3365 |
| RAD6 | 3169 | -0.482 | -0.3345 |

| TON41 | 2475 | 0.492 | 0.2221 |
|---------------|------|--------|---------|
| TOM1 | 3175 | -0.483 | -0.3331 |
| HRR25 | 3224 | -0.506 | -0.3404 |
| SCC2 | 3234 | -0.51 | -0.3397 |
| BUB1 | 3237 | -0.511 | -0.3376 |
| MSH6 | 3295 | -0.543 | -0.3465 |
| CTF3 | 3335 | -0.557 | -0.3517 |
| <u>RIM101</u> | 3345 | -0.563 | -0.3508 |
| BNS1 | 3351 | -0.565 | -0.349 |
| CLB3 | 3354 | -0.567 | -0.3465 |
| SET3 | 3357 | -0.568 | -0.3441 |
| MCM21 | 3383 | -0.585 | -0.3463 |
| MUM2 | 3431 | -0.619 | -0.3528 |
| IDS2 | 3444 | -0.624 | -0.3521 |
| STH1 | 3463 | -0.632 | -0.3526 |
| HHT2 | 3483 | -0.641 | -0.3533 |
| RMI1 | 3486 | -0.641 | -0.3505 |
| KIP3 | 3490 | -0.643 | -0.3479 |
| APC1 | 3491 | -0.644 | -0.3446 |
| BUB2 | 3522 | -0.66 | -0.3475 |
| RAD57 | 3527 | -0.662 | -0.345 |
| MSC3 | 3562 | -0.678 | -0.3486 |
| TGS1 | 3571 | -0.686 | -0.3467 |
| RIM15 | 3573 | -0.689 | -0.3435 |
| SWE1 | 3578 | -0.692 | -0.3408 |
| HOS2 | 3589 | -0.701 | -0.3394 |
| SIN3 | 3592 | -0.703 | -0.3362 |
| PPH3 | 3603 | -0.708 | -0.3347 |
| IRC15 | 3630 | -0.725 | -0.3364 |
| BIM1 | 3655 | -0.74 | -0.3376 |
| POL2 | 3663 | -0.744 | -0.3353 |
| MAD1 | 3668 | -0.746 | -0.3324 |
| SET2 | 3681 | -0.753 | -0.3311 |
| DON1 | 3706 | -0.769 | -0.3321 |
| SSN8 | 3711 | -0.774 | -0.329 |
| ZIP1 | 3712 | -0.774 | -0.3252 |
| EBP2 | 3720 | -0.781 | -0.3227 |
| RDH54 | 3721 | -0.782 | -0.3187 |
| MSH4 | 3725 | -0.784 | -0.3154 |
| FIN1 | 3746 | -0.795 | -0.3155 |
| BMH1 | 3760 | -0.806 | -0.3141 |
| TEM1 | 3780 | -0.817 | -0.3139 |
| PDS5 | 3787 | -0.822 | -0.311 |
| 1033 | 3101 | 0.022 | 0.011 |

| TOR1 | 3799 | -0.83 | -0.3091 |
|---------------|------|--------|---------|
| NIS1 | 3813 | -0.84 | -0.3075 |
| <u>RAD30</u> | 3815 | -0.843 | -0.3035 |
| SRC1 | 3849 | -0.863 | -0.3059 |
| CSE4 | 3850 | -0.863 | -0.3016 |
| PAP2 | 3878 | -0.878 | -0.3027 |
| KIP1 | 3898 | -0.89 | -0.3022 |
| IME1 | 3941 | -0.923 | -0.3061 |
| AMA1 | 3943 | -0.924 | -0.3017 |
| NUP53 | 3965 | -0.945 | -0.3013 |
| CAK1 | 4014 | -0.982 | -0.3062 |
| TOP1 | 4017 | -0.983 | -0.3016 |
| IME2 | 4068 | -1.021 | -0.3068 |
| DBF4 | 4084 | -1.034 | -0.3047 |
| DMA2 | 4092 | -1.044 | -0.3008 |
| NUD1 | 4095 | -1.047 | -0.296 |
| <u>SPO11</u> | 4098 | -1.048 | -0.2911 |
| CDC5 | 4118 | -1.065 | -0.2897 |
| BFA1 | 4124 | -1.075 | -0.2853 |
| CDC24 | 4133 | -1.085 | -0.2815 |
| <u>SGO1</u> | 4134 | -1.086 | -0.276 |
| BUD2 | 4152 | -1.097 | -0.274 |
| ALK1 | 4160 | -1.104 | -0.2699 |
| DBF20 | 4164 | -1.106 | -0.2649 |
| SCC4 | 4166 | -1.108 | -0.2596 |
| MPS1 | 4193 | -1.145 | -0.2591 |
| SAE2 | 4199 | -1.149 | -0.2544 |
| REC8 | 4214 | -1.16 | -0.2514 |
| RIM4 | 4232 | -1.176 | -0.249 |
| CSM4 | 4250 | -1.195 | -0.2465 |
| HOS4 | 4252 | -1.196 | -0.2407 |
| SWM1 | 4258 | -1.203 | -0.2357 |
| ULP2 | 4259 | -1.203 | -0.2296 |
| GMC1 | 4327 | -1.271 | -0.237 |
| CTF8 | 4332 | -1.281 | -0.2313 |
| WTM2 | 4359 | -1.305 | -0.2301 |
| ARP10 | 4360 | -1.305 | -0.2236 |
| ZIP2 | 4381 | -1.33 | -0.221 |
| <u>REC107</u> | 4385 | -1.336 | -0.2149 |
| <u>REC114</u> | 4394 | -1.347 | -0.2097 |
| PDS1 | 4421 | -1.38 | -0.2081 |
| SAE3 | 4438 | -1.397 | -0.2044 |

| <u>REC102</u> | 4445 | -1.404 | -0.1986 |
|---------------|------|--------|---------|
| BUB3 | 4453 | -1.408 | -0.1929 |
| CSM3 | 4466 | -1.422 | -0.1882 |
| RAD51 | 4510 | -1.482 | -0.1896 |
| PCH2 | 4540 | -1.53 | -0.1879 |
| GMC2 | 4559 | -1.556 | -0.1837 |
| <u>ECO1</u> | 4584 | -1.599 | -0.1806 |
| <u>VIK1</u> | 4608 | -1.627 | -0.1772 |
| CDH1 | 4620 | -1.641 | -0.1712 |
| IPL1 | 4627 | -1.657 | -0.1641 |
| TOP3 | 4650 | -1.701 | -0.16 |
| BIR1 | 4652 | -1.703 | -0.1517 |
| DMC1 | 4685 | -1.776 | -0.1493 |
| CDC14 | 4713 | -1.823 | -0.1457 |
| BRN1 | 4746 | -1.899 | -0.1427 |
| CHL4 | 4748 | -1.91 | -0.1333 |
| SLZ1 | 4755 | -1.925 | -0.1249 |
| MOB1 | 4757 | -1.931 | -0.1154 |
| GAC1 | 4766 | -1.946 | -0.1072 |
| <u>UME6</u> | 4811 | -2.067 | -0.1059 |
| CTF19 | 4845 | -2.194 | -0.1016 |
| KAR3 | 4849 | -2.21 | -0.0911 |
| MND1 | 4851 | -2.22 | -0.0801 |
| SLK19 | 4886 | -2.343 | -0.0753 |
| MPS3 | 4919 | -2.483 | -0.0694 |
| SOH1 | 4931 | -2.508 | -0.0591 |
| DSN1 | 4950 | -2.595 | -0.0497 |
| ECM11 | 4952 | -2.599 | -0.0368 |
| <u>SPO13</u> | 4960 | -2.647 | -0.025 |
| <u>CIK1</u> | 5039 | -3.286 | -0.0244 |
| MEI5 | 5042 | -3.347 | -0.008 |
| IME4 | 5045 | -3.39 | 0.0086 |

Organelle Fission

| Gene Name | Rank in Gene List | Rank Metric Score | Running Enrichment Score |
|--------------|-------------------|-------------------|-----------------------------|
| YVH1 | 204 | 2.212 | -0.031 |
| RCK1 | 228 | 2.127 | -0.0252 |
| NDJ1 | 266 | 2.036 | -0.0227 |
| SCP160 | 322 | 1.864 | -0.0248 |
| WTM1 | 396 | 1.708 | -0.0313 |
| BFR1 | 398 | 1.706 | -0.0231 |
| PSE1 | 452 | 1.619 | -0.0259 |
| TPD3 | 587 | 1.4 | -0.0466 |
| KAR4 | 616 | 1.362 | -0.0456 |
| MSH2 | 661 | 1.314 | -0.0481 |
| AMN1 | 673 | 1.296 | -0.044 |
| CLB4 | 795 | 1.184 | -0.063 |
| <u>SPO23</u> | 816 | 1.168 | -0.0613 |
| POL30 | 906 | 1.086 | -0.0742 |
| REC104 | 914 | 1.08 | -0.0703 |
| SMC3 | 1001 | 1.002 | -0.083 |
| RCK2 | 1181 | 0.864 | -0.1156 |
| MSH5 | 1197 | 0.855 | -0.1144 |
| <u>SPO16</u> | 1275 | 0.798 | -0.1263 |
| CPR1 | 1294 | 0.788 | -0.1261 |
| GLC7 | 1426 | 0.691 | -0.1496 |
| <u>TRS85</u> | 1487 | 0.661 | -0.1587 |
| KAP104 | 1511 | 0.649 | -0.1602 |
| <u>SPO22</u> | 1539 | 0.637 | -0.1626 |
| RTT101 | 1559 | 0.622 | -0.1634 |
| PSY2 | 1584 | 0.61 | -0.1653 |
| BRE1 | 1667 | 0.572 | -0.1793 |
| HOP1 | 1732 | 0.539 | -0.1898 |
| CDC10 | 1819 | 0.497 | -0.205 |
| TOF1 | 1833 | 0.486 | -0.2053 |
| MRE11 | 1840 | 0.484 | -0.2041 |
| RAD50 | 1855 | 0.478 | -0.2047 |
| CAF4 | 1865 | 0.473 | -0.2042 |
| RAD1 | 1908 | 0.46 | -0.2105 |
| KIN4 | 1914 | 0.458 | -0.2093 |
| SMC4 | 1918 | 0.457 | -0.2076 |
| RFA2 | 1921 | 0.452 | -0.2058 |
| CHL1 | 1923 | 0.451 | -0.2038 |
| <u>PEX11</u> | 1945 | 0.439 | -0.2059 |
| LRS4 | 1997 | 0.415 | -0.2143 |
| DOT1 | 2020 | 0.405 | -0.2169 |

| RME1 | 2025 | 0.403 | -0.2157 |
|--------------|------|--------|---------|
| MLH1 | 2039 | 0.396 | -0.2164 |
| LTE1 | 2057 | 0.386 | -0.218 |
| CDC42 | 2060 | 0.385 | -0.2165 |
| CDC7 | 2062 | 0.384 | -0.2148 |
| DCC1 | 2087 | 0.372 | -0.2179 |
| TOP2 | 2144 | 0.348 | -0.2277 |
| RFA3 | 2190 | 0.326 | -0.2353 |
| SHS1 | 2194 | 0.324 | -0.2343 |
| RPN11 | 2239 | 0.302 | -0.2419 |
| CDC20 | 2243 | 0.3 | -0.241 |
| RAD17 | 2248 | 0.297 | -0.2404 |
| BUR2 | 2259 | 0.289 | -0.241 |
| XRS2 | 2269 | 0.286 | -0.2414 |
| MND2 | 2305 | 0.274 | -0.2473 |
| SKI8 | 2345 | 0.258 | -0.254 |
| MAD2 | 2358 | 0.252 | -0.2552 |
| NPA3 | 2412 | 0.227 | -0.265 |
| SKP1 | 2429 | 0.221 | -0.2672 |
| PPH21 | 2467 | 0.201 | -0.2738 |
| CDC28 | 2494 | 0.186 | -0.2782 |
| HAC1 | 2511 | 0.171 | -0.2807 |
| MCK1 | 2576 | -0.185 | -0.2929 |
| MMS22 | 2587 | -0.193 | -0.294 |
| KEL1 | 2674 | -0.239 | -0.3105 |
| IRR1 | 2690 | -0.248 | -0.3124 |
| SNF3 | 2694 | -0.251 | -0.3117 |
| RIM8 | 2706 | -0.258 | -0.3127 |
| FPR3 | 2722 | -0.268 | -0.3145 |
| CDC15 | 2736 | -0.276 | -0.3158 |
| SPO12 | 2748 | -0.28 | -0.3167 |
| DMA1 | 2753 | -0.283 | -0.3161 |
| PDR16 | 2760 | -0.286 | -0.3159 |
| MCD1 | 2778 | -0.291 | -0.3179 |
| STE20 | 2790 | -0.298 | -0.3187 |
| MAD3 | 2797 | -0.3 | -0.3185 |
| RAD10 | 2798 | -0.301 | -0.317 |
| SPC72 | 2801 | -0.303 | -0.3159 |
| <u>RAD61</u> | 2813 | -0.309 | -0.3166 |
| CLB5 | 2829 | -0.318 | -0.3181 |
| CTF4 | 2835 | -0.322 | -0.3176 |
| MLH3 | 2845 | -0.326 | -0.3178 |

| Г | | T | |
|---------------|------|--------|---------|
| CTF18 | 2851 | -0.329 | -0.3172 |
| RAD52 | 2867 | -0.336 | -0.3186 |
| RTS1 | 2871 | -0.337 | -0.3176 |
| RFA1 | 2886 | -0.34 | -0.3188 |
| ESP1 | 2918 | -0.359 | -0.3234 |
| FIS1 | 2944 | -0.372 | -0.3267 |
| HFM1 | 2950 | -0.375 | -0.3258 |
| SMC2 | 2973 | -0.388 | -0.3284 |
| NDT80 | 2976 | -0.39 | -0.3269 |
| IML3 | 2991 | -0.398 | -0.3278 |
| SAC3 | 3000 | -0.401 | -0.3275 |
| GPN2 | 3014 | -0.407 | -0.3281 |
| KEL2 | 3019 | -0.409 | -0.3269 |
| CIN8 | 3031 | -0.413 | -0.3271 |
| CEP3 | 3055 | -0.426 | -0.3298 |
| RMR1 | 3057 | -0.426 | -0.3279 |
| YPI1 | 3083 | -0.437 | -0.3308 |
| NPR3 | 3085 | -0.439 | -0.3289 |
| ELG1 | 3091 | -0.442 | -0.3277 |
| SGS1 | 3097 | -0.446 | -0.3265 |
| RED1 | 3145 | -0.467 | -0.3339 |
| CDC55 | 3160 | -0.478 | -0.3344 |
| GIC2 | 3166 | -0.482 | -0.333 |
| RAD6 | 3169 | -0.482 | -0.331 |
| TOM1 | 3175 | -0.483 | -0.3297 |
| HRR25 | 3224 | -0.506 | -0.337 |
| SCC2 | 3234 | -0.51 | -0.3364 |
| BUB1 | 3237 | -0.511 | -0.3342 |
| MSH6 | 3295 | -0.543 | -0.3433 |
| CTF3 | 3335 | -0.557 | -0.3485 |
| <u>RIM101</u> | 3345 | -0.563 | -0.3476 |
| BNS1 | 3351 | -0.565 | -0.3458 |
| CLB3 | 3354 | -0.567 | -0.3434 |
| SET3 | 3357 | -0.568 | -0.341 |
| MCM21 | 3383 | -0.585 | -0.3433 |
| MUM2 | 3431 | -0.619 | -0.3499 |
| IDS2 | 3444 | -0.624 | -0.3493 |
| STH1 | 3463 | -0.632 | -0.3498 |
| HHT2 | 3483 | -0.641 | -0.3506 |
| RMI1 | 3486 | -0.641 | -0.3478 |
| KIP3 | 3490 | -0.643 | -0.3452 |
| APC1 | 3491 | -0.644 | -0.342 |

| NUM1 | 3500 | -0.646 | -0.3405 |
|--------------|------|--------|---------|
| BUB2 | 3522 | -0.66 | -0.3415 |
| RAD57 | 3527 | -0.662 | -0.3391 |
| MSC3 | 3562 | -0.678 | -0.3427 |
| TGS1 | 3571 | -0.686 | -0.3409 |
| <u>RIM15</u> | 3573 | -0.689 | -0.3377 |
| SWE1 | 3578 | -0.692 | -0.3351 |
| HOS2 | 3589 | -0.701 | -0.3337 |
| SIN3 | 3592 | -0.703 | -0.3306 |
| PPH3 | 3603 | -0.708 | -0.3292 |
| IRC15 | 3630 | -0.725 | -0.3309 |
| BIM1 | 3655 | -0.74 | -0.3322 |
| POL2 | 3663 | -0.744 | -0.33 |
| MAD1 | 3668 | -0.746 | -0.3271 |
| SET2 | 3681 | -0.753 | -0.3258 |
| DON1 | 3706 | -0.769 | -0.3269 |
| SSN8 | 3711 | -0.774 | -0.3239 |
| ZIP1 | 3712 | -0.774 | -0.3201 |
| EBP2 | 3720 | -0.781 | -0.3177 |
| RDH54 | 3721 | -0.782 | -0.3138 |
| MSH4 | 3725 | -0.784 | -0.3105 |
| <u>VPS1</u> | 3736 | -0.79 | -0.3087 |
| FIN1 | 3746 | -0.795 | -0.3066 |
| BMH1 | 3760 | -0.806 | -0.3053 |
| TEM1 | 3780 | -0.817 | -0.3051 |
| PDS5 | 3787 | -0.822 | -0.3023 |
| TOR1 | 3799 | -0.83 | -0.3004 |
| NIS1 | 3813 | -0.84 | -0.2989 |
| <u>RAD30</u> | 3815 | -0.843 | -0.295 |
| SRC1 | 3849 | -0.863 | -0.2975 |
| CSE4 | 3850 | -0.863 | -0.2932 |
| PAP2 | 3878 | -0.878 | -0.2944 |
| KIP1 | 3898 | -0.89 | -0.2939 |
| IME1 | 3941 | -0.923 | -0.298 |
| AMA1 | 3943 | -0.924 | -0.2936 |
| NUP53 | 3965 | -0.945 | -0.2932 |
| CAK1 | 4014 | -0.982 | -0.2982 |
| TOP1 | 4017 | -0.983 | -0.2938 |
| IME2 | 4068 | -1.021 | -0.299 |
| DBF4 | 4084 | -1.034 | -0.297 |
| DMA2 | 4092 | -1.044 | -0.2932 |
| NUD1 | 4095 | -1.047 | -0.2884 |

| <u>SPO11</u> | 4098 | -1.048 | -0.2837 |
|---------------|------|--------|---------|
| CDC5 | 4118 | -1.065 | -0.2823 |
| BFA1 | 4124 | -1.075 | -0.278 |
| CDC24 | 4133 | -1.085 | -0.2743 |
| <u>SGO1</u> | 4134 | -1.086 | -0.2689 |
| BUD2 | 4152 | -1.097 | -0.2669 |
| ALK1 | 4160 | -1.104 | -0.2629 |
| DBF20 | 4164 | -1.106 | -0.258 |
| SCC4 | 4166 | -1.108 | -0.2528 |
| MPS1 | 4193 | -1.145 | -0.2524 |
| SAE2 | 4199 | -1.149 | -0.2478 |
| REC8 | 4214 | -1.16 | -0.2449 |
| RIM4 | 4232 | -1.176 | -0.2426 |
| CSM4 | 4250 | -1.195 | -0.2402 |
| HOS4 | 4252 | -1.196 | -0.2344 |
| SWM1 | 4258 | -1.203 | -0.2295 |
| ULP2 | 4259 | -1.203 | -0.2235 |
| GMC1 | 4327 | -1.271 | -0.231 |
| CTF8 | 4332 | -1.281 | -0.2255 |
| WTM2 | 4359 | -1.305 | -0.2244 |
| <u>ARP10</u> | 4360 | -1.305 | -0.2179 |
| ZIP2 | 4381 | -1.33 | -0.2154 |
| <u>REC107</u> | 4385 | -1.336 | -0.2094 |
| <u>REC114</u> | 4394 | -1.347 | -0.2044 |
| PDS1 | 4421 | -1.38 | -0.2029 |
| SAE3 | 4438 | -1.397 | -0.1993 |
| <u>REC102</u> | 4445 | -1.404 | -0.1936 |
| BUB3 | 4453 | -1.408 | -0.188 |
| CSM3 | 4466 | -1.422 | -0.1835 |
| RAD51 | 4510 | -1.482 | -0.185 |
| PCH2 | 4540 | -1.53 | -0.1833 |
| GMC2 | 4559 | -1.556 | -0.1793 |
| <u>ECO1</u> | 4584 | -1.599 | -0.1763 |
| VIK1 | 4608 | -1.627 | -0.173 |
| CDH1 | 4620 | -1.641 | -0.1671 |
| IPL1 | 4627 | -1.657 | -0.1602 |
| TOP3 | 4650 | -1.701 | -0.1563 |
| BIR1 | 4652 | -1.703 | -0.148 |
| DMC1 | 4685 | -1.776 | -0.1458 |
| CDC14 | 4713 | -1.823 | -0.1423 |
| BRN1 | 4746 | -1.899 | -0.1395 |
| CHL4 | 4748 | -1.91 | -0.1302 |

| SLZ1 | 4755 | -1.925 | -0.1219 |
|--------------|------|--------|---------|
| MOB1 | 4757 | -1.931 | -0.1126 |
| GAC1 | 4766 | -1.946 | -0.1046 |
| <u>UME6</u> | 4811 | -2.067 | -0.1034 |
| CTF19 | 4845 | -2.194 | -0.0993 |
| KAR3 | 4849 | -2.21 | -0.089 |
| MND1 | 4851 | -2.22 | -0.0782 |
| SLK19 | 4886 | -2.343 | -0.0736 |
| MPS3 | 4919 | -2.483 | -0.0678 |
| SOH1 | 4931 | -2.508 | -0.0577 |
| <u>DSN1</u> | 4950 | -2.595 | -0.0485 |
| <u>ECM11</u> | 4952 | -2.599 | -0.0358 |
| <u>SPO13</u> | 4960 | -2.647 | -0.0242 |
| <u>CIK1</u> | 5039 | -3.286 | -0.0239 |
| MEI5 | 5042 | -3.347 | -0.0077 |
| IME4 | 5045 | -3.39 | 0.0086 |

Sister Chromatid Segregation

| Gene Name | Rank in Gene List | Rank Metric Score | Running Enrichment Score |
|--------------|-------------------|-------------------|-----------------------------|
| TPD3 | 587 | 1.4 | -0.0999 |
| POL30 | 906 | 1.086 | -0.15 |
| SMC3 | 1001 | 1.002 | -0.1563 |
| GLC7 | 1426 | 0.691 | -0.2324 |
| TOF1 | 1833 | 0.486 | -0.3076 |
| KIN4 | 1914 | 0.458 | -0.3178 |
| SMC4 | 1918 | 0.457 | -0.3127 |
| CHL1 | 1923 | 0.451 | -0.3079 |
| LTE1 | 2057 | 0.386 | -0.3297 |
| DCC1 | 2087 | 0.372 | -0.3309 |
| CDC20 | 2243 | 0.3 | -0.3581 |
| BUR2 | 2259 | 0.289 | -0.3575 |
| MND2 | 2305 | 0.274 | -0.3631 |
| MAD2 | 2358 | 0.252 | -0.3703 |
| NPA3 | 2412 | 0.227 | -0.3781 |
| <u>PPH21</u> | 2467 | 0.201 | -0.3864 |
| MCK1 | 2576 | -0.185 | -0.4057 |
| MMS22 | 2587 | -0.193 | -0.4053 |
| IRR1 | 2690 | -0.248 | -0.4226 |
| DMA1 | 2753 | -0.283 | -0.4314 |
| MCD1 | 2778 | -0.291 | -0.4326 |

| MAD3 | 2797 | -0.3 | -0.4325 |
|--------------|--------------|--------|-------------------|
| SPC72 | 2801 | -0.303 | -0.4293 |
| RAD61 | 2813 | -0.309 | -0.4276 |
| CTF4 | 2835 | -0.322 | -0.4278 |
| CTF18 | 2851 | -0.329 | -0.4267 |
| RTS1 | 2871 | -0.337 | -0.4263 |
| ESP1 | 2918 | -0.359 | -0.431 |
| SMC2 | 2973 | -0.388 | -0.437 |
| IML3 | 2991 | -0.398 | -0.4354 |
| GPN2 | 3014 | -0.407 | -0.4348 |
| CIN8 | 3031 | -0.413 | -0.4328 |
| CEP3 | 3055 | -0.426 | -0.4321 |
| | 3083 | -0.420 | -0.432 |
| YPI1 | 3091 | -0.442 | -0.4279 |
| ELG1 SGS1 | 3097 | -0.442 | -0.4279 |
| | | -0.446 | |
| <u>CDC55</u> | 3160 3234 | -0.478 | -0.4298 -0.438 |
| SCC2 | | | |
| BUB1 | 3237 | -0.511 | -0.4321 |
| CTF3 | 3335 | -0.557 | -0.4445 |
| MCM21 | 3383 | -0.585 | -0.4466 |
| HHT2 | 3483 | -0.641 | -0.4584 |
| RMI1 | 3486 | -0.641 | -0.4508 |
| APC1 | 3491 | -0.644 | -0.4436 |
| BUB2 | 3522 | -0.66 | -0.4414 |
| IRC15 | 3630 | -0.725 | -0.4537 |
| BIM1 | 3655 | -0.74 | -0.4493 |
| POL2 | 3663 | -0.744 | -0.4414 |
| MAD1 | 3668 | -0.746 | -0.4329 |
| RDH54 | 3721 | -0.782 | -0.4336 |
| <u>FIN1</u> | 3746 | -0.795 | -0.4284 |
| BMH1 | 3760 | -0.806 | -0.421 |
| PDS5 | 3787 | -0.822 | -0.4159 |
| RAD30 | 3815 | -0.843 | -0.4108 |
| SRC1 | 3849 | -0.863 | -0.4067 |
| CSE4 | 3850 | -0.863 | -0.3959 |
| KIP1 | 3898 | -0.89 | -0.3942 |
| TOP1 | 4017 | -0.983 | -0.4056 |
| DMA2 | 4092 | -1.044 | -0.4073 |
| BFA1 | 4124 | -1.075 | -0.4001 |
| <u>SGO1</u> | 4134 | -1.086 | -0.3884 |
| BUD2 | 4152 | -1.097 | -0.3781 |
| SCC4 | 4166 | -1.108 | -0.3669 |
| | | | |

| MPS1 | 4193 | -1.145 | -0.3578 |
|--------------|------|--------|---------|
| REC8 | 4214 | -1.16 | -0.3473 |
| SWM1 | 4258 | -1.203 | -0.3409 |
| ULP2 | 4259 | -1.203 | -0.3259 |
| CTF8 | 4332 | -1.281 | -0.3244 |
| PDS1 | 4421 | -1.38 | -0.3248 |
| BUB3 | 4453 | -1.408 | -0.3134 |
| CSM3 | 4466 | -1.422 | -0.2981 |
| <u>ECO1</u> | 4584 | -1.599 | -0.3015 |
| <u>VIK1</u> | 4608 | -1.627 | -0.2858 |
| CDH1 | 4620 | -1.641 | -0.2676 |
| IPL1 | 4627 | -1.657 | -0.2481 |
| TOP3 | 4650 | -1.701 | -0.2313 |
| BIR1 | 4652 | -1.703 | -0.2103 |
| BRN1 | 4746 | -1.899 | -0.2052 |
| CHL4 | 4748 | -1.91 | -0.1816 |
| GAC1 | 4766 | -1.946 | -0.1607 |
| CTF19 | 4845 | -2.194 | -0.149 |
| KAR3 | 4849 | -2.21 | -0.122 |
| MPS3 | 4919 | -2.483 | -0.1048 |
| SOH1 | 4931 | -2.508 | -0.0757 |
| DSN1 | 4950 | -2.595 | -0.047 |
| <u>SPO13</u> | 4960 | -2.647 | -0.0158 |
| <u>CIK1</u> | 5039 | -3.286 | 0.0096 |